FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Alper, CA Larsen, CE Dubey, DP Awdeh, ZL Fici, DA Yunis, EJ AF Alper, CA Larsen, CE Dubey, DP Awdeh, ZL Fici, DA Yunis, EJ TI The haplotype structure of the human major histocompatibility complex SO HUMAN IMMUNOLOGY LA English DT Article DE major histocompatibility complex; susceptibility genes; complex diseases; single-nucleotide polymorphisms; linkage disequilibrium ID COMMON VARIABLE IMMUNODEFICIENCY; EXTENDED HLA HAPLOTYPES; SINGLE NUCLEOTIDE POLYMORPHISMS; GLUTEN-SENSITIVE ENTEROPATHY; LINKAGE DISEQUILIBRIUM MAP; MHC SUSCEPTIBILITY GENES; PRIMERS PCR-SSP; ANCESTRAL HAPLOTYPES; IGA DEFICIENCY; UNRELATED INDIVIDUALS AB There is great interest in the use of single-nucleoilde poly morphisms (SNPs) and linkage disequilibrium (LD) analysis to localize human disease genes. The results Suggest that the human genome, including the major histocompatibility complex (MHC), consists largely of 5- to 200-kb blocks of sequence fixity between which random recombination occurs. Direct determination of MHC haptorypes from family studies also demonstrates similar-sized blocks, but otherwise gives a very different picture, with a third to a half of Caucasian haplotypes fixed from HLA-B to HLA-DR/DQ (at least 1 Mb) as conserved extended haplotypes (CEHs), some of which encompass more than 3 Mb. These fixed haplotypes differ in frequency both in different Caucasian subpopulations and in Caucasian patients with HLA-associated diseases, complicating disease susceptibility gene localization. The inherent inability of LD analysis to "see" DNA fixity beyond three markets contributes to the failure SNP/LD analysis to define in detail or even detect CEHs in the MHC and probably elsewhere in the genome. More importantly, the use of statistical analysis, rather than direct haplotype determination and counting, fails to reveal the details of haplotype structure essential for gene localization. Given the oversimplified picture of the MHC (and probably the rest of the genome) provided only by SNP/LD-defined blocks, it is questionable whether this approach will be of great help in disease susceptibility gene localization or identification. C1 CBR Inst Biomed Res, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RP Alper, CA (reprint author), CBR Inst Biomed Res, 800 Huntington Ave, Boston, MA 02115 USA. EM alper@vbr.med.harvard.edu FU NHLBI NIH HHS [HL-29583] NR 88 TC 63 Z9 64 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PD JAN-FEB PY 2006 VL 67 IS 1-2 BP 73 EP 84 DI 10.1016/j.humimm.2005.11.006 PG 12 WC Immunology SC Immunology GA 049AK UT WOS:000237987500010 PM 16698428 ER PT J AU Silberstein, T MacLaughlin, DT Shai, I Trimarchi, JR Lambert-Messerlian, G Seifer, DB Keefe, DL Blazar, AS AF Silberstein, T MacLaughlin, DT Shai, I Trimarchi, JR Lambert-Messerlian, G Seifer, DB Keefe, DL Blazar, AS TI Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology SO HUMAN REPRODUCTION LA English DT Article DE embryo morphology; IVF; Mullerian inhibiting substance; ovarian reserve; pregnancy rate ID IN-VITRO FERTILIZATION; RIBONUCLEIC-ACID EXPRESSION; STROMAL BLOOD-FLOW; FOLLICLE GROWTH; GRANULOSA-CELLS; MOUSE OVARY; HORMONE; SERTOLI; VOLUME; RESPONSIVENESS AB BACKGROUND: Pre-antral and early antral follicles secrete Mullerian inhibiting substance (MIS), suggesting that MIS may directly reflect ovarian reserve. Since little is known about how ovarian reserve affects oocyte quality, we attempt here to assess the predictive value of MIS on embryo morphology and IVF outcome. To do so, we measured MIS at the time of HCG administration 36 h prior to oocyte retrieval. METHODS: A total of 257 patients undergoing IVF were prospectively recruited. We measured MIS levels by enzyme-linked immunosorbent assay at the time of HCG, and compared the MIS values to day 3 FSH levels in the prediction of embryo morphology and IVF outcome. RESULTS: The distribution of MIS levels was skewed, with a median of 2.7 ng/ml (range 0 to 28.5 ng/ml). MIS values at the time of HCG administration inversely correlated with basal FSH levels (P = 0.002), and both correlated significantly with patient age, number of mature follicles, number of oocytes retrieved and serum estradiol levels. MIS levels correlated significantly with a greater number of 6-cell embryos and better embryo morphology score, while basal FSH levels did not correlate with these outcome variables. MIS levels > 2.7 ng/ml portended improved oocyte quality as reflected in a higher implantation rate (P = 0.001) and a trend toward a better clinical pregnancy rate (P = 0.084). CONCLUSIONS: MIS levels seem to predict not only ovarian reserve, but also embryo morphology. Measurement of MIS at the time of HCG administration may, therefore, in the future improve management of patients undergoing treatments with assisted reproductive technology. C1 Brown Univ, Women & Infants Hosp, Div Biol & Med, Providence, RI USA. Dept Pathol & Lab Med, Div Prenatal & Special Testing, Providence, RI USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. Maimonides Hosp, Div Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, Brooklyn, NY 11219 USA. RP Blazar, AS (reprint author), Women & Infants Hosp Rhode Isl, Div Reprod Med & Infertil, 101 Dudley St,Suite 1440, Providence, RI 02905 USA. EM Ablazar@wihri.org OI Seifer, David/0000-0003-3950-9341; Messerlian, Geralyn/0000-0002-9440-3411 NR 27 TC 97 Z9 106 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 J9 HUM REPROD JI Hum. Reprod. PD JAN PY 2006 VL 21 IS 1 BP 159 EP 163 DI 10.1093/humrep/dei270 PG 5 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 991XA UT WOS:000233846700021 PM 16123085 ER PT J AU Halperin, RO Sesso, HD Ma, J Buring, JE Stampfer, MJ Gaziano, JM AF Halperin, RO Sesso, HD Ma, J Buring, JE Stampfer, MJ Gaziano, JM TI Dyslipidemia and the risk of incident hypertension in men SO HYPERTENSION LA English DT Article DE cholesterol; lipids; hypertension; blood pressure; men; prospective studies ID AT1-TYPE ANGIOTENSIN RECEPTOR; HIGH BLOOD-PRESSURE; INSULIN-RESISTANCE; METABOLIC SYNDROME; CHOLESTEROL LEVELS; EDUCATION-PROGRAM; OXIDATIVE STRESS; FOLLOW-UP; DISEASE; ATHEROGENESIS AB Evidence suggests that hypertension may share a similar pathophysiology with cardiovascular disease (CVD). Thus, dyslipidemia, a strong predictor of CVD, may also predict incident hypertension. We analyzed 3110 men free of hypertension, CVD, and cancer from the Physicians' Health Study, who provided baseline blood samples from which we measured total cholesterol (TC) and HDL cholesterol (HDL-C), and calculated non-HDL-C and the TC/HDL-C ratio. We categorized each lipid parameter into quintiles and considered National Cholesterol Education Project clinical cut points. Other risk factor information was provided from self-reports on the baseline questionnaire. Incident hypertension was defined as either the initiation of antihypertensive treatment, self-reported systolic blood pressure >= 140 mm Hg, or diastolic blood pressure >= 90 mm Hg. Over a mean follow-up of 14.1 years, 1019 men developed hypertension. In Cox proportional hazards models adjusted for lifestyle and clinical risk factors, men in the highest quintile of TC, non-HDL-C, and TC/HDL-C ratio had increased risks of developing hypertension of 23%, 39%, and 54%, respectively, compared with participants in the lowest quintile. Furthermore, men in the highest quintile of HDL-C had a 32% decreased risk of developing hypertension compared with those in the lowest quintile. Models using National Cholesterol Education Project cut points demonstrated similar associations with hypertension. Models excluding men with diabetes and obesity maintained an independent association between baseline lipids and hypertension. These prospective cohort data suggest that dyslipidemias may lead to the subsequent development of hypertension. Thus, plasma lipids may be useful in the identification of men at risk for hypertension. C1 Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02215 USA. Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02215 USA. Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA USA. VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Sesso, HD (reprint author), Brigham & Womens Hosp, Dept Med, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA. EM hsesso@hsph.harvard.edu FU NCI NIH HHS [CA 34944, CA 40360, CA 97193, R01 CA097193]; NHLBI NIH HHS [HL 34595, HL 26490] NR 28 TC 100 Z9 107 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD JAN PY 2006 VL 47 IS 1 BP 45 EP 50 DI 10.1161/01.HYP.0000196306.42418.0e PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 996BN UT WOS:000234149500011 PM 16344375 ER PT J AU Wolf, M Marei, S Chafetz, I Gibor, Y Meiri, H Tal, Y Kuhnreich, I Cuckle, H Thadhani, R AF Wolf, Myles Marei, Samar Chafetz, Ilana Gibor, Yair Meiri, Hamutal Tal, Yossi Kuhnreich, Ido Cuckle, Howard Thadhani, Ravi TI First trimester placental protein 13 screening for preeclampsia, growth restriction, and preterm delivery. SO HYPERTENSION IN PREGNANCY LA English DT Meeting Abstract C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Renal Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. Diagnost Technol Ltd, IL-25266 Haifa, Israel. Technostat Ltd, Kefar Sava, Israel. Univ Leeds, Leeds, W Yorkshire, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1064-1955 J9 HYPERTENS PREGNANCY JI Hypertens. Pregnancy PY 2006 VL 25 SU 1 BP 64 EP 64 PG 1 WC Obstetrics & Gynecology; Physiology; Peripheral Vascular Disease SC Obstetrics & Gynecology; Physiology; Cardiovascular System & Cardiology GA 062KK UT WOS:000238942800096 ER PT J AU Dechend, R Wolf, M Markovic, N Wallukat, G Herse, F Wallukat, G Hubel, CA AF Dechend, Ralf Wolf, Myles Markovic, Nina Wallukat, Gerd Herse, Florian Wallukat, Gerd Hubel, Carl A. TI Presence of activating autoantibodies against the AT1-receptor more than 1 year postpartum in women with a history of preeclampsia more than 1 year postpartum. SO HYPERTENSION IN PREGNANCY LA English DT Meeting Abstract C1 Charite, HELIOS Clin, Berlin, Germany. Max Delbrueck Ctr, Berlin, Germany. Massachusetts Gen Hosp, Magee Womens Res Inst, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Renal Unit, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1064-1955 J9 HYPERTENS PREGNANCY JI Hypertens. Pregnancy PY 2006 VL 25 SU 1 BP 85 EP 85 PG 1 WC Obstetrics & Gynecology; Physiology; Peripheral Vascular Disease SC Obstetrics & Gynecology; Physiology; Cardiovascular System & Cardiology GA 062KK UT WOS:000238942800125 ER PT J AU Barbieri, R Brown, EN AF Barbieri, R Brown, EN TI Analysis of heartbeat dynamics by point process adaptive filtering SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE adaptive filters; heart rate variability; point processes; state estimation ID POWER SPECTRUM ANALYSIS; RATE-VARIABILITY; CARDIOVASCULAR VARIABILITY; WAVELET TRANSFORM; AUTONOMIC CONTROL; MODEL; FLUCTUATION; EXTRACTION; INTERVALS; SIGNALS AB Heartbeats are a point process yet, most of the current analysis methods do not model this important characteristic of these data. We describe human heartbeat time series as a history dependent inverse Gaussian model. We present a point process adaptive filter algorithm to estimate the model's time-varying parameters, and use it to compute new measures of heart rate variability. We apply our algorithm to analyze simulated heartbeat data and actual heartbeat data from a tilt table experiment and from healthy subjects and subjects with congestive heart failure during sleep. Our results suggest a new approach for characterizing heartbeat dynamics. C1 Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neurosci Stat Res Lab, Boston, MA 02114 USA. MIT, MIT Harvard Med Sch, Div Hlth Sci & Technol, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. RP Barbieri, R (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neurosci Stat Res Lab, Boston, MA 02114 USA. EM barbieri@neurostat.mgh.harvard.edu; brown@neurostat.mgh.harvard.edu OI Barbieri, Riccardo/0000-0001-9381-3833 FU NIDA NIH HHS [DA015644]; NIMH NIH HHS [MH59733, MH61637, MH65018] NR 45 TC 51 Z9 51 U1 0 U2 3 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD JAN PY 2006 VL 53 IS 1 BP 4 EP 12 DI 10.1109/TBME.2005.859779 PG 9 WC Engineering, Biomedical SC Engineering GA 996TO UT WOS:000234197900002 PM 16402597 ER PT J AU Nagler-Anderson, C AF Nagler-Anderson, C TI Functional aspects of the mucosal immune system SO IMMUNE MECHANISMS IN INFLAMMATORY BOWEL DISEASE SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Article ID THYMUS-EXPRESSED CHEMOKINE; REGULATORY T-CELLS; GROWTH-FACTOR-BETA; INTESTINAL EPITHELIAL-CELLS; ANTIBODY-SECRETING CELLS; DENDRITIC CELLS; IN-VIVO; PEYERS PATCH; LYMPH-NODES; LAMINA PROPRIA C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Immunol, Charlestown, MA USA. RP Nagler-Anderson, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Immunol, Charlestown, MA USA. FU NIDDK NIH HHS [R0-1 DK 55678] NR 73 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 0065-2598 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2006 VL 579 BP 15 EP 23 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA BEC63 UT WOS:000236805000002 PM 16620009 ER PT J AU Victoratos, P Lagnel, J Tzima, S Alimzhanov, MB Rajewsky, K Pasparakis, M Kollias, G AF Victoratos, P Lagnel, J Tzima, S Alimzhanov, MB Rajewsky, K Pasparakis, M Kollias, G TI FDC-specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses SO IMMUNITY LA English DT Article ID TUMOR-NECROSIS-FACTOR; FOLLICULAR DENDRITIC CELLS; NF-KAPPA-B; PEYERS PATCH ORGANOGENESIS; LYMPHOID ORGAN DEVELOPMENT; LYMPHOTOXIN-BETA-RECEPTOR; GERMINAL-CENTER FORMATION; CYTIDINE DEAMINASE AID; TNF RECEPTOR; MICE LACKING AB The FDC-specific molecular signals required in the formation of FDC networks, B cell follicles, and germinal centers (GCs) have remained poorly understood. We used FDC-specific gene targeting to investigate the function of p55TNFR and IKK2 in lymphoid organ structure and function. Here we show that FDC-specific expression of p55TNFR is necessary and sufficient to promote FDC network and B cell follicle formation, restore the expression of CXCL13 and VCAM-1/ICAM-1 in FDCs, and lead to productive GCs. Notably, FDC-specific disruption of IKK2 does not affect formation of FDC networks. Yet, after antigen engagement or immune complex (IC) deposition, FDCs lacking IKK2 fail to upregulate VCAM-1 and ICAM-1, and GCs remain sterile. These findings demonstrate that IKK2-independent function of p55TNFR on FDCs is sufficient to support the development of FDC networks and GCs, while FDC-specific IKK2 is indispensable for the generation of efficient humoral immune responses. C1 Biomed Sci Res Ctr Al Fleming, Inst Immunol, Vari 16672, Greece. Univ Cologne, Genet Inst, D-50931 Cologne, Germany. Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA. European Mol Biol Lab, Mouse Biol Programme, I-00016 Monterotondo, Italy. RP Kollias, G (reprint author), FORTH HELLAS, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece. EM g.kollias@fleming.gr RI Kollias, George/A-7079-2012 OI Kollias, George/0000-0003-1867-3150 NR 58 TC 72 Z9 75 U1 1 U2 2 PU CELL PRESS PI CAMBRIDGE PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA SN 1074-7613 J9 IMMUNITY JI Immunity PD JAN PY 2006 VL 24 IS 1 BP 65 EP 77 DI 10.1016/j.immuni.2005.11.013 PG 13 WC Immunology SC Immunology GA 005UT UT WOS:000234850200011 PM 16413924 ER PT J AU McMullen, ME Hart, ML Walsh, MC Buras, J Takahashi, K Stahl, GL AF McMullen, Meghan E. Hart, Melanie L. Walsh, Mary C. Buras, Jon Takahashi, Kazue Stahl, Gregory L. TI Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo SO IMMUNOBIOLOGY LA English DT Article DE antibody; classical pathway; ischemia-reperfusion; lectin pathway and surface plasmon resonance ID ISCHEMIA-REPERFUSION INJURY; INTESTINAL ISCHEMIA/REPERFUSION; NATURAL ANTIBODY; IMMUNOGLOBULIN-M; SKELETAL-MUSCLE; MYELOMA PROTEIN; TISSUE-INJURY; HEXAMERIC IGM; IDENTIFICATION; MODEL AB Recent evidence has implicated a role for the MBL-dependent lectin pathway in gastrointestinal and myocardial ischemia/reperfusion (I/R)-induced injury. However, previous studies have implicated IgM and the classical pathway as initiators of complement activation following I/R. Thus, we investigated the potential interaction between MBL and IgM leading to complement activation. Using surface plasmon resonance, we demonstrate that MBL does bind human IgM. Subsequently, functional complement activation was demonstrated in vitro following sensitization of human RBCs with mouse anti-human CD59 IgM and more lysis was observed with MBL SLIfficient sera compared to MBL deficient (KO) sera. Similarly, treatment of human endothelial cells with mouse anti-human CD59 IgM, MBL and MASP-2 activated and deposited C4. These data suggest that the presence of both IgM and MBL can activate the lectin pathway in vitro. Serum ALT levels increased significantly in sIgM/MBL-A/C KO mice reconstituted with WT plasma compared to slgM/MBL-A/C KO mice reconstituted with MBL-A/C KO plasma following gastrointestinal (G) I/R. Similarly, intestinal C3 deposition was greater in sIgM/MBL-A/C KO mice reconstituted with WT plasma compared to sIgM/MBL-A/C KO mice treated with MBL-A/C KO plasma. These data indicate for the first time that both IgM and MBL-A/C are required for GI/R-induced complement activation and subsequent injury. (c) 2006 Elsevier GmbH. All rights reserved. C1 Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury,Dept Anesthe, Boston, MA 02115 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lab Dev Immunol, Boston, MA 02115 USA. Northeastern Univ, NE Inflammat & Tissue Protect Inst, Boston, MA 02115 USA. RP Stahl, GL (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury,Dept Anesthe, Boston, MA 02115 USA. EM gstahl@zeus.bwh.harvard.edu FU NHLBI NIH HHS [HL52886, HL56086, HL76130, HL79758]; NIDDK NIH HHS [DK067782] NR 34 TC 67 Z9 69 U1 0 U2 2 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 0171-2985 J9 IMMUNOBIOLOGY JI Immunobiology PY 2006 VL 211 IS 10 BP 759 EP 766 DI 10.1016/j.imbio.2006.06.011 PG 8 WC Immunology SC Immunology GA 121CH UT WOS:000243135200001 PM 17113913 ER PT J AU Eccles, MP Mittman, BS AF Eccles, Martin P. Mittman, Brian S. TI Welcome to Implementation Science SO IMPLEMENTATION SCIENCE LA English DT Editorial Material AB Implementation research is the scientific study of methods to promote the systematic uptake of research findings and other evidence-based practices into routine practice, and, hence, to improve the quality and effectiveness of health services and care. This relatively new field includes the study of influences on healthcare professional and organisational behaviour. Implementation Science will encompass all aspects of research in this field, in clinical, community and policy contexts. This online journal will provide a unique platform for this type of research and will publish a broad range of articles - study protocols, debate, theoretical and conceptual articles, rigorous evaluations of the process of change, and articles on methodology and rigorously developed tools - that will enhance the development and refinement of implementation research. No one discipline, research design, or paradigm will be favoured. Implementation Science looks forward to receiving manuscripts that facilitate the continued development of the field, and contribute to healthcare policy and practice. C1 [Eccles, Martin P.] Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Mittman, Brian S.] VA Greater Angeles Healthcare Syst, VA Ctr Study Healthcare Provider Behav, Sepulveda, CA USA. [Mittman, Brian S.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Eccles, MP (reprint author), Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. EM Martin.Eccles@newcastle.ac.uk; Brian.Mittman@va.gov NR 8 TC 157 Z9 158 U1 2 U2 16 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PY 2006 VL 1 AR 1 DI 10.1186/1748-5908-1-1 PG 3 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA V99JR UT WOS:000206717500001 ER PT J AU Hysong, SJ Best, RG Pugh, JA AF Hysong, Sylvia J. Best, Richard G. Pugh, Jacqueline A. TI Audit and feedback and clinical practice guideline adherence: Making feedback actionable SO IMPLEMENTATION SCIENCE LA English DT Article AB Background: As a strategy for improving clinical practice guideline (CPG) adherence, audit and feedback (A&F) has been found to be variably effective, yet A&F research has not investigated the impact of feedback characteristics on its effectiveness. This paper explores how high performing facilities (HPF) and low performing facilities (LPF) differ in the way they use clinical audit data for feedback purposes. Method: Descriptive, qualitative, cross-sectional study of a purposeful sample of six Veterans Affairs Medical Centers (VAMCs) with high and low adherence to six CPGs, as measured by external chart review audits. One-hundred and two employees involved with outpatient CPG implementation across the six facilities participated in one-hour semi-structured interviews where they discussed strategies, facilitators and barriers to implementing CPGs. Interviews were analyzed using techniques from the grounded theory method. Results: High performers provided timely, individualized, non-punitive feedback to providers, whereas low performers were more variable in their timeliness and non-punitiveness and relied on more standardized, facility-level reports. The concept of actionable feedback emerged as the core category from the data, around which timeliness, individualization, non-punitiveness, and customizability can be hierarchically ordered. Conclusion: Facilities with a successful record of guideline adherence tend to deliver more timely, individualized and non-punitive feedback to providers about their adherence than facilities with a poor record of guideline adherence. Consistent with findings from organizational research, feedback intervention characteristics may influence the feedback's effectiveness at changing desired behaviors. C1 [Hysong, Sylvia J.] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Hysong, Sylvia J.] Baylor Coll Med, Dept Med, Hlth Serv Res Sect, Houston, TX 77030 USA. [Best, Richard G.] Lockheed Martin Informat Technol, Healthcare Solut Div, San Antonio, TX USA. [Pugh, Jacqueline A.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat, San Antonio, TX USA. [Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Hysong, SJ (reprint author), Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. EM sylvia.hysong@med.va.gov; rbest@satx.rr.com; pugh@uthscsa.edu RI Hysong, Sylvia/B-8420-2008; OI Hysong, Sylvia/0000-0002-9063-5207; Pugh, Jacqueline/0000-0003-4933-141X FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (VA HSRD) [CPI 99-129] FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (VA HSR&D) (CPI 99-129). Dr. Hysong is a health services researcher at the Houston Center for Quality of Care and Utilization Studies, a VA HSR&D Center of Excellence, and she is an Instructor of Medicine at Baylor College of Medicine in Houston. This research was conducted during her tenure at the Veterans Evidence-Based Research Dissemination and Implementation Center (VERDICT), a VA HSR&D Research Enhancement Award Program. Dr. Best is a Senior Healthcare Consultant at Lockheed Martin Information Systems; this research was conducted during his tenure at VERDICT. Dr. Pugh is the director of VERDICT, a Professor of Internal Medicine at the University of Texas Health Science Center at San Antonio, TX, and a staff physician at the South Texas Veterans Health Care System, where VERDICT is housed. All three authors' salaries were supported, in part, by the Department of Veterans Affairs. The views expressed in this article are solely those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, Baylor College of Medicine, Lockheed Corporation, or the University of Texas. NR 28 TC 80 Z9 80 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PY 2006 VL 1 AR 9 DI 10.1186/1748-5908-1-9 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA V99JR UT WOS:000206717500009 PM 16722539 ER PT J AU Magnabosco, JL AF Magnabosco, Jennifer L. TI Innovations in mental health services implementation: a report on state-level data from the US Evidence-Based Practices Project SO IMPLEMENTATION SCIENCE LA English DT Article AB Background: The Evidence-Based Practice (EBP) Project has been investigating the implementation of evidence-based mental health practices (Assertive Community Treatment, Family Psychoeducation, Integrated Dual Diagnosis Treatment, Illness Management and Recovery, and Supported Employment) in state public mental health systems in the United States since 2001. To date, Project findings have yielded valuable insights into implementation strategy characteristics and effectiveness. This paper reports results of an effort to identify and classify state-level implementation activities and strategies employed across the eight states participating in the Project. Methods: Content analysis and Greenhalgh et al's (2004) definition of innovation were used to identify and classify state-level activities employed during three phases of EBP implementation: Pre-Implementation, Initial Implementation and Sustainability Planning. Activities were coded from site visit reports created from documents and notes from key informant interviews conducted during two periods, Fall 2002 - Spring 2003, and Spring 2004. Frequency counts and rank-order analyses were used to examine patterns of implementation activities and strategies employed across the three phases of implementation. Results: One hundred and six discreet implementation activities and strategies were identified as innovative and were classified into five categories: 1) state infrastructure building and commitment, 2) stakeholder relationship building and communications, 3) financing, 4) continuous quality management, and 5) service delivery practices and training. Implementation activities from different categories were employed at different phases of implementation. Conclusion: Insights into effective strategies for implementing EBPs in mental health and other health sectors require qualitative and quantitative research that seeks to: a) empirically test the effects of tools and methods used to implement EBPs, and b) establish a stronger evidence-base from which to plan, implement and sustain such efforts. This paper offers a classification scheme and list of innovative implementation activities and strategies. The classification scheme offers potential value for future studies that seek to assess the effects of various implementation processes, and helps establish widely accepted standards and criteria that can be used to assess the value of innovative activities and strategies. C1 VA Greater Angeles Healthcare Syst, VA Ctr Study Healthcare Provider Behav, Sepulveda, CA USA. RP Magnabosco, JL (reprint author), VA Greater Angeles Healthcare Syst, VA Ctr Study Healthcare Provider Behav, Sepulveda, CA USA. EM jlmagnabosco@mindspring.com FU MacArthur Foundation Network on Mental Health Policy Research FX The author would like to thank the John D. and Catherine T. MacArthur Foundation Network on Mental Health Policy Research for funding the preparation of data analyses and writing of the manuscript associated with this phase of the EBP Project, and the following colleagues from the MacArthur Foundation Network on Mental Health Policy Research for their collegiality, contributions to the acquisition of site visit data and writing of site visit reports, and comments on an earlier version of this manuscript: Howard Goldman, Audrey Burnam, Joseph Morrissey, Pam Hyde, Kimberly Roussin Isett, Brenda Coleman-Beattie, Vijay Ganju, Charlie Rapp, and Katie Falls. The author would especially like to thank Howard Goldman for his guidance and support. The author also would like to thank Cynthia Gammage for technical assistance in preparing this manuscript. NR 55 TC 31 Z9 31 U1 2 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PY 2006 VL 1 AR 13 DI 10.1186/1748-5908-1-13 PG 11 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA V99JR UT WOS:000206717500013 PM 16734913 ER PT J AU Stetler, CB Legro, MW Rycroft-Malone, J Bowman, C Curran, G Guihan, M Hagedorn, H Pineros, S Wallace, CM AF Stetler, Cheryl B. Legro, Marcia W. Rycroft-Malone, Joanne Bowman, Candice Curran, Geoffrey Guihan, Marylou Hagedorn, Hildi Pineros, Sandra Wallace, Carolyn M. TI Role of "external facilitation" in implementation of research findings: a qualitative evaluation of facilitation experiences in the Veterans Health Administration SO IMPLEMENTATION SCIENCE LA English DT Article AB Background: Facilitation has been identified in the literature as a potentially key component of successful implementation. It has not, however, either been well-defined or well-studied. Significant questions remain about the operational definition of facilitation and about the relationship of facilitation to other interventions, especially to other change agent roles when used in multi-faceted implementation projects. Researchers who are part of the Quality Enhancement Research Initiative (QUERI) are actively exploring various approaches and processes, including facilitation, to enable implementation of best practices in the Veterans Health Administration health care system - the largest integrated healthcare system in the United States. This paper describes a systematic, retrospective evaluation of implementation-related facilitation experiences within QUERI, a quality improvement program developed by the US Department of Veterans Affairs. Methods: A post-hoc evaluation was conducted through a series of semi-structured interviews to examine the concept of facilitation across several multi-site QUERI implementation studies. The interview process is based on a technique developed in the field of education, which systematically enhances learning through experience by stimulating recall and reflection regarding past complex activities. An iterative content analysis approach relative to a set of conceptually-based interview questions was used for data analysis. Findings: Findings suggest that facilitation, within an implementation study initiated by a central change agency, is a deliberate and valued process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship. Facilitation was described primarily as a distinct role with a number of potentially crucial behaviors and activities. Data further suggest that external facilitators were likely to use or integrate other implementation interventions, while performing this problem-solving and supportive role. Preliminary Conclusions: This evaluation provides evidence to suggest that facilitation could be considered a distinct implementation intervention, just as audit and feedback, educational outreach, or similar methods are considered to be discrete interventions. As such, facilitation should be well-defined and explicitly evaluated for its perceived usefulness within multi-intervention implementation projects. Additionally, researchers should better define the specific contribution of facilitation to the success of implementation in different types of projects, different types of sites, and with evidence and innovations of varying levels of strength and complexity. C1 [Legro, Marcia W.; Pineros, Sandra; Wallace, Carolyn M.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Rycroft-Malone, Joanne] Univ Wales, Ctr Hlth Related Res, Reader Hlth Serv Res, Bangor, Gwynedd, Wales. [Bowman, Candice] Hlth Serv Res & Dev, QUERI HIV, VA San Diego Healthcare Syst, San Diego, CA 92161 USA. [Curran, Geoffrey] Ctr Mental Healthcare & Outcomes Res, Cent Arkansas Vet Healthcare Syst, N Little Rock, AR 72114 USA. [Guihan, Marylou] Jr VA Hosp, Midwest Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA. [Hagedorn, Hildi] Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA. RP Stetler, CB (reprint author), 321 Middle St, Amherst, MA 01002 USA. EM Cheryl.Stetler@comcast.net; mlegro@earthlink.net; j.rycroft-malone@bangor.ac.uk; Candice.Bowman@va.gov; CURRAN.GEOFFREYM@va.gov; Marylou.guihan@va.gov; Hildi.Hagedorn@va.gov; Sandra.Pineros@va.gov; Carolyn.Wallace1@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service FX Nancy Sharp, PhD, VA Puget Sound Health Care System is acknowledged for her support of and feedback regarding this exploration. NR 20 TC 88 Z9 88 U1 1 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PY 2006 VL 1 AR 23 DI 10.1186/1748-5908-1-23 PG 15 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA V99JR UT WOS:000206717500023 PM 17049080 ER PT S AU Dieckgraefe, BK Korzenik, JR Anant, S AF Dieckgraefe, Brian K. Korzenik, Joshua R. Anant, Shrikant BE Domschke, WW Kagnoff, MF Kucharzik, TF Mayer, LF Targan, SR TI Growth factors as treatment options for intestinal inflammation SO INFLAMMATORY BOWEL DISEASE: GENETICS, BARRIER FUNCTION, IMMUNOLOGIC MECHANISMS, AND MICROBIAL PATHWAYS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT International Symposium on Inflammatory Bowel Diseases CY SEP 01-03, 2005 CL Munster, GERMANY SP Crohns & Colitis Fdn Amer, German Res Council, BAXTER, BRAUM, CENTOCOR, ESSEX, FALK, ABBOTT, ALTANA, AstraZeneca, Bayer Vital, Eisai, Ferring, Forderkre Univ Munster, Fresenius, Fujinon GmbH, Immundiagnostik, Medinal Medizinprodukte GmbH, Miltenyi Biotec, MSD Sharp & Dohme, New England Biolabs/Cell Signalling Technol, Novartis, Schering, Sigma Tau, UCB Celltech, Wyeth Pharma DE growth factors; Crohn's disease; inflammatory bowel disease; sargramostim ID COLONY-STIMULATING FACTOR; ACTIVE CROHNS-DISEASE AB On the basis of several studies that have been completed to date, some growth factors appear promising for the treatment of inflammatory bowel disease: keratinocyte-like growth factor-2 (KGF-2), epidermal growth factor (EGF) enemas used in combination with oral mesalamine, somatropin (human growth hormone), and sargramostim (recombinant human GM-CSF). The results of these studies are highlighted and suggest that new insights into the regulation of intestinal immunity may provide effective synergistic or single-agent treatment alternatives to immunosuppression for inflammatory bowel disease. These data focus on the reparative components of mucosal homeostasis. C1 Washington Univ, Sch Med, Siteman Canc Ctr, Div Gastroenterol, St Louis, MO 63110 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Inflammatory Bowel Dis Ctr, Boston, MA USA. Washington Univ, Sch Med, Siteman Canc Ctr, Dept Med Mol Biol & Pharmacol, St Louis, MO 63110 USA. RP Dieckgraefe, BK (reprint author), Washington Univ, Sch Med, Siteman Canc Ctr, Div Gastroenterol, Campus Box 8124,660 S Euclid Ave, St Louis, MO 63110 USA. EM dieck@im.wustl.edu NR 9 TC 13 Z9 16 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 1-57331-568-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2006 VL 1072 BP 300 EP 306 DI 10.1196/annals.1326.007 PG 7 WC Gastroenterology & Hepatology; Immunology; Multidisciplinary Sciences SC Gastroenterology & Hepatology; Immunology; Science & Technology - Other Topics GA BFD22 UT WOS:000241134900025 PM 17057209 ER PT S AU Cario, E Podolsky, DK AF Cario, Elke Podolsky, Daniel K. BE Domschke, WW Kagnoff, MF Kucharzik, TF Mayer, LF Targan, SR TI Toll-like receptor signaling and its relevance to intestinal inflammation SO INFLAMMATORY BOWEL DISEASE: GENETICS, BARRIER FUNCTION, IMMUNOLOGIC MECHANISMS, AND MICROBIAL PATHWAYS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT International Symposium on Inflammatory Bowel Diseases CY SEP 01-03, 2005 CL Munster, GERMANY SP Crohns & Colitis Fdn Amer, German Res Council, BAXTER, BRAUM, CENTOCOR, ESSEX, FALK, ABBOTT, ALTANA, AstraZeneca, Bayer Vital, Eisai, Ferring, Forderkre Univ Munster, Fresenius, Fujinon GmbH, Immundiagnostik, Medinal Medizinprodukte GmbH, Miltenyi Biotec, MSD Sharp & Dohme, New England Biolabs/Cell Signalling Technol, Novartis, Schering, Sigma Tau, UCB Celltech, Wyeth Pharma DE innate immunity; inflammatory bowel diseases; resident microflora; host defense; intestinal epithelium; therapy ID SODIUM-INDUCED COLITIS; EPITHELIAL-CELLS; BOWEL-DISEASE; CROHNS-DISEASE; BACTERIAL FLAGELLIN; ULCERATIVE-COLITIS; DENDRITIC CELLS; PROTEIN-KINASE; RESPONSES; MICE AB This review discusses the current progress in the understanding of how commensal-mediated activation of toll-like receptors (TLRs) may be involved in the regulation of physiological and pathophysiological processes of the intestinal mucosa including tissue regeneration and inflammation. While regulation of TLRs and their downstream signaling mediators might be used to prevent and treat inflammatory bowel diseases, paradoxically, at this time, it remains uncertain whether this would be more effectively accomplished by enhancing or inhibiting these pathways. C1 Univ Hosp Essen, Div Gastroenterol & Hepatol, Inst Grp 1, D-45147 Essen, Germany. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Study Inflammatory Bowel Dis,Gastrointestinal, Boston, MA 02114 USA. RP Cario, E (reprint author), Univ Hosp Essen, Div Gastroenterol & Hepatol, Inst Grp 1, Virchowstr 171, D-45147 Essen, Germany. EM elke.cario@uni-due.de NR 45 TC 24 Z9 24 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 1-57331-568-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2006 VL 1072 BP 332 EP 338 DI 10.1196/annals.1326.006 PG 7 WC Gastroenterology & Hepatology; Immunology; Multidisciplinary Sciences SC Gastroenterology & Hepatology; Immunology; Science & Technology - Other Topics GA BFD22 UT WOS:000241134900029 PM 17057213 ER PT J AU Windbichler, M Echtenacher, B Takahashi, K Ezekowitz, RAB Schwaeble, WJ Jensenius, JC Mannel, DN AF Windbichler, Michaela Echtenacher, Bernd Takahashi, Kazue Ezekowitz, R. Alan B. Schwaeble, Wilhelm J. Jensenius, Jens C. Maennel, Daniela N. TI Investigations on the involvement of the lectin pathway of complement activation in anaphylaxis SO INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY LA English DT Article DE mannan-binding lectin; mast cells; anaphylactic shock; proteoglycans; chondroitin sulphate ID MANNAN-BINDING LECTIN; MAST-CELLS; DEFICIENT MICE; SYSTEMIC-ANAPHYLAXIS; SERUM COMPLEMENT; EPITHELIAL-CELLS; IMMUNE DEFENSE; FACTOR-B; HEPARIN; IGE AB Background: Systemic anaphylaxis is the most severe form of immediate hypersensitivity reaction. The activation of the complement system occurs during anaphylactic shock. The purpose of this study was to determine in a mouse model whether the lectin pathway of complement activation is involved in anaphylaxis. Methods: To see whether the lectin pathway is involved in anaphylactic shock, serum mannan-binding lectin (MBL) levels were measured after passive anaphylaxis. Also MBL expression and binding to potential ligands were investigated. To determine whether complement or mast cell activation is essential for hypothermia in anaphylactic shock, mouse strains deficient in MBL-A and MBL-C, C1q, factors B and C2, C5, C5aR, or mast cells were tested. Results: After antigenic challenge a marked drop in body temperature as well as a rapid decrease in serum MBIL levels were observed. The decrease of serum MBL levels in shock could not be attributed to MBL binding to immune complexes or tissues, but an interaction of MBL with mast cell-derived proteoglycans was seen. In contrast to mast cell-deficient mice, none of the complement-deficient mouse strains were protected from shock-associated hypothermia. Conclusions: These results indicate that neither MBL nor activation of the complement cascade is crucial for the induction of anaphylaxis. In contrast mast cell activation is associated with the development of hypothermia and possibly the observed decrease in serum MBL levels. Copyright (c) 2006 S. Karger AG, Basel. C1 Univ Regensburg, Inst Immunol, D-8400 Regensburg, Germany. Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat,Lab Dev Immunol, Cambridge, MA 02138 USA. Univ Aarhus, Dept Med Microbiol & Immunol, DK-8000 Aarhus C, Denmark. RP Mannel, DN (reprint author), Univ Regensburg, Inst Immunol, D-8400 Regensburg, Germany. EM daniela.maennel@klinik.uni-regensburg.de NR 49 TC 3 Z9 4 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-2438 J9 INT ARCH ALLERGY IMM JI Int. Arch. Allergy Immunol. PY 2006 VL 141 IS 1 BP 11 EP 23 DI 10.1159/000094177 PG 13 WC Allergy; Immunology SC Allergy; Immunology GA 075QF UT WOS:000239899600002 PM 16804320 ER PT J AU Swirski, FK D'Sa, A Kianpour, S Inman, MD Stampfli, MR AF Swirski, Filip K. D'Sa, Abigail Kianpour, Sussan Inman, Mark D. Stampfli, Martin R. TI Prolonged ovalbumin exposure attenuates airway hyperresponsiveness and T cell function in mice SO INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY LA English DT Article DE airway hyperresponsiveness; Th2 cells; mouse; inflammation; chronic allergen challenge ID COLONY-STIMULATING FACTOR; INHALED ANTIGEN; MURINE MODEL; IMMUNE-RESPONSE; GM-CSF; IMMUNOLOGICAL-TOLERANCE; ALLERGIC SENSITIZATION; PULMONARY EOSINOPHILIA; INHALATION TOLERANCE; POLLEN IMMUNOTHERAPY AB Background: Continuous exposure of sensitized mice to an innocuous antigen, such as OVA, does not lead to chronic airway eosinophilia, but induces antigen unresponsiveness and resolution of the inflammatory response. In this study we explored mechanisms underlying attenuation of the airway inflammatory response, assessed whether the phenomenon is strain-specific, and determined its consequences to airway physiology. Methods: Mice were sensitized and exposed to OVA for two and four weeks. Analysis involved BAL, flow cytometry, adoptive transfer of OVA specific CD4 T cells, ex vivo cytokine expression and response to methacholine challenge. Results: Chronic exposure to antigen resulted in decreased eosinophilia in 5 different mouse strains. Likewise, numbers of lung CD4 T cells expressing activation and Th2 markers sharply declined following continuous OVA exposure. Transfer studies using OVA TcR transgenic cells revealed that the contraction of lung T cells included antigen-specific cells. Systemically, we observed a loss of Th2 memory effector function. Finally, we observed significantly attenuated airway hyper-responsiveness (AHR) in chronically exposed animals. Conclusions: Attenuation of airway eosinophilia in response to chronic OVA exposure is independent of genetic background. Airway eosinophilia, but not systemic responses, correlates with and is predictive for airway hyperresponsiveness. Our study contributes to the understanding of immune regulatory processes controlling antigen-driven airway inflammatory responses. Copyright (c) 2006 S. Karger AG, Basel. C1 McMaster Univ, Dept Pathol & Mol Med, Ctr Gene Therapeut, Hamilton, ON, Canada. McMaster Univ, Dept Med, Hamilton, ON, Canada. RP Swirski, FK (reprint author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, CNY 149,Room 5406, Charlestown, MA 02129 USA. EM fswirski@rics.bwh.harvard.edu NR 45 TC 10 Z9 12 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-2438 J9 INT ARCH ALLERGY IMM JI Int. Arch. Allergy Immunol. PY 2006 VL 141 IS 2 BP 130 EP 140 DI 10.1159/000094715 PG 11 WC Allergy; Immunology SC Allergy; Immunology GA 086NC UT WOS:000240679300005 PM 16864992 ER PT J AU Ahearn, EP Mussey, M Johnson, C Krohn, A Krahn, D AF Ahearn, EP Mussey, M Johnson, C Krohn, A Krahn, D TI Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE post-traumatic stress disorder; quetiapine ID BORDERLINE PERSONALITY-DISORDER; COMBAT-RELATED PTSD; MAJOR DEPRESSION; SELECTIVE ACTIVATION; ANXIOLYTIC ACTIVITY; OLANZAPINE; RISPERIDONE; RESISTANT; SYMPTOMS; SCALE AB This study evaluated the effectiveness of quetiapine for subjects with post-traumatic stress disorder (PTSD) who were already on a stable dose of a selective serotonin reuptake inhibitor (SSRI) but had significant PTSD symptoms. Fifteen subjects were enrolled in an 8-week open-label trial for PTSD in which quetiapine was added to an SSRI. Subjects were on a stable dose of the SSRI for at least 6 weeks before study entry and had a Clincian-Administered PTSD Scale (CAPS) score of greater than or equal to 50 at study baseline. The mean age of subjects was 49 years (eight men and seven women). The average duration of PTSD was 29 years, one-third of subjects had combat-related PTSD, and two-thirds had noncombat PTSD. The mean dose prescribed in the study was 216 mg per day. The initial median CAPS score was 80, indicating severe PTSD. The addition of a modest dose of quetiapine provided significant relief from PTSD symptoms with a 42% overall improvement in PTSD symptoms based on the CAPS and significant improvement along each dimension of symptoms: re-experiencing (Z = - 3.24, P = 0.0012), hyperarousal (Z = -3.30, P = 0.001) and avoidance (Z = -2.13, P = 0.03). Subjects rated themselves as 45% improved on average on the Davidson Trauma Scale and reported a 44% decrease in their level of disability and impairment as reflected by the Sheehan Disability Scale. Subjects with PTSD who had significant PTSD symptoms when on an SSRI benefited from the addition of quetiapine. Patients improved significantly on all three clusters of PTSD symptoms: re-experiencing, hyperarousal and avoidance. C1 Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. RP Ahearn, EP (reprint author), Univ Wisconsin, William S Middleton Mem Vet Hosp, 2500 Overlook Terrace, Madison, WI 53705 USA. EM eileen.ahearn@med.va.gov NR 52 TC 28 Z9 28 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0268-1315 J9 INT CLIN PSYCHOPHARM JI Int. Clin. Psychopharmacol. PD JAN PY 2006 VL 21 IS 1 BP 29 EP 33 DI 10.1097/01.yic.0000182116.49887.ae PG 5 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 996QK UT WOS:000234189100004 PM 16317314 ER PT J AU Petersen, T Iosifescu, DV Papakostas, GI Shear, DL Fava, M AF Petersen, T Iosifescu, DV Papakostas, GI Shear, DL Fava, M TI Clinical characteristics of depressed patients with cornorbid diabetes mellitus SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE clinical characteristics; diabetes; major depressive disorder; medical comorbidity ID PLACEBO-CONTROLLED TRIAL; GLYCEMIC CONTROL; PSYCHIATRIC-DISORDERS; RATING-SCALE; DOUBLE-BLIND; PREVALENCE; SYMPTOMS; QUESTIONNAIRE; METAANALYSIS; THERAPY AB Both diabetes and depression are highly prevalent. Patients with diabetes experience higher rates of depression compared to the general population. When present, depression is associated with an increase in the morbidity and mortality of diabetes, suggesting the importance of treatment in this population. The objective of the present study was to characterize depressive characteristics in depressed patients with and without comorbid diabetes. Seventeen patients with type 1 or type 2 diabetes were drawn from outpatient clinical trials. Depressed patients without diabetes were identified from the same studies. Unpaired t-tests and multiple chi-square analyses were used to compare demographic and clinical characteristics between the samples. Diabetic patients in our sample were more depressed and reported lower levels of somatic well-being and contentment compared to non-diabetic patients. The samples did not differ significantly along other dimensions of depression, including course of illness, response to previous treatments and comorbid conditions. These findings suggest that depressed diabetic patients are more similar than not to non-diabetic depressed patients, although important differences exist. C1 Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. RP Petersen, T (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 15 Parkman St,WAC 812, Boston, MA 02114 USA. EM tpetersen@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 NR 39 TC 4 Z9 4 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0268-1315 J9 INT CLIN PSYCHOPHARM JI Int. Clin. Psychopharmacol. PD JAN PY 2006 VL 21 IS 1 BP 43 EP 47 DI 10.1097/01.yic.0000182122.36425.b1 PG 5 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 996QK UT WOS:000234189100006 PM 16317316 ER PT J AU Hong, O Ronis, DL Lusk, SL Kee, GS AF Hong, OiSaeng Ronis, David L. Lusk, Sally L. Kee, Gwang-Soog TI Efficacy of a computer-based hearing test and tailored hearing protection intervention SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE tailored intervention; computer-based; hearing protection; construction worker ID CONSTRUCTION WORKERS USE; HEALTH-PROMOTION MODEL; EXPERT-SYSTEM INTERVENTION; INDICATORS; BEHAVIORS; PEOPLE AB Advances in computer technology and accessibility enable researchers to provide individually tailored interventions for behavioral change. Using multimedia technology, this study developed and tested a computer-based heating test and a tailored intervention. The purpose of this study was to evaluate, using a randomized experimental design, the efficacy of the intervention to increase workers' use of hearing protection. The tailored intervention developed by the research team showed more significant short-term effect measured immediately after the intervention than the control intervention. For the long-term effect measured I year after the intervention, both tailored and control groups showed significant increase in their reported use (7% vs. 6%)from preintervention to postintervention, but no significant difference between the two groups. The change accomplished in this study was small progress toward the desired level of 100% use of hearing protection to prevent noise-induced hearing loss. This finding showed that changing workers' hearing protection behavior is difficult. C1 Univ Michigan, Occupat Hlth Nursing Program, Sch Nursing, Ann Arbor, MI 48109 USA. Univ Michigan, US Dept Vet Affairs, Ann Arbor, MI 48109 USA. RP Hong, O (reprint author), Univ Michigan, Occupat Hlth Nursing Program, Sch Nursing, 400 N Ingalls,Room 3182, Ann Arbor, MI 48109 USA. EM oshong@umich.edu FU NIOSH CDC HHS [5R01OH04034-01A1] NR 40 TC 16 Z9 17 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1070-5503 J9 INT J BEHAV MED JI Int. J. Behav. Med. PY 2006 VL 13 IS 4 BP 304 EP 314 DI 10.1207/s15327558ijbm1304_5 PG 11 WC Psychology, Clinical SC Psychology GA 137FF UT WOS:000244277700004 PM 17228988 ER PT J AU Bennett, GG Wolin, KY AF Bennett, Gary G. Wolin, Kathleen Y. TI Satisfied or unaware? Racial differences in perceived weight status SO INTERNATIONAL JOURNAL OF BEHAVIORAL NUTRITION AND PHYSICAL ACTIVITY LA English DT Article AB Background: Obesity is disproportionately prevalent among many racial/ethnic minority communities. The efficacy of weight control efforts in these groups may depend on individual's ability to accurately perceive their weight status. We examined whether racial/ethnic differences exist in weight status misperception among overweight adults. Methods: Nationally-representative data from the National Health and Nutrition Examination Survey (NHANES) 1999-2002 were examined. Participants included overweight and obese adult men (n = 3115) and women (n = 3437). Weight status misperception was identified among respondents who self-reported being "about the right weight/underweight." Results: Blacks (OR = 2.06, 95% CI: 1.71, 2.54) were twice as likely and Hispanics (OR = 1.70, 95% CI: 1.33, 2.17) were 70-percent more likely than Whites to misperceive their weight, in models adjusted for age, education, income, marital status, self-reported health, and self-reported medical diagnosis of overweight. Black overweight (OR = 2.03, 95% CI: 1.26, 3.26) and obese (OR = 3.56, 95% CI: 1.57, 8.11) women were considerably more likely to exhibit misperception compared to their White female counterparts. Odds of misperception were higher among overweight Black (OR = 2.20, 95% CI: 1.54, 3.15), Hispanic (OR = 1.89, 95% CI: 1.30, 2.75), and obese Black men (OR = 2.84, 95% CI: 1.54, 5.22), compared to White men. Conclusion: Weight status misperceptions among the overweight are more common among Blacks, and Hispanic men. The persistence of racial/ethnic differences after adjustment for medical diagnosis of overweight may suggest some resistance to physician weight counseling. Identifying strategies to correct weight status misperceptions status may be necessary to ensure the efficacy of clinical and public health obesity interventions conducted among these groups. C1 [Bennett, Gary G.] Harvard Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Bennett, Gary G.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Wolin, Kathleen Y.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. RP Bennett, GG (reprint author), Harvard Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. EM gbennett@hsph.harvard.edu; kwolin@northwestern.edu FU Dana-Farber/Harvard Cancer Center; NCI [3 R01 CA098864-02S1, R25 CA100600-01A1] FX G. Bennett is supported by an award from the Dana-Farber/Harvard Cancer Center and NCI # 3 R01 CA098864-02S1. K.Y. Wolin is supported by NCI R25 CA100600-01A1. NR 21 TC 45 Z9 45 U1 4 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1479-5868 J9 INT J BEHAV NUTR PHY JI Int. J. Behav. Nutr. Phys. Act. PY 2006 VL 3 AR 40 DI 10.1186/1479-5868-3-40 PG 5 WC Nutrition & Dietetics; Physiology SC Nutrition & Dietetics; Physiology GA V44TZ UT WOS:000209772600040 PM 17096859 ER PT J AU Ma, RYM Tam, TSM Suen, APM Yeung, PML Tsang, SW Chung, SK Thomas, MK Leung, PS Yao, KM AF Ma, RYM Tam, TSM Suen, APM Yeung, PML Tsang, SW Chung, SK Thomas, MK Leung, PS Yao, KM TI Secreted PDZD2 exerts concentration-dependent effects on the proliferation of INS-1E cells SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY LA English DT Article DE PDZD2; sPDZD2; pancreas; INS-1E; insulin ID INSULIN GENE-TRANSCRIPTION; PANCREATIC BETA-CELLS; STEM-CELLS; ORGANOGENESIS; ISLETS; DIFFERENTIATION; REPRESSION; ENDOCRINE AB PDZD2 (PDZ domain containing 2) is a multi-PDZ protein expressed in pancreas and many other tissues. PDZD2 shows extensive homology to pro-interleukin-16 (pro-IL-16) and is localized mainly to the endoplasmic reticulum. We have recently demonstrated that PDZD2, like pro-IL-16, is proteolytically cleaved at its C-terminus to generate a secreted protein, sPDZD2 (for secreted PDZD2). To understand the possible functional role of PDZD2 in pancreas, we investigated the cellular distribution of PDZD2 in adult pancreas using an antiserum that recognizes both the full-length and secreted forms of PDZD2. Immunohistochemical analysis revealed a strong expression of PDZD2 in pancreatic islet P cells but not a cells. Consistent with the P-cell-enriched expression of PDZD2, immunoblot analysis indicated expression of both full-length PDZD2 and sPDZD2 in the insulinoma cell line INS-1E. A recombinant sPDZD2 protein was synthesized for study of its functional effect on INS-1E cells. In culture media with limiting serum, co-incubation with sPDZD2 stimulated the proliferation of INS-1E cells. The mitogenic effect of sPDZD2 was concentration-dependent, and was associated with a slight inhibition of the insulin promoter activity at high sPDZD2 concentrations. As a potential mitogen of P-like cells, sPDZD2 may be useful for the optimization of P-cell growth and differentiation in vitro. (c) 2005 Elsevier Ltd. All rights reserved. C1 Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China. Chinese Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China. Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China. Massachusetts Gen Hosp, Mol Endocrinol Lab, Boston, MA 02114 USA. Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Yao, KM (reprint author), Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China. EM kmyao@hkusua.hku.hk RI Yao, Kwok Ming/C-4457-2009; Leung, Po Sing/P-5758-2014 NR 24 TC 7 Z9 7 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1357-2725 J9 INT J BIOCHEM CELL B JI Int. J. Biochem. Cell Biol. PY 2006 VL 38 IS 5-6 BP 1015 EP 1022 DI 10.1016/j.biocel.2005.11.012 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 028YX UT WOS:000236525800031 PM 16413998 ER PT J AU Nakuci, E Xu, M Pujana, MA Valls, J ElShamy, WM AF Nakuci, E Xu, M Pujana, MA Valls, J ElShamy, WM TI Geminin is bound to chromatin in G2/M phase to promote proper cytokinesis SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY LA English DT Article DE geminin; cytokinesis; phosphorylation; cell cycle; mitotic checkpoint ID DNA-REPLICATION; CELL-CYCLE; PROTEIN GEMININ; PHOSPHORYLATION; PROGRESSION; INHIBITION; EXPRESSION; IDENTIFICATION; DEGRADATION; CYCLIN-B1 AB Previous studies suggested that geminin plays a vital role in both origin assembly and DNA re-replication during S-phase; however, no data to support a role for geminin in G2/M cells have been described. Here it is shown that in G2/M-phase, geminin participates in the promotion of proper cytokinesis. This claim can be supported through a series of observations. First, geminin in G2/M is loaded onto chromatin after it is tyrosine phosphorylated. It is unlike S-phase geminin that resides in the nuclear soluble fraction, where it is exclusively S/T phosphorylated. Secondly, on chromatin, geminin gets S/T phosphorylated in late G1; this modification causes the release of geminin from the chromatin. Cyclins bind and phosphorylate geminin in a sequential, cell cycle-dependent manner. These modifications correlated well with geminin departure from the chromatin. This suggests that cyclin functions to either release geminin from chromatin or at least keep it at bay until late S-phase. Thirdly, depletion of geminin from a diploid mammary epithelial cell line (HME) causes cells to arrest in late G2/M-phase. Massive serine-10 phosphorylated histone H3 staining and survivin localization to mid-body were observed; this suggests that they could be arrested in either mitosis or at cytokinesis. Finally, while in the absence of geminin, cyclin B1, chk1 and cdc7 are all over expressed. This paper will demonstrate that only cdc7 is important in maintaining the cytokinesis arrest in the absence of geminin. Only double depletion of geminin and cdc7 induce apoptosis. Our results taken together show, for the first time, that phosphorylation-induction activates oscillation of geminin between both nuclear soluble and chromatin compartments. Chromatin-bound geminin species functions to initiate or maintain proper cytokineses. In the absence of geminin, cells arrest in cytokinesis; this defines a novel checkpoint, monitored by cdc7, rather than cyclin B1 or chk1. (c) 2006 Elsevier Ltd. All rights reserved. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Catalan Inst Oncol, Dept Canc Epidemiol, Unit Biostat & Bioinformat, Barcelona 08907, Spain. RP ElShamy, WM (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM wael_elshamy@dfci.harvard.edu RI pujana, Miguel Angel/N-3127-2014 OI pujana, Miguel Angel/0000-0003-3222-4044 NR 45 TC 11 Z9 13 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1357-2725 J9 INT J BIOCHEM CELL B JI Int. J. Biochem. Cell Biol. PY 2006 VL 38 IS 7 BP 1207 EP 1220 DI 10.1016/j.biocel.2005.12.017 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 047VD UT WOS:000237905900020 PM 16487741 ER PT J AU Zhao, J Zhang, X Zhou, YL Ansell, PJ Klibanski, A AF Zhao, Jing Zhang, Xun Zhou, Yunli Ansell, Peter J. Klibanski, Anne TI Cyclic AMP stimulates MEG3 gene expression in cells through a cAMP-response element (CRE) in the MEG3 proximal promoter region SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY LA English DT Article DE MEG3; pituitary; promoter; cyclic AMP ID KINASE-A PATHWAY; MOUSE GTL2 GENE; REGULATED KINASE; CHROMOSOME 14; INDUCED INHIBITION; PITUITARY-TUMORS; IMPRINTED GENES; PROLIFERATION; GROWTH; RNA AB MEG3 is a human maternally expressed gene that potentially acts as a non-coding RNA. Our laboratory found that a cDNA isoform of MEG3, MEG3a, inhibits cell proliferation. MEG3 is highly expressed in the normal human pituitary but not expressed in clinically non-functioning pituitary tumors, suggesting that this imprinted gene may be involved in pituitary tumorigenesis. Previously we demonstrated that hypermethylation of the MEG3 promoter region is associated with the loss of MEG3 expression in pituitary tumors, potentially by blocking the binding of transcription factors to their cis-elements. To further investigate the cis- and trans-factors that are important for the regulation of MEG3, we have characterized the human MEG3 promoter. A single transcription initiation site was identified by 5' RACE. Up to 5 kb of the 5'-flanking region of MEG3 gene was cloned into a reporter plasmid. Deletion and mutation analysis suggest that a cAMP response element (CRE), located between -69 and -49 of the MEG3 proximal promoter region, is critical for promoter activity. Consistent with this finding, Northern blot analysis demonstrate that elevated intracellular cAMP levels stimulate MEG3 expression in human fibroblasts in culture. Furthermore, gel shifting, ChIP analysis, and co-transfection experiments show that CREB directly binds to the CRE site and stimulates MEG3 promoter activity. Therefore, MEG3 is a downstream target gene of cAMP. Together with the anti-proliferative function of cAMP, our data suggest that MEG3 may interact with the cAMP-dependent signaling pathway to be involved in the control of cell proliferation and other cAMP-related physiological functions. (c) 2006 Elsevier Ltd. All rights reserved. C1 Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Klibanski, A (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B,55 Fruit St, Boston, MA 02114 USA. EM aklibanski@partners.org FU NIDDK NIH HHS [R01-DK-40947] NR 45 TC 15 Z9 19 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1357-2725 J9 INT J BIOCHEM CELL B JI Int. J. Biochem. Cell Biol. PY 2006 VL 38 IS 10 BP 1808 EP 1820 DI 10.1016/j.biocel.2006.05.004 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 074HB UT WOS:000239802200019 PM 16793321 ER PT J AU Yan, X Shen, H Jiang, HJ Zhang, CS Hu, D Wang, J Wu, XQ AF Yan, Xin Shen, Hua Jiang, Hongjian Zhang, Chengsheng Hu, Dan Wang, Jun Wu, Xinqi TI External Qi of Yan Xin Qigong differentially regulates the Akt and extracellular signal-regulated kinase pathways and is cytotoxic to cancer cells but not to normal cells SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY LA English DT Article DE Akt; ERK1/2; external Qi; Yan Xin Qigong; pancreatic cancer ID EPIDERMAL-GROWTH-FACTOR; NF-KAPPA-B; PANCREATIC-CARCINOMA CELLS; FACTOR RECEPTOR; IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; K-RAS; ULTRASOUND; INHIBITION AB Long-term clinical observations and ongoing studies have shown significant antitumor effect of external Qi of Yan Xin Qigong which originated from traditional Chinese medicine. In order to understand the molecular and cellular mechanisms underlying the antitumor effect of external Qi of Yan Xin Qigong, we have examined its cytotoxic effect on BxPC3 pancreatic cancer cells and its effect on the Akt and extracellular signal-regulated kinase pathways. We found that external Qi of Yan Xin Qigong dramatically inhibited basal phosphorylation levels of Akt and extracellular signal-regulated kinases, epidermal growth factor-mediated phosphorylation of extracellular signal-regulated kinases, and phosphatidylinositol 3-kinase activity. External Qi of Yan Xin Qigong also inhibited constitutive and inducible activities of nuclear factor-kappa 13, a target of the Akt and epidermal growth factor receptor pathways. Furthermore, a single 5 min exposure of BxPC3 cells to external Qi of Yan Xin Qigong induced apoptosis, accompanied by a dramatic increase of the sub-G1 cell population, DNA fragmentation, and cleavage of caspases 3, 8 and 9, and poly(ADP-ribose) polymerase. Prolonged treatment with external Qi of Yan Xin Qigong caused rapid lysis of BxPC3 cells. In contrast, treatment of fibroblasts with external Qi of Yan Xin Qigong induced transient activation of extracellular signal-regulated kinases and Akt, and caused no cytotoxic effect. These findings suggest that external Qi of Yan Xin Qigong may differentially regulate these survival pathways in cancer versus normal cells and exert cytotoxic effects preferentially on cancer cells, and that it could potentially be a valuable approach for therapy of pancreatic carcinomas. (c) 2006 Elsevier Ltd. All rights reserved. C1 Inst Chongqing Trad Chinese Med, Chongqing, Peoples R China. New Med Sci Res Inst, New York, NY 10107 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA. RP Yan, X (reprint author), Inst Chongqing Trad Chinese Med, Chongqing, Peoples R China. EM smkj2006@yahoo.com RI Hu, Dan/D-9642-2015 NR 63 TC 17 Z9 18 U1 1 U2 31 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1357-2725 J9 INT J BIOCHEM CELL B JI Int. J. Biochem. Cell Biol. PY 2006 VL 38 IS 12 BP 2102 EP 2113 DI 10.1016/j.biocel.2006.06.002 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 095LQ UT WOS:000241309600012 PM 16893670 ER PT J AU Goggins, W Daniels, GH Tsao, H AF Goggins, W Daniels, GH Tsao, H TI Elevation of thyroid cancer risk among cutaneous melanoma survivors SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE thyroid cancer; cutaneous melanoma ID HIGH PREVALENCE; BRAF GENE; MALIGNANCIES; INSTABILITY; ACTIVATION; MUTATIONS; RET/PTC; BENIGN; NODULE AB Recent molecular studies have identified recurrent BRAF mutations in both cutaneous melanoma and thyroid malignancies. This relatively selective shared genetic vulnerability raises the possibility that these 2 tumors are connected through a common undisclosed pathogenic mechanism. To assess for possible associations between these 2 genetically related tumors at the population level, we calculated standardized incidence ratios (SIRs) for thyroid cancer (TC) among cutaneous melanoma (CM) survivors and CM among TC survivors using the National Cancer Institute's Surveillance, Epidemiology and End Result (SEER) database. Between 1973 and 2000, there were 73,274 and 27,138 cases of CM and TC cases, respectively. Overall, we found a 2.17-fold increase (P < 0.0000001) in the risk of TC after a diagnosis of CM. This augmented risk or TIC is somewhat higher for males, for those diagnosed more recently and for the first 3 years after the CM diagnosis. We also detected a considerably smaller and borderline significant increased risk of CM (25%, p = 0.063) among the post-TC survivors. Of note, TC patients who received radiation therapy had a 57% increased risk or a subsequent CM (p = 0.034). Our study documents a strong unilateral risk of TC after CM. More studies are clearly needed to better delineate this mechanism. (c) 2005 Wiley-Liss, Inc. C1 Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. Chinese Univ Hong Kong, Sch Publ Hlth, Ctr Biostat & Epidemiol, Hong Kong, Hong Kong, Peoples R China. Massachusetts Gen Hosp, Dept Med, Thyroid Unit, Boston, MA 02114 USA. Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Tsao, H (reprint author), Massachusetts Gen Hosp, Dept Dermatol, Bartlett 622,48 Blossom St, Boston, MA 02114 USA. EM htsao@partners.org NR 20 TC 16 Z9 16 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD JAN 1 PY 2006 VL 118 IS 1 BP 185 EP 188 DI 10.1002/ijc.21300 PG 4 WC Oncology SC Oncology GA 985KJ UT WOS:000233376000025 PM 16049985 ER PT J AU Vaidya, AP Littell, R Krasner, C Duska, LR AF Vaidya, AP Littell, R Krasner, C Duska, LR TI Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Article; Proceedings Paper CT Annual Meeting of the New-England-Association-of-Gynecologic-Oncologists CY JUN, 2004 CL Chatham, MA SP New England Assoc Gynecol Oncologists DE paclitaxel; platinum; serous endometrial cancer ID WHOLE ABDOMINOPELVIC IRRADIATION; ENDOMETRIAL CANCER-PATIENTS; OVARIAN-CANCER; CYCLOPHOSPHAMIDE; CISPLATIN; UPSC; DOXORUBICIN; SURVIVAL; TRIAL AB Uterine papillary serous carcinoma (UPSC) is more aggressive than endometrioid endometrial cancer, as it often presents with advanced disease and follows a pattern of spread that resemblesthe serous carcinoma of the ovary. There exists little data on evaluating the combination of carboplatin and paclitaxel in UPSC. Institutional Review Board permission was obtained for a retrospective review. Tumor registry search was used to identify all patients with UPSC from 1990 to 2003. Charts were retrospectively evaluated from patients who had received at least three cycles of carboplatin and paclitaxel as first-line chemotherapy. Only patients with histologically confirmed UPSC who were treated first line with carboplatin/paclitaxel chemotherapy were included. Nineteen patients with UPSC were identified, who were treated with carboplatin and paclitaxel in the first-line adjuvant setting after initial surgical cytoreduction. All patients received at least three cycles, with 12 of the 19 patients receiving six cycles. Five patients were treated with consolidation radiotherapy following first-line chemotherapy. Mean age was 69 years (range 55-88). The majority of patients had stage III disease (n = 11). Mean follow-up for the group was 29.5 months (7-76 months). A median progression-free interval of 12 months was seen across the entire cohort. Fourteen patients achieved a complete response following chemotherapy. The results of Gynecologic Oncology Group protocol 122 suggest that patients with advanced endometrial cancer have an improved progression-free survival when treated primarily with chemotherapy rather than radiation therapy. The results of our study show a high response rate to paclitaxel/carboplatin outpatient chemotherapy in a group of patients historically believed to have chemoresistant disease. Further prospective study of this regimen is planned. C1 Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Div Gynecol Oncol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA. RP Duska, LR (reprint author), Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Div Gynecol Oncol, 100 Blossom St,Cox 501, Boston, MA 02114 USA. EM lduska@partners.org NR 24 TC 23 Z9 25 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1048-891X J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PY 2006 VL 16 SU 1 BP 267 EP 272 DI 10.1111/j.1525-1438.2006.00413.x PG 6 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 025MH UT WOS:000236269900043 PM 16515602 ER PT J AU Morgello, S Holzer, CE Ryan, E Young, C Naseer, M Castellon, SA Frol, AB Atkinson, JH Gelman, BB Grant, I Singer, EJ AF Morgello, S. Holzer, C. E., III Ryan, E. Young, C. Naseer, M. Castellon, S. A. Frol, A. B. Atkinson, J. Hampton Gelman, B. B. Grant, I. Singer, E. J. TI Interrater reliability of the psychiatric research interview for substance and mental disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium SO INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH LA English DT Article DE interrater reliability; PRISM; HIV ID HUMAN-IMMUNODEFICIENCY-VIRUS; STRUCTURED CLINICAL INTERVIEW; TEST-RETEST RELIABILITY; MOOD DISORDERS; HOMOSEXUAL MEN; DRUG-USERS; PSYCHOPATHOLOGY; AIDS; PREVALENCE; VALIDITY AB The interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders (PRISM) was assessed in a multicentre study. Four sites of the National NeuroAIDS Tissue Consortium performed blinded reratings of audio-taped PRISM interviews of 63 HIV-infected patients. Diagnostic modules for substance-use disorders and major depression were evaluated. Seventy-six per cent of the patient sample displayed one or more substance-use disorder diagnoses and 54% had major depression. Kappa coefficients for lifetime histories of substance abuse or dependence (cocaine, opiates, alcohol, cannabis, sedative, stimulant, hallucinogen) and major depression ranged from 0.66 to 1.00. Overall the PRISM was reliable in assessing both past and current disorders except for current cannabis disorders when patients had concomitant cannabinoid prescriptions for medical therapy. The reliability of substance-induced depression was poor to fair although there was a low prevalence of this diagnosis in our group. We conclude that the PRISM yields reliable diagnoses in a multicentre study of substance-experienced, HIV-infected individuals. Copyright (c) 2006 John Wiley & Sons, Ltd. C1 Mt Sinai Sch Med, New York, NY USA. Univ Texas, Med Branch, Galveston, TX 77550 USA. Univ Calif San Diego, San Diego, CA 92103 USA. Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Texas, SW Med Ctr, Dallas, TX 75230 USA. VA San Diego Healthcare Syst, San Diego, CA USA. RP Morgello, S (reprint author), Mt Sinai Med Ctr, Box 1134,1 Gustave L Levy Pl, New York, NY 10029 USA. EM susan.morgello@mssm.edu FU NCRR NIH HHS [M01-RR-00071]; NIMH NIH HHS [R24MH59745, R24MH59724]; NINDS NIH HHS [R24NS38841, R24NS45491] NR 27 TC 22 Z9 22 U1 5 U2 5 PU WHURR PUBLISHERS LTD PI LONDON PA 19B COMPTON TERRACE, LONDON N1 2UN, ENGLAND SN 1049-8931 J9 INT J METH PSYCH RES JI Int. J. Methods Psychiatr. Res. PY 2006 VL 15 IS 3 BP 131 EP 138 DI 10.1002/mpr.189 PG 8 WC Psychiatry SC Psychiatry GA 087JX UT WOS:000240739800004 PM 17019897 ER PT J AU Mannino, DM Mott, J Ferdinands, JM Camargo, CA Friedman, M Greves, HM Redd, SC AF Mannino, DM Mott, J Ferdinands, JM Camargo, CA Friedman, M Greves, HM Redd, SC TI Boys with high body masses have an increased risk of developing asthma: findings from the National Longitudinal Survey of Youth (NLSY) SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE asthma; body mass index; children ID PULMONARY-FUNCTION; SWEDISH TEENAGERS; WEIGHT-GAIN; OBESITY; CHILDREN; INDEX; ASSOCIATION; ADULTS; POPULATION; OVERWEIGHT AB Objective: To determine the relation between body mass index and the development of asthma in children. Design: Prospective study of 4393 asthma-free children followed for up to 14 years. Setting: Children of participants in the National Longitudinal Survey of Youth. Methods: Analysis was limited to children who were followed from birth and were asthma-free during the first 24 months of life. The outcome was the development of asthma during follow-up (incident asthma). Body mass index (BMI) was our main predictor of interest. Survival analyses, using time to development of asthma as the main endpoint, were stratified by sex and controlled for race/ethnicity, poverty status, and prenatal maternal smoking. Results: Asthma developed in 218 (5.0%) children during the follow-up period. The relation between BMI and incident asthma varied by sex. A BMI >= 85th percentile at age 2-3 years was a risk factor for subsequent asthma development in boys ( hazard ratio (HR) 1.6 95% confidence interval (CI) 1.1, 2.4) but not girls (HR 0.8, 95% CI 0.5, 1.4). Similarly, boys with BMIs always >= 85th percentile were at increased risk for subsequent asthma development ( HR 2.4, 95% CI 1.4, 4.4) but not girls (HR 1.5, 95% CI 0.7, 2.9). Conclusion: Boys with high body masses may be at an increased risk for developing asthma. C1 Univ Kentucky, Med Ctr, Div Pulm Crit Care & Sleep Med, Lexington, KY 40536 USA. Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Air Pollut & Resp Hlth Branch, Atlanta, GA USA. Harvard Univ, Sch Med, EMNet Coordinating Ctr, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Mannino, DM (reprint author), Univ Kentucky, Med Ctr, Div Pulm Crit Care & Sleep Med, 740 S Limestone,K 528, Lexington, KY 40536 USA. EM dmannino@uky.edu OI Mannino, David/0000-0003-3646-7828 NR 43 TC 101 Z9 105 U1 1 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD JAN PY 2006 VL 30 IS 1 BP 6 EP 13 DI 10.1038/sj.ijo.0803145 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 992SQ UT WOS:000233904700003 PM 16344843 ER PT J AU Lu, S Ren, CX Liu, Y Epner, DE AF Lu, S Ren, CX Liu, Y Epner, DE TI PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells SO INTERNATIONAL JOURNAL OF ONCOLOGY LA English DT Article DE prostate cancer; androgen receptor; androgen-independent growth; signal transduction ID INHIBITOR P21 GENE; RECEPTOR GENE; DEPRIVATION THERAPY; PROGNOSTIC-SIGNIFICANCE; FREQUENT INACTIVATION; PROGRAMMED DEATH; TYROSINE KINASE; BETA-CATENIN; AKT ACTIVITY; PROTEIN AB The purpose of this study is to investigate the role of PI3K-Akt signaling in prostate cancer cell growth and androgen receptor (AR)-mediated gene expression. Androgen-dependent LNCaP cells and their androgen-independent counterpart, LNCaP-AI cells, were used. We found that PI3K-Akt signaling is elevated in LNCaP-AI cells compared to that in LNCaP cells and is involved in androgen-independent growth. More importantly, PI3K-Akt signaling enhances AR activity and is involved in the induction of AR target genes, such as p21(WAF/CIP), a gene with anti-apoptosis activity and associated with androgen-independent growth in human prostate cancer. A receptor tyrosine kinase inhibitor also inhibits the PI3K-Akt signaling and compromises AR activity and cell growth. These findings suggest that the PI3K-Akt cell growth survival pathway and its downstream-regulated gene, p21(WAF/CIP), are targets for developing novel therapies against prostate cancer, especially those androgen-independent diseases. C1 Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX 77030 USA. RP Lu, S (reprint author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 231 Albert Sabin Way,POB 670529, Cincinnati, OH 45267 USA. EM shan.lu@uc.edu NR 59 TC 27 Z9 29 U1 0 U2 1 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1019-6439 J9 INT J ONCOL JI Int. J. Oncol. PD JAN PY 2006 VL 28 IS 1 BP 245 EP 251 PG 7 WC Oncology SC Oncology GA 996UU UT WOS:000234201400028 PM 16328002 ER PT J AU Zimmermann, CE Troulis, MJ Kaban, LB AF Zimmermann, CE Troulis, MJ Kaban, LB TI Pediatric facial fractures: recent advances in prevention, diagnosis and management (vol 35, pg 2, 2006) SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Correction ID MOTOR-VEHICLE COLLISIONS; RIGID PLATE FIXATION; CHILD RESTRAINT LAW; MANDIBULAR FRACTURES; MAXILLOFACIAL TRAUMA; CONDYLAR FRACTURES; BONE-FRACTURES; CRANIOFACIAL SURGERY; MIDFACIAL FRACTURES; INJURIES AB During the last 25 years, there have been considerable advances in the prevention, diagnosis and management of craniomaxillofacial injuries in children. When compared to adults, the pattern of fractures and frequency of associated injuries are similar but the overall incidence is much lower. Diagnosis is more difficult than in adults and fractures are easily overlooked. Clinical diagnosis is best confirmed by computed tomographic (CT) scans. Treatment is usually performed without delay and can be limited to observation or closed reduction in non-displaced or minimally displaced fractures. Operative management should involve minimal manipulation and may be modified by the stage of skeletal and dental development. Open reduction and rigid internal fixation is indicated for severely displaced fractures. Primary bone grafting is preferred over secondary reconstruction and alloplastic materials should be avoided when possible. Children require long-term follow-up to monitor potential growth abnormalities. This article is a review of the epidemiology, diagnosis and management of facial fractures in children. C1 Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. RP Kaban, LB (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, 55 Fruit St, Boston, MA 02114 USA. EM LKaban@partners.org NR 138 TC 7 Z9 7 U1 1 U2 2 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0901-5027 J9 INT J ORAL MAX SURG JI Int. J. Oral Maxillofac. Surg. PD JAN PY 2006 VL 35 IS 1 BP 1 EP 13 DI 10.1016/j.ijom.2005.06.015 PG 13 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA 997QW UT WOS:000234262800001 ER PT J AU Mendez, MF AF Mendez, Mario F. TI The accurate diagnosis of early-onset dementia SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE dementia; Alzheimer's disease; vascular dementia; frontotemporal dementia; traumatic brain injury ID ISCHEMIC VASCULAR DEMENTIA; ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; PRESENILE-DEMENTIA; PREVALENCE; FEATURES; POPULATION; CRITERIA; HEALTH; ASCERTAINMENT AB Early-onset dementia (EOD, < 65 years at onset) is a relatively common and frequently misdiagnosed condition. One reason for misdiagnosis is that EOD has a more varied differential diagnosis than late-onset dementia (LOD). For example, Alzheimer's disease (AD), the preponderant LOD, makes up only about one-third of EODs; the rest are due to vascular dementias, frontotemporal lobar degenerations, traumatic head injury, alcohol-related dementia, and a great many other conditions. Another reason for misdiagnosis is that early-onset AD may have predominant cognitive deficits other than memory loss and a potential familial inheritance with spastic paraparesis, seizures, or myoclonus. A third reason is that EOD often presents with neuropsychiatric features out-of-proportion to any cognitive deficits. Despite these obstacles, it is important to accurately diagnose EODs, particularly because they differ in management and course. Clinicians can successfully diagnose most EODs with careful cognitive and family histories, mental status and neurological examinations, and neuroimaging. C1 VA Greater Los Angeles Healthcare Syst, Neurobiol Unit, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Syst, Neurobiol Unit, 116AF,Bldg 500,3S,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu NR 50 TC 57 Z9 57 U1 4 U2 17 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2006 VL 36 IS 4 BP 401 EP 412 DI 10.2190/Q6J4-R143-P630-KW41 PG 12 WC Psychiatry SC Psychiatry GA 150VY UT WOS:000245248900002 PM 17407994 ER PT J AU Kinnunen, T Haukkala, A Korhonen, T Quiles, ZN Spiro, A Garvey, AJ AF Kinnunen, Taru Haukkala, Ari Korhonen, Tellervo Quiles, Zandra N. Spiro, Avron, III Garvey, Arthur J. TI Depression and smoking across 25 years of the normative aging study SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE depressive symptoms; smoking cessation; smoking; males ID CIGARETTE-SMOKING; MAJOR DEPRESSION; UNITED-STATES; CESSATION; DISEASE; PREVALENCE; SYMPTOMS; TRENDS; RISK AB Objective: The majority of past findings indicate that smokers are more likely than non-smokers to report depressive symptoms and that depression may act as an impediment to smoking cessation. The aim of the present study is to examine the stability of the relationship between depressive symptoms and smoking status and to determine whether the presence of depressive symptoms predicts continued smoking. Methods Subjects were initially healthy men (n = 2208) from the Veterans Administration Normative Aging Study, an ongoing cohort of older men who have been re-assessed every 3-5 years for a period of 25 years. Depressive symptoms measures employed were the Cornell Medical Index, the MMPI-2 Content Depression Scale, and the Center for Epidemiological Studies Depression Scale. Results: Depression scores were higher among continuing smokers compared to never and former smokers and those who quit after entering the study. None of the three depressive symptoms measures were associated with decreased likelihood of smoking cessation. The change in MMPI-2 depression scores observed in a 4-year follow-up was the same among those who quit and those who remained smokers. Conclusions: Higher prevalence of depressive symptoms among male smokers is stable across time and is likely to contribute to higher morbidity and mortality among these smokers. However, presence of depressive symptoms did not have a significant impact on smoking cessation. C1 Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, Boston, MA 02115 USA. Univ Helsinki, FIN-00014 Helsinki, Finland. CUNY Herbert H Lehman Coll, New York, NY USA. VA Boston Healthcare Syst, Boston, MA USA. Boston Univ, Boston, MA 02215 USA. RP Kinnunen, T (reprint author), Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, 188 Longwood Ave, Boston, MA 02115 USA. EM taru_kinnunen@hms.harvard.edu OI Korhonen, Tellervo/0000-0003-2838-3085; Haukkala, Ari/0000-0001-8567-1548 FU NIDA NIH HHS [DA 10073] NR 32 TC 30 Z9 30 U1 1 U2 4 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2006 VL 36 IS 4 BP 413 EP 426 DI 10.2190/G652-T403-73H7-2X28 PG 14 WC Psychiatry SC Psychiatry GA 150VY UT WOS:000245248900003 PM 17407995 ER PT J AU Alexander, BM Kachnic, LA Willett, CG Fernandez-del Castillo, C Warshaw, AL Blaszkowsky, LS Ryan, DP Clark, JW Niemierko, A Hong, TS AF Alexander, B. M. Kachnic, L. A. Willett, C. G. Fernandez-del Castillo, C. Warshaw, A. L. Blaszkowsky, L. S. Ryan, D. P. Clark, J. W. Niemierko, A. Hong, T. S. TI Adjuvant therapy for invasive intraductal papillary mucinous neoplasms of the pancreas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Univ, Radiat Oncol Program, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Duke Univ, Dept Radiat Oncol, Durham, NC USA. Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Hematol & Med Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2099 BP S264 EP S265 DI 10.1016/j.ijrobp.2006.07.503 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601045 ER PT J AU Allen, AM Mentzer, S Sugarbaker, DJ Mamon, H Baldini, EH Soto, R Rabin, M Janne, PA Bueno, R AF Allen, A. M. Mentzer, S. Sugarbaker, D. J. Mamon, H. Baldini, E. H. Soto, R. Rabin, M. Janne, P. A. Bueno, R. TI Preoperative chemoradiotherapy does not increase the risk of complications for pneumonectomy in non-small-cell lung cancer patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 1035 BP S149 EP S150 DI 10.1016/j.ijrobp.2006.07.300 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600250 ER PT J AU Bellon, JR Gover, MT Keshaviah, A Wong, JS Harris, JR AF Bellon, J. R. Gover, M. T. Keshaviah, A. Wong, J. S. Harris, J. R. TI Is local recurrence increased with the use of a heart block in radiation therapy for breast cancer? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2019 BP S220 EP S220 DI 10.1016/j.ijrobp.2006.07.421 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600370 ER PT J AU Chakravarti, A Berkey, B Robins, HI Guha, A Curran, W Brachman, D Shultz, C Mehta, M AF Chakravarti, A. Berkey, B. Robins, H. I. Guha, A. Curran, W. Brachman, D. Shultz, C. Mehta, M. TI An update of phase II results from RTOG 0211: A phase I/II study of Gefitinib plus radiation for newly-diagnosed glioblastoma patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Amer Coll Radiol, Philadelphia, PA USA. Univ Wisconsin, Madison, WI USA. Univ Toronto, Toronto, ON, Canada. Thomas Jefferson Med Coll, Philadelphia, PA USA. Fdn Canc Res, Phoenix, AZ USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 149 BP S83 EP S84 DI 10.1016/j.ijrobp.2006.07.180 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600141 ER PT J AU Chambers, MS Hodge, K Holland, J Jones, C Vitti, R Garden, AS Haddad, RI AF Chambers, M. S. Hodge, K. Holland, J. Jones, C. Vitti, R. Garden, A. S. Haddad, R. I. TI A phase III, open-label, long-term safety study of cevimeline hydrochloride in patients with xerostomia secondary to radiation therapy for cancer in the head and neck region SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Commonwealth Ear Nose & Throat, Louisville, KY USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Radiol Associates Sacramento Med Grp Inc, Sacramento, CA USA. Daiichi Pharmaceut Co, Montvale, NJ USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2377 BP S419 EP S420 DI 10.1016/j.ijrobp.2006.07.786 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601321 ER PT J AU Chan, AW Barker, FG Lopes, VV Martuza, R Loeffler, JS AF Chan, A. W. Barker, F. G. Lopes, V. V. Martuza, R. Loeffler, J. S. TI Comparison of fractionated stereotactic radiotherapy with proton radiosurgery for vestibular schwannoma: A risk-stratified analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 1119 BP S198 EP S199 DI 10.1016/j.ijrobp.2006.07.384 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600334 ER PT J AU Chang, AJ Suit, HD Paganetti, H AF Chang, A. J. Suit, H. D. Paganetti, H. TI Assessment of the relative biological effectiveness of clinical carbon ion beams SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2883 BP S709 EP S710 DI 10.1016/j.ijrobp.2006.07.1302 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602394 ER PT J AU Chawla, S Tarbell, N Hudson, M Schwartz, C Fisher, S Basu, S Muhs, A Kun, L Mauch, P Mendenhall, N AF Chawla, S. Tarbell, N. Hudson, M. Schwartz, C. Fisher, S. Basu, S. Muhs, A. Kun, L. Mauch, P. Mendenhall, N. TI Secondary bone and soft tissue sarcomas in children treated for Hodgkin lymphoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Univ Rochester, Rochester, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. St Jude Childrens Hosp, Memphis, TN 38105 USA. Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Florida, Med Ctr, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 204 BP S113 EP S114 DI 10.1016/j.ijrobp.2006.07.236 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600192 ER PT J AU Chen, AB Punglia, RS Kuntz, KM Mauch, PM Ng, AK AF Chen, A. B. Punglia, R. S. Kuntz, K. M. Mauch, P. M. Ng, A. K. TI Cost-effectiveness of lipid screening in Hodgkin's disease survivors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Univ, Radiat Oncol Program, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 168 BP S94 EP S95 DI 10.1016/j.ijrobp.2006.07.200 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600160 ER PT J AU Chen, RC Fidias, P Yock, TI Niemierko, A Ancukiewicz, M Hong, TS Wolfgang, JA Gurubhagavatula, S Choi, NC AF Chen, R. C. Fidias, P. Yock, T. I. Niemierko, A. Ancukiewicz, M. Hong, T. S. Wolfgang, J. A. Gurubhagavatula, S. Choi, N. C. TI Treatment-related pneumonitis after concurrent cisplatin/etoposide and thoracic radiation therapy in lung cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Radiat Oncol Program, Boston, MA USA. Massachusetts Gen Hosp, Ctr Canc, Ctr Thorac Canc, Boston, MA USA. Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. N Shore Med Ctr, Peabody, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2490 BP S483 EP S483 DI 10.1016/j.ijrobp.2006.07.901 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602002 ER PT J AU Chung, CS Trofimov, A Adams, J Kung, J Kirsch, D Yoon, S Doppke, K Bortfeld, T Delaney, T AF Chung, C. S. Trofimov, A. Adams, J. Kung, J. Kirsch, D. Yoon, S. Doppke, K. Bortfeld, T. Delaney, T. TI A comparison of 3D conformal proton therapy, intensity modulated proton therapy, and intensity modulated photon therapy for retroperitoneal sarcoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Radiat Oncol Program, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 207 BP S116 EP S116 DI 10.1016/j.ijrobp.2006.07.239 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600195 ER PT J AU Crowley, EM Kachnic, LA Mamon, HJ Ritter, MA Niemerko, A Yock, TI Choi, NC Hong, TS AF Crowley, E. M. Kachnic, L. A. Mamon, H. J. Ritter, M. A. Niemerko, A. Yock, T. I. Choi, N. C. Hong, T. S. TI Optimizing the cardiac and pulmonary dose in treatment planning for distal esophageal cancer: Does IMRT always produce the best plan? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2128 BP S281 EP S282 DI 10.1016/j.ijrobp.2006.07.532 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601074 ER PT J AU Czerminska, MA Schofield, D Hacker, FL Baldini, EH Allen, A AF Czerminska, M. A. Schofield, D. Hacker, F. L. Baldini, E. H. Allen, A. TI Restricted field IMRT dramatically enhances IMRT planning for mesothelioma patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2836 BP S680 EP S680 DI 10.1016/j.ijrobp.2006.07.1254 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602347 ER PT J AU D'Amico, AV Dedham, JW Crook, J Chen, M Goldhaber, SZ Lamb, DS Malone, S Ludgate, C Steigler, A Kantoff, PW AF D'Amico, A. V. Dedham, J. W. Crook, J. Chen, M. Goldhaber, S. Z. Lamb, D. S. Malone, S. Ludgate, C. Steigler, A. Kantoff, P. W. TI The influence of androgen suppression therapy for prostate cancer on the frequency and timing of a fatal myocardial infarction SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp Dana Farber, Boston, MA M4X 1K9 USA. Princess Margaret Hosp, Toronto, ON, Canada. Univ Connecticut, Storrs, CT 02115 USA. Brigham & Womens Hosp, Dana Farb, Boston, MA K1Y 4K7 USA. Ottawa Reg Canc Ctr, Ottawa, ON, Canada. Vancouver Isl Canc Ctr, Victoria, BC 02115, Canada. Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2239 BP S342 EP S343 DI 10.1016/j.ijrobp.2006.07.645 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601185 ER PT J AU DeLaney, TF Liebsch, NJ Spiro, IJ Kirsch, DG McManus, PA Adams, J Dean, S Hornicek, FJ Pedlow, FX Rosenberg, AE AF DeLaney, T. F. Liebsch, N. J. Spiro, I. J. Kirsch, D. G. McManus, P. A. Adams, J. Dean, S. Hornicek, F. J. Pedlow, F. X. Rosenberg, A. E. TI Proton radiotherapy for spine and paraspinal sarcomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 206 BP S115 EP S116 DI 10.1016/j.ijrobp.2006.07.238 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600194 ER PT J AU Efstathiou, JA Chen, M Renshaw, AA Loffredo, M D'Amico, AV AF Efstathiou, J. A. Chen, M. Renshaw, A. A. Loffredo, M. D'Amico, A. V. TI The influence of body mass index on PSA failure following androgen suppression and radiation therapy for localized prostate cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Connecticut, Storrs, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2309 BP S382 EP S382 DI 10.1016/j.ijrobp.2006.07.717 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601254 ER PT J AU Elshaikh, MA Kuban, D Levy, L Potters, L Blasko, J Beyer, D Zietman, A Moran, BJ Ciezki, J Zelefsky, MJ AF Elshaikh, M. A. Kuban, D. Levy, L. Potters, L. Blasko, J. Beyer, D. Zietman, A. Moran, B. J. Ciezki, J. Zelefsky, M. J. TI Long-term multi-institutional outcome and biochemical failure definition analysis of combined permanent brachytherapy with external beam radiation for prostate cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Univ Michigan, Ann Arbor, MI 48109 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. New York Prostate Inst, Oceanside, NY USA. Seattle Prostate Inst, Seattle, WA USA. Arizona Oncol Serv, Scottsdale, AZ USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Chicago Prostate Inst, Chicago, IL USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 101 BP S57 EP S58 DI 10.1016/j.ijrobp.2006.07.131 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600097 ER PT J AU Folkert, MR Chen, GTY AF Folkert, M. R. Chen, G. T. Y. TI Biological lung phantom for image-guided proton therapy validation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2514 BP S496 EP S496 DI 10.1016/j.ijrobp.2006.07.926 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602026 ER PT J AU Gerweck, LE Vijayappa, S Kurimasa, A Ogawa, K Chen, DJ AF Gerweck, L. E. Vijayappa, S. Kurimasa, A. Ogawa, K. Chen, D. J. TI Tumor cell radiosensitivity is the primary determinant of tumor response to radiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Tottori Univ, Tottori 680, Japan. Univ Texas, SW Med Ctr, Dallas, TX 75230 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2653 BP S573 EP S573 DI 10.1016/j.ijrobp.2006.07.1068 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602165 ER PT J AU Gierga, DP Turcotte, JC Riboldi, M Sharp, GC Jiang, SB Chen, GTY AF Gierga, D. P. Turcotte, J. C. Riboldi, M. Sharp, G. C. Jiang, S. B. Chen, G. T. Y. TI Comparison of target registration errors for multiple modalities in image-guided partial breast irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Polytechn Milan Univ, Milan, Italy. NR 0 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 186 BP S103 EP S104 DI 10.1016/j.ijrobp.2006.07.218 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600174 ER PT J AU Gunderson, LL Winter, KA Ajani, JA Pedersen, JE Benson, AB Thomas, CR Mayer, RJ Haddock, MG Willett, CG Rich, TA AF Gunderson, L. L. Winter, K. A. Ajani, J. A. Pedersen, J. E. Benson, A. B. Thomas, C. R. Mayer, R. J. Haddock, M. G. Willett, C. G. Rich, T. A. TI Intergroup RTOG 9811 phase III comparison of chemoradiation with 5-FU and mitomycin vs 5-FU and cisplatin for anal canal carcinoma: Impact on disease-free, overall and colostomy-free survival SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Mayo Clin Canc Ctr Arizona, Scottsdale, AZ USA. Radiat Therapy Oncol Grp, Philadelphia, PA USA. M D Anderson Canc Ctr, Houston, TX USA. Univ Alberta, Edmonton, AB, Canada. Northwestern Univ, Chicago, IL 60611 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mayo Clin Canc Ctr Rochester, Rochester, MN USA. Duke Univ, Med Ctr, Durham, NC USA. Univ Virginia, Med Ctr, Charlottesville, VA USA. NR 0 TC 6 Z9 6 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 43 BP S24 EP S24 DI 10.1016/j.ijrobp.2006.07.070 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600044 ER PT J AU Haddad, RI Ramoni, M Posner, M Watkins, B Fey, E Mookanamparambil, L Morgan, T Sonis, S AF Haddad, R. I. Ramoni, M. Posner, M. Watkins, B. Fey, E. Mookanamparambil, L. Morgan, T. Sonis, S. TI Use of peripheral blood monocytes (PBM) to define changes in gene expression associated with amifostine treatment and their association with oral mucositis (OM) in patients being treated with chemoradiotherapy for squamous cell carcinoma of the head and neck(SCCHN) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Partners Ctr Genet & Genom, Boston, MA USA. Biomodels LLC, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2378 BP S420 EP S420 DI 10.1016/j.ijrobp.2006.07.787 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601322 ER PT J AU Hanks, GE Bae, K Porter, AT Grignon, D Brereton, HD Venkatesan, VM Horwitz, EM Lawton, C Sandler, HM Shipley, WU AF Hanks, G. E. Bae, K. Porter, A. T. Grignon, D. Brereton, H. D. Venkatesan, V. M. Horwitz, E. M. Lawton, C. Sandler, H. M. Shipley, W. U. TI Ten year follow-up of RTOG 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Radiat Therapy Oncol Grp, Philadelphia, PA USA. McGill Univ, Hlth Ctr, Montreal, PQ, Canada. Wayne State Univ, Detroit, MI USA. NE Radiat Oncol Ctr, Scranton, PA USA. Univ Western Ontario, London, ON, Canada. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 22 BP S13 EP S13 DI 10.1016/j.ijrobp.2006.07.046 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600027 ER PT J AU Hoffman, KE Hong, TS Zietman, AL Russell, AH AF Hoffman, K. E. Hong, T. S. Zietman, A. L. Russell, A. H. TI Pelvic irradiation for rectal cancer is associated with a decreased risk of subsequent clinically detected prostate cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Univ, Radiat Oncol Program, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2232 BP S339 EP S339 DI 10.1016/j.ijrobp.2006.07.638 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601178 ER PT J AU Holloway, CL O'Farrell, DA Cormack, RA Viswanathan, AN AF Holloway, C. L. O'Farrell, D. A. Cormack, R. A. Viswanathan, A. N. TI Sigmoid dose delivered by high-dose-rate brachytherapy versus low-dose-rate brachytherapy for cervical cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 1061 BP S165 EP S165 DI 10.1016/j.ijrobp.2006.07.326 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600276 ER PT J AU Hong, TS Crowley, EM Tsai, HK Blake, MA Napolitano, BN Kachnic, LA AF Hong, T. S. Crowley, E. M. Tsai, H. K. Blake, M. A. Napolitano, B. N. Kachnic, L. A. TI A 3-dimensional CT-based atlas for radiation planning in gastric cancer: Target delineation and implications for treatment planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Boston Univ, Med Ctr, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2150 BP S294 EP S294 DI 10.1016/j.ijrobp.2006.07.555 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601096 ER PT J AU Horwitz, EM Levy, LB Martinez, AA Potters, L Beyer, DC Blasko, JC Sandler, HM Buskirk, SJ Zietman, AL Kuban, DA AF Horwitz, E. M. Levy, L. B. Martinez, A. A. Potters, L. Beyer, D. C. Blasko, J. C. Sandler, H. M. Buskirk, S. J. Zietman, A. L. Kuban, D. A. TI The post-treatment PSA bounce for prostate cancer patients treated with external beam RT or permanent brachytherapy alone is not biochemically or clinically significant: A multi-institutional pooled analysis of more than 7500 patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. MD Anderson Canc Ctr, Houston, TX USA. William Beaumont Hosp, Royal Oak, MI 48072 USA. New York Prostate Inst, Oceanside, NY USA. Arizona Oncol Serv, Scottsdale, AZ USA. Seattle Prostate Inst, Seattle, WA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Mayo Clin, Coll Med, Jacksonville, FL USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 1129 BP S205 EP S205 DI 10.1016/j.ijrobp.2006.07.394 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600344 ER PT J AU Hurwitz, MD Halabi, S Ou, SS McGinnis, LS Keuttel, MR DiBiase, SJ Smal, EJ AF Hurwitz, M. D. Halabi, S. Ou, S. S. McGinnis, L. S. Keuttel, M. R. DiBiase, S. J. Smal, E. J. TI Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate risk prostate cancer: An initial report of CALGB 99-809 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. CALGB, Ctr Stat, Durham, NC USA. SE Canc Control Consortium, Winston Salem, NC USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Univ Maryland, Med Ctr, Baltimore, MD 21201 USA. Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2230 BP S337 EP S338 DI 10.1016/j.ijrobp.2006.07.636 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601176 ER PT J AU James, S Lyatskaya, Y Soto, R Nissen, K Mamon, H Killoran, J Chin, L Allen, AM AF James, S. Lyatskaya, Y. Soto, R. Nissen, K. Mamon, H. Killoran, J. Chin, L. Allen, A. M. TI iGPS(infrared guided patient setup) dramatically improves port films for patient setup of lung cancer patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2517 BP S497 EP S497 DI 10.1016/j.ijrobp.2006.07.929 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602029 ER PT J AU Kachnic, L Tsai, HK Willins, J Kung, JH Feng, JK Shih, HA Hong, TS AF Kachnic, L. Tsai, H. K. Willins, J. Kung, J. H. Feng, J. K. Shih, H. A. Hong, T. S. TI Dose-painted intensity modulated radiation therapy for anal cancer: Dosimetric comparison and acute toxicity SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Boston Med Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2126 BP S280 EP S280 DI 10.1016/j.ijrobp.2006.07.530 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601072 ER PT J AU Katz, A Smith, BL Golshan, M Niemierko, A Kobayashi, W Gadd, M Specht, M Rizk, L Kelada, A Taghian, A AF Katz, A. Smith, B. L. Golshan, M. Niemierko, A. Kobayashi, W. Gadd, M. Specht, M. Rizk, L. Kelada, A. Taghian, A. TI Factors associated with involvement of four or more axillary nodes for sentinel lymph node positive patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 11 BP S6 EP S7 DI 10.1016/j.ijrobp.2006.07.025 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600016 ER PT J AU Katz, MS D'Amico, AV Cowan, JE Chan, JM Latini, DM Carroll, PR AF Katz, M. S. D'Amico, A. V. Cowan, J. E. Chan, J. M. Latini, D. M. Carroll, P. R. TI Association of statin and NSAID use and prostate cancer outcomes: Results from CaPSURE SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Paycon Ctr Canc Care, Concord, NH USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2231 BP S338 EP S338 DI 10.1016/j.ijrobp.2006.07.637 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601177 ER PT J AU Khor, L Bae, K Hammond, ME Pollack, A Venkatesan, V Rosenthal, SA Sandler, H Hanks, GE Shipley, WU Dicker, AP AF Khor, L. Bae, K. Hammond, M. E. Pollack, A. Venkatesan, V. Rosenthal, S. A. Sandler, H. Hanks, G. E. Shipley, W. U. Dicker, A. P. TI Cox-2 overexpression predicts prostate cancer outcome: An analysis of RTOG 92-02 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Radiat Therapy Oncol Grp, Philadelphia, PA USA. LDS Hosp, Salt Lake City, UT USA. Univ Western Ontario, London, ON, Canada. Radiol Associates Sacramento, Sacramento, CA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. NR 0 TC 0 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 1124 BP S202 EP S202 DI 10.1016/j.ijrobp.2006.07.389 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600339 ER PT J AU Kirsch, DG Santiago, PM Haigis, KM di Tomaso, E Takeuchi, O Korsmeyer, SJ Bronson, RT Jain, RK Jacks, T AF Kirsch, D. G. Santiago, P. M. Haigis, K. M. di Tomaso, E. Takeuchi, O. Korsmeyer, S. J. Bronson, R. T. Jain, R. K. Jacks, T. TI Utilizing mouse genetics to dissect the cellular target and molecular mechanism of acute and late toxicity of abdominal radiation therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. MIT, Cambridge, MA 02139 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Tufts Univ, Sch Vet Med, Boston, MA 02111 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2685 BP S590 EP S590 DI 10.1016/j.ijrobp.2006.07.1100 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602196 ER PT J AU Kleinberg, LR Eapen, S Hamilton, S Keller, S Forastiere, A Anne, P Benson, AB AF Kleinberg, L. R. Eapen, S. Hamilton, S. Keller, S. Forastiere, A. Anne, P. Benson, A. B. TI E1201: An eastern cooperative oncology group (ECOG) randomized phase II trial to measure response rate and toxicity of preoperative combined modality paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in adenocarcinoma of the esophagus SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA. Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Montefiore Hosp, Div Thorac Surg, Bronx, NY USA. Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA. Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA. Northwestern Univ, Div Hematol & Oncol, Chicago, IL 60611 USA. NR 0 TC 1 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 143 BP S80 EP S80 DI 10.1016/j.ijrobp.2006.07.174 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600135 ER PT J AU Landry, JC Catalano, P Hoffman, J Staley, C Harris, W Burtness, B Frontiera, MS Berlin, J Benson, A AF Landry, J. C. Catalano, P. Hoffman, J. Staley, C. Harris, W. Burtness, B. Frontiera, M. S. Berlin, J. Benson, A. TI ECOG 1200: A randomized phase II trial of gemcitabine plus radiotherapy vs gemcitabine, 5-Fluorouracil and cisplatin followed by radiotherapy and 5-Fluorouracil in patients with locally advanced, potentially resectable pancreatic adenocarcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Emory Univ, Atlanta, GA 30322 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Dean Med Ctr, Madison, WI USA. Vanderbilt Univ, Nashville, TN USA. Northwestern Univ, Chicago, IL 60611 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2111 BP S272 EP S272 DI 10.1016/j.ijrobp.2006.07.515 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601057 ER PT J AU Lawenda, BD Tokarz, VA Silverstein, JR Busse, PM Deschler, DG Baldini, EH Kachnic, LA AF Lawenda, B. D. Tokarz, V. A. Silverstein, J. R. Busse, P. M. Deschler, D. G. Baldini, E. H. Kachnic, L. A. TI Merkel cell carcinoma of the head and neck: Radiotherapy to the regional lymphatics appears to improve outcome SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Naval Med Ctr San Diego, San Diego, CA USA. Boston Univ, Med Ctr, Boston, MA USA. Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 1105 BP S190 EP S191 DI 10.1016/j.ijrobp.2006.07.370 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600320 ER PT J AU Liebsch, NJ Truong, M Lopes, VV Loeffler, JS Chan, AW AF Liebsch, N. J. Truong, M. Lopes, V. V. Loeffler, J. S. Chan, A. W. TI Conformal proton radiotherapy for primary sphenoid sinus malignancies SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2375 BP S418 EP S419 DI 10.1016/j.ijrobp.2006.07.784 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601319 ER PT J AU Liu, AK Marcus, KJ Fischl, B Grant, PE Poussaint, TY Rivkin, MJ Davis, P Tarbell, NJ Yock, TI AF Liu, A. K. Marcus, K. J. Fischl, B. Grant, P. E. Poussaint, T. Y. Rivkin, M. J. Davis, P. Tarbell, N. J. Yock, T. I. TI Changes in the cerebral cortex of children treated for medulloblastoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Radiat Oncol Program, Boston, MA USA. Childrens Hosp, Boston, MA 02115 USA. MGH, Martinos Ctr, Charlestown, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2575 BP S528 EP S529 DI 10.1016/j.ijrobp.2006.07.988 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602087 ER PT J AU Lopez, CA Michalski, JM Kuban, D Mahadevan, A Kaplan, ID Lee, SP Zietman, AL Suh, WW Dunn, RL Sandler, HM AF Lopez, C. A. Michalski, J. M. Kuban, D. Mahadevan, A. Kaplan, I. D. Lee, S. P. Zietman, A. L. Suh, W. W. Dunn, R. L. Sandler, H. M. TI Early complications following contemporary radiotherapy for prostate cancer in a multi-institutional study at high-volume health care centers in the United States SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Univ Michigan, Med Ctr, Ann Arbor, MI USA. Washington Univ, Sch Med, St Louis, MO USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Cleveland Clin, Cleveland, OH 44106 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2241 BP S344 EP S344 DI 10.1016/j.ijrobp.2006.07.647 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601187 ER PT J AU Lu, H Safai, S Schneider, R Adams, J Chen, Y Sharp, G Brett, R Kirsch, D Hong, T Delaney, T AF Lu, H. Safai, S. Schneider, R. Adams, J. Chen, Y. Sharp, G. Brett, R. Kirsch, D. Hong, T. Delaney, T. TI Respiratory-gated proton therapy treatment SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2734 BP S618 EP S619 DI 10.1016/j.ijrobp.2006.07.1150 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602245 ER PT J AU Mamon, HJ Hattangadi, J Yeap, B AF Mamon, H. J. Hattangadi, J. Yeap, B. TI Retrospective analysis of patients treated with adjuvant chemoradiation for pancreatic cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2141 BP S289 EP S289 DI 10.1016/j.ijrobp.2006.07.545 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601087 ER PT J AU Nedea, EA Spiro, IJ Suit, HD Gebhardt, MC Hornicek, FJ Mankin, HJ Rosenberg, AL Nemierko, A Goldberg, S Delaney, TF AF Nedea, E. A. Spiro, I. J. Suit, H. D. Gebhardt, M. C. Hornicek, F. J. Mankin, H. J. Rosenberg, A. L. Nemierko, A. Goldberg, S. Delaney, T. F. TI Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 211 BP S118 EP S118 DI 10.1016/j.ijrobp.2006.07.244 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600199 ER PT J AU Ng, AK Li, S Neuberg, D Silver, B Diller, L Mauch, PM AF Ng, A. K. Li, S. Neuberg, D. Silver, B. Diller, L. Mauch, P. M. TI Health practice in long-term survivors of Hodgkin's disease SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 169 BP S95 EP S95 DI 10.1016/j.ijrobp.2006.07.201 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600161 ER PT J AU Nguyen, PL Katz, AB Raad, RA Niemierko, A Rizk, LA Kelada, A Goldberg, SI Taghian, AG AF Nguyen, P. L. Katz, A. B. Raad, R. A. Niemierko, A. Rizk, L. A. Kelada, A. Goldberg, S. I. Taghian, A. G. TI Women with 10 years of recurrence-free survival following lumpectomy and radiation for invasive breast cancer continue to be at risk for subsequent relapse SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Radiat Oncol Program, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 14 BP S8 EP S8 DI 10.1016/j.ijrobp.2006.07.030 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600019 ER PT J AU Pan, CC Bae, K Hanks, GE Shipley, WU Roach, M Sandler, HM AF Pan, C. C. Bae, K. Hanks, G. E. Shipley, W. U. Roach, M. Sandler, H. M. TI Comparison of two types of biochemical failures within the ASTRO and Phoenix Consensus Definitions in patients treated on RTOG 92-02 and 94-13 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Univ Michigan, Ann Arbor, MI 48109 USA. Radiat Therapy Oncol Grp, Philadelphia, PA USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2196 BP S318 EP S318 DI 10.1016/j.ijrobp.2006.07.602 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601142 ER PT J AU Park, JL Cesaretti, JA Kao, J Stone, NN Stock, RG AF Park, J. L. Cesaretti, J. A. Kao, J. Stone, N. N. Stock, R. G. TI Vardenafil is more efficacious than tadalafil for patient's who requested an alternative to sildenafil following prostate brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 James J Peters Vet Adm, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2593 BP S540 EP S540 DI 10.1016/j.ijrobp.2006.07.1006 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602105 ER PT J AU Patel, AA Wolfgang, JA Niemierko, A Hong, TS Yock, T Choi, NC AF Patel, A. A. Wolfgang, J. A. Niemierko, A. Hong, T. S. Yock, T. Choi, N. C. TI Implications of respiratory motion as measured by 4D CT for radiation treatment planning of esophageal tumors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Radiat Oncol Program, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2715 BP S607 EP S607 DI 10.1016/j.ijrobp.2006.07.1131 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602226 ER PT J AU Pisansky, TM Bae, K Hanks, GE Shipley, WU Sandler, HM AF Pisansky, T. M. Bae, K. Hanks, G. E. Shipley, W. U. Sandler, H. M. TI Temporal profile of serum testosterone with goserelin use and cessation: Analysis of radiation therapy oncology group protocol 92-02 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Mayo Clin, Rochester, MN USA. Radiat Therapy Oncol Grp, Philadelphia, PA USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 65 BP S38 EP S38 DI 10.1016/j.ijrobp.2006.07.095 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600065 ER PT J AU Pollack, A Moughan, J Khor, L Al-Saleem, T Hammond, ME Venkatesan, V Rosenthal, SA Hanks, GE Shipley, W Sandler, H AF Pollack, A. Moughan, J. Khor, L. Al-Saleem, T. Hammond, M. E. Venkatesan, V. Rosenthal, S. A. Hanks, G. E. Shipley, W. Sandler, H. TI Bcl-2 and bax predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on RTOG 92-02 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Radiat Therapy Oncol Grp, Philadelphia, PA USA. LDS Hosp, Salt Lake City, UT USA. Univ Western Ontario, London, ON, Canada. Radiol Associates, Sacramento, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 1123 BP S201 EP S201 DI 10.1016/j.ijrobp.2006.07.388 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600338 ER PT J AU Punglia, RS Weeks, JC Neville, BA Earle, CC AF Punglia, R. S. Weeks, J. C. Neville, B. A. Earle, C. C. TI Response to clinical trial information: Use of radiation therapy after mastectomy between 1991-1999 in elderly women SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 165 BP S93 EP S93 DI 10.1016/j.ijrobp.2006.07.197 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221600157 ER PT J AU Rodrigues, NA Killion, L Silver, B Mauch, PM Ng, AK AF Rodrigues, N. A. Killion, L. Silver, B. Mauch, P. M. Ng, A. K. TI A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Radiat Oncol Program, Boston, MA USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2600 BP S543 EP S544 DI 10.1016/j.ijrobp.2006.07.1014 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602112 ER PT J AU Sher, DJ Posner, MR Norris, CM Haddad, RI Wirth, LJ Goguen, L Annino, D Court, L Allen, A Tishler, RB AF Sher, D. J. Posner, M. R. Norris, C. M. Haddad, R. I. Wirth, L. J. Goguen, L. Annino, D. Court, L. Allen, A. Tishler, R. B. TI Re-irradiation with IMRT for head and neck cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Radiat Oncol Program, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2440 BP S454 EP S455 DI 10.1016/j.ijrobp.2006.07.850 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601384 ER PT J AU Shih, HA Parodi, K Paganetti, H Michaud, S Loeffler, JS DeLaney, TF Liebsch, NJ Munzenrider, JE Fischman, AJ Bortfeld, T AF Shih, H. A. Parodi, K. Paganetti, H. Michaud, S. Loeffler, J. S. DeLaney, T. F. Liebsch, N. J. Munzenrider, J. E. Fischman, A. J. Bortfeld, T. TI Clinical feasibility of PET/CT image guidance after proton radiotherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2874 BP S704 EP S704 DI 10.1016/j.ijrobp.2006.07.1293 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602385 ER PT J AU Taussky, D Bae, K Bahary, J Roach, M Lawton, CA Shipley, WU Sandler, HM AF Taussky, D. Bae, K. Bahary, J. Roach, M. Lawton, C. A. Shipley, W. U. Sandler, H. M. TI Does testosterone influence radiation-induced toxicity in radiotherapy of the prostate? A secondary analysis of RTOG protocol 9413 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Univ Montreal, Dept Radiat Oncol, Montreal, PQ, Canada. RTOG, Dept Biostat, Philadelphia, PA USA. Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA. Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA. Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2215 BP S329 EP S330 DI 10.1016/j.ijrobp.2006.07.621 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601161 ER PT J AU Trofimov, A Nguyen, PL Coen, JJ Doppke, KP Schneider, RJ Adams, JA Bortfeld, TR Zietman, AL DeLaney, TF Shipley, WU AF Trofimov, A. Nguyen, P. L. Coen, J. J. Doppke, K. P. Schneider, R. J. Adams, J. A. Bortfeld, T. R. Zietman, A. L. DeLaney, T. F. Shipley, W. U. TI Treatment of prostate cancer with photon IMRT and proton therapy: a treatment planning comparison SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2321 BP S389 EP S390 DI 10.1016/j.ijrobp.2006.07.729 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601266 ER PT J AU Truong, M Liebsch, NJ Adams, JG Lopes, VV Loeffler, JS Chan, AW AF Truong, M. Liebsch, N. J. Adams, J. G. Lopes, V. V. Loeffler, J. S. Chan, A. W. TI Combined modality treatment with proton radiotherapy for locally advanced sinonasal squamous cell carcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2386 BP S424 EP S425 DI 10.1016/j.ijrobp.2006.07.795 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601330 ER PT J AU Tsai, HK Lie, S Ng, AK Silver, B Stevenson, MA Mauch, PM AF Tsai, H. K. Lie, S. Ng, A. K. Silver, B. Stevenson, M. A. Mauch, P. M. TI Role of radiation therapy in the treatment of stage I/II MALT lymphoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Radiat Oncol Program, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2524 BP S501 EP S502 DI 10.1016/j.ijrobp.2006.07.936 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602036 ER PT J AU Tuamokumo, N Truong, MT Hartford, AC Serrano, CM Kachnic, LA AF Tuamokumo, N. Truong, M. T. Hartford, A. C. Serrano, C. M. Kachnic, L. A. TI Dose effect relationship of postoperative radiation for the prevention of keloids SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Boston Univ, Med Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2540 BP S510 EP S510 DI 10.1016/j.ijrobp.2006.07.952 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221602052 ER PT J AU Weber, DC Miller, RC Taghian, A Hanssens, P Villa, S Ozsahin, M Mirimanoff, RO Nishioka, H Castadot, P Rutz, H AF Weber, D. C. Miller, R. C. Taghian, A. Hanssens, P. Villa, S. Ozsahin, M. Mirimanoff, R. O. Nishioka, H. Castadot, P. Rutz, H. TI Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: A retrospective study from the rare cancer network SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Univ Hosp Geneva, CH-1211 Geneva, Switzerland. Paul Scherrer Inst, Villigen, Switzerland. Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dr Bernard Verbeeten Inst, Tilburg, Netherlands. Inst Catala Oncol, Barcelona, Spain. CHU Vaudois, CH-1011 Lausanne, Switzerland. Tokyo Med Univ, Tokyo, Japan. Inst Jules Bordet, B-1000 Brussels, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2076 BP S252 EP S252 DI 10.1016/j.ijrobp.2006.07.479 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601022 ER PT J AU Zhang, M Ho, A Hammond, E Sause, W Pilepich, M Shipley, W Sandler, H Khor, L Pollack, A Chakravarti, A AF Zhang, M. Ho, A. Hammond, E. Sause, W. Pilepich, M. Shipley, W. Sandler, H. Khor, L. Pollack, A. Chakravarti, A. TI The prognostic value of survivin in locally advanced prostate cancer: A study based on RTOG 8610 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Amer Coll Radiol, Philadelphia, PA USA. LDS Hosp, Salt Lake City, UT USA. Univ Calif Los Angeles, Los Angeles, CA USA. Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2006 VL 66 IS 3 SU S MA 2210 BP S326 EP S327 DI 10.1016/j.ijrobp.2006.07.616 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 094EF UT WOS:000241221601156 ER PT J AU Pieters, RS Niemierko, A Fullerton, BC Munzenrider, JE AF Pieters, RS Niemierko, A Fullerton, BC Munzenrider, JE TI Cauda equina tolerance to high-dose fractionated irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article; Proceedings Paper CT 46th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 03-07, 2004 CL Atlanta, GA SP Amer Soc Therapeut Radiol & Oncol DE cauda equina; high-dose fractionated irradiation; proton; radiation morbidity; late effects AB Purpose: To report late neurologic toxicity rates and clinical outcomes for patients treated with high dose fractionated radiation therapy using three-dimensional treatment planning and combined proton and photon beams to portions of the cauda equina (L2-coccyx). Methods and Materials: Medical records of 53 patients treated to fields encompassing the cauda equina were reviewed for the onset of neurologic symptoms in the absence of local failure. All doses were normalized to equivalent dose delivered in 2-Gy fractions. Median cauda dose was 65.8 cobalt Gray equivalents (CGE) (range, 31.9-85.1). Median follow-up was 87 months (range, 14-217 months). Results: Nineteen patients experienced local recurrences, and 13 others had neurologic toxicity. A total of 54% (i.e., 7/13) of the toxicities occurred 5 years or more after treatment. Median caudal dose was 73.7 CGE in the group with neurologic toxicity, and 55.6 CGE in those without. On multivariate actuarial analysis, cauda dose and gender were statistically significant for neurotoxicity at p = 0.002 and p = 0.017, respectively. The estimated tolerance doses 5 years from treatment, TD 515 and TD 5015, were 55 CGE and 72 CGE, respectively, for males and 67 CGE and 84 CGE for females. The tolerance doses were about 8 CGE lower when estimated at 10 years from treatment. Disease-free survival rates at 5 and 10 years were 66% and 53%, respectively. Conclusions: This study suggests that the probability of neurotoxicity is a relatively steep function of dose to cauda equina (slope gamma(50) = approximately 3). The cauda equina tolerance is greater for females than males by about 11 CGE (at 2 CGE per fraction). Extended follow-up is necessary to accurately assess neurologic damage and then differentiate that phenomenon from local recurrence; the traditional 5-year assessment has limited meaning in this population. Local control remains an issue for these patients, even with the radical doses used. (c) 2006 Elsevier Inc. C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. RP Munzenrider, JE (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St,Cox 301, Boston, MA 02114 USA. EM jmunzenrider@partners.org FU NCI NIH HHS [CA21239, CA50628] NR 11 TC 23 Z9 24 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2006 VL 64 IS 1 BP 251 EP 257 DI 10.1016/j.ijrobp.2005.04.019 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 000DX UT WOS:000234442200035 PM 15993548 ER PT J AU Rosenberg, AE AF Rosenberg, AE TI Epithelioid Hemangioma of bone: a potentially metastasizing tumor? Expert commentary 2 SO INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY LA English DT Editorial Material ID ANGIOLYMPHOID HYPERPLASIA; HISTIOCYTOID HEMANGIOMA; VASCULAR TUMORS; EOSINOPHILIA; ANGIOSARCOMA; HEMANGIOENDOTHELIOMA; MIMICKING; DISEASE; GRADE; HEART C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol,James Homer Wright Labs, Boston, MA USA. RP Rosenberg, AE (reprint author), 55 Fruit St,Warren Bldg,Room 225, Boston, MA 02114 USA. NR 34 TC 1 Z9 1 U1 0 U2 0 PU WESTMINSTER PUBL INC PI GLEN HEAD PA 708 GLEN COVE AVE, GLEN HEAD, NY 11545 USA SN 1066-8969 J9 INT J SURG PATHOL JI Int. J. Surg. Pathol. PD JAN PY 2006 VL 14 IS 1 BP 17 EP 20 DI 10.1177/106689690601400104 PG 4 WC Pathology; Surgery SC Pathology; Surgery GA 009CC UT WOS:000235087700004 ER PT J AU Post, JB Wilkes, BM Michelis, MF AF Post, James B. Wilkes, Barry M. Michelis, Michael F. TI Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin SO INTERNATIONAL UROLOGY AND NEPHROLOGY LA English DT Article DE anemia iron-deficiency; chronic; dialysis; erythropoietin; ferritin; kidney failure ID CHRONIC-RENAL-FAILURE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; LEFT-VENTRICULAR HYPERTROPHY; HEMODIALYSIS-PATIENTS; MAINTENANCE HEMODIALYSIS; PREDIALYSIS PATIENTS; DIALYSIS PATIENTS; HEMATOCRIT LEVEL; SUPPLEMENTATION; ABSORPTION AB The prevalence of iron deficiency and its contribution to the anemia of end stage renal disease has been extensively studied, but much less is known about the role of iron deficiency in the pathogenesis of the anemia of chronic kidney disease in predialysis patients. All new hemodialysis patients entering a single hemodialysis unit between July 1999 and April 2002 were included in the study. The admission laboratory tests and the Health Care Financing Administration (HCFA) 2728 form were examined to determine the prevalence of erythropoietin use, anemia (Hb < 11 g/dl), and iron deficiency (ferritin < 100 ng/ml and transferrin saturation % < 20%). In a second part of the study, the effect of intravenous iron gluconate replacement in patients with stage III & IV chronic kidney disease was examined. Anemia was present in 68% of all patients starting hemodialysis. Iron deficiency was a common feature occurring in 29% of patients taking erythropoietin (49% of all patients) and 26% of patients without erythropoietin (51 % of all patients). Following the administration of intravenous iron gluconate to four patients, there was a significant rise in hemoglobin levels from 10.6 +/- 0.19 to 11.7 +/- g/dl (p=0.02). Conclusion: Iron deficiency is common in predialysis patients. Replenishing iron stores in anemic patients with chronic kidney disease significantly increases hemoglobin levels and should be considered as an integral part of the therapy for treating anemia in the predialysis population. C1 James J Peters Hosp, Dept Vet Affairs, Bronx, NY 10468 USA. Lenox Hill Hosp, Div Nephrol, New York, NY 10021 USA. RP Post, JB (reprint author), James J Peters Hosp, Dept Vet Affairs, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM james.post@med.va.gov OI Michelis, Michael F/0000-0003-4677-1559 NR 24 TC 8 Z9 12 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0301-1623 J9 INT UROL NEPHROL JI Int. Urol. Nephrol. PY 2006 VL 38 IS 3-4 BP 719 EP 723 DI 10.1007/s11255-006-0035-0 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 150KN UT WOS:000245215800070 PM 17106764 ER PT J AU Aiello, LP Clermont, A Arora, V Davis, MD Sheetz, MJ Bursell, SE AF Aiello, LP Clermont, A Arora, V Davis, MD Sheetz, MJ Bursell, SE TI Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID PROTEIN-KINASE-C; ENDOTHELIAL GROWTH-FACTOR; MACULAR EDEMA; LY333531; RATS; COMPLICATIONS; RETINOPATHY; PROGRESSION; ACTIVATION; MELLITUS AB PURPOSE. To assess ocular and systemic safety and pharmacodynamic effects of the oral PKC beta selective inhibitor ruboxistaurin (RBX; LY333531) mesylate in patients with diabetes. METHODS. This was a double-masked, placebo-controlled, parallel, randomized, single-center clinical study evaluating the effect of oral administration of RBX ( 8 mg twice a day, 16 mg per day, or 16 mg twice a day) or placebo for 28 days in patients with no or very mild diabetic retinopathy on mean retinal circulation time (RCT), retinal blood flow (RBF), treatment-emergent adverse events, and other safety parameters. RESULTS. Twenty-nine persons aged 18 to 65 years with type 1 or 2 diabetes were evaluated. The only treatment-emergent adverse event with a statistically significant difference among treatment groups was abdominal pain, which was more common in placebo-treated subjects ( P = 0.049). Statistically significant effects of RBX were observed on several hematologic and laboratory parameters, but values were within the normal reference range and none of the changes was deemed clinically meaningful. In patients receiving 16 mg RBX twice daily, the diabetes-induced increase in RCT was ameliorated, with a baseline-to-endpoint difference of - 0.84 seconds ( P = 0.046) relative to placebo. Increasing RBX dose was linearly associated with greater effect on RCT ( P = 0.03). Similar results were observed with RBF. CONCLUSIONS. RBX was well tolerated at doses up to 16 mg twice daily for 28 days in patients with diabetes. It ameliorated diabetes-induced RCT abnormalities. No serious safety problems were identified in this patient population. Compared with prior published data, these findings represent the first direct human evidence of both bioavailability of RBX to retinal vessels and amelioration of diabetes-induced retinal hemodynamic abnormalities by an oral PKC beta inhibitor. C1 Joslin Diabet Ctr, Beethman Eye Inst, Boston, MA 02215 USA. Joslin Diabet Ctr, Eye Res Sect, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA. Lilly Res Labs, Indianapolis, IN USA. Univ Wisconsin, Fundus Photograph Reading Ctr, Madison, WI USA. RP Aiello, LP (reprint author), Joslin Diabet Ctr, Beethman Eye Inst, 1 Joslin Pl, Boston, MA 02215 USA. EM lpaiello@joslin.harvard.edu NR 30 TC 87 Z9 96 U1 0 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 2006 VL 47 IS 1 BP 86 EP 92 DI 10.1167/iovs.05-0757 PG 7 WC Ophthalmology SC Ophthalmology GA 998AH UT WOS:000234289700013 PM 16384948 ER PT J AU Kim, IK Husain, D Michaud, N Connolly, E Lane, AM Durrani, K Hafezi-Moghadam, A Gragoudas, ES O'Neill, CA Beyer, JC Miller, JW AF Kim, IK Husain, D Michaud, N Connolly, E Lane, AM Durrani, K Hafezi-Moghadam, A Gragoudas, ES O'Neill, CA Beyer, JC Miller, JW TI Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; NEOVASCULARIZATION; REGENERATION; EXPRESSION; MEMBRANES; MONKEY AB PURPOSE. To evaluate the effect of intravitreal injection of a monoclonal antibody fragment (ranibizumab, also known as rhuFab V2 and Lucentis; Genentech, S. San Francisco, CA) directed against vascular endothelial growth factor (VEGF) in combination with verteporfin photodynamic therapy (PDT) on normal primate retina and choroid. METHODS. Eight cynomolgus monkeys were treated with intravitreal ranibizumab in one eye and placebo in the other, alternating with verteporfin PDT in both eyes on a weekly basis for 6 to 7 weeks. Treatment effects were evaluated by color fundus photography, fluorescein angiography, and light and electron microscopy. RESULTS. Over the course of the study, increasing retinal pigment epithelial changes, with corresponding window defects, developed in both eyes of all animals on fluorescein angiography over the course of the study. No complications attributable to the intravitreal injection of ranibizumab were observed. Histologic analysis revealed a similar reduction in choriocapillaris density in the irradiated area of eyes treated with PDT alone compared with those that received combination treatment. CONCLUSIONS. In this limited study of normal monkey eyes, no severe adverse effects from the combination of intravitreal ranibizumab and verteporfin PDT were demonstrated compared with PDT alone. C1 Harvard Univ, Retina Serv, Massachusetts Eye & Ear Infirm,Dept Ophthalmol, Sch Med,Angiogenesis & Laser Lab,Retina Res Inst, Boston, MA 02114 USA. Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA. BioMarin Pharmaceut, Novato, CA USA. Genentech Inc, Dept Safety Assessment, San Francisco, CA 94080 USA. RP Kim, IK (reprint author), Harvard Univ, Retina Serv, Massachusetts Eye & Ear Infirm,Dept Ophthalmol, Sch Med,Angiogenesis & Laser Lab,Retina Res Inst, 243 Charles St, Boston, MA 02114 USA. EM ivana_kim@meei.harvard.edu OI Hafezi-Moghadam, Ali/0000-0002-5336-0697 NR 16 TC 35 Z9 42 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 2006 VL 47 IS 1 BP 357 EP 363 DI 10.1167/iovs.04-0087 PG 7 WC Ophthalmology SC Ophthalmology GA 998AH UT WOS:000234289700050 PM 16384985 ER PT J AU Yosefy, C Beeri, R Reisin, L AF Yosefy, C Beeri, R Reisin, L TI Silent type A aortic dissection SO ISRAEL MEDICAL ASSOCIATION JOURNAL LA English DT Article C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA. Barzilai Govt Hosp, Dept Cardiol, Ashqelon, Israel. Ben Gurion Univ Negev, Fac Hlth Sci, IL-84105 Beer Sheva, Israel. RP Yosefy, C (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, VBK 508,55 Fruit St, Boston, MA 02114 USA. EM cyosefy@partners.org NR 2 TC 0 Z9 0 U1 0 U2 0 PU ISRAEL MEDICAL ASSOC JOURNAL PI RAMAT GAN PA 2 TWIN TOWERS, 11TH FL, 35 JABOTINSKY ST, PO BOX 3604, RAMAT GAN 52136, ISRAEL SN 1565-1088 J9 ISRAEL MED ASSOC J JI Isr. Med. Assoc. J. PD JAN PY 2006 VL 8 IS 1 BP 75 EP 75 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 004SG UT WOS:000234771900022 PM 16450763 ER PT J AU Luetkemeyer, A Hare, CB Stansell, J Tien, PC Charlesbois, E Lum, P Havlir, D Peters, M AF Luetkemeyer, A Hare, CB Stansell, J Tien, PC Charlesbois, E Lum, P Havlir, D Peters, M TI Clinical presentation and course of acute hepatitis c infection in HIV-infected patients SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE acute hepatitis C; HIV; pegylated interferon; men who have sex with men ID HUMAN-IMMUNODEFICIENCY-VIRUS; ALPHA-2A PLUS RIBAVIRIN; RANDOMIZED CONTROLLED-TRIAL; SEXUAL TRANSMISSION; NATURAL-HISTORY; HOMOSEXUAL-MEN; INTERFERON-ALPHA-2B; COINFECTION; PREVALENCE; TERM AB Hepatitis C virus (HCV) has become a significant source of morbidity and mortality in HIV-infected patients. However, little is known about the clinical presentation and course of acute HCV infection in this population. This study reports the outcomes of acute HCV infection in 9 HIV-infected men. Sex with men was the only reported risk factor for HCV infection in 6 of the subjects. Clinical presentation of acute HCV ranged from incidentally discovered elevated transaminases to severe liver dysfunction requiring hospitalization. At the time of HCV diagnosis, 8 of 9 patients had CD4(+) counts > 250 cells/mm(3), and 6 had HIV vital loads of <= 5000 copies/mL. Eight patients were receiving antiretroviral therapy. outcome of these acute HCV infections varied. Five patients experienced virologic clearance, 2 in whom virus cleared spontaneously and 3 who were treated with pegylated interferon and ribavirin. Four patients developed chronic infection, one of whom had a relapse during HCV treatment and 3 of whom Were untreated. All 4 patients to whom HCV therapy was administered experienced significant anemia or neutropenia, necessitating close reduction or Support with growth factors. Prompt recognition of acute HCV infection May minimize antiretroviral treatment interruption and will allow early treatment, which may improve virologic clearance. Unexplained transaminase elevations in HIV-infected patients, including men who have sex with men, should trigger an evaluation for acute HCV infection. C1 Univ Calif San Francisco, San Francisco Gen Hosp, HIV AIDS Div, San Francisco, CA 94110 USA. Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA. RP Luetkemeyer, A (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, HIV AIDS Div, Box 0874,Bldg 80,995 Potrero Ave, San Francisco, CA 94110 USA. EM aluetkemeyer@php.ucsf.edu FU NIAID NIH HHS [K24 AI051982, K24-AI51982, P30 AI027763]; NIDDK NIH HHS [P30 DK026743, P30 DK26743]; NIMH NIH HHS [T32 MH-19105, T32 MH019105] NR 37 TC 80 Z9 83 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2006 VL 41 IS 1 BP 31 EP 36 DI 10.1097/01.qai.0000191281.77954.27 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 000CM UT WOS:000234438500005 PM 16340470 ER PT J AU Goetz, MB Holodniy, M Poulton, JS Rodriguez, FH Rigsby, MO AF Goetz, MB Holodniy, M Poulton, JS Rodriguez, FH Rigsby, MO TI Utilization and access to Antiretroviral genotypic resistance testing and results within the US department of veterans affairs SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV infections; genotype; drug resistance; veterans; data collection ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV DRUG-RESISTANCE; EXPERT ADVICE; RECOMMENDATIONS; TYPE-1; CARE AB We Sought to characterize variation in the use of HIV genotypic resistance tests and how results were reported. Methods: Clinicians and laboratory managers at all Veterans Affairs (VA) medical centers were asked to complete a survey in March 2003 regarding HIV resistance testing practices. Results: Surveys from 13 1 of 150 sites were returned. Forty-eight percent of HIV clinicians indicated that US Department of Health and Human Services guidelines were the usual basis for ordering tests. Although between 12% and 31% of respondents indicated that they always, sometimes, seldom, or never ordered resistance tests in patients with acute or chronic HIV infection, > 70% ordered tests it) adherent patients with treatment failure. Among the 32 centers with > 200 patients in care, 13 +/- 8 (mean standard deviation) tests were performed per 100 patients in care during 2002. Forty-nine percent of clinicians said that tests were helpful, but only 33% expressed confidence in using test results. Only 40% of sites entered results in the VA electronic medical record. Conclusion: Ordering patterns for HIV resistance tests differed significantly among VA sites. A minority of clinicians indicated confidence in the use of test results. A consistent system to capture and present complete results was absent. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Infect Dis Sect 111F, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Vet Affairs Palo Alto Healthcare Syst, AIDS Res Ctr, Palo Alto, CA USA. Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA. Publ Healthcare Strateg Healthcare Grp, Dept Vet Affairs, Washington, DC USA. Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. Yale Univ, Dept Med, Infect Dis Sect, New Haven, CT 06520 USA. Louisiana State Univ, Sch Med, Vet Affairs Med Ctr, Pathol & Lab Med Serv, New Orleans, LA 70112 USA. Louisiana State Univ, Sch Med, Dept Pathol, New Orleans, LA 70112 USA. RP Goetz, MB (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Infect Dis Sect 111F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM matthew.goetz@med.va.gov OI Goetz, Matthew/0000-0003-4542-992X NR 21 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2006 VL 41 IS 1 BP 59 EP 62 DI 10.1097/01.qai.0000187445.76579.08 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 000CM UT WOS:000234438500009 PM 16340474 ER PT J AU Ogawa, K Nakamura, K Onishi, H Sasaki, T Koizumi, M Shioyama, Y Komiyama, T Miyabe, Y Teshima, T AF Ogawa, K Nakamura, K Onishi, H Sasaki, T Koizumi, M Shioyama, Y Komiyama, T Miyabe, Y Teshima, T CA JPCS Grp TI Radical external beam radiotherapy for prostate cancer in Japan: Results of the 1999-2001 patterns of care process survey SO JAPANESE JOURNAL OF CLINICAL ONCOLOGY LA English DT Article DE patterns of care study; prostatic carcinoma; type of institution; radiation therapy; hormone therapy ID RADIATION ONCOLOGY; CHANGING TRENDS; ANDROGEN SUPPRESSION; DOSE-ESCALATION; UNITED-STATES; THERAPY; CARCINOMA; STRATIFICATION; INSTITUTION; GOSERELIN AB Background: The Patterns of Care Study evaluated standards of practice for patients with clinically localized prostate cancer treated with radiotherapy in Japan. This study examined the influence of institutional stratification on care for patients receiving radical external beam radiotherapy. Methods: A national survey of 66 institutions was conducted using two-stage cluster sampling, and detailed information was accumulated on 283 patients who received radiotherapy between 1999 and 2001. Results: In A (academic) and B (non-academic) institutions, more than 80% of patients had intermediate or unfavorable risk disease. Although there were no significant differences in disease characteristics between A and B institutions, institutional stratification significantly affected radiotherapy practice patterns, such as the use of a CT-based treatment planning (A1: 91.5%, B: 77.1%; P = 0.0007) and the use of conformal therapy (A: 56.4%, B: 24.1%; P < 0.0001). CT-based treatment planning and conformal therapy significantly influenced total radiation dose (P < 0.0001 for each). Hormonal therapy was commonly used in both A and B institutions (A: 89.0%, B: 90.7%). Many patients with a favorable prognosis (A: 62.5%, B: 91.7%) received hormonal therapy, and most patients with unfavorable risk disease (A: 93.6%, B: 91.6%) also received hormonal therapy. Conclusion: During the period 1999-2001, the majority of prostate cancer patients treated in Japan with radical external beam radiotherapy had advanced diseases. Institutional stratification significantly affected radiotherapy practice patterns, with the notable exception that radiotherapy was commonly combined with hormonal therapy regardless of the institutional stratification and individual risk. C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Osaka Univ, Dept Med Phys & Engn, Osaka, Japan. Kyoto Prefectural Univ, Dept Radiol, Kyoto 606, Japan. Yamanashi Univ, Dept Radiol, Yamanashi, Japan. Kyushu Univ, Dept Clin Radiol, Fukuoka, Japan. Univ Ryukyus, Dept Radiol, Okinawa 90301, Japan. RP Ogawa, K (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox 7, Boston, MA 02114 USA. EM kogawa@med.u-ryukyu.ac.jp NR 27 TC 9 Z9 9 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0368-2811 J9 JPN J CLIN ONCOL JI Jpn. J. Clin. Oncol. PD JAN PY 2006 VL 36 IS 1 BP 40 EP 45 DI 10.1093/jjcol/hyi216 PG 6 WC Oncology SC Oncology GA 024FL UT WOS:000236180800006 PM 16418185 ER PT J AU Davison, JW Sweeney, ML Bush, KR Correale, TMD Calsyn, DA Reoux, JP Sloan, KL Kivlahan, DR AF Davison, John W. Sweeney, Marie L. Bush, Kristen R. Correale, Tania M. Davis Calsyn, Donald A. Reoux, Joseph P. Sloan, Kevin L. Kivlahan, Daniel R. TI Outpatient treatment engagement and abstinence rates following inpatient opioid detoxification SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article DE opioid detoxification; outpatient treatment; chronic opiold dependence; antagonist; naltrexone ID DRUG-ABUSE TREATMENT; METHADONE-MAINTENANCE; CONTROLLED-TRIAL; OUTCOMES; DEPENDENCE; ADDICTS; OPIATE; NALTREXONE; SERVICES; RELAPSE AB Many patients with chronic opioid dependence are referred to drug-free outpatient treatment following inpatient detoxification even though successful outpatient treatment engagement and abstinence from opioids occur only in a minority of cases. This retrospective cohort analysis of medical records documents the post-discharge outcome in a treatment setting that maximizes the support during transition to abstinence-oriented outpatient care, with comprehensive social, medical and mental health services, including the availability of naltrexone. Participants were male veterans (N = 112) admitted at an urban VA medical center. Most patients (78%) successfully completed acute detoxification, 49% initiated naltrexone, and 76% accepted a VA aftercare plan. At 90-day follow-up, only 22% remained in aftercare, and < 3% had toxicology-verified abstinence from opioids. At one-year follow-up, 1 out of 5 had been readmitted for detoxification and 4.5% had died. Most patients successfully detoxified from opioids, but very few remained engaged and stabilized in abstinence-oriented outpatient treatment. C1 Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. VA Ctr Excellence Substance Abuse Treatment & Edu, Seattle, WA 98108 USA. Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA. Univ Washington, VA Ctr Excellence Substance Abuse Treatment & Edu, Seattle, WA 98195 USA. Univ Washington, Inst Alcohol & Drug Abuse, Seattle, WA 98195 USA. Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. RP Davison, JW (reprint author), Dept Vet Affairs, Publ Hlth Strateg Hlth Care Grp 13B, 810 Vermont Ave NW, Washington, DC 20420 USA. EM John.Davison@va.gov NR 31 TC 2 Z9 2 U1 1 U2 2 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 1055-0887 J9 J ADDICT DIS JI J. Addict. Dis. PY 2006 VL 25 IS 4 BP 27 EP 35 DI 10.1300/J069v25n04_03 PG 9 WC Substance Abuse SC Substance Abuse GA 116YN UT WOS:000242839800003 PM 17088223 ER PT J AU Rowe, BH Carnargo, CA AF Rowe, BH Carnargo, CA CA MARC Investigators TI The use of magnesium sulfate in acute asthma: Rapid uptake of evidence in North American emergency departments SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE asthma; treatment; emergency department; magnesium; severe ID INTRAVENOUS MAGNESIUM; GUIDELINES; IMPACT AB Background: Systematic reviews of approximately 13 randomized trials support treatment with intravenous magnesium sulfate (MgSO4) in patients with severe acute asthma; however, little is known about its actual clinical use. Objective: We sought to examine the use of intravenous MgSO4 in the emergency department (ED) and physician attitudes toward its use. Methods: Data for MgSO4 use were obtained from observational cohort studies of ED patients with acute asthma. Investigators were asked about MgSO4 through a brief Internet-based survey. The main outcomes were the percentage of sites reporting MgSO4 use and patient factors that potentially modified the use of this agent. Results: Among 9745 ED patients with acute asthma, 240 (2.5%) received MgSO4, Increasing age, previous intubation, higher initial respiratory rate, lower initial PEF, higher number of beta-agonists in the ED, and use of systemic corticosteroids were associated with MgSO4 use (P < .01). Overall, 103 (87%) of 119 potential sites completed the survey. Most (92%) respondents stated their EDs had MgSO4 available, and 64% had recently used it. More respondents listed severity (96%) and failure to respond to initial beta-agonists (87%) as factors prompting their use of MgSO4. Other factors, such as age, sex, and duration of exacerbation, less commonly influenced MgSO4 use. Conclusion: Most ED physicians accept the efficacy of MgSO4 in acute asthma. Despite this belief and the ready availability of MgSO4, its ED use remains uncommon (2.5% of cases). In both practice and theory, emergency physicians appear to appropriately restrict its use to patients with severe acute asthma. C1 Univ Alberta, Dept Emergency Med, Edmonton, AB T6G 2B7, Canada. Capital Hlth, Edmonton, AB, Canada. Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab,Dept Med, Boston, MA 02115 USA. RP Rowe, BH (reprint author), Univ Alberta, Dept Emergency Med, 1G1-43,WMC,8440-112th St, Edmonton, AB T6G 2B7, Canada. EM brian.rowe@ualberta.ca FU NHLBI NIH HHS [HL-63841, HL-63253] NR 12 TC 19 Z9 20 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2006 VL 117 IS 1 BP 53 EP 58 DI 10.1016/j.jaci.2005.09.033 PG 6 WC Allergy; Immunology SC Allergy; Immunology GA 017IK UT WOS:000235687100009 PM 16387584 ER PT J AU Skoch, J Hyman, BT Bacskai, BJ AF Skoch, Jesse Hyman, Bradley T. Bacskai, Brian J. TI Preclinical characterization of amyloid imaging probes with multiphoton microscopy SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article AB Multiphoton microscopy is an optical imaging technique that allows high resolution detection of fluorescence in thick, scattering tissues. The technique has been used for trans-cranial imaging of the brains of living transgenic mouse models of Alzheimer's disease. Direct detection of senile plaques in these mice has allowed the characterization of the natural history of individual senile plaques, the evaluation of plaque clearance during immunotherapy, and the characterization of the kinetics and biodistribution of the PET ligand, PIB. With the expanding repertoire of structural and functional fluorescent probes, and the preclinical characterization of new contrast agents for complementary imaging modalities like MRI, PET, SPECT, and NIRS, multiphoton microscopy will continue to be a powerful tool in understanding and combating Alzheimer's disease. C1 [Skoch, Jesse; Hyman, Bradley T.; Bacskai, Brian J.] Massachusetts Gen Hosp, Dept Neurol, Alzheimers Dis Res Lab, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA. RP Bacskai, BJ (reprint author), Massachusetts Gen Hosp, Dept Neurol, Alzheimers Dis Res Lab, 114 16th St,2850, Charlestown, MA 02129 USA. EM bbacskai@partners.org FU NIH [AG020570, EB00768, AG08487]; Pioneer Award from the Alzheimer Association FX This work was supported by NIH AG020570, EB00768 (BJB), AG08487, and a Pioneer Award from the Alzheimer Association (BTH). NR 37 TC 10 Z9 10 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2006 VL 9 SU 3 BP 401 EP 407 PG 7 WC Neurosciences SC Neurosciences & Neurology GA V33DM UT WOS:000208999500045 PM 16914878 ER PT J AU Chen, ZY Hauser, R Trbovich, AM Shifren, JL Dorer, DJ Godfrey-Bailey, L Singh, NP AF Chen, ZY Hauser, R Trbovich, AM Shifren, JL Dorer, DJ Godfrey-Bailey, L Singh, NP TI The relationship between human semen characteristics and sperm apoptosis: A pilot study SO JOURNAL OF ANDROLOGY LA English DT Article DE semen quality; sperm motility; sperm morphology; DNA diffusion assay ID PLASMA-MEMBRANE TRANSLOCATION; GERM-CELL APOPTOSIS; HUMAN SPERMATOZOA; DNA-DAMAGE; EJACULATED SPERMATOZOA; OXIDATIVE STRESS; FERTILIZATION; PHOSPHATIDYLSERINE; SPERMATOGENESIS; FRAGMENTATION AB This work was undertaken to explore the association between human semen characteristics and apoptosis in ejaculated sperm. We collected semen samples from 23 consecutive male patients who presented to the Andrology Laboratory at Massachusetts General Hospital (MGH) for routine semen analysis. Sperm concentration and motility were measured using computer-assisted sperm analysis. Morphology was assessed using Tygerberg strict criteria. The DNA diffusion assay was used to assess the percentage of apoptosis in ejaculated sperm. In this assay, cells were mixed with agarose and placed into a microgel on a microscopic slide. The cells were stained with YOYO-1 dye, and apoptotic cells were viewed under a fluorescent microscope. Among 23 men, the mean (SD) sperm concentration, percent motility, percent progressive motility, and normal morphology were 125.5 (92.3) million/mL, 45.6% (22.2), 28.4% (15.2), and 8.0 (4.6), respectively. The mean (SD) percent of apoptosis in ejaculated sperm was 8.3% (6.2) with a range from 1.1% to 20.1%. There were inverse associations between percent apoptosis and sperm motility (P = .0025), progressive motility (P = .0051), and morphology with a normal or good pattern of fertilization by Kruger strict criteria (P = .0045), and a positive relationship between percent apoptosis and sperm tail defects (P = .0053). In ejaculated semen, the percent sperm apoptosis was associated with several measures of semen quality. C1 Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Occupat Hlth Program, Boston, MA 02115 USA. Massachusetts Gen Hosp, Vincent Mem Obstet, Boston, MA 02114 USA. Massachusetts Gen Hosp, Gynecol Serv, Androl Lab, Boston, MA 02114 USA. Massachusetts Gen Hosp, In Vitro Fertilizat Unit, Boston, MA 02114 USA. Univ Washington, Dept Bioengn, Seattle, WA 98195 USA. RP Hauser, R (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Occupat Hlth Program, Bldg 1,Room 1405,665 Huntington Ave, Boston, MA 02115 USA. EM rhauser@hohp.harvard.edu FU NIEHS NIH HHS [ES00002, ES09718] NR 44 TC 25 Z9 28 U1 1 U2 1 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA SN 0196-3635 J9 J ANDROL JI J. Androl. PD JAN-FEB PY 2006 VL 27 IS 1 BP 112 EP 120 DI 10.2164/jandrol.05073 PG 9 WC Andrology SC Endocrinology & Metabolism GA 002AR UT WOS:000234584300019 PM 16400087 ER PT J AU Taylor, S Abramowitz, JS McKay, D Calamari, JE Sookman, D Kyrios, M Wilhelm, S Carmin, C AF Taylor, S Abramowitz, JS McKay, D Calamari, JE Sookman, D Kyrios, M Wilhelm, S Carmin, C TI Do dysfunctional beliefs play a role in all types of obsessive-compulsive disorder? SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE obsessive-compulsive disorder; dysfunctional beliefs; cognitive-behavioral theories; cluster analysis ID INTRUSIONS INVENTORY; QUESTIONNAIRE; VALIDATION; SYMPTOMS AB Some but not all models of obsessive-compulsive disorder (OCD) emphasize the role of dysfunctional beliefs in the etiology and maintenance of this disorder. Clinical observations suggest that some OCD patients have prominent dysfunctional beliefs associated with their obsessions and compulsions, while other patients do not show this pattern. It is possible that dysfunctional beliefs play a role in only a subgroup of cases of OCD and, by extension, that different models might apply to different subtypes of the disorder. To examine this issue, patients with OCD (N = 244) completed measures of dysfunctional OC-related beliefs, along with measures of OC symptoms and demographics. These measures were also completed by three comparison groups; anxious (N = 103), student (N = 284), and community (N = 86) controls. Cluster analysis revealed two OCD clusters: low versus high scores on beliefs (OC-low, OC-high). Belief scores for OC-low were in the range of scores for the comparison groups, which were all significantly lower than those of OC-high. Thus, a cluster of OCD patients was identified who did not have elevated scores on measures of dysfunctional beliefs. OC-low and OC-high did not differ on some OC measures (contamination, checking, grooming), but OC-high had higher scores on measures of harming obsessions. These results are consistent with the view that dysfunctional beliefs may play a role in only some types of OCD. (c) 2004 Elsevier Inc. All rights reserved. C1 Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada. Mayo Clin, Rochester, MN 55905 USA. Fordham Univ, Bronx, NY 10458 USA. McGill Univ, Montreal, PQ H3A 2T5, Canada. Univ Melbourne, Parkville, Vic 3052, Australia. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Illinois, Chicago, IL 60680 USA. RP Taylor, S (reprint author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada. EM taylor@unixg.ubc.ca RI Carmin, Cheryl/F-8004-2014 NR 35 TC 77 Z9 78 U1 2 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2006 VL 20 IS 1 BP 85 EP 97 DI 10.1016/j.janxdis.2004.11.005 PG 13 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 996GJ UT WOS:000234162100006 PM 16325116 ER PT J AU Hinton, DE Chhean, D Pich, V Um, K Fama, JM Pollack, MH AF Hinton, DE Chhean, D Pich, V Um, K Fama, JM Pollack, MH TI Neck-focused panic attacks among Cambodian refugees; a logistic and linear regression analysis SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE posuraumatic stress disorder; panic attack; flashbacks; catastrophic cognitions; Cambodian refugees; panic attack subtypes ID POSTTRAUMATIC-STRESS-DISORDER; ANXIETY SENSITIVITY; INTRUSIVE MEMORIES; COGNITIONS; DEPRESSION; TRAUMA; PTSD; FEAR; PREVALENCE; HYPOTHESIS AB Consecutive Cambodian refugees attending a psychiatric clinic were assessed for the presence and severity of current-i.e., at least one episode in the last month-neck-focused panic. Among the whole sample (N = 130), in a logistic regression analysis, the Anxiety Sensitivity Index (ASI; odds ratio = 3.70) and the Clinician-Administered PTSD Scale (CAPS; odds ratio = 2.61) significantly predicted the presence of current neck panic (NP). Among the neck panic patients (N = 60), in the linear regression analysis, NP severity was significantly predicted by NP-associated flashbacks (beta = .42), NP-associated catastrophic cognitions (beta = .22), and CAPS score (beta = .28). Further analysis revealed the effect of the CAPS score to be significantly mediated (Sobel test [Baron, R. M., & Kenny, D. A. (1986). The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology, 51, 1173-1182]) by both NP-associated flashbacks and catastrophic cognitions. In the care of traumatized Cambodian refugees, NP severity, as well as NP-associated flashbacks and catastrophic cognitions, should be specifically assessed and treated. (c) 2005 Elsevier Inc. All rights reserved. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. SE Asian Clin, Lowell, MA USA. RP Hinton, DE (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM devon_hinton@hms.harvard.edu NR 59 TC 28 Z9 29 U1 4 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2006 VL 20 IS 2 BP 119 EP 138 DI 10.1016/j.janxdis.2005.02.001 PG 20 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 018LK UT WOS:000235765600001 PM 16464700 ER PT J AU Hinton, DE Pich, V Safren, SA Pollack, MH McNally, RJ AF Hinton, DE Pich, V Safren, SA Pollack, MH McNally, RJ TI Anxiety sensitivity among Cambodian refugees with panic disorder: A factor analytic investigation SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE panic disorder; anxiety sensitivity index; Cambodian refugees; panic attacks; catastrophic cognitions ID HIERARCHICAL STRUCTURE; CLINICAL-SAMPLE; INDEX; SENSATIONS; CONSTRUCT; STRESS AB Among Cambodian refugees with panic disorder (N = 208), we performed two factor analyses, one with the ASI, another with an Augmented ASI (consisting of the 16-item ASI supplemented with a 9-item addendum that assesses additional Cambodian concerns about anxiety-related sensations). The principal component analysis of the ASI yielded a 3-factor solution (I, "Weak Heart Concerns"; II, "Social Concerns"; III, "Control Concerns"); the Augmented ASI, a 4-factor solution: I, "Wind Attack Concerns"; II, "Weak Heart Concerns"; III, "Social Concerns"; and IV, "Control Concerns." The item clustering within the factor solution of both the ASI and Augmented ASI illustrates the role of cultural syndromes in generating fear of mental and bodily events. (c) 2005 Elsevier Inc. All rights reserved. C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. SE Asian Clin, Arbour Counseling Ctr, Lowell, MA USA. RP Hinton, DE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM devon_hinton@hms.harvard.edu NR 30 TC 21 Z9 23 U1 3 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2006 VL 20 IS 3 BP 281 EP 295 DI 10.1016/j.janxdis.2005.02.006 PG 15 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 030NK UT WOS:000236641200002 PM 16564433 ER PT J AU Morissette, SB Brown, TA Kamholz, BW Gulliver, SB AF Morissette, SB Brown, TA Kamholz, BW Gulliver, SB TI Differences between smokers and nonsmokers with anxiety disorders SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE anxiety disorders; smoking; tobacco ID OBSESSIVE-COMPULSIVE DISORDER; STRESS SCALES DASS; PANIC DISORDER; SMOKING-CESSATION; CIGARETTE-SMOKING; YOUNG-ADULTS; PSYCHOMETRIC PROPERTIES; NICOTINE DEPENDENCE; NEGATIVE AFFECT; SUBSTANCE USE AB Epidemiological data suggest that early smoking increases the risk for emergence of certain anxiety disorders (e.g., panic disorder, generalized anxiety disorder (GAD)), and that presence of certain anxiety disorders (e.g., social anxiety) increases the risk for later development of nicotine dependence. Although some studies report a high prevalence of smoking among anxiety disorders, the extent to which smokers with anxiety disorders differ from their nonsmoking counterparts remains uncertain. Differences between smokers and nonsmokers with anxiety disorders (N = 527) were examined with respect to multiple measures of theoretical and clinical interest. Compared to nonsmokers, smokers with anxiety disorders reported greater anxiety sensitivity, anxiety symptoms, agoraphobic avoidance, depressed mood, negative affect, stress and life interference; however, these differences were largely accounted for by panic disorder. No differences were found between smokers and nonsmokers regarding social anxiety, worry, obsessive-compulsive symptoms or positive affect. Differential patterns were observed when evaluating constructs within anxiety disorder diagnoses. (c) 2005 Elsevier Inc. All rights reserved. C1 VA Boston Healthcare Syst, Psychol Serv, Boston, MA 02130 USA. Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. Boston Univ, Dept Psychol, Boston, MA 02215 USA. RP Morissette, SB (reprint author), VA Boston Healthcare Syst, Psychol Serv, 116B,150 S Huntington Ave, Boston, MA 02130 USA. EM sandra.morissette@med.va.gov FU NIDA NIH HHS [K23 DA016376, K23-DA-16376]; NIMH NIH HHS [R01-MH-39096] NR 52 TC 24 Z9 27 U1 8 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2006 VL 20 IS 5 BP 597 EP 613 DI 10.1016/j.janxdis.2005.08.003 PG 17 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 052LT UT WOS:000238235900004 PM 16202562 ER PT J AU Grisham, JR Frost, RO Steketee, G Kim, HJ Hood, S AF Grisham, JR Frost, RO Steketee, G Kim, HJ Hood, S TI Age of onset of compulsive hoarding SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE hoarding; saving; collecting; discarding; acquisition; clutter ID FACTOR-ANALYZED SYMPTOM; DISORDER; DIMENSIONS; VALIDITY; SUBTYPE AB Although compulsive hoarding appears to be a chronic, progressive disorder, little is known about its onset and course. The current study employed retrospective assessment of 51 individuals with compulsive hoarding difficulties to determine onset of various hoarding symptoms (clutter, acquisition, difficulty discarding), as well as the individual's degree of recognition of the problem at various times throughout his or her life. Participants were asked to describe life events from each decade that occurred at the time hoarding symptoms were developing. Symptoms of clutter and difficulty discarding appeared to begin at approximately the same age, whereas acquiring problems began slightly later. Recognition of the problem developed significantly later than any of the symptoms themselves. A portion of participants reported that their hoarding symptoms were reduced at some point in their lives, but few reported full remission of hoarding at any point. Survival analysis of age of onset of hoarding symptoms indicated that individuals who reported a stressful event when saving behavior started had a significantly later age of onset than those who reported no events at the age of onset. Perhaps for some individuals compulsive hoarding is a lifelong characterological phenomenon, whereas for others hoarding behavior develops later as a reaction to stress or loss. (c) 2005 Published by Elsevier Inc. C1 Boston Univ, Boston, MA 02215 USA. Smith Coll, Northampton, MA 01063 USA. RP Grisham, JR (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave 116B,Jamaica Plain, Boston, MA 02130 USA. EM jgrisham@bu.edu OI Grisham, Jessica/0000-0002-5035-1744 NR 24 TC 98 Z9 101 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2006 VL 20 IS 5 BP 675 EP 686 DI 10.1016/j.janxdis.2005.07.004 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 052LT UT WOS:000238235900009 PM 16112837 ER PT J AU Otto, MW Simon, NM PowerS, M Hinton, D Zalta, AK Pollack, MH AF Otto, MW Simon, NM PowerS, M Hinton, D Zalta, AK Pollack, MH TI Rates of isolated sleep paralysis in outpatients with anxiety disorders SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE isolated sleep paralysis; anxiety disorder; REM ID REM-SLEEP; PREVALENCE; HALLUCINATIONS AB Initial research suggests that rates of isolated sleep paralysis (ISP) are elevated in individuals with panic disorder and particularly low in individuals with other anxiety disorders. To further evaluate these findings, we examined rates of 1SP in a sample outpatients with primary diagnoses of panic disorder (n = 24), social anxiety disorder (n = 18), or generalized anxiety disorder (n = 18). We obtained an overall rate of 1SP of 19.7%; rates for patients with panic disorder (20.8%) fell between those with generalized anxiety disorder (15.8%) and social phobia (22.2%). Analysis of comorbidities failed to provide evidence of link between depressive disorders and ISP, but did indicate a significant association between anxiety comorbidity and higher rates of ISR Results are discussed relative to other variables predicting variability in the occurrence of ISR (c) 2005 Elsevier Inc. All rights reserved. C1 Boston Univ, Ctr Anxiety & Related Disorders, Boston, MA 02114 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Otto, MW (reprint author), Boston Univ, Ctr Anxiety & Related Disorders, 648 Beacon St,Floor 6, Boston, MA 02114 USA. EM mwotto@bu.edu OI Zalta, Alyson/0000-0002-5159-8431; Powers, Mark/0000-0001-7898-073X NR 26 TC 25 Z9 25 U1 0 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2006 VL 20 IS 5 BP 687 EP 693 DI 10.1016/j.janxdis.2005.07.002 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 052LT UT WOS:000238235900010 PM 16099138 ER PT J AU Olatunji, BO AF Olatunji, Bunmi O. TI Evaluative learning and emotional responding to fearful and disgusting stimuli in spider phobia SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE evaluative learning; fear; disgust; spider phobia; emotions ID BLOOD-INJECTION-INJURY; CONTAMINATION FEARS; FACIAL EXPRESSIONS; ANIMAL PHOBIAS; SENSITIVITY; ACQUISITION; AVOIDANCE; RESPONSES; EXPOSURE; DISLIKES AB The present study explores possible changes between spider phobics (N = 22) and nonphobics (N = 28) in fear, disgust, and neutral ratings of neutral expressions as a result of their pairing with spiders. No statistically significant differences were detected between pre and post fear ratings of the expressions as a result of their association with spiders. However, post disgust ratings were marginally higher than pre disgust ratings and post neutral ratings were significantly lower than pre neutral ratings. The present study also examined differences in fear and disgust responding to threat-relevant and disgust-relevant stimuli between spider phobics and nonphobics. Spider phobics reported significantly more fear and disgust than nonphobics towards threat and disgust-relevant stimuli. The relation between spider phobia and disgust responding to spiders was partially mediated by fear whereas the relation between spider phobia and disgust responding to rotting foods and body products was fully mediated by fear. Emotional responding to threat-relevant and disgust-relevant stimuli was also significantly associated with disgust sensitivity when controlling for trait anxiety. These findings support the notion that the disgust response in spider phobia is independent of fear to the extent that it is specifically bound to spiders. (c) 2006 Elsevier Ltd. All rights reserved. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Olatunji, BO (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 15 Parkman St,ACC 812, Boston, MA 02114 USA. EM bolatunji@partners.org NR 46 TC 28 Z9 28 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2006 VL 20 IS 7 BP 858 EP 876 DI 10.1016/j.janxdis.2006.01.005 PG 19 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 084ZT UT WOS:000240573600002 PM 16504462 ER PT J AU Biggs, PJ AF Biggs, Peter J. TI Long-term stability of a 50-kV X-ray unit for stereotactic irradiation SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE low-energy X-rays; scintillation counters; stereotactic irradiation AB A low-energy (50 kV) X-ray tube used for the stereotactic irradiation of intracranial lesions has been in use since 1999. The unit is calibrated prior to every procedure and during periodic quality assurance (QA) tests. The unit uses an internal and an external scintillation detector to monitor dose as well as a conventional timer. The records of these calibrations were reviewed to see whether a change in the output had occurred over that period. Using time as the reference, it was found that both the internal radiation monitor (IRM) and the beam output, determined with a parallel plate ionization chamber, dropped by variable amounts over the given period. The beam output dropped significantly more than the IRM, while the external radiation monitor (ERM) showed no significant deviation from its initial value. The beam output dropped to about 90% of its initial value after about 200 days but remained relatively constant thereafter. The IRM dropped steadily to about 96% to 97% of its initial value at 1000 days, but recovered to about 98% after that. Calibration prior to each procedure is strongly recommended. C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Biggs, PJ (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM pjbiggs@partners.org NR 2 TC 3 Z9 3 U1 0 U2 0 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2006 VL 7 IS 3 BP 12 EP 20 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 180DY UT WOS:000247343100002 PM 17533340 ER PT J AU Lyatskaya, Y Lu, HM Chin, L AF Lyatskaya, Yulia Lu, Hsiao-Ming Chin, Lee TI Performance and characteristics of an IR localizing system for radiation therapy SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE posture control; respiratory control; IR system ID INITIAL CLINICAL-EXPERIENCE; STEREOTACTIC RADIOSURGERY; EXTRACRANIAL RADIOSURGERY; CONFORMAL RADIOTHERAPY; TARGET LOCALIZATION; QUALITY-ASSURANCE; PROSTATE-CANCER; MOTION ANALYSIS; SET-UP; VERIFICATION AB We report the development of a new system for interactive patient posture, position, and respiratory control during radiation therapy treatment. The system consists of an infrared (IR) camera, retroreflective markers, and dedicated software that makes it practical to use in the clinic. The system is designed to be used with multiple retroreflective markers to monitor not only the position, but also the posture of the patient in real time. Specific features of the system include the following: (1) The system reports an absolute misalignment at several points on a patient and also provides feedback on any necessary adjustments in terms of site-specific setup parameters, such as focus-to-surface distance (PIN), superior and inferior alignment, and chest-wall angle. (2) The system is based on a set of predefined templates containing the number and position of control points and feedback parameters developed for different treatment sites. (3) A noninvasive IR-based "virtual portal vision" procedure projects organ contours in the beam's-eye-view (BEV) based on the IR marker locations obtained in real time and compares them with digitally reconstructed radiographs (DRRs) from CT simulation. Assuming good correlation between external markers and internal anatomy, the system offers the possibility of mimicking a verification procedure without taking port-films, which can potentially reduce the setup time. In this paper, we concentrate on the system properties and performance while initial applications on a number of clinical sites are ongoing. Accuracy and precision of this system are evaluated in the context of breast/chest treatments using rigid phantoms. The system has an intrinsic uncertainty of +/- 1 mm. When two systems in different rooms (CT and treatment rooms) are used for correlating positional information, the uncertainty is less than 2 mm. C1 Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. RP Lyatskaya, Y (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. EM ylyatskaya@lroc.harvard.edu NR 25 TC 5 Z9 5 U1 0 U2 4 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2006 VL 7 IS 2 BP 18 EP 37 PG 20 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 180DX UT WOS:000247343000003 PM 17533324 ER PT J AU Berbeco, RI Pope, CJ Jiang, SB AF Berbeco, Ross I. Pope, Cynthia J. Jiang, Steve B. TI Measurement of the interplay effect in lung IMRT treatment using EDR2 films SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE radiotherapy; IMRT; organ motion; lung treatment; interplay effect ID RADIATION-THERAPY SMART; FRACTION ORGAN MOTION; INTRAFRACTION MOTION; DOSE DELIVERY; RADIOTHERAPY; ISSUES AB Intrafraction organ motion during the dynamic delivery of intensity-modulated radiation therapy (IMRT) treatment of lung tumors may cause unexpected hot/cold spots within the target volume, due to the interplay effect between tumor motion and multileaf collimator (MLC) leaf motion. In the past, this has been investigated through theoretical analysis, computer simulation, and experimental measurement using an ionization chamber dosimeter. In the work presented here, the interplay effect was studied experimentally in 2D, using Kodak EDR2 films. A five-field lung IMRT plan was delivered to a solid water phantom with embedded film. The phantom was placed on a motor-driven platform with a sinusoidal motion to simulate the respiration-induced tumor motion. The delivery of each field began at one of eight equally spaced initial breathing phases. The dose distribution for each treatment fraction was estimated by combining the dose distributions for all fields with randomly sampled initial breathing phases. The dose variation caused by the interplay effect was estimated by looking at the dose values from 1000 trials of 30 fractions. It was found that, on a day-to-day basis, the standard deviation of the dose to a given pixel in the high-dose region could be as high as 2% to 4% due to the motion interplay effect. After 30 fractions, the standard deviation in the dose to each pixel is reduced to 0.4% to 0.7%. However, compared to the static delivery, the dose distribution from a 30-fraction case in the presence of motion shows some underdosing in the region of interest. We found that the maximum dose in the target remains within 1% of the maximum dose in the static case, but the minimum dose in the target is most likely to be about 6% lower than the static case. Our results indicate that there can be some underdosing of the tumor due to the interplay effect in lung IMRT delivery over the entire course of a 30-fraction treatment. C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Berbeco, RI (reprint author), Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. EM rberbeco@lroc.harvard.edu NR 22 TC 41 Z9 41 U1 1 U2 3 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2006 VL 7 IS 4 BP 33 EP 42 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 180DZ UT WOS:000247343200004 PM 17533350 ER PT J AU Xie, AL Skatrud, JB Puleo, DS Dempsey, JA AF Xie, AL Skatrud, JB Puleo, DS Dempsey, JA TI Influence of arterial O-2 on the susceptibility to posthyperventilation apnea during sleep SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE apnea threshold ID CONGESTIVE-HEART-FAILURE; OXYGEN-SENSING NEURONS; CARBON-DIOXIDE; VENTILATORY RESPONSE; MECHANICAL VENTILATION; RESPIRATORY RESPONSE; STEP CHANGES; HYPOXIA; CO2; CHEMORECEPTOR AB To investigate the contribution of the peripheral chemoreceptors to the susceptibility to posthyperventilation apnea, we evaluated the time course and magnitude of hypocapnia required to produce apnea at different levels of peripheral chemoreceptor activation produced by exposure to three levels of inspired P-O2. We measured the apneic threshold and the apnea latency in nine normal sleeping subjects in response to augmented breaths during normoxia ( room air), hypoxia ( arterial O-2 saturation = 78-80%), and hyperoxia ( inspired O-2 fraction = 50 - 52%). Pressure support mechanical ventilation in the assist mode was employed to introduce a single or multiple numbers of consecutive, sighlike breaths to cause apnea. The apnea latency was measured from the end inspiration of the first augmented breath to the onset of apnea. It was 12.2 +/- 1.1 s during normoxia, which was similar to the lung-to-ear circulation delay of 11.7 s in these subjects. Hypoxia shortened the apnea latency (6.3 +/- 0.8 s; P < 0.05), whereas hyperoxia prolonged it ( 71.5 +/- 13.8 s; P < 0.01). The apneic threshold end-tidal P-CO2 ( PETCO2) was defined as the PETCO2 at the onset of apnea. During hypoxia, the apneic threshold PETCO2 was higher ( 38.9 +/- 1.7 Torr; P < 0.01) compared with normoxia ( 35.8 +/- 1.1; Torr); during hyperoxia, it was lower ( 33.0 +/- 0.8 Torr; P < 0.05). Furthermore, the difference between the eupneic PETCO2 and apneic threshold PETCO2 was smaller during hypoxia ( 3.0 +/- 1.0 Torr P < 001) and greater during hyperoxia ( 10.6 +/- 0.8 Torr; P < 0.05) compared with normoxia ( 8.0 +/- 0.6 Torr). Correspondingly, the hypocapnic ventilatory response to CO2 below the eupneic PETCO2 was increased by hypoxia (3.44 +/- 0.63 l (.) min(-1) (.) Torr(-1); P < 0.05) and decreased by hyperoxia ( 0.63 +/- 0.04 l (.) min(-1) (.) Torr(-1); P < 0.05) compared with normoxia ( 0.79 +/- 0.05 l (.) min(-1) (.) Torr(-1)). These findings indicate that posthyperventilation apnea is initiated by the peripheral chemoreceptors and that the varying susceptibility to apnea during hypoxia vs. hyperoxia is influenced by the relative activity of these receptors. C1 William S Middleton Mem Vet Adm Med Ctr, Pulm Physiol Lab, Madison, WI 53705 USA. Univ Wisconsin, Dept Med, Madison, WI USA. Univ Wisconsin, Dept Populat & Hlth Sci, Madison, WI USA. RP Xie, AL (reprint author), William S Middleton Mem Vet Adm Med Ctr, Pulm Physiol Lab, 2500 Overlook Terrace, Madison, WI 53705 USA. EM axie@facstaff.wisc.edu NR 52 TC 27 Z9 27 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD JAN PY 2006 VL 100 IS 1 BP 171 EP 177 DI 10.1152/japplphysiol.00440.2005 PG 7 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 993SC UT WOS:000233974200028 PM 16179400 ER PT J AU Edwards, RL Edwards, AD AF Edwards, Robert L. Edwards, Annabel D. TI Life history and ecology of the armored spider Monoblemma muchmorei (Araneae, Tetrablemmidae) SO JOURNAL OF ARACHNOLOGY LA English DT Article DE bamboo litter; reproduction; predation; Puerto Rico; leaf litter AB The armored spider Monoblemma muchmorei Shear 1978 occurs in the wet subtropical forest of the Caribbean National Forest, Luquillo, Puerto Rico. It is found almost entirely in bamboo litter between 100 and 1 10 in in elevation and shares this habitat with a number of other species of spiders, ants and other small arthropods. The two sexes come together with no evidence of prior courtship, mate, and may remain in copula for many hours. A small decorated egg sac is produced with only one egg in each sac. The female tends the unusually large spiderling for a week or more and appears to offer some protection from other small invertebrates. For reasons not understood, second instar spiders suffered a high mortality rate, up to 70%. In captivity, the adults May live for eight months or more. Observations on the predator-prey interactions among M. muchmorei and other small invertebrates are reported. At least 30 species of spiders in 16 families are found associated with M. muchmorei in the bamboo litter. C1 Massachusetts Gen Hosp, Pain Ctr, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. RP Edwards, RL (reprint author), Box 505, Woods Hole, MA 02543 USA. EM rle@cape.com NR 11 TC 5 Z9 7 U1 1 U2 1 PU AMER ARACHNOLOGICAL SOC PI COLLEGE PARK PA UNIV MARYLAND, DEPT ENTOMOLOGY, 4112 PLANT SCIENCES BLDG, COLLEGE PARK, MD 20742-4454 USA SN 0161-8202 J9 J ARACHNOL JI J. Arachnol. PY 2006 VL 34 IS 3 BP 599 EP 609 DI 10.1636/S04-109.1 PG 11 WC Entomology SC Entomology GA 158EA UT WOS:000245772800013 ER PT J AU Jamali, AA Lozynsky, AJ Harris, WH AF Jamali, AA Lozynsky, AJ Harris, WH TI The effect of surface finish and of vertical ribs on the stability of a cemented femoral stem: An in vitro stair climbing test SO JOURNAL OF ARTHROPLASTY LA English DT Article DE femoral; total hip arthroplasty; cemented; stair climbing; CLS; micromotion ID TOTAL HIP-ARTHROPLASTY; FOLLOW-UP; REPLACEMENT; COMPONENT; PROSTHESIS; GEOMETRY; FAILURE; FATIGUE; ROUGH AB The search for improved femoral fixation in cemented total hip arthroplasty is ongoing. Two design variables, surface finish and stem contour, were evaluated. Sixteen titanium femoral stems of one design were cemented into fiberglass femora. one half of the components had a polished surface and the rest had a roughened finish. Within each group, 4 stems had vertically oriented ribs on the proximal portion and 4 did not. Micromotion was measured in a stair climbing simulator with loading to a joint reaction force of 200 kg for 6 million cycles. Micromotion increased throughout the course of the experiment. Stems with a polished surface had significantly higher micromotion. Although stems with ribs had less micromotion compared with those without ribs, this difference was not statistically significant. C1 Massachusetts Gen Hosp, Orthopaed Biomech & Biomat Lab, Boston, MA 02114 USA. Univ Calif Davis, Med Ctr, Dept Orthopaed Surg, Sacramento, CA 95817 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Dept Orthopaed Surg, Adult Reconstruct Unit, Boston, MA 02114 USA. RP Harris, WH (reprint author), Massachusetts Gen Hosp, Orthopaed Biomech & Biomat Lab, Boston, MA 02114 USA. NR 33 TC 4 Z9 4 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 J9 J ARTHROPLASTY JI J. Arthroplast. PD JAN PY 2006 VL 21 IS 1 BP 122 EP 128 DI 10.1016/j.arth.2005.05.018 PG 7 WC Orthopedics SC Orthopedics GA 014CZ UT WOS:000235457700019 PM 16446196 ER PT J AU Clark, S Pelletier, AJ Brenner, BE Lang, DM Strunk, RC Camargo, CA AF Clark, S Pelletier, AJ Brenner, BE Lang, DM Strunk, RC Camargo, CA TI Feasibility of a national fatal asthma registry: More evidence of IRB variation in evaluation of a standard protocol SO JOURNAL OF ASTHMA LA English DT Article DE Institutional Review Board; HIPAA; asthma; mortality; registry ID RISK-FACTORS AB Purpose. Approximately 4,500 Americans die from asthma each year. Our objective was to determine the feasibility of creating a national fatal asthma registry to better understand this problem. Methods. Using a standard questionnaire, 18 state vital statistics departments and 22 medical examiners offices were contacted in 2001 to assess availability of fatal asthma data. Funding was obtained in 2002 to implement a fatal asthma registry. During 2003, the project was put on hold due to uncertainty about the impact of the Health Insurance Portability and Accountability Act (HIPAA). The project was revived in 2004 when a standard protocol was submitted to Institutional Review Boards (IRBs) in four different states. Results. All vital statistics departments reported that they were able to identify the decedent's name and demographic characteristics. Contact information for a relative or doctor was available in all states. Demographic characteristics and autopsy findings were available from 100% of the medical examiners offices. However, IRBs at the four institutions required major protocol modifications, including language and approach for contacting next of kin. Conclusion. Availability of demographic and clinical data across states is consistent. The creation of a national fatal asthma registry appears feasible, but different IRB interpretations of what is permissible preclude a standard approach across states. C1 Massachusetts Gen Hosp, Dept Emergency Med, EMNet Coordinat Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Univ Arkansas Med Sci, Little Rock, AR 72205 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. St Louis Childrens Hosp, St Louis, MO 63178 USA. RP Clark, S (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, EMNet Coordinat Ctr, 326 Cambridge St,Suite 410, Boston, MA 02114 USA. EM sclark3@partners.org FU NIAID NIH HHS [AI-52338]; NIEHS NIH HHS [T32 ES07069] NR 17 TC 13 Z9 13 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PY 2006 VL 43 IS 1 BP 19 EP 23 DI 10.1080/00102200500446896 PG 5 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 008OQ UT WOS:000235050700003 PM 16448960 ER PT J AU Sweitzer, R Scholz, C Montezuma, S Rizzo, JF AF Sweitzer, R Scholz, C Montezuma, S Rizzo, JF TI Evaluation of subretinal implants coated with amorphous aluminum oxide and diamond-like carbon SO JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS LA English DT Article DE rentinal prosthesis; biomaterials; diamond-like carbon; amorphous aluminium oxide ID CENTRIFUGAL BLOOD PUMP; IN-VITRO; FILMS; COATINGS; BIOCOMPATIBILITY; ACTIVATION; COMPATIBILITY; MACROPHAGES; DEPOSITION; ADHESION AB Retinal prostheses may be used to support patients suffering from age-related macular degeneration (AMD) or retinitis pigmentosa (RP). A hermetic encapsulation of the poly(imide) (PI)-based prosthesis is important in order to prevent the leakage of water and ions into the electric circuitry embedded in the poly(imide) matrix. The deposition of amorphous aluminum oxide (by sputtering) and diamond like carbon (by pulsed laser ablation) were made for applications in retinal prostheses. The thin films obtained were characterized for composition, thickness, adhesion and smoothness by scanning electron microscopy-energy dispersive spectroscopy, atomic force microscopy, profilometry and light microscopy. Biocompatibility was tested in vivo by implanting coated specimen subretinally in the eye of Yucatan pigs. While amorphous aluminum oxide is more readily deposited with sufficient adhesion quality, superior biocompatibility behavior was shown by diamond-like carbon. Amorphous aluminum oxide had more adverse effects and caused more severe damage to the retinal tissue. C1 Univ Alabama, Dept Chem, Huntsville, AL 35899 USA. Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. VA Ctr Innovat Visual Rehabil, Boston, MA USA. RP Scholz, C (reprint author), Univ Alabama, Dept Chem, Huntsville, AL 35899 USA. EM cscholz@chemistry.uah.edu NR 44 TC 12 Z9 13 U1 1 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0883-9115 J9 J BIOACT COMPAT POL JI J. Bioact. Compat. Polym. PD JAN PY 2006 VL 21 IS 1 BP 5 EP 22 DI 10.1177/0883911506060202 PG 18 WC Biotechnology & Applied Microbiology; Materials Science, Biomaterials; Polymer Science SC Biotechnology & Applied Microbiology; Materials Science; Polymer Science GA 002ZX UT WOS:000234652500001 ER PT J AU Bellino, S Fulcheri, M Zizza, M Paradiso, E Conti, CM Doyle, R Bogetto, F AF Bellino, S. Fulcheri, M. Zizza, M. Paradiso, E. Conti, C. M. Doyle, R. Bogetto, F. TI Psychometric comparison of students in medicine and other faculties: social factors and psychologic symptoms SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS LA English DT Article DE medical students; university faculties; personality; psychiatric symptoms ID PERSONALITY DIAGNOSTIC QUESTIONNAIRE; UNIVERSITY-STUDENTS; MENTAL-HEALTH AB Few studies have investigated personality and psychopathological profiles associated to the choice of university education. Our study examined students from four faculties of Turin University, in Turin, Italy (Medicine, Engineering, Education, Law), comparing sociodemographic features, personality characteristics and psychiatric symptoms. A heterogeneous group of 1,323 students were assessed using a semistructured interview, the Personality Diagnostic Questionnaire-Revised (PDQ-R), and the Symptoms Checklist 90 (SCL-90). Statistical analysis included four logistic regression models, each fitted for one faculty, considering the other three as a control group. Associations were found in Medical and Engineering students concerning type of high school, school final score, and father's socioeducational level. Factors associated with students of Law and Education included socioeducational characteristics, but stronger correlations were seen with PDQ-R personality scales and SCL-90 symptom clusters. In conclusion, four different profiles were identified. Medicine was not significantly related to personality and psychiatric factors. Engineering was related to male gender, choice of technical high school and father's social level. Law was related to female gender and narcissistic personality profile. These data may be useful for counseling activities addressed to high school and university students. C1 [Fulcheri, M.] Univ G dAnnunzio, Sch Psychol, Unit Clin Psychol, Chieti, Italy. [Bellino, S.; Zizza, M.; Paradiso, E.; Bogetto, F.] Univ Turin, Sch Med, Dept Neurosci, Unit Psychiat, I-10124 Turin, Italy. [Conti, C. M.] Univ G dAnnunzio, Sch Med, Immunol Unit, Chieti, Italy. [Doyle, R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Fulcheri, M (reprint author), Univ G dAnnunzio, Sch Psychol, Unit Clin Psychol, Chieti, Italy. OI Fulcheri, Mario/0000-0002-2389-9800 NR 32 TC 3 Z9 3 U1 0 U2 2 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 0393-974X J9 J BIOL REG HOMEOS AG JI J. Biol. Regul. Homeost. Agents PY 2006 VL 20 IS 3-4 BP 73 EP 79 PG 7 WC Endocrinology & Metabolism; Immunology; Medicine, Research & Experimental; Physiology SC Endocrinology & Metabolism; Immunology; Research & Experimental Medicine; Physiology GA 256HZ UT WOS:000252720500005 PM 18187022 ER PT J AU DeFrate, LE van der Ven, A Boyer, PJ Gill, TJ Li, GA AF DeFrate, LE van der Ven, A Boyer, PJ Gill, TJ Li, GA TI The measurement of the variation in the surface strains of Achilles tendon grafts using imaging techniques SO JOURNAL OF BIOMECHANICS LA English DT Article DE soft tissue; biomechanics; tensile testing; material properties; tendon; ligament ID HUMAN PATELLAR TENDON; MEDIAL COLLATERAL LIGAMENT; ANTERIOR CRUCIATE LIGAMENT; MECHANICAL-PROPERTIES; VISCOELASTIC PROPERTIES; TENSILE; AGE; RESPONSES; MODEL AB Uniaxial tensile tests are commonly used to characterize the structural and material properties of tendons and ligaments. During these tests, the stress and strain distributions applied to the specimen are assumed to be uniform. However, few studies have investigated the strain distributions throughout the tissue. The purpose of this study was to use imaging techniques to measure the strains around the circumference of 11 mm wide Achilles tendon grafts during a uniaxial tensile test. Pairs of radiopaque beads with a diameter of 2 mm were affixed around the midsubstance of the tendon in four different locations. The motion of the beads was recorded using a cine fluoroscope. This system was shown to measure the displacement of the beads with an accuracy of 0.02 mm. During the uniaxial tensile test, large variations in local tissue strains were observed. At 10 MPa of applied stress, the local tissue strain varied from an average of 2.5-8.7%, an increase in strain of more than three times. As a result of these large variations, the modulus calculated from the stress-strain data varied from an average of 217 to 897 MPa, an increase of approximately 4 times. Furthermore, these data suggest that underestimates of the elastic modulus may result if a uniform strain distribution is assumed. These results indicate that during uniaxial tensile tests, the assumption of uniform stress and strain distributions should be carefully considered and small, uniform specimens should be used when measuring the material properties of soft tissues. (c) 2005 Elsevier Ltd. All rights reserved. C1 Massachusetts Gen Hosp, Dept Orthopaed Surg, Bioengn Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. MIT, Dept Mech Engn, Cambridge, MA USA. Tufts Univ, Sch Med, Boston, MA USA. RP Li, GA (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Bioengn Lab, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA. EM gli1@partners.org NR 28 TC 15 Z9 15 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 J9 J BIOMECH JI J. Biomech. PY 2006 VL 39 IS 3 BP 399 EP 405 DI 10.1016/j.jbiomech.2004.12.021 PG 7 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 006BH UT WOS:000234869600001 PM 16389080 ER PT J AU Li, GA Pierce, JE Herndon, JH AF Li, GA Pierce, JE Herndon, JH TI A global optimization method for prediction of muscle forces of human musculoskeletal system SO JOURNAL OF BIOMECHANICS LA English DT Article DE optimization; joint biomechanics; inverse dynamic optimization; muscle forces ID INVERSE DYNAMIC OPTIMIZATION; ELBOW JOINT; BIOMECHANICAL ANALYSIS; PASSIVE MOTION; KNEE; KINEMATICS; FLEXION; LOCOMOTION; EXTENSION; EXTREMITY AB Inverse dynamic optimization is a popular method for predicting muscle and joint reaction forces within human musculoskeletal joints. However, the traditional formulation of the optimization method does not include the joint reaction moment in the moment equilibrium equation, potentially violating the equilibrium conditions of the joint. Consequently, the predicted muscle and joint reaction forces are coordinate system-dependent. This paper presents an improved optimization method for the prediction of muscle forces and joint reaction forces. In this method, the location of the rotation center of the joint is used as an optimization variable, and the moment equilibrium equation is formulated with respect to the joint rotation center to represent an accurate moment constraint condition. The predicted muscle and joint reaction forces are independent of the joint coordinate system. The new optimization method was used to predict muscle forces of an elbow joint. The results demonstrated that the joint rotation center location varied with applied loading conditions. The predicted muscle and joint reaction forces were different from those predicted by using the traditional optimization method. The results further demonstrated that the improved optimization method converged to a minimum for the objective function that is smaller than that reached by using the traditional optimization method. Therefore, the joint rotation center location should be involved as a variable in an inverse dynamic optimization method for predicting muscle and joint reaction forces within human musculoskeletal joints. (c) 2005 Elsevier Ltd. All rights reserved. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Orthopaed Surg,Bioengn Lab, Boston, MA 02114 USA. MIT, Dept Mech Engn, Cambridge, MA USA. RP Li, GA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Orthopaed Surg,Bioengn Lab, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA. EM gli1@partners.org NR 26 TC 14 Z9 15 U1 2 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 J9 J BIOMECH JI J. Biomech. PY 2006 VL 39 IS 3 BP 522 EP 529 DI 10.1016/j.jbiomech.2004.11.027 PG 8 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 006BH UT WOS:000234869600014 PM 16389092 ER PT J AU Fischer, KJ Vikoren, THH Ney, S Kovach, C Hasselman, C Agrawal, M Rubash, H Shanbhag, AS AF Fischer, KJ Vikoren, THH Ney, S Kovach, C Hasselman, C Agrawal, M Rubash, H Shanbhag, AS TI Mechanical evaluation of bone samples following alendronate therapy in healthy male dogs SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS LA English DT Article DE biomechanics; bone; alendronate; bisphosphonate ID SEVERE OSTEOGENESIS IMPERFECTA; BIOMECHANICAL PROPERTIES; AMINOBISPHOSPHONATE ALENDRONATE; MICRODAMAGE ACCUMULATION; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; OSTEOPOROTIC WOMEN; MINERAL DENSITY; TRABECULAR BONE; BISPHOSPHONATES AB Alendronate and other bisphosphonates are clinically efficacious in treating postmenopausal osteoporosis, Paget's disease and hypercalcemia associated with malignancy. Because bisphosphonates are being considered for use in younger patients with joint replacements to prevent osteolysis, and for stress fracture prophylaxis in military recruits, it is important to know how bisphosphonate therapy affects healthy bone. We sought to determine whether bones from healthy male dogs exhibit alterations in structural or mechanical properties following alendronate treatment for 23 weeks. We tested trabecular tissue samples in compression and determined tissue ash density. We tested whole long bones in bending and torsion. For trabecular samples, we evaluated trabecular modulus, strength, and density. For whole bone specimens, we compared structural stiffness and ultimate load. We found no significant differences in any measure, between canines treated with alendronate for 23 weeks and controls, although we found consistent trends toward higher properties in the treated group. Correlation analysis revealed significant relationships between stiffness and strength measures for each mechanical test. Our results indicate bisphosphonate treatment in healthy canines does not weaken the properties of bone. The trends indicate a slight positive overall effect of alendronate treatment on the mechanical properties of healthy canine bone. (c) 2005 Wiley Periodicals, Inc. C1 Univ Kansas, Dept Mech Engn, Lawrence, KS 66045 USA. Univ Pittsburgh, Dept Orthopaed Surg, Musculoskeletal Res Ctr, Pittsburgh, PA 15219 USA. Univ Texas, Hlth Sci Ctr, Musculoskeletal Bioengn Ctr, San Antonio, TX 78240 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Biomat Lab, Boston, MA 02114 USA. RP Fischer, KJ (reprint author), Univ Kansas, Dept Mech Engn, Learned Hall,1530 W 15th St,Room 3138, Lawrence, KS 66045 USA. EM fischer@ku.edu NR 32 TC 7 Z9 8 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4973 J9 J BIOMED MATER RES B JI J. Biomed. Mater. Res. Part B PD JAN PY 2006 VL 76B IS 1 BP 143 EP 148 DI 10.1002/jbm.b.30341 PG 6 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 998FO UT WOS:000234304200019 PM 16047323 ER PT J AU Marin, NM MacKinnon, N MacAulay, C Chang, SK Atkinson, EN Cox, D Serachitopol, D Pikkula, B Follen, M Richards-Kortum, R AF Marin, NM MacKinnon, N MacAulay, C Chang, SK Atkinson, EN Cox, D Serachitopol, D Pikkula, B Follen, M Richards-Kortum, R TI Calibration standards for multicenter clinical trials of fluorescence spectroscopy for in vivo diagnosis SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE cervix; fluorescence spectroscopy; tissue diagnostics; optical standards; optics instrumentation; calibration ID MULTIVARIATE STATISTICAL ALGORITHM; INTRAEPITHELIAL NEOPLASIA CIN; CERVICAL PRECANCER DETECTION; TURBID MEDIA; INTRINSIC FLUORESCENCE; EXCITATION WAVELENGTHS; CONFOCAL MICROSCOPY; TISSUE FLUORESCENCE; LIGHT-SCATTERING; REFLECTANCE AB In the context of clinical trials, calibration protocols for optical instruments that ensure measurement accuracy and the ability to carry out meaningful comparisons of data acquired from multiple instruments are required. A series of calibration standards and procedures are presented to assess technical feasibility of optical devices for cervical precancer detection. Measurements of positive and negative standards, and tissue are made with two generations of research grade spectrometers. Calibration accuracy, ability of standards to correct and account for changes in experimental conditions, and device components are analyzed. The relative frequency of measured calibration standards is investigated retrospectively using statistical analysis of trends in instrument performance. Fluorescence measurements of standards and tissue made with completely different spectrometers show good agreement in intensity and lineshape. Frequency of wavelength calibration standards is increased to every 2 h to compensate for thermal drifts in grating mount. Variations in illumination energy detected between standards and patient measurements require probe redesign to allow for simultaneous acquisition of illumination power with every patient measurement. The use of frequent and well-characterized standards enables meaningful comparison of data from multiple devices and unambiguous interpretation of experiments among the biomedical optics community. (c) 2006 Society of Photo-Optical Instrumentation Engineers. C1 Rice Univ, Dept Bioengn, Houston, TX 77005 USA. Univ Texas, Dept Biomed Engn, Austin, TX 78712 USA. British Columbia Canc Res Ctr, Canc Imaging Dept, Vancouver, BC V5Z 1L3, Canada. Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA. Rice Univ, Dept Stat, Houston, TX 77005 USA. Univ Texas, MD Anderson Canc Ctr, Ctr Biomed Engn, Houston, TX 77030 USA. Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA. Univ Texas, Hlth Sci Ctr, Dept Obstet Gynecol & Reprod Sci, Houston, TX 77030 USA. RP Richards-Kortum, R (reprint author), Rice Univ, Dept Bioengn, 6100 Main St, Houston, TX 77005 USA. EM rkortum@rice.edu RI MacKinnon, Nicholas/G-3314-2012; Richards-Kortum, Rebecca/P-4074-2014; MacAulay, Calum/K-1795-2016 OI MacKinnon, Nicholas/0000-0001-7124-7420; Richards-Kortum, Rebecca/0000-0003-2347-9467; FU NCI NIH HHS [2PO1CA082710-06] NR 33 TC 21 Z9 22 U1 1 U2 1 PU SPIE-INT SOCIETY OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2006 VL 11 IS 1 AR 014010 DI 10.1117/1.2166389 PG 14 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 024CR UT WOS:000236173100011 PM 16526887 ER PT J AU Jassal, DS Nomura, CH Neilan, TG Holmvang, G Fatima, U Januzzi, J Brady, TJ Cury, RC AF Jassal, DS Nomura, CH Neilan, TG Holmvang, G Fatima, U Januzzi, J Brady, TJ Cury, RC TI Delayed enhancement cardiac MR imaging in noncompaction of left ventricular myocardium SO JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE LA English DT Article DE cardiac MRI; echocardiography; cardiomyopathy AB A 49-year-old female with a history of paroxysmal atrial fibrillation, presented with worsening dyspnea on minimal exertion. During the follow-up period, transthoracic echocardiography and cardiac magnetic resonance imaging (CMR) were consistent with the diagnosis of noncompaction of the left ventricle. Delayed-enhancement CMR demonstrated hyperenhancement of the prominent trabeculations located at the mid and apical portions of the left ventricle, suggesting areas of fibrosis. Although previous cases of left ventricular noncompaction diagnosed with CMR have been described in the literature, this is the first case to describe the utility of delayed-enhancement imaging in the pathohistological confirmation of myocardial fibrosis and scarring in the hypertrabeculated myocardium. C1 Massachusetts Gen Hosp, Dept Cardiol, Cardiac Ultrasound Lab, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Radiol, Cardiac MRI Unit, Boston, MA 02114 USA. RP Jassal, DS (reprint author), Massachusetts Gen Hosp, Dept Cardiol, Cardiac Ultrasound Lab, VBK-508,55 Fruit St, Boston, MA 02114 USA. EM djassal@partners.org RI Nomura, Cesar/H-1636-2012 NR 7 TC 14 Z9 16 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1097-6647 J9 J CARDIOV MAGN RESON JI J. Cardiov. Magn. Reson. PY 2006 VL 8 IS 3 BP 489 EP 491 DI 10.1080/10976640600599502 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 048ZV UT WOS:000237986000011 PM 16755837 ER PT J AU Henderson, BA Naveiras, M Butler, N Hertzmark, E Ferrufino-Ponce, Z AF Henderson, BA Naveiras, M Butler, N Hertzmark, E Ferrufino-Ponce, Z TI Incidence and causes of ocular surgery cancellations in an ambulatory surgical center SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY LA English DT Article ID ELECTIVE SURGERY; UNITED-STATES; OPERATIONS; CATARACT AB PURPOSE: To report the incidence and analyze potentially preventable causes of ocular surgery cancellations. SETTING: Ambulatory Care Surgical Center of the Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA. METHODS: A retrospective review of the ambulatory surgical center cancellation records and patient medical records from December 2001 to December 2003 was conducted. The primary statistical analysis was conditional logistic regression. RESULTS: Three hundred seventy-nine of 7153 (5.3%) ambulatory ophthalmic surgeries were cancelled within 24 hours of the scheduled start time. Cancellation rates varied by patient age, with the rate among children being highest (8.7%) and that among older patients (age 60+) lowest (4.9%; P =.08). Surgeons who performed at least 4 surgeries per month on average had the lowest cancellation rate (P =.08). Cancellations occurred less frequently in warmer months (June, 3.3%; August, 4.2%) than during the rest of the seasons (P <.001). The highest incidence of cancellations occurred in February (7.8%) and the lowest in June (3.3%). Of the total causes, 41% were considered "preventable," 45% "unpreventable," and 14% "no reason given." Cancellations deemed preventable were lower in general anesthesia cases (1.0%) than in local anesthesia cases (2.0%; P =.02). Preventable cancellation rates also varied by procedure and were statistically significant. CONCLUSIONS: Among ambulatory ophthalmic surgeries, there was a higher incidence of late cancellations in pediatric cases. Late cancellation rates were highest in cases scheduled in the winter, especially in February. Of the reasons documented for cancellations, 41% were considered "preventable" with proper preoperative counseling and instructions. The costs of late cancellations to the particular institution are estimated to be at least $100 000 per year, or nearly I month of scheduled surgeries in a 2-year period. C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. Tech Univ Dresden, D-8027 Dresden, Germany. McGill Univ, Montreal, PQ H3A 2T5, Canada. Harvard Univ, Sch Publ Hlth, Boston, MA 02114 USA. Harvard Univ, Sch Med, Mt Auburn Hosp, Cambridge, MA 02138 USA. RP Henderson, BA (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA. EM bhenderson@meei.harvard.edu NR 19 TC 6 Z9 6 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0886-3350 J9 J CATARACT REFR SURG JI J. Cataract. Refract. Surg. PD JAN PY 2006 VL 32 IS 1 BP 95 EP 102 DI 10.1016/j.jcrs.2005.11.013 PG 8 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA 024MO UT WOS:000236199300028 PM 16516786 ER PT J AU Horch, RE AF Horch, Raymund E. TI Tribute to the vacantis - Dr. Joseph P. Vacanti, MD SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE LA English DT Biographical-Item C1 Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Horch, RE (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAROL DAVILA UNIV PRESS PI BUCHARESST PA 8 EROILOR SANITARI BLVD, BUCHARESST 76241, ROMANIA SN 1582-1838 J9 J CELL MOL MED JI J. Cell. Mol. Med. PD JAN-MAR PY 2006 VL 10 IS 1 BP 3 EP 3 PG 1 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 074FR UT WOS:000239798600002 ER PT J AU Levine, AJ Hardy, DJ Miller, E Castellon, SA Longshore, D Hinkin, CH AF Levine, AJ Hardy, DJ Miller, E Castellon, SA Longshore, D Hinkin, CH TI The effect of recent stimulant use on sustained attention in HIV-Infected adults SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article ID ABSTINENT COCAINE ABUSERS; IMMUNODEFICIENCY-VIRUS-INFECTION; AIDS DEMENTIA COMPLEX; CEREBRAL VOLUME LOSS; NEUROPSYCHOLOGICAL CONSEQUENCES; COGNITIVE FUNCTION; WORKING-MEMORY; DRUG-ABUSE; PERFORMANCE; DEFICITS AB Evidence suggests that stimulant use may exacerbate the deleterious cognitive effects of HIV, and that it has similar neuropathological consequences. In the current study, we examined the effect of recent stimulant use on sustained attention in adults infected with HIV. The sample consisted of 23 non-drug users and 17 stimulant users (cocaine and/or methamphetamine), all who were HIV-positive. Drug use was determined via urine toxicology. Sustained attention was assessed with the Conners' Continuous Performance Task - second edition (CPT-II). Groups were compared on overall performance variables, as well as patterns of performance across time. Compared to the non-drug users, stimulant users showed a gradual increase in reaction time variability and omission errors. Stimulant users' scores indicated impaired vigilance relative to an age and gender-matched normative sample. The groups were equivalent on other measures of attention, global neuropsychological functioning, mood, and demographic variables. The results indicate that recent stimulant use among HIV-infected adults adversely affects sustained attention. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Inst Neuropsychiat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Loyola Marymount Univ, Dept Psychol, Los Angeles, CA 90045 USA. RP Levine, AJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Inst Neuropsychiat, 760 Westwood Pl,Room C8-747, Los Angeles, CA 90024 USA. EM ajlevine@mednet.ucla.edu FU NIDA NIH HHS [R01 DA013799, R01 DA13799]; NIMH NIH HHS [R01 MH58552, R01 MH058552] NR 63 TC 24 Z9 25 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JAN PY 2006 VL 28 IS 1 BP 29 EP 42 DI 10.1080/13803390490918066 PG 14 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 014XX UT WOS:000235515100003 PM 16448974 ER PT J AU Pope, JW Kern, RS AF Pope, JW Kern, RS TI An "Errorful" learning deficit in schizophrenia? SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article ID YOUNG NONPSYCHOTIC SCHIZOPHRENICS; SEVERE MENTAL-ILLNESS; NEUROCOGNITIVE DEFICITS; MEMORY; REHABILITATION; IMPAIRMENT AB Disturbances in learning are prominent in schizophrenia. The present study examined the effect of committing mistakes (errors) on learning in schizophrenia. Subjects included schizophrenia and schizoaffective disorder patients (n = 36) and healthy adults (n = 22) who were administered a word-stem completion task under "errorfree" (no guessing) and "errorful" (guessing) conditions. The data were analyzed using a 2 (group) x 2 (order) x 2 (condition) repeated-measures ANOVA and by comparing standard residualized scores between patients and controls. The results from the ANOVA revealed a significant group x condition interaction with patients showing greater impairment relative to controls on the errorful versus errorfree condition. Similarly, contrasts of standard residualized scores revealed patients' scores on the errorful condition to be deviant from that of healthy adults. The findings implicate problems in the ability to self-correct and suggest that rehabilitation efforts incorporating errorless learning methods may benefit persons with schizophrenia. C1 Fuller Grad Sch Psychol, Pasadena, CA USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Dept Vet Affairs VISN 22 Mental Illness Res Educ, Los Angeles, CA USA. RP Kern, RS (reprint author), VA Greater Los Angeles Healthcare Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM rkern@ucla.edu NR 34 TC 19 Z9 19 U1 4 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JAN PY 2006 VL 28 IS 1 BP 101 EP 110 DI 10.1080/13803390490918138 PG 10 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 014XX UT WOS:000235515100008 PM 16448979 ER PT J AU Motzer, RJ Michaelson, MD Redman, BG Hudes, GR Wilding, G Figlin, RA Ginsberg, MS Kim, ST Baum, CM DePrimo, SE Li, JZ Bello, CL Theuer, CP George, DJ Rini, BI AF Motzer, RJ Michaelson, MD Redman, BG Hudes, GR Wilding, G Figlin, RA Ginsberg, MS Kim, ST Baum, CM DePrimo, SE Li, JZ Bello, CL Theuer, CP George, DJ Rini, BI TI Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 40th Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 05-08, 2004 CL New Orleans, LA SP Amer Soc Clin Oncol ID TYROSINE KINASE INHIBITOR; TUMOR-SUPPRESSOR GENE; LUNG-CANCER; IN-VIVO; THERAPY; VHL; INTERLEUKIN-2; INTERFERON; MUTATIONS; TRIAL AB Purpose Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in high expression of pro-angiogenic growth factors: vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). SU11248 (Sunitinib malate), a small molecule inhibitor with high binding affinity for VEGF and PDGF receptors, was tested for clinical activity in patients with metastatic RCC. Patients and Methods Patients with metastatic RCC and progression on first-line cytokine therapy were enrolled onto a multicenter phase II trial. SU11248 monotherapy was administered in repeated 6-week cycles of daily oral therapy for 4 weeks, followed by 2 weeks off, Overall response rate was the primary end point, and time to progression and safety were secondary end points. Results Twenty-five (40%) of 63 patients treated with SU11248 achieved partial responses; 17 additional patients (27%) demonstrated stable disease lasting >= 3 months, Median time to progression in the 63 patients was 8.7 months. Dosing was generally tolerated with manageable toxicities, Conclusion SU11248, a multitargeted receptor tyrosine kinase inhibitor of VEGF and PDGF receptors, demonstrates antitumor activity in metastatic RCC as second-line therapy, a setting where no effective systemic therapy is presently recognized. The genetics of RCC and these promising clinical results support the hypothesis that VEGF and PDGF receptor-mediated signaling is an effective therapeutic target in RCC. C1 Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, Div Solid Tumor Oncol, Dept Med, New York, NY 10021 USA. Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, Div Solid Tumor Oncol, Dept Radiol, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Univ Wisconsin, Madison, WI USA. Univ Calif Los Angeles, Los Angeles, CA USA. Pfizer Inc, La Jolla, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Motzer, RJ (reprint author), Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, Div Solid Tumor Oncol, Dept Med, 1275 York Ave, New York, NY 10021 USA. EM motzerr@mskcc.org NR 43 TC 1128 Z9 1194 U1 3 U2 41 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2006 VL 24 IS 1 BP 16 EP 24 DI 10.1200/JCO.2005.022574 PG 9 WC Oncology SC Oncology GA 998QS UT WOS:000234334700007 PM 16330672 ER PT J AU Keating, NL Landrum, MB Guadagnoli, E Winer, EP Ayanian, JZ AF Keating, NL Landrum, MB Guadagnoli, E Winer, EP Ayanian, JZ TI Factors related to underuse of surveillance mammography among breast cancer survivors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID SEER-MEDICARE DATA; HEALTH-INSURANCE; OLDER WOMEN; SOCIOECONOMIC CHARACTERISTICS; RACIAL-DIFFERENCES; COLORECTAL-CANCER; LINKED MEDICARE; UNITED-STATES; CLAIMS DATA; CARE AB Purpose Many older breast cancer survivors do not undergo annual mammography despite guideline recommendations. We identified factors associated with underuse of surveillance mammography and examined whether variation was explained by differences in follow-up care. Patients and Methods We used Surveillance, Epidemiology, and End Results-Medicare data to identify a population-based sample of 44,511 women fee-for-service Medicare enrollees aged >= 65 years who were diagnosed with stage I or II breast cancer in 1992 to 1999 who underwent primary surgical therapy. We assessed factors associated with mammography during months 7 to 18, 19 to 30, and 31 to 42 after breast cancer diagnosis using repeated-measures logistic regression; and we examined whether follow-up care with providers of various specialties explained variation in mammography use. Results Only three quarters of women (77.6%) underwent mammography during months 7 to 18 after diagnosis, and only 56.7% had mammography yearly over 3 years. In multivariable analyses, women who were older, black, unmarried, and living in certain regions were less likely than other women to undergo surveillance mammography (all P <.05). Patients with more visits and patients who continued to see a medical oncologist, radiation oncologist, or surgeon were most likely to have mammograms (P <.001); however, adjusting for visits with providers did not explain the lower mammography rates based on age, race, marital status, and geographic region. Conclusion Many elderly breast cancer survivors do not undergo annual surveillance mammography, particularly women who are older, black, and unmarried, and this underuse was not explained by access to follow-up care. New strategies are needed to increase use of surveillance mammography and decrease variations based on nonclinical factors that are likely unrelated to appropriateness of medical care. C1 Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. Brigham & Womens Hosp, Div Gen Internal Med, Dept Med, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA. RP Keating, NL (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM keating@hcp.med.harvard.edu NR 64 TC 74 Z9 75 U1 2 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2006 VL 24 IS 1 BP 85 EP 94 DI 10.1200/JCO.2005.02.4174 PG 10 WC Oncology SC Oncology GA 998QS UT WOS:000234334700016 PM 16382117 ER PT J AU Bernstein, ML Devidas, M Lafreniere, D Souid, AK Meyers, PA Gebhardt, M Stine, K Nicholas, R Perlman, EJ Dubowy, R Wainer, IW Dickman, PS Link, MP Goorin, A Grier, HE AF Bernstein, ML Devidas, M Lafreniere, D Souid, AK Meyers, PA Gebhardt, M Stine, K Nicholas, R Perlman, EJ Dubowy, R Wainer, IW Dickman, PS Link, MP Goorin, A Grier, HE TI Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric oncology group/children's cancer group phase II study 9457 - A report from the children's oncology group SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID PRIMITIVE NEUROECTODERMAL TUMOR; SOLID TUMORS; SARCOMA; CYCLOPHOSPHAMIDE; BONE; AMIFOSTINE; TOPOTECAN; ETOPOSIDE; MESNA; TRIAL AB Purpose Prognosis is poor for Ewing sarcoma patients with metastasis at diagnosis. We intensified a five-drug therapy (ifosfamide, etoposide alternated with vincristine, doxorubicin, and cyclophosphamide) using filgrastim but not stem-cell support, We studied topotecan alone and combined with cyclophosphamide in therapeutic windows before the five-drug therapy, A randomly assigned proportion of patients received amifostine as a cytoprotective agent. Patients and Methods Eligible patients were <= 30 years old and had histologically proven Ewing sarcoma or primitive neuroectodermal tumor (PNET) and metastasis at diagnosis, Chemotherapeutlic cycles began every 21 days, after recovery from toxicities. Results One hundred ten of the 117 patients enrolled were eligible. Thirty-six patients received initial topotecan. Three had partial responses (PRs), and 17 had progressive disease (PD), Thirty-seven patients were administered topotecan and cyclophosphamide; 21 of these patients achieved PR, and one patient had PD. In a randomly assigned group of 69 patients, amifostine did not provide myeloprotection, which was measured by absolute neutrophil count, platelet count, or cycle intervals. The best responses to the overall therapy included 45 complete responses, 41 PRs, stable disease in 14 patients, and PD in five patients, For all patients, the 2-year event-free survival (EFS) rate was 24% ( +/- 4%), and the overall survival rate was 46% ( +/- 5%). For the 39 patients with isolated pulmonary metastases, the 2-year EFS rate was 31% ( +/- 7%) compared with 20% ( +/- 5%) for patients with more widespread disease. Conclusion Topotecan had limited activity in patients with Ewing sarcoma or PNET metastatic at diagnosis. The topotecan-cyclophosphamide combination was active. Arnifostine was not myeloprotective, Overall results showed no improvement compared with previous Studies. C1 Hop St Justine, Montreal, PQ H3T 1C5, Canada. Ctr Data, Childrens Oncol Grp, Gainesville, FL USA. SUNY Upstate Med Univ, Syracuse, NY USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Hosp, Boston, MA 02115 USA. Univ Arkansas, Little Rock, AR 72204 USA. Childrens Mem Med Ctr Chicago, Chicago, IL USA. NIA, NIH, Ctr Gerontol Res, Baltimore, MD 21224 USA. Childrens Hosp, Phoenix, AZ USA. Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA. RP Bernstein, ML (reprint author), Hop St Justine, 3174 Cote Ste Catherine Rd, Montreal, PQ H3T 1C5, Canada. EM bernstm@magellan.umontreal.ca OI Meyers, Paul/0000-0001-6146-6101 NR 30 TC 54 Z9 63 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2006 VL 24 IS 1 BP 152 EP 159 DI 10.1200/JCO.2005.02.1717 PG 8 WC Oncology SC Oncology GA 998QS UT WOS:000234334700026 PM 16382125 ER PT J AU Biederman, J AF Biederman, Joseph TI New developments in the treatment of attention-deficit/hyperactivity disorder - Introduction SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Editorial Material ID DEFICIT HYPERACTIVITY DISORDER; GUANFACINE TREATMENT; CHILDREN; METHYLPHENIDATE; ADHD C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Biederman, J (reprint author), 15 Pakrman St,WAC 725, Boston, MA 02114 USA. EM jbiederman@partners.org NR 14 TC 5 Z9 5 U1 1 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 8 BP 3 EP 6 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 076WL UT WOS:000239988700001 ER PT J AU Green, MF AF Green, Michael F. TI Cognitive impairment and functional outcome in schizophrenia and bipolar disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Roundtable Meeting on Improving Cognitive Function and Functional Outcome in Severe Mental Illness CY JAN 13, 2006 CL Dallas, TX ID NEUROCOGNITIVE DEFICITS; CLINICAL-TRIALS; MATRICS; BATTERY AB A considerable amount of evidence supports the relationship between cognitive impairment and functional outcomes in schizophrenia. Cognitive impairment is considered a core feature of schizophrenia that includes problems in speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. These deficits can also serve as an endophenotype for the illness in studies of genetics. Cognition is considered a reasonable treatment target in individuals with schizophrenia, partly because cognitive deficits contribute to poor functional outcomes. Similarly, evidence is beginning to emerge that cognitive impairment may also be a core feature of bipolar disorder. In addition, cognitive deficits adversely affect functional outcomes in bipolar disorder. This evidence suggests that cognition can be considered a reasonable target for intervention in both schizophrenia and bipolar disorder. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Green, MF (reprint author), 300 ULCA Plaza,Rm 2263, Los Angeles, CA 90095 USA. EM mgreen@ucla.edu NR 20 TC 192 Z9 202 U1 3 U2 28 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 9 BP 3 EP 8 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 076WM UT WOS:000239988900001 PM 16965182 ER PT J AU Nierenberg, AA Ostacher, MJ Borrelli, DJ Iosifescu, DV Perlis, RH Desrosiers, A Armistead, MS Calkins, AW Sachs, GS AF Nierenberg, Andrew A. Ostacher, Michael J. Borrelli, David J. Iosifescu, Dan V. Perlis, Roy H. Desrosiers, Astrid Armistead, Molly S. Calkins, Amanda W. Sachs, Gary S. TI The integration of measurement and management for the treatment of bipolar disorder: A STEP-BD model of collaborative care in psychiatry SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID TREATMENT ENHANCEMENT PROGRAM; WEEKLY SYMPTOMATIC STATUS; SHARED DECISION-MAKING; RATING-SCALE; NATURAL-HISTORY; DEPRESSION; COMORBIDITY; PARTICIPANTS; SERVICES; DISEASE AB Patients with bipolar disorder are among the most challenging to treat. These patients frequently present with complex mood and other symptoms that change over time, complex psychiatric and medical comorbid conditions, and multiple medications. Clinicians rarely systematically assess or measure all of these factors and instead rely on memory and general impressions. It is imperative that clinicians systematically track and monitor these relevant variables to ensure treatment decisions are based on precise clinical data. By integrating measurement and management, clinicians and patients can collaborate to assess the effectiveness of treatments and to make joint decisions about critical points at which to adjust treatment. This method was shown to be successful in the National Institute of Mental Health (NIMH) Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). C1 Massachusetts Gen Hosp, Bipolar Clin & Res Program, Boston, MA 02114 USA. RP Nierenberg, AA (reprint author), Massachusetts Gen Hosp, Bipolar Clin & Res Program, 50 Staniford St,5th Floor, Boston, MA 02114 USA. EM ANierenberg@partners.org OI Ostacher, Michael/0000-0003-0353-7535 NR 39 TC 20 Z9 20 U1 0 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 11 BP 3 EP 7 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 088VF UT WOS:000240838500001 PM 17029489 ER PT J AU Sachs, GS AF Sachs, Gary S. TI A review of agitation in mental illness: Burden of illness and underlying pathology SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Review ID CATECHOL O-METHYLTRANSFERASE; ALZHEIMERS-DISEASE; BIPOLAR DISORDER; BEHAVIORAL SYMPTOMS; RATING-SCALE; PSYCHIATRIC-PATIENTS; DEMENTIA; SCHIZOPHRENIA; VIOLENCE; PREVALENCE AB Agitation has been poorly addressed as a unique entity in many psychiatric disorders. Recent medical literature and a range of instruments have measured agitation in various clinical settings. Agitation is a common problem in many patients with schizophrenia, bipolar mania, or dementia. Moreover, agitation adversely impacts many facets of the healing process, including direct patient care, caregiver burden, and community resources. Frontal lobe dysfunction and mutations in the catechol O-methyltransferase (COMT) gene involved in dopamine metabolism and catecholamine inactivation have been linked to agitation in patients with schizophrenia and bipolar disorder. Cerebral impairment and deficits in cognitive function predispose patients with dementia to agitation. In patients with Alzheimer's dementia, both frontal and temporal lobe pathology may be associated with agitation. Addressing agitation as a symptom of psychiatric illness would represent a great opportunity for therapeutic intervention and the alleviation of patient suffering, family burden, and societal costs. C1 Harvard Univ, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. RP Sachs, GS (reprint author), 50 Staniford St,Suite 580, Boston, MA 02114 USA. EM sachsg@bhms.harvard.edu NR 58 TC 26 Z9 26 U1 1 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 10 BP 5 EP 12 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 080IG UT WOS:000240240500002 PM 16965190 ER PT J AU Baldwin, DS Papakostas, GI AF Baldwin, David S. Papakostas, George I. TI Symptoms of fatigue and sleepiness in major depressive disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID BUPROPION SUSTAINED-RELEASE; PLACEBO-CONTROLLED TRIAL; EUROPEAN-SOCIETY II; DOUBLE-BLIND; MODAFINIL AUGMENTATION; PSYCHIATRIC COMORBIDITY; ADJUNCTIVE TREATMENT; SELECTIVE SEROTONIN; PRIMARY-CARE; FLUOXETINE AB Fatigue and sleepiness (hypersomnia) are symptoms that are highly prevalent in patients with major depressive disorder (MDD). Individuals who complain of fatigue but do not have diagnosable depression are at a higher risk for developing MDD later in life than individuals who do not complain of fatigue. Fatigue and sleepiness also appear to be particularly difficult to treat, as they are often encountered as residual symptoms among MDD patients who have remitted following treatment with standard antidepressants. There are 3 main approaches for addressing fatigue and sleepiness in depression: first, prescribing antidepressant medications that are less likely to exacerbate these particular symptoms; second, prescribing antidepressant medications that are more likely to resolve these symptoms; third, the use of adjunctive treatments to specifically target residual fatigue and sleepiness in depression. C1 Harvard Univ, Depress Clin & Res Program, Dept Psychiat, Massachusetts Gen Hosp,Med Sch, Boston, MA 02114 USA. Univ Southampton, Fac Med Hlth & Life Sci, Southampton, Hants, England. RP Papakostas, GI (reprint author), Harvard Univ, Depress Clin & Res Program, Dept Psychiat, Massachusetts Gen Hosp,Med Sch, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM gpapakostas@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 NR 59 TC 69 Z9 71 U1 4 U2 7 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 6 BP 9 EP 15 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 061EH UT WOS:000238853500002 PM 16848671 ER PT J AU Fava, M AF Fava, Maurizio TI Prospective studies of adverse events related to antidepressant discontinuation SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SEROTONIN REUPTAKE INHIBITORS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ABRUPT DISCONTINUATION; WITHDRAWAL SYMPTOMS; PANIC DISORDER; PAROXETINE; DEPRESSION; INTERRUPTION; VENLAFAXINE AB The value of a prospective assessment of discontinuation-emergent symptoms proximal to the termination of antidepressant treatment cannot be overstated. Though varying in frequency and intensity, nearly all classes of antidepressants have been linked with discontinuation reactions and the associated psychological, physical, and somatic discomfort. Spontaneous reports have been typically used to gauge the risks of discontinuation reactions. Judging from a number of prospective studies, spontaneous reports very likely underestimate the occurrence of discontinuation reactions. This probability suggests that systematic inquiry must urgently become a part of the assessment in antidepressant discontinuation studies. Insight into the number and type of events that may occur following antidepressant discontinuation may be gleaned from instruments such as the Discontinuation-Emergent Signs and Symptoms Scale. This article takes a comprehensive view of a number of studies dealing with discontinuation-related adverse events. It discusses key issues in the analysis of incidence rates of antidepressant discontinuation-emergent adverse events such as the obvious bias of both clinicians' and patients' being aware of the treatment discontinuation. This article also looks at early prospective studies of antidepressant discontinuation reactions based on spontaneous reports and discusses, while making the case for, prospective studies based on systematic inquiry. C1 Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02144 USA. RP Fava, M (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 15 Parkman St,ACC 812, Boston, MA 02144 USA. EM mfava@partners.org NR 27 TC 29 Z9 29 U1 0 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 4 BP 14 EP 21 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 047AL UT WOS:000237852100003 PM 16683858 ER PT J AU Souery, D Papakostas, GI Trivedi, MH AF Souery, Daniel Papakostas, George I. Trivedi, Madhukar H. TI Treatment-resistant depression SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID REFRACTORY DEPRESSION; DOUBLE-BLIND; ANTIDEPRESSANT TREATMENT; TREATMENT STRATEGY; RESIDUAL SYMPTOMS; MAJOR DEPRESSION; EFFICACY; FLUOXETINE; VENLAFAXINE; DISORDER AB Treatment-resistant depression (TRD) is a common clinical occurrence among patients treated for major depressive disorder. However, a clear consensus regarding the criteria defining TRD is lacking in the psychiatric community. Many patients who are considered treatment resistant are actually misdiagnosed or inadequately treated. Clinicians need to accurately diagnose TRD by examining primary and secondary (organic) causes of depression and acknowledging paradigm failures that contribute to a misdiagnosis of TRD. A correct determination of what constitutes TRD requires consensus on criteria of treatment response (i.e., dose, duration, and compliance) and on the number of adequate trials required before a patient is determined to be nonresponsive. Additionally, clinical validation of available staging models needs to be completed. While several studies have identified predictors of nonresponse, clinical studies investigating the predictors of resistance following the failure of 2 or more antidepressant trials should be pursued. In managing TRD, 3 pharmacotherapy strategies are in clinical use: optimization of antidepressant dose, augmentation/combination therapies, and switching therapies. However, the optimal strategy for treating TRD has yet to be identified. Therefore, further controlled clinical trials are essential to identify the most effective treatment strategies. C1 Univ Libre Bruxelles, Dept Psychiat, Erasme Hosp, B-1070 Brussels, Belgium. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75230 USA. RP Souery, D (reprint author), Univ Libre Bruxelles, Dept Psychiat, Erasme Hosp, Lennik Rd 808, B-1070 Brussels, Belgium. EM dsouery@ulb.ac.be RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 NR 56 TC 122 Z9 128 U1 4 U2 10 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 6 BP 16 EP 22 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 061EH UT WOS:000238853500003 PM 16848672 ER PT J AU Ostacher, MJ AF Ostacher, Michael J. TI The evidence for antidepressant use in bipolar depression SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID I DEPRESSION; DOUBLE-BLIND; PLACEBO; IMIPRAMINE; DISORDER; IMPACT AB Mood elevation, which includes mania, hypomania, and mixed states, was previously considered the defining symptom of bipolar disorder, but bipolar depression by comparison is actually a much more substantial challenge to diagnose and treat. Recent studies, including research by the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), found that patients with bipolar disorder spend longer periods of time in depressive episodes and are more likely to relapse to depression compared with mania or hypomania. However, the treatment of bipolar depression is hampered by the limited number and varying quality of available studies of pharmacologic treatments to guide clinical decision making. Clinicians should rely on studies with the highest level of evidence (category A) when prescribing appropriate antidepressant treatments. The standard care pathways outlined by STEP-BD to aid clinicians in treating varying phases of bipolar disorder provide data on the use of various treatments for bipolar depression and their outcomes. While some treatments have the potential to induce mania, others appear to have some efficacy without inducing mania. C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Ostacher, MJ (reprint author), Massachusetts Gen Hosp, Dept Psychiat, S-50-5,55 Fruit St, Boston, MA 02114 USA. EM mostacher@partners.org OI Ostacher, Michael/0000-0003-0353-7535 NR 16 TC 10 Z9 10 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 11 BP 18 EP 21 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 088VF UT WOS:000240838500004 PM 17029492 ER PT J AU Doyle, AE AF Doyle, Alysa E. TI Executive functions in attention-deficit/hyperactivity disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Teleconference on New Developments in the Treatment of Attention-Deficit/Hyperactivity Disorder CY MAY 16, 2005 CL ELECTR NETWORK ID DEFICIT-HYPERACTIVITY DISORDER; COGNITIVE-ENERGETIC MODEL; NEUROPSYCHOLOGICAL PERFORMANCE; WORKING-MEMORY; RESPONSE-INHIBITION; DELAY AVERSION; DEVELOPMENTAL PSYCHOPATHOLOGY; LEARNING-DISABILITIES; SUSTAINED ATTENTION; COMORBID ANXIETY AB Objective: To examine the association between weaknesses in executive functions and attentiondeficit/hyperactivity disorder (ADHD). Method: Empirical studies examining executive functions in ADHD samples were reviewed, with particular attention to results of recent meta-analyses. Results: ADHD is associated with impaired performance on measures of response inhibition, working memory, and other aspects of executive functions, yet data also suggest significant neuropsychological variability within and across ADHD samples. Conclusion: ADHD may be best conceptualized as a neuropsychologically heterogeneous condition. More work is needed to characterize this heterogeneity and its clinical and pathophysiologic implications. C1 Harvard Univ, Dept Child Psychiat, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Doyle, AE (reprint author), Harvard Univ, Dept Child Psychiat, Massachusetts Gen Hosp, Sch Med, YAW 6-6A,55 Fruit St, Boston, MA 02114 USA. EM doylea@helix.mgh.harvard.edu NR 67 TC 101 Z9 102 U1 6 U2 20 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 8 BP 21 EP 26 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 076WL UT WOS:000239988700004 PM 16961426 ER PT J AU Schatzberg, AF Blier, P Delgado, PL Fava, M Haddad, PM Shelton, RC AF Schatzberg, Alan F. Blier, Pierre Delgado, Pedro L. Fava, Maurizio Haddad, Peter M. Shelton, Richard C. TI Antidepressant discontinuation syndrome: Consensus panel recommendations for clinical management and additional research SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Meeting on Antidepressant Discontinuation Syndrome - Current Perspectives and Consensus Recommedations for Management CY APR 30, 2004 CL New York, NY SP Wyeth Pharmaceut Inc ID SEROTONIN REUPTAKE INHIBITORS; NEUROENDOCRINE RESPONSES; PAROXETINE TREATMENT; SYMPTOMS; RECEPTORS; DESENSITIZATION; INTERRUPTION; FLUOXETINE; PROTEINS; EXPOSURE AB Objective: Currently, no evidence-based guidelines exist for the management of serotonin reuptake inhibitor (SRI) discontinuation syndrome. This article summarizes recommendations with respect to future research as well as clinical management recommendations for SRI discontinuation syndrome. Participants: In April 2004, a panel of physicians convened in New York City to discuss recommendations for clinical management of and additional research on SRI discontinuation syndrome. Evidence: Previous guidance for management of SRI discontinuation syndrome was proposed in 1997 in a consensus meeting also chaired by Alan F. Schatzberg. A literature search of the PubMed database was conducted to identify articles on SRI discontinuation syndrome that have been published since 1997. Consensus Process: The 2004 panel reviewed important preclinical and clinical studies, discussed prospective investigation of this syndrome in clinical trials, and suggested the establishment of a research network to collect data in naturalistic settings. The panel also reviewed the management recommendations published in 1997 and subsequently updated the recommendations, taking into account the latest clinical data as well as the personal experience of its members with patients. Conclusions: Additional preclinical and clinical studies are necessary to further elucidate the underlying biological mechanisms of SRI discontinuation syndrome and to identify the patient populations and agents that are most affected by this phenomenon. Management strategies include gradual tapering of doses and should emphasize clinical monitoring and patient education. C1 Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. Univ Ottawa, Mental Hlth Res Inst, Dept Psychiat, Ottawa, ON, Canada. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78285 USA. Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. Univ Manchester, Neurosci & Psychiat Unit, Manchester, Lancs, England. Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37212 USA. RP Schatzberg, AF (reprint author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd,Adm,3rd Floor, Stanford, CA 94305 USA. EM afschatz@stanford.edu NR 24 TC 39 Z9 39 U1 0 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 4 BP 27 EP 31 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 047AL UT WOS:000237852100005 PM 16683860 ER PT J AU Spencer, TJ AF Spencer, Thomas J. TI DHD and comorbidity in childhood SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Teleconference on New Developments in the Treatment of Attention-Deficit/Hyperactivity Disorder CY MAY 16, 2005 CL ELECTR NETWORK ID DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; SUBSTANCE USE DISORDERS; PROSPECTIVE FOLLOW-UP; CONDUCT DISORDER; BIPOLAR DISORDER; LEARNING-DISABILITIES; ACADEMIC-ACHIEVEMENT; REFERRED CHILDREN; MAJOR DEPRESSION AB In recent years, evidence has been accumulating regarding high levels of comorbidity between attention-deficit/hyperactivity disorder (ADHD) and a number of disorders, including mood and anxiety disorders and conduct disorder. Thus, ADHD is most likely a group of conditions, rather than a single homogeneous clinical entity, with potentially different etiologic and modifying risk factors and different outcomes. Follow-up studies of children with ADHD indicate that subgroups of subjects with ADHD and comorbid disorders have a poorer outcome as evidenced by significantly greater social, emotional, and psychological difficulties. Investigation of these issues should help to clarify the etiology, course, and outcome of ADHD. C1 Massachusetts Gen Hosp, Psychiat Serv, Pediat Psychopharmacol Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Spencer, TJ (reprint author), Massachusetts Gen Hosp, Psychiat Serv, Pediat Psychopharmacol Unit, ACC-725,Fruit St, Boston, MA 02114 USA. EM tspencer@partners.org NR 54 TC 104 Z9 106 U1 1 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 8 BP 27 EP 31 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 076WL UT WOS:000239988700005 PM 16961427 ER PT J AU Marder, SR AF Marder, Stephen R. TI Drug initiatives to improve cognitive function SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Roundtable Meeting on Improving Cognitive Function and Functional Outcome in Severe Mental Illness CY JAN 13, 2006 CL Dallas, TX ID SEVERELY IMPAIRED SCHIZOPHRENIA; ANTIPSYCHOTIC-DRUGS; CLINICAL-TRIALS; MATRICS; REMEDIATION; SYMPTOMS; SUBTYPE; BATTERY AB Unlike for other chronic illnesses, the development of new medications for the treatment of schizophrenia has been relatively dormant since the 1950s. Recently, the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) program was established by the National Institute of Mental Health (NIMH) in order to facilitate the development of treatments for cognitive impairment and functional outcome in schizophrenia. Although effective medications for managing the positive symptoms of schizophrenia have permitted many patients to live in the community, these medications often fail to improve social and vocational function. As a result, some experts believe that research into new treatments should focus instead on the functional outcomes of patients by improving cognitive abilities and social competence. The MATRICS program brought together scientists from academia, government, and industry to discuss ways of promoting the development of new treatments for schizophrenia and gain consensus on treatment targets. The initiatives that have come out of the MATRICS program include focusing on adjunct medications, addressing regulatory issues with the U.S. Food and Drug Administration, determining the best way to measure functional outcomes, classifying symptoms, developing a battery of cognitive tests for assessing outcomes in clinical trials, and ranking promising targets for new treatment development. C1 Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. W Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Marder, SR (reprint author), 11301 Wilshire Blvd,MIRECC 210A, Los Angeles, CA 90073 USA. EM marder@ucla.edu NR 29 TC 27 Z9 30 U1 0 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 9 BP 31 EP 35 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 076WM UT WOS:000239988900006 PM 16965187 ER PT J AU Wilens, TE AF Wilens, Timothy E. TI Mechanism of action of agents used in attention-deficit/hyperactivity disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Teleconference on New Developments in the Treatment of Attention-Deficit/Hyperactivity Disorder CY MAY 16, 2005 CL ELECTR NETWORK ID DEFICIT-HYPERACTIVITY DISORDER; STIMULANT DRUG-ACTION; THREO-METHYLPHENIDATE HYDROCHLORIDE; HUMAN BRAIN; D,L-THREO-METHYLPHENIDATE HYDROCHLORIDE; DOPAMINE TRANSPORTER; ORAL METHYLPHENIDATE; SLI381 ADDERALL; CHILDREN; ADHD AB Several medications have been demonstrated effective in treating individuals with attentiondeficit/hyperactivity disorder (ADHD). There appears to be some commonality in the physiologic mechanisms of action of these agents relevant to the treatment of ADHD. Either direct or indirect attenuation of dopamine and norepinephrine neurotransmission appears related to both the stimulant and nonstimulant medications efficacious in ADHD. However, important differences exist both between and within the specific classes of agents. Elucidating the various mechanisms of action of ADHD medications may lead to better choices in matching potential response to the characteristics (e.g., genotype) of individuals. C1 Harvard Univ, Pediat Psychopharmacol Unit, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Wilens, TE (reprint author), Harvard Univ, Pediat Psychopharmacol Unit, Massachusetts Gen Hosp, Sch Med, YAW 6A,32 Fruit St, Boston, MA 02114 USA. EM twilens@partners.org FU NIDA NIH HHS [R01 DA14419-01, K24 DA016264] NR 62 TC 65 Z9 66 U1 11 U2 41 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 8 BP 32 EP 37 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 076WL UT WOS:000239988700006 PM 16961428 ER PT J AU Nutt, DJ Baldwin, DS Clayton, AH Elgie, R Lecrubier, Y Montejo, AL Papakostas, GI Souery, D Trivedi, MH Tylee, A AF Nutt, David J. Baldwin, David S. Clayton, Anita H. Elgie, Rodney Lecrubier, Yves Montejo, Angel L. Papakostas, George I. Souery, Daniel Trivedi, Madhukar H. Tylee, Andre TI The role of dopamine and norepinephrine in depression and antidepressant treatment SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID DYSFUNCTION; SERTRALINE; SYMPTOMS; FAILURE; RESPOND; DISEASE; SSRIS AB During a special session, the faculty identified several specific areas related to the role of dopamine and norepinephrine in depression and antidepressant treatment that either warrant the clinician's attention or are in need of more research. Areas of interest include fatigue and lethargy in depression, treatment strategies for treatment-resistant depression, the somatic presentation of depression, neurobiology of fatigue and its role in determining treatment, symptom rating scales, and sexual side effects. In addition, the faculty discussed the importance of patient psychoeducation and self-management as well as the ways in which disease models of depression affect treatment. C1 Univ Bristol, Sch Med Sci, Psychopharmacol Unit, Bristol BS1 3NY, Avon, England. Univ Southampton, Clin Neurosci Div, Southampton SO9 5NH, Hants, England. Univ Virginia Hlth Syst, Dept Psychiat Med, Charlottesville, VA USA. GAMIAN Europe, Tonbridge, England. Hop La Pitie Salpetriere, INSERM, Paris, France. Univ Hosp Salamanca, Psychiat Teaching Area, Sch Med, E-37008 Salamanca, Spain. Massachusetts Gen Hosp, Depress Clin & Res Program, Dept Psychiat, Boston, MA USA. Univ Libre Bruxelles, Erasme Hosp, Dept Psychiat, Brussels, Belgium. Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA. Kings Coll, Inst Psychiat, London, England. RP Nutt, DJ (reprint author), Univ Bristol, Sch Med Sci, Psychopharmacol Unit, Dorthy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England. EM david.j.nutt@bristol.ac.uk RI Tylee, Andre/D-8468-2010; MONTEJO GONZALEZ, ANGEL/A-7957-2008; Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 NR 17 TC 24 Z9 26 U1 1 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2006 VL 67 SU 6 BP 46 EP 49 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 061EH UT WOS:000238853500009 PM 16848678 ER PT J AU Bauer, MS Wisniewski, SR Marangell, LB Chessick, CA Allen, MH Dennehy, EB Miklowitz, DJ Thase, ME Sachs, GS AF Bauer, MS Wisniewski, SR Marangell, LB Chessick, CA Allen, MH Dennehy, EB Miklowitz, DJ Thase, ME Sachs, GS CA STEP-BD Investigators TI Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD) SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SEROTONIN REUPTAKE INHIBITORS; RANDOMIZED CONTROLLED-TRIALS; I DISORDER; DEPRESSIVE-MANIA; MOOD DISORDERS; FOLLOW-UP; BEHAVIOR; RISK; LITHIUM; METAANALYSIS AB Objective: Depressive episodes are common in bipolar disorder, and the disorder is characterized by high suicide rates. Recent analyses indicate a possible association of antidepressant treatment and suicidality in children and adults with depressive or anxiety disorders. However, few data are available to inform the suicidality risk assessment of antidepressant use specifically in bipolar disorder. Method: Of the first 2000 participants followed for 18 months in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), 425 experienced a prospectively observed, new-onset major depressive episode without initial suicidal ideation. Standardized ratings of suicidality and antidepressant exposure at index depressive episode and next evaluation were used to investigate the primary hypothesis that new-onset suicidality was associated with increased antidepressant exposure (antidepressant initiation or dose increase). Secondary analysis investigated correlates of new-onset suicidality and antidepressant exposure. Data were collected from November 8, 1999, to April 24, 2002. Results: Twenty-four participants (5.6%) developed new-onset suicidality at follow-up, including 2 suicide attempts. There was no association of new-onset suicidality with increased antidepressant exposure or any change in antidepressant exposure, and no association with initiation of antidepressant treatment. New-onset suicidality was associated with neuroticism, prior attempt, and higher depressive or manic symptom ratings at index episode. Increased antidepressant exposure was negatively associated with higher manic symptom rating at index episode; control for this sole empirically identified confound did not alter the primary results. Conclusions: Although careful monitoring for suicidality is always warranted in bipolar disorder, this cohort study provides no evidence that increased antidepressant exposure is associated with new-onset suicidality in this already high-risk population. Correlates of both suicidality and antidepressant exposure indicate directions for further research. C1 VAMC, Providence, RI 02908 USA. Brown Univ, Dept Psychiat & Human Behav, Providence, RI USA. Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Colorado, Baylor Coll Med, Denver, CO USA. Univ Colorado, Dept Psychiat, Denver, CO USA. Purdue Univ, Dept Psychol Sci, W Lafayette, IN USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Bauer, MS (reprint author), VAMC, 116R-830 Chalkstone Ave, Providence, RI 02908 USA. EM mark_bauer@brown.edu RI Allen, Michael/A-8776-2011; OI Wisniewski, Stephen/0000-0002-3877-9860 FU NIMH NIH HHS [N01 MH 80001] NR 47 TC 52 Z9 52 U1 1 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2006 VL 67 IS 1 BP 48 EP 55 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 009ZA UT WOS:000235151000008 PM 16426088 ER PT J AU Fonseca, M Soares, JC Hatch, JP Santin, AP Kapczinski, F AF Fonseca, M Soares, JC Hatch, JP Santin, AP Kapczinski, F TI An open trial of adjunctive escitalopram in bipolar depression SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ANTIDEPRESSANT-INDUCED MANIA; OBSESSIVE-COMPULSIVE DISORDER; DOUBLE-BLIND; I DEPRESSION; RATING-SCALE; FLUOXETINE; PLACEBO; OUTPATIENTS; IMIPRAMINE; OLANZAPINE AB Objective: This study was designed to evaluate the efficacy and safety of a highly potent and selective serotonergic antidepressant, escitalopram, in the treatment of bipolar depression. Method: Twenty outpatients with DSM-IV bipolar depression types I and II were enrolled in a 12-week open trial of escitalopram, 10 mg daily, adjunctive to their ongoing mood stabilizer. Assessments were carried Out using the Hamilton Rating Scale for Depression (HAM-D), the Young Mania Rating Scale (YMRS), and the Clinical Global Impressions for Severity (CGI-S) and Improvement (CGI-I) scales. The study was conducted from August 2003 to February 2004. Results: Escitalopram was associated with significant improvement as measured by the HAM-D total score, which showed a mean reduction from baseline (mean = 20.9, SD = 4.2) to endpoint (mean = 8.9, SD = 3.6; p < .001) of 12 points. The mean CGI-S score decreased by 3.3 points (baseline: mean = 4.8, SD = 0.7; week 12: mean = 1.5, SD = 0.6; p < .001). Adverse events emerged in 75% of the patients (N = 15), usually of mild-to-moderate severity. Four dropouts took place due to manic switch (N = 1), hypomanic symptoms (N = 2), and hospitalization due to the emergence of suicidal ideation and psychosis (N = 1). Conclusion: These findings suggest that escitalopram in association with mood stabilizers may be an effective and reasonably well-tolerated treatment for patients with moderate-to-severe bipolar depression. The switch rate was similar to what is described in the literature for the selective serotonin reuptake inhibitors. Randomized controlled trials of escitalopram in bipolar depression are warranted. C1 Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, San Antonio, TX 78229 USA. Fed Univ Rio Grande Sul, Psychiat Res Unit, Porto Alegre, RS, Brazil. S Texas Vet Hlth Care Syst, Psychiat Serv, Audie L Murphys Div, San Antonio, TX USA. Fed Univ Rio Grande, Sch Med, Clin Hosp, Psychait Serv, Porto Alegre, RS, Brazil. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX USA. RP Fonseca, M (reprint author), Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM fonsecam2@uthscsa.edu RI Kapczinski, Flavio/D-3175-2013; Kapczinski, Flavio/J-5803-2014 NR 38 TC 10 Z9 10 U1 1 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2006 VL 67 IS 1 BP 81 EP 86 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 009ZA UT WOS:000235151000012 PM 16426092 ER PT J AU Swanson, JM Greenhill, LL Lopez, FA Sedillo, A Earl, CQ Jiang, JG Biederman, J AF Swanson, JM Greenhill, LL Lopez, FA Sedillo, A Earl, CQ Jiang, JG Biederman, J TI Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID DEFICIT HYPERACTIVITY DISORDER; INDUCED WAKEFULNESS; OPEN-LABEL; ATOMOXETINE; METHYLPHENIDATE; TRIAL; ADHD; AMPHETAMINE; NARCOLEPSY; SOMNOLENCE AB Objective: The objective of this fixed-dose study was to determine the efficacy and safety of a new formulation of modafinil (modafinil film-coated tablets) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). In addition, the effect of abrupt discontinuation of modafinil was evaluated in a 2-week observation period. Method: Patients aged 6 to 17 years with DSM-IVTR-defined ADHD were randomly assigned to 7 weeks of double-blind treatment with modafinil or placebo in a 2:1 ratio, followed by abrupt discontinuation of modafinil and a 2-week, double-blind observation period in which 46% of patients receiving modafinil were switched to placebo without tapering and half continued to receive modafinil. Study drug was administered once daily and titrated over the first 7 to 9 days to daily doses of 340 mg for patients < 30 kg or 425 mg for patients >= 30 kg. Assessment instruments included the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) School and Home Versions and Clinical Global Impressions-Improvement scale (CGI-I). The study was conducted from November 2003 to June 2004. Results: A total of 190 patients were randomly assigned to receive modafinil (340 mg, N = 44; 425 mg, N = 82) or placebo (N = 64). 189 patients were evaluated for safety. Modafinil significantly improved symptoms of ADHD as shown by reductions in ADHD-RS-IV School Version total scores compared with placebo at all visits (p <= 009), including the final visit of the double-blind phase (p < .0001). With modafinil, ADHD-RS-IV School Version mean total scores changed from 37.8 at baseline to 29.3 at week 1 and 20.7 at final visit; corresponding placebo values were 36.6, 32.8, and 28.4, respectively; effect size at final visit was 0.76 (95% CI = 0.63 to 0.88). Total scores on the ADHD-RS-IV Home Version were also significantly reduced at all visits (p <= 022) and final visit (p = .001) in patients receiving modafinil compared with those receiving placebo. Significantly higher proportions of patients receiving modafinil were rated '' much improved '' or '' very much improved '' in overall clinical condition (CGI-I) at all visits compared with patients receiving placebo (p < .001). No withdrawal symptoms were observed when modafinil was abruptly discontinued at the beginning of the final 2-week observation period. Modafinil was generally well tolerated. Insomnia, headache, and decreased appetite were the most commonly reported adverse events. Sixty-three percent of patients who received modafinil completed the study; 13% discontinued because of lack of efficacy; 10%, because of adverse events; and 13%, for other reasons (e.g., consent withdrawn, lost to follow-up). Conclusion: Modafinil significantly improved symptoms of ADHD both at school and at home and was well tolerated by children and adolescents. Abrupt discontinuation of modafinil was not associated with symptoms of withdrawal or with rebound of symptoms of ADHD. C1 Univ Calif Irvine, Child Dev Ctr, Irvine, CA 92697 USA. New York State Psychiat Inst & Hosp, New York, NY 10032 USA. Childrens Dev Ctr PA, Maitland, FL USA. Pedia Res LLC, Owensboro, KY USA. Cephalon Inc, Frazer, PA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Swanson, JM (reprint author), Univ Calif Irvine, Child Dev Ctr, 19722 MacArthur Blvd, Irvine, CA 92697 USA. EM jmswanso@uci.edu NR 46 TC 66 Z9 68 U1 0 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2006 VL 67 IS 1 BP 137 EP 147 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 009ZA UT WOS:000235151000020 PM 16426100 ER PT J AU Biederman, J Arnsten, AFT Faraone, SV Doyle, AE Spencer, TJ Wilens, TE Weiss, MD Safren, SA Culpepper, L AF Biederman, J Arnsten, AFT Faraone, SV Doyle, AE Spencer, TJ Wilens, TE Weiss, MD Safren, SA Culpepper, L TI New developments in the treatment of ADHD SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Editorial Material ID DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DOPAMINE TRANSPORTER GENE; ALPHA-2A ADRENERGIC-RECEPTOR; WORKING-MEMORY PERFORMANCE; IRISH POPULATION; ADULTS; ASSOCIATION; LINKAGE; CHILDREN C1 Massachusetts Gen Hosp, Clin Program Pediat Psychopharmacol & Adult ADHD, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Res Program Pediat Psychopharmacol & Adult ADHD, Dept Psychiat, Boston, MA 02114 USA. Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA. SUNY Upstate Med Univ, Med Genet Res Program, Syracuse, NY USA. Massachusetts Gen Hosp, Clin Program Pediat Psychopharmacol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada. Boston Univ, Dept Family Med, Boston, MA 02215 USA. RP Biederman, J (reprint author), Massachusetts Gen Hosp, Clin Program Pediat Psychopharmacol & Adult ADHD, Dept Psychiat, Boston, MA 02114 USA. NR 63 TC 20 Z9 20 U1 3 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2006 VL 67 IS 1 BP 148 EP 159 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 009ZA UT WOS:000235151000021 PM 16426101 ER PT J AU Ancoli-Israel, S Martin, JL AF Ancoli-Israel, Sonia Martin, Jennifer L. TI Insomnia and Daytime Napping in Older Adults SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Review DE Elderly; insomnia; daytime sleepiness; napping AB Insomnia, daytime sleepiness, and napping are all highly prevalent among the elderly, reflecting changes in sleep architecture, sleep efficiency, sleep quality, and circadian sleep-wake cycles. Insomnia is sometimes associated with subjective daytime sleepiness, as well as other clinical and socioeconomic consequences. The daytime sleepiness will at times lead to napping. Although napping is viewed as a common age-related occurrence, little is known about its benefits or consequences. Factors reported to be contributors to daytime napping include sleep-maintenance difficulty and sleep fragmentation with consequent daytime sleepiness, nighttime use of long-acting sedating agents, daytime use of sedating medications, and dementia. However, a correlation between sleep disturbance and daytime napping has not been consistently observed. Whether napping is beneficial, neutral, or detrimental is an important issue, in light of conflicting findings regarding the impact of daytime napping on nighttime sleep and recent reports of an association between napping and adverse clinical outcomes, including increased mortality risk. Further research is needed to determine whether there is a cause-and-effect relationship between napping and insomnia, and between napping and adverse clinical outcomes, and to explore the clinical implications of improving insomnia and reducing daytime napping. Clinical evaluations of hypnotic agents should assess efficacy for both improving insomnia symptoms (particularly sleep-maintenance difficulty, in the case of elderly patients) and reducing daytime sleepiness that would lead to inadvertent napping. C1 [Ancoli-Israel, Sonia] Univ Calif San Diego, San Diego, CA 92103 USA. [Ancoli-Israel, Sonia] VASDHS, San Diego, CA USA. [Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Martin, Jennifer L.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Ancoli-Israel, S (reprint author), Univ Calif San Diego, Psychiat, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM sancoliisrael@ucsd.edu FU NIA [AG08415, 5 P60 AG10415]; NCI [A85264, M01 RR00827] FX Funding support was provided by NIA AG08415, NCI A85264, M01 RR00827, and NIA 5 P60 AG10415. The authors would like to acknowledge Amy Yamamoto and H. Heith Durrence of Sepracor, Inc., for their assistance in the preparation of earlier drafts of this manuscript. NR 83 TC 33 Z9 33 U1 5 U2 6 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2006 VL 2 IS 3 BP 333 EP 342 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA V44VF UT WOS:000209775800015 PM 17561549 ER PT J AU Viswanath, K Emmons, KM AF Viswanath, K. Emmons, Karen M. TI Message effects and social determinants of health: Its application to cancer disparities SO JOURNAL OF COMMUNICATION LA English DT Review ID AFRICAN-AMERICAN WOMEN; SELF-RATED HEALTH; WORKING-CLASS; INCOME INEQUALITY; KNOWLEDGE GAP; TELEVISION COMMERCIALS; DIETARY INTERVENTION; RANDOMIZED-TRIAL; MANAGED CARE; NEWS MEDIA AB Recent work on message effects theories offers a fruitful way to systematically explore how features, formats, structures of messages may attract audience attention and influence the audience and is of great relevance to public health communications. Much of this work, however, has been pursued primarily at the individual level of analysis. It is our contention that message effects on health outcomes could potentially be moderated and mediated by social contextual factors in public health such as social class, social organizations and neighborhoods among others, leading to differential effects among different audience sub-groups. This essay, through a selective review of literatures in communication and social epidemiology, will explore how major message effects may moderate and mediate the role of social determinants of health on cancer control, specifically cancer-related health disparities. C1 Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Viswanath, K (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA. EM vish_viswanath@dfci.harvard.edu NR 136 TC 53 Z9 54 U1 5 U2 27 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0021-9916 J9 J COMMUN JI J. Commun. PY 2006 VL 56 SU S BP S238 EP S264 DI 10.1111/j.1460-2466.2006.00292.x PG 27 WC Communication SC Communication GA 085TD UT WOS:000240626400013 ER PT J AU Bhasin, M Reinherz, EL Reche, PA AF Bhasin, M Reinherz, EL Reche, PA TI Recognition and classification of histones using support vector machine SO JOURNAL OF COMPUTATIONAL BIOLOGY LA English DT Article DE histones; classification; support vector machine ID CRYSTAL-STRUCTURE; DATABASE; PREDICTION; CHROMATIN; FAMILIES AB Histones are DNA-binding proteins found in the chromatin of all eukaryotic cells. They are highly conserved and can be grouped into five major classes: H1/H5, H2A, H2B, H3, and H4. Two copies of H2A, H2B, H3, and H4 bind to about 160 base pairs of DNA forming the core of the nucleosome ( the repeating structure of chromatin) and H1/H5 bind to its DNA linker sequence. Overall, histones have a high arginine/lysine content that is optimal for interaction with DNA. This sequence bias can make the classification of histones difficult using standard sequence similarity approaches. Therefore, in this paper, we applied support vector machine (SVM) to recognize and classify histones on the basis of their amino acid and dipeptide composition. On evaluation through a five-fold cross-validation, the SVM-based method was able to distinguish histones from nonhistones ( nuclear proteins) with an accuracy around 98%. Similarly, we obtained an overall > 95% accuracy in discriminating the five classes of histones through the application of 1-versus-rest (1-v-r) SVM. Finally, we have applied this SVM-based method to the detection of histones from whole proteomes and found a comparable sensitivity to that accomplished by hidden Markov motifs (HMM) profiles. C1 Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Immunobiol Lab, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Reche, PA (reprint author), Harvard Univ, Sch Med, Dept Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA. EM reche@research.dfci.harvard.edu RI Reche, Pedro/B-1881-2013 OI Reche, Pedro/0000-0003-3966-5838 FU NIAID NIH HHS [AI57330] NR 18 TC 31 Z9 33 U1 1 U2 11 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1066-5277 J9 J COMPUT BIOL JI J. Comput. Biol. PD JAN-FEB PY 2006 VL 13 IS 1 BP 102 EP 112 DI 10.1089/cmb.2006.13.102 PG 11 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Computer Science; Mathematical & Computational Biology; Mathematics GA 016LG UT WOS:000235621100006 PM 16472024 ER PT J AU Phillips, RA Nadel, ES Brown, DFM AF Phillips, RA Nadel, ES Brown, DFM TI Epigastric pain SO JOURNAL OF EMERGENCY MEDICINE LA English DT Editorial Material ID ACUTE-PANCREATITIS; VALPROIC ACID; APACHE-II C1 Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA. Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA. RP Nadel, ES (reprint author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD JAN PY 2006 VL 30 IS 1 BP 81 EP 84 DI 10.1016/j.jemermed.2005.11.014 PG 4 WC Emergency Medicine SC Emergency Medicine GA 009VP UT WOS:000235141800014 PM 16434341 ER PT J AU Borgialli, DA Camargo, CA AF Borgialli, DA Camargo, CA TI Healthy People 2010 emergency medicine module: A multicenter survey and educational intervention SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the SAEM CY MAY, 2003 CL Boston, MA SP SAEM DE Healthy People 2010; public health; residency training; emergency medicine AB To educate emergency medicine (EM) residents about Healthy People 2010 (HP2010), the nation's public health agenda. Participating EM residency programs were given a 40-min slide presentation and a 4-item post-test that we developed. In two residency programs, we conducted a "before-after" study to assess the reliability of the test instrument. Fifteen residencies participated, with 289 individuals (70% EM residents) attending the lectures. Only 19% reported any knowledge of HP2010 before exposure to the Module. Nevertheless, after exposure, 182 (90%) scored 75% or better on the four questions specifically testing the informational content of the Module. In the reliability study, residents showed significant improvement from the pre-test on both the immediate and 2-week posttests (both p < 0.001). In conclusion, we found that EM residents' baseline knowledge of HP2010 was poor, and that the EM Module improved knowledge about this important public health document. (c) 2006 Elsevier Inc. C1 Michigan State Univ, Emergency Med Residency Program, Lansing, MI USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA. RP Borgialli, DA (reprint author), Hurley Med Ctr, Dept Emergency Med, 1 Hurley Pl, Flint, MI 48503 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD JAN PY 2006 VL 30 IS 1 BP 103 EP 106 DI 10.1016/j.jemermed.2005.03.015 PG 4 WC Emergency Medicine SC Emergency Medicine GA 009VP UT WOS:000235141800022 PM 16434349 ER PT J AU Sundy, JS Wood, WA Watt, JL Kline, JN Schwartz, DA AF Sundy, JS Wood, WA Watt, JL Kline, JN Schwartz, DA TI Safety of incremental inhaled lipopolysaccharide challenge in humans SO JOURNAL OF ENDOTOXIN RESEARCH LA English DT Article DE lipopolysaccharide; endotoxin; inhalation challenge; systemic responses ID INFLAMMATORY RESPONSE; COTTON DUST; GRAIN DUST; ENDOTOXIN; INHALATION; RESPONSIVENESS; EXPOSURE; ASTHMA; SEVERITY; SYMPTOMS AB Background: Inhalation of environmental endotoxin is important in the pathogenesis of asthma and other environmental airway diseases. Inhaled airway challenge using lipopolysaccharide in humans has been performed for over 20 years to assess the airway response to endotoxin. However, there are no published data on the short-term safety of endotoxin inhalation protocols. Objective: To characterize the safety and tolerability of incremental inhaled lipopolysaccharide challenge in humans. Patients and Methods: We performed a retrospective analysis of data obtained from 119 subjects who underwent inhaled challenge with up to 41.5 mu g of lipopolysaccharide. We measured pulmonary function, temperature, mean arterial pressure, heart rate, and systemic symptoms for 3 h after challenge. Results: Fever occurred in 30% of subjects and was associated with a higher cumulative dose of lipopolysaccharide. Reduced mean arterial pressure occurred in 21% of subjects and was dose-related. There was no association between fever or decreased mean arterial pressure and airway responsiveness to inhaled lipopolysaccharide. Common symptoms reported by subjects included: chills (64%), malaise (56%), cough (56%), chest tightness (49%), headache (43%), and myalgias (27%). None of the subjects experienced delayed discharge or a serious adverse event. Conclusions: Inhaled lipopolysaccharide causes dose-related systemic responses that include fever, reduced blood pressure, and constitutional symptoms that are not associated with the airway response to inhaled lipopolysaccharide. Systemic responses to inhaled lipopolysaccharide should be expected and subjects undergoing inhaled lipopolysaccharide challenge in the research setting should be carefully monitored for non-pulmonary adverse events for several hours after challenge. C1 Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. Massachusetts Gen Hosp, Harvard Comined Med Pediat Training Program, Boston, MA 02114 USA. Univ Iowa, Dept Med, Iowa City, IA 52242 USA. Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA. RP Sundy, JS (reprint author), Duke Univ, Med Ctr, Dept Med, Box 3278,014 Baker House, Durham, NC 27710 USA. EM sundy001@mc.duke.edu FU NCRR NIH HHS [RR00059]; NIEHS NIH HHS [ES005605, ES07498, ES 11185, ES 11375, ES 12496] NR 31 TC 4 Z9 4 U1 0 U2 1 PU MANEY PUBLISHING PI LEEDS PA HUDSON RD, LEEDS LS9 7DL, ENGLAND SN 0968-0519 J9 J ENDOTOXIN RES JI J. Endoxtin Res. PY 2006 VL 12 IS 2 BP 113 EP 119 DI 10.1179/096805106X102174 PG 7 WC Biochemistry & Molecular Biology; Immunology; Medicine, Research & Experimental; Microbiology SC Biochemistry & Molecular Biology; Immunology; Research & Experimental Medicine; Microbiology GA 038MV UT WOS:000237226900005 PM 16690014 ER PT J AU Smith, TJ Davis, ME Reaser, P Natkin, J Hart, JE Laden, F Heff, A Garshick, E AF Smith, Thomas J. Davis, Mary E. Reaser, Paul Natkin, Jonathan Hart, Jaime E. Laden, Francine Heff, Allan Garshick, Eric TI Overview of particulate exposures in the US trucking industry SO JOURNAL OF ENVIRONMENTAL MONITORING LA English DT Article ID DIESEL-EXHAUST; SAMPLING ARTIFACTS; ELEMENTAL CARBON; RISK ASSESSMENT; LUNG-CANCER; MATTER; EMISSIONS; VEHICLES; WORKERS AB As part of a large epidemiologic study of lung cancer, 55 000 subjects, we have conducted a nation-wide survey of particulate exposures in the US trucking industry. The goal is to differentiate the risks from various types of particulate exposures, such as traffic emissions and general air pollution. We hypothesize that exposures defined by job and work site characteristics can be linked with subjects using their personal job histories. This report covers exposures at 36 randomly chosen large truck freight terminals in the US. Measurements were made of PM2.5, elemental carbon (EC), and organic carbon (OC) upwind of the terminal (background) and in work areas, and by personal samples. Significant differences in exposure intensity, mu g m(-3), were found for work locations and jobs relative to background levels (GM[GSD]) at terminal sites: PM2.5 9.8[2.34], EC 0.5[3.24], and OC 5.0[1.76]. Using EC as a marker for diesel particles, work locations varied significantly: office 0.3[3.7], dock area 0.7[2.89] and shop area 1.5[3.52]), as did job titles (non-smokers): clerk 0.1[9.98], dock worker 0.8[2.13], and mechanic 2.0[3.82]. Cigarette smoking contributed substantially to personal exposures, approximately doubling PM2.5 and OC, but having less of an effect on EC. Large differences were seen across the terminal sites due to differences in local regional air pollution levels from traffic and other sources. We conclude that it will be possible to estimate current exposures of the cohort using an exposure assignment matrix based on job title, work location, and terminal site. This distribution overlaps substantially with the general public's exposure to these sources. C1 Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Exposure Epidemiol & Risk Program, Boston, MA 02115 USA. Univ Massachusetts, Environm Earth & Ocean Sci Dept, Boston, MA 02125 USA. Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA USA. RP Smith, TJ (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Exposure Epidemiol & Risk Program, Boston, MA 02115 USA. EM tsmith@hohp.harvard.edu FU NCI NIH HHS [R01 CA090792, R01 CA90792] NR 22 TC 34 Z9 34 U1 2 U2 9 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1464-0325 J9 J ENVIRON MONITOR JI J. Environ. Monit. PY 2006 VL 8 IS 7 BP 711 EP 720 DI 10.1039/b601809b PG 10 WC Chemistry, Analytical; Environmental Sciences SC Chemistry; Environmental Sciences & Ecology GA 060SD UT WOS:000238821000004 PM 16826284 ER PT J AU Guarino, CM Ko, CY Baker, LC Klein, DJ Quiter, ES Escarce, JJ AF Guarino, CM Ko, CY Baker, LC Klein, DJ Quiter, ES Escarce, JJ TI Impact of instructional practices on student satisfaction with attendings' teaching in the inpatient component of internal medicine clerkships SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE medical education; Internal Medicine clerkship; medical student satisfaction ID PERCEPTIONS; EDUCATION AB OBJECTIVE: To determine the prevalence and influence of specific attending teaching practices on student evaluations of the quality of attendings' teaching in the inpatient component of Internal Medicine clerkships. DESIGN: Nationwide survey using a simple random sample. SETTING: One hundred and twenty-one allopathic 4-year medical schools in the United States. PARTICIPANTS: A total of 2,250 fourth-year medical students. MEASUREMENTS AND MAIN RESULTS: In the spring of 2002, student satisfaction with the overall quality of teaching by attendings in the inpatient component of Internal Medicine clerkships was measured on a 5-point scale from very satisfied to very dissatisfied (survey response rate, 68.3%). Logistic regression was used to determine the association of specific teaching practices with student evaluations of the quality of their attendings' teaching. Attending physicians' teaching practices such as engaging students in substantive discussions (odds ratio (OR) =3.0), giving spontaneous talks and prepared presentations (OR=1.6 and 1.8), and seeing new patients with the team (OR=1.2) were strongly associated with higher student satisfaction, whereas seeming rushed and eager to finish rounds was associated with lower satisfaction (OR=0.6). CONCLUSION: Findings suggest that student satisfaction with attendings' teaching is high overall but there is room for improvement. Specific teaching behaviors used by attendings affect student satisfaction. These specific behaviors could be taught and modified for use by attendings and clerkship directors to enhance student experiences during clerkships. C1 RAND Corp, Santa Monica, CA 90407 USA. W Los Angeles VA Med Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA USA. Stanford Univ, Sch Med, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. RP Guarino, CM (reprint author), RAND Corp, MSN,1776 Main St, Santa Monica, CA 90407 USA. EM cassie@rand.org OI Baker, Laurence/0000-0001-5032-794X NR 10 TC 13 Z9 14 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2006 VL 21 IS 1 BP 7 EP 12 DI 10.1111/j.1525-1497.2005.0253.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 010CD UT WOS:000235163600002 PM 16423117 ER PT J AU Lester, WT Grant, RW Barnett, GO Chueh, HC AF Lester, WT Grant, RW Barnett, GO Chueh, HC TI Randomized controlled trial of an informatics-based intervention to increase statin prescription for secondary prevention of coronary disease SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE hyperlipidemia; electronic health records; reminder systems; randomized-controlled trial ID DECISION-SUPPORT-SYSTEMS; CLINICAL-PRACTICE GUIDELINES; ELECTRONIC MEDICAL-RECORD; QUALITY-OF-CARE; COMPUTERIZED REMINDERS; PHYSICIAN PERFORMANCE; CHOLESTEROL; MANAGEMENT; OPPORTUNITIES; HYPERTENSION AB OBJECTIVE: Suboptimal treatment of hyperlipidemia in patients with coronary artery disease (CAD) is well documented. We report the impact of a computer-assisted physician-directed intervention to improve secondary prevention of hyperlipidemia. DESIGN AND SETTING: Two hundred thirty-five patients under the care of 14 primary care physicians in an academically affiliated practice with an electronic health record were enrolled in this proof-of-concept physician-blinded randomized, controlled trial. Each patient with CAD or risk equivalent above National Cholesterol Education Program-recommended low-density lipoprotein (LDL) treatment goal for greater than 6 months was randomized, stratified by physician and baseline LDL. Physicians received a single e-mail per intervention patient. E-mails were visit independent, provided decision support, and facilitated "one-click" order writing. MEASUREMENTS: The primary outcomes were changes in hyperlipidemia prescriptions, time to prescription change, and changes in LDL levels. The time spent using the system was assessed among intervention patients. RESULTS: A greater proportion of intervention patients had prescription changes at I month (15.3% vs 2%, P=.001) and 1 year (24.6% vs 17.1%, P=.14). The median interval to first medication adjustment occurred earlier among intervention patients (0 vs 7.1 months, P=.005). Among patients with baseline LDLs > 130 mg/dL. the first postintervention LDLs were substantially lower in the intervention group (119.0 vs 138.0 mg/dL, P=.04). Physician processing time was under 60 seconds per e-mail. CONCLUSION: A visit-independent disease management tool resulted in significant improvement in secondary prevention of hyperlipidemia at I-month postintervention and showed a trend toward improvement at I year. C1 Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. Massachusetts Gen Hosp, Gen Med Unit, Boston, MA 02114 USA. Massachusetts Gen Hosp, Clin Res Program, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Lester, WT (reprint author), Massachusetts Gen Hosp, Comp Sci Lab, 50 Stanford St,5th Floor, Boston, MA 02114 USA. EM wlester@partners.org OI Lester, William/0000-0003-4086-9280; Grant, Richard/0000-0002-6164-8025 FU NIDDK NIH HHS [K23 DK067452-01A1, K23 DK067452] NR 40 TC 44 Z9 44 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2006 VL 21 IS 1 BP 22 EP 29 DI 10.1111/j.1525-1497.2005.00268.x PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 010CD UT WOS:000235163600004 PM 16423119 ER PT J AU Oslin, DW Ross, J Sayers, S Murphy, J Kane, V Katz, IR AF Oslin, DW Ross, J Sayers, S Murphy, J Kane, V Katz, IR TI Screening, assessment, and management of depression in VA primary care clinics - The Behavioral Health Laboratory SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE depression; primary care; adult; elderly ID RANDOMIZED CONTROLLED-TRIAL; TELEPHONE ASSESSMENT; COST-EFFECTIVENESS; RELIABILITY; POPULATION; PROGRAM; PREVALENCE; INTERVIEWS; SEVERITY; DEMENTIA AB OBJECTIVES: The purpose of this project was to assess the utility and feasibility of a telephone-based systematic clinical assessment service, the Behavioral Health Laboratory (BHL), in the context of primary care. The BHL is a clinical service that provides primary care providers with an assessment and a summary of mental health and substance abuse (MH/SA) symptoms and provides treatment decision support, including triage to specialty MH/SA services. The BHL was implemented to assist in the evaluation of patients who screened positively for depression at an annual clinical appointment or who were identified through routine care. METHODS: Results from systematic screening of primary care patients were extracted during a period of 6 months prior to implementation of the BHL and after implementation of the BHL. Descriptive results of the 580 evaluations conducted during this time were available. RESULTS: Results suggest an association between the implementation of the BHL and an increase in the proportion of patients screened for depression in primary care. In addition, there was an increase in the proportion of patients who screened positively (2.8% vs 7.0%). The BHL was successful in providing a comprehensive assessment for 78% of those referred. Significant co-occurring mental illness and substance misuse were found among those assessed. CONCLUSIONS., Introducing the BHL into primary care was associated with an apparent change in clinical practice in primary care at the Philadelphia VA Medical Center. Not only were more patients identified. the broad-based approach of the BHL identified significant comorbidity with alcohol misuse, illicit drugs. and suicidal ideation, symptoms likely to have been missed in routine clinical practice. The BHL offers a practical, low-cost method of assessment. monitoring, and treatment planning for patients identified in primary care with MH/SA needs. C1 Univ Penn, Dept Psychiat, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Dept Psychiat, Ctr Study Addict, Philadelphia, PA 19104 USA. Univ Penn, Hlth Syst, Div Gen Internal Med, Dept Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. VISN 4 Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Oslin, DW (reprint author), Univ Penn, Dept Psychiat, Sect Geriatr Psychiat, 3535 Market St,Room 3002, Philadelphia, PA 19104 USA. EM oslin@mail.med.upenn.edu FU NIMH NIH HHS [P30 MH066270, P30 MH66270, K08MH01599, K08 MH001599] NR 30 TC 84 Z9 86 U1 2 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2006 VL 21 IS 1 BP 46 EP 50 DI 10.1111/j.1525-1497.2005.00267.x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 010CD UT WOS:000235163600007 PM 16423122 ER PT J AU Tanner, CE Eckstrom, E Desai, SS Joseph, CL Ririe, MR Bowen, JL AF Tanner, CE Eckstrom, E Desai, SS Joseph, CL Ririe, MR Bowen, JL TI Uncovering frustrations - A qualitative needs assessment of academic general internists as geriatric care providers and teachers SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE geriatrics; general internal medicine; medical education; faculty development; qualitative methods; curriculum development ID MEDICINE; FACULTY AB BACKGROUND: General internists commonly provide medical care for older adults and geriatric education to trainees, but lack the necessary knowledge and skills to fulfill these tasks. OBJECTIVE: Assess the geriatric training needs of academic general internists in 3 hospital systems in Portland, OR. DESIGN: Ten focus groups and 1 semi-structured interview. Interview transcripts were analyzed using thematic analysis. a well-recognized qualitative technique. PARTICIPANTS: A convenience sample of 22 academic general internists and 8 geriatricians from 3 different teaching hospitals. MEASUREMENTS: We elicited stories of frustration and success in caring for elderly patients and in teaching about their care. We asked geriatricians to recount their experiences as consultants to general internists and to comment on the training of Internists in geriatrics. RESULTS: In addition to deficits in their medical knowledge and skills. our Internists reported frustration with the process of delivering care to older adults. In particular, they felt ill prepared to guide care transitions for patients, use multidisciplinary teams effectively. and were frustrated with health care system issues. Additionally. general internists' approach to medical care, which largely relies on the medical model, is different from that of geriatricians, which focuses more on social and functional issues. CONCLUSIONS: Although our findings may not be broadly representative, improving our general internists' abilities to care for the elderly and to teach learners how to do the same should address deficits in medical knowledge and skills, barriers to the processes of delivering care, and philosophical approaches to care. Prioritizing and quantifying these needs and measuring the effectiveness of curricula to address them are areas for future research. C1 Oregon Hlth Sci Univ, Portland VA Med Ctr, Portland, OR USA. Legacy Hlth Syst, Portland, OR USA. RP Bowen, JL (reprint author), Oregon Hlth Sci Univ, Portland VA Med Ctr, 3181 SW Sam Jackson Pk Rd,Mail Code L475, Portland, OR USA. EM bowenj@ohsu.edu NR 11 TC 15 Z9 15 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2006 VL 21 IS 1 BP 51 EP 55 DI 10.1111/j.1525-1497.2005.00281.x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 010CD UT WOS:000235163600008 PM 16423123 ER PT J AU Moye, J Karel, MJ Gurrera, RJ Azar, AR AF Moye, J Karel, MJ Gurrera, RJ Azar, AR TI Neuropsychological predictors of decision-making capacity over 9 months in mild-to-moderate dementia SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE dementia; consent; capacity; competency ID DIFFERENT LEGAL STANDARDS; ALZHEIMERS-DISEASE; PHYSICIAN JUDGMENTS; INFORMED CONSENT; COMPETENCE; CARE; CONSISTENCY AB BACKGROUND: Older adults with dementia may have diminished capacity to make medical treatment decisions. OBJECTIVE: To examine rates and neuropsychological predictors of treatment decision making, or consent capacity, among older adults with dementia over 9 months. DESIGN. Consent capacity was assessed initially and 9 months later in subjects with and without dementia using a longitudinal repeated measures design. PARTICIPANTS: Fifty-three older adults with dementia and 53 similarly aged adults without dementia. MEASUREMENTS: A standardized measure MacArthur Competence Assessment Tool-Treatment of 4 legal standards for capacity (Understanding, Appreciation, Reasoning, and Expressing a Choice) and a neuropsychological battery. RESULTS: In the dementia group, 9.4% had impaired capacity initially, and 26.4% had impaired capacity at 9 months. Mean scores in the dementia group were impaired relative to controls initially and at 9 months for Understanding (initial t=2.49. P=.01: 9-month t=3.22. P <.01) and Reasoning (initial t=2.18. P=.03: 9-month t=4.77. P <.01). Declining capacity over 9 months was attributable to a further reduction in Reasoning (group x time F=9.44, P=.003). Discriminant function analysis revealed that initial scores on naming, delayed Logical Memory, and Trails B were associated with impaired capacity at 9 months. CONCLUSIONS: Some patients with mild-to-moderate dementia develop a clinically relevant impairment of consent capacity within a year. Consent capacity in adults with mild-to-moderate dementia should be reassessed periodically to ensure that it is adequate for each specific informed consent situation. Interventions that maximize Understanding and Reasoning by supporting naming. memory, and flexibility may help to optimize capacity in this patient group. C1 VA Boston Healthcare Syst, Mental Hlth Serv Line, Brockton, MA 02301 USA. Harvard Univ, Sch Med, Dept Psychiat, Brockton, MA 02401 USA. Univ Louisville, Dept Psychol & Brain Sci, Louisville, KY 40292 USA. RP Moye, J (reprint author), VA Boston Healthcare Syst, Mental Hlth Serv Line, Brockton Campus,940 Belmont St, Brockton, MA 02301 USA. EM Jennifer.moye@med.va.gov RI Moye, Jennifer/F-2240-2017 OI Moye, Jennifer/0000-0002-3434-347X NR 33 TC 37 Z9 37 U1 0 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2006 VL 21 IS 1 BP 78 EP 83 DI 10.1111/j.1525-1497.2005.00288.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 010CD UT WOS:000235163600014 PM 16423129 ER PT J AU Haidet, P Stein, HF AF Haidet, P Stein, HF TI The role of the student-teacher relationship in the formation of physicians - The hidden curriculum as process SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 9th Biannual Regenstreif Conference CY SEP 29-OCT 01, 2004 CL Marshall, IN SP Regenstreif Inst Inc, Regenstreif Fdn, Feitzer Inst DE education; medical; culture; professional role; students; medical; relationship-centered care ID MEDICAL-EDUCATION; INTERVIEWING SKILLS; INFORMAL CURRICULUM; HUMAN DIMENSIONS; CENTERED CARE; PROFESSIONALISM; IDENTIFICATION; COMMUNICATION; ACQUISITION; ENVIRONMENT AB Relationship-Centered Care acknowledges the central importance of relationships in medical care. In a similar fashion, relationships hold a central position in medical education. and are critical for achieving favorable learning outcomes. However, there is little empirical work in the medical literature that explores the development and meaning of relationships in medical education. In this essay, we explore the growing body of work on the culture of medical school, often termed the "hidden curriculum." We suggest that relationships are a critical mediating factor in the hidden curriculum. We explore evidence from the educational literature with respect to the student-teacher relationship, and the relevance that these studies hold for medical education. We conclude with suggestions for future research on student-teacher relationships in medical education settings. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Univ Oklahoma, Sch Med, Dept Family & Prevent Med, Oklahoma City, OK USA. RP Haidet, P (reprint author), 2002 Holcombe Blvd,152, Houston, TX 77030 USA. EM phaidet@bcm.tmc.edu NR 71 TC 111 Z9 114 U1 3 U2 18 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2006 VL 21 SU 1 BP S16 EP S20 DI 10.1111/j.1525-1497.2006.00304.x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 007OW UT WOS:000234980000004 PM 16405704 ER PT J AU Ring, D Rhim, R Carpenter, C Jupiter, JB AF Ring, D Rhim, R Carpenter, C Jupiter, JB TI Isolated radial shaft fractures are more common than Galeazzi fractures SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE fracture; radius; forearm; distal radioulnar joint; Galeazzi ID MONTEGGIA FRACTURES; PLATE FIXATION; DISLOCATIONS; CLASSIFICATION AB Purpose: In contrast to isolated diaphyseal fractures of the ulna (so-called night-stick fractures), isolated fractures of the radial diaphysis generally are expected to have associated injury of the distal radioulnar joint (DRUJ), the so-called Galeazzi fracture. This study retrospectively reviewed isolated fractures of the radial diaphysis in a large cohort of patients to determine how often such fractures occur without DRUJ injury Methods: Thirty-six patients with fracture of the radius without fracture of the ulna were followed up for at least 6 months after injury. Injury of the DRUJ was defined as more than 5 mm of ulnar-positive variance on radiographs taken before any manipulative or surgical reduction. All of the fractures were treated with plate and screw fixation (8 with autogenous bone grafting) and all healed. Patients with DRUJ injury had either temporary pinning or immobilization of the DRUJ or surgical fixation of a large ulnar styloid fracture. Patients without DRUJ injury were mobilized within 2 weeks. Results: Nine patients had dislocation of the DRUJ, 4 with large ulnar styloid fractures. Among the remaining 27 patients 1 had displacement of the proximal radioulnar joint noted after surgery, leading to a secondary procedure for radial head resection. The functional results were satisfactory or excellent in all but 2 patients with functional limitations related to central nervous system injury. No patient had DRUJ dysfunction at the final follow-up evaluation. Conclusions: isolated fractures of the radial diaphysis are more common than true Galeazzi fractures. Surgeons should take great care not to overlook injury to the distal or proximal radioulnar joint in association with isolated diaphyseal fractures of the radius; however, fractures without identifiable radioulnar disruption can be treated without specific treatment of the DRUJ and with immediate mobilization. C1 Massachusetts Gen Hosp, Yawkee Ctr, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkee Ctr, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 18 TC 14 Z9 15 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD JAN PY 2006 VL 31A IS 1 BP 17 EP 21 DI 10.1016/j.jhsa.2005.09.003 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 009VS UT WOS:000235142100004 PM 16443098 ER PT J AU Doornberg, JN Ring, D AF Doornberg, JN Ring, D TI Coronoid fracture patterns SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE coronoid; elbow; fracture; injury patterns ID RADIAL HEAD; ELBOW; DISLOCATIONS AB Purpose: It has been suggested that specific types of coronoid fractures are associated strongly with specific patterns of traumatic elbow instability. This hypothesis was tested in a review of a large consecutive series of patients with a fracture of the coronoid as part of a fracture-dislocation of the elbow. Methods: One surgeon repaired 67 coronoid fractures as part of a fracture-dislocation of the elbow over a 7-year period. Each coronoid fracture was characterized on the basis of surgical exposure. Pearson chi-square analysis was used to evaluate the association of the coronoid fracture type with 1 of 4 common patterns of elbow fracture-dislocation. Results: The coronoid fracture was associated with an anterior (6 patients) or posterior (18 patients) olecranon fracture-dislocation in 24 patients, an elbow dislocation and radial head fracture in 32 patients, and a varus posteromedial rotational instability pattern injury in 11 patients. Among the 24 patients with olecranon fracture-dislocations 22 had large coronoid fractures and 2 had small (< 50%) coronoid fractures. All 32 patients with terrible-triad injuries had small (< 50%) coronoid fractures with 1 of these being a fracture of the anteromedial facet of the coronoid. Among patients with varus posteromedial rotational pattern injuries 9 had small fractures of the anteromedial facet and 2 had larger fractures. The association of coronoid fracture type with injury pattern was strongly statistically significant for both classification systems. Conclusions: The following strong associations were confirmed by this study: large fractures of the coronoid process with anterior and posterior olecranon fracture-dislocations, small transverse fractures with terrible-triad injuries, and anteromedial facet fractures with varus posteromedial rotational instability pattern injuries. An awareness of these associations and their exceptions may help guide the optimal management of these injuries. C1 Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 17 TC 69 Z9 87 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD JAN PY 2006 VL 31A IS 1 BP 45 EP 52 DI 10.1016/j.jhsa.2005.08.014 PG 8 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 009VS UT WOS:000235142100009 PM 16443103 ER PT J AU Doornberg, JN Linzel, DS Zurakowski, D Ring, D AF Doornberg, JN Linzel, DS Zurakowski, D Ring, D TI Reference points for radial head prosthesis size SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE coronoid; elbow; fracture; injury patterns ID UNSTABLE ELBOW FRACTURES; REPLACEMENT; MORPHOLOGY; DESIGN AB Purpose: Metallic radial head implants are useful when the radial head cannot be repaired reliably and when either the elbow or the forearm is unstable. Problems arise when the radial head prosthesis is too thick, causing erosions of the capitellum and incongruity of the ulnohumeral joint. We used quantitative 3-dimensional computed tomography analysis to investigate the relative height of the radial head relative to the lateral edge and central ridge of the coronoid process as reference points for optimal insertion of a radial head prosthesis. Methods: Seventeen computed tomography scans of the elbow were analyzed. The anatomic coronal plane of the forearm was determined using 3-dimensional images and a 2-dimensional image bisecting the articular surface of the radial head was created in this plane. The distance between the plane of the articular surface of the radial head and parallel planes at the most proximal aspect of the coronoid (the central ridge) and the lateral edge of the coronoid articular surface were measured. Negative values indicate the radial head is proximal to the coronoid. Results: The average distance between the planes defined by the radial head articular surface and the coronoid central ridge was -0.8 nim. The average distance between the planes defined by the radial head articular surface and the lateral edge of the coronoid articular surface was -0.9 mm. Conclusions: Because the radial head was on average only 0.9 mm more proximal than the lateral edge of the coronoid process and because the key is to not overstuff the joint a useful general guideline would be to place the plane of the articular surface of the radial head even with or just slightly more proximal than the lateral edge of the coronoid articular surface. Considering the substantial variability of the normal height of the articular surface of the radial head with respect to that of the coronoid, preoperative radiographs of the opposite elbow may be useful to avoid overstuffing the elbow. C1 Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Orthopaed Surg, Boston, MA USA. Childrens Hosp, Dept Biostat, Boston, MA USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 22 TC 50 Z9 52 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD JAN PY 2006 VL 31A IS 1 BP 53 EP 57 DI 10.1016/j.jhsa.2005.06.012 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 009VS UT WOS:000235142100010 PM 16443104 ER PT J AU Viswanath, K Breen, N Meissner, H Moser, RP Hesse, B Steele, WR Rakowski, W AF Viswanath, K Breen, N Meissner, H Moser, RP Hesse, B Steele, WR Rakowski, W TI Cancer knowledge and disparities in the information age SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID AREA SOCIOECONOMIC PATTERNS; HEALTH INTERVIEW SURVEY; NEWS MEDIA COVERAGE; MASS MEDIA; GAP; WOMEN; MAMMOGRAPHY; PREVALENCE; MORTALITY; BEHAVIOR AB Increasing information flow often leads to widening gaps in knowledge between different socioeconomic status (SES) groups as higher SES groups are more likely to acquire this new information at a faster rate than lower SES groups. These gaps in knowledge may offer a partial but robust explanation for differential risk behaviors and health disparities between different social groups. Drawing on the Health Information National Trends Survey (HINTS 2003), a national survey of communication behaviors conducted by the National Cancer Institute (NCI), we examine the relationship between publicity and knowledge gaps on two cancer topics that received different levels of publicity: knowledge about tobacco and sun exposure and their respective links to cancer. Analyses of the HINTS 2003 data suggest that differential knowledge levels of causes of cancer between SES groups are one potential explanation of cancer disparities that have been extensively reported in the literature. It is evident that high income and high education are associated with awareness about causes of major cancers such as lung and skin, and may allow people to protect themselves and minimize their risks. The data also show that heavier media attention could attenuate the knowledge gaps though moderate publicity or lack of news coverage may actually widen them. Last, the findings in this article suggest that it is necessary to take into account the SES variation within different racial and ethnic groups rather than mask them by treating the groups as one. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NCI, Bethesda, MD 20892 USA. Westat Corp, Rockville, MD USA. Brown Univ, Providence, RI 02912 USA. RP Viswanath, K (reprint author), Dana Farber Canc Inst, SM251,Smith Bldg,44 Binney St, Boston, MA 02115 USA. EM vish_viswanath@dfci.harvard.edu OI Hesse, Bradford/0000-0003-1142-1161 NR 45 TC 151 Z9 153 U1 3 U2 25 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 J9 J HEALTH COMMUN JI J. Health Commun. PY 2006 VL 11 SU 1 BP 1 EP 17 DI 10.1080/10810730600637426 PG 17 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 046ZV UT WOS:000237850500004 PM 16641071 ER PT J AU Lembcke, A Dushe, S Dohmen, PM Hoffmann, U Wegner, B Kloeters, C Enzweiler, CNH Hamm, B Konertz, WF AF Lembcke, A Dushe, S Dohmen, PM Hoffmann, U Wegner, B Kloeters, C Enzweiler, CNH Hamm, B Konertz, WF TI Early and late effects of passive epicardial constraint on left ventricular geometry: Ellipsoidal re-shaping confirmed by electron-beam computed tomography SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Article ID CARDIAC-SUPPORT DEVICE; IDIOPATHIC DILATED CARDIOMYOPATHY; FUNCTIONAL MITRAL REGURGITATION; CONGESTIVE-HEART-FAILURE; CORONARY-ARTERY-DISEASE; DYNAMIC CARDIOMYOPLASTY; WALL STRESS; LUNG-TRANSPLANTATION; VALVE REGURGITATION; EXERCISE CAPACITY AB Background: Previous studies have shown that passive epicardial constraint using a cardiac support device (CSD) reduces left ventricular (LV) size. However, specific data describing IV shape and the time course of changes in IV geometry are still incomplete. Thus, the aim of this study was- using 3-dimensional data sets obtained by computed tomography (CT)-to test the hypothesis that the CSD not only alters IV size but also IV shape, and that short-term post-operative changes in IV geometry are maintained during long-term follow-up. Methods: Ten patients with non-ischemic dilated cardiomyopathy underwent electron-beam CT examination before and again at 2.6 +/- 0.5 and 32.4 +/- 8.7 months after CSD implantation. At end-diastole and end-systole LV volumes, the length-to-width diameter ratio and a sphericity index were determined and ejection fraction and end-systolic meridional and circumferential wall stress were calculated. Results: Implantation of the CSD led to a significant reduction in IV size, a more ellipsoidal LV shape and a subsequent decrease of IV wall stress post-operatively (p < 0.05 for each), but no substantial changes were found between short- and long-term follow-up (P > 0.05 each). Mean preoperative and early and late post-operative, end-diastolic values were 310.4 +/- 87.8, 235.5 +/- 102.0 and 229.4 +/- 103.1 ml for volume; 1.27 +/- 0.20, 1.37 +/- 0.20 and 1.38 +/- 0.20 for diameter ratio; and 0.78 +/- 0.22, 0.67 +/- 0.26 and 0.65 +/- 0.23 for sphericity index. A similar pattern was observed for end-systolic values. Ejection fraction was 23.4 +/- 6.2%, 32.9 +/- 11.6% and 34.4 +/- 14.9%. End-systolic meridional and circumferential wall stress was 182.2 +/- 45.6, 128.2 +/- 52.6, 130.6 +/- 56.7 kdyn/cm(2) and 411.5 +/- 94.0, 297.4 +/- 108.4 and 302.8 +/- 117.5 kdyn/cM2, respectively. Conclusions: Three-dimensional data obtained by CT demonstrate that passive cardiac constraint leads not only to a size reduction but also to an ellipsoidal re-shaping. Our data indicate that these effects are primarily a short-term consequence of the CSD implantation but are maintained during long-term follow-up. J Heart Lung Transplant 2006;25:90 - 8. Copyright (c) 2006 by the International Society for Heart and Lung Transplantation. C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. Free Univ Berlin, Charite Univ Med Berlin, Dept Radiol, Berlin, Germany. Free Univ Berlin, Charite Univ Med Berlin, Dept Cardiovasc Surg, Berlin, Germany. Free Univ Berlin, Charite Univ Med Berlin, Dept Med Stat, Berlin, Germany. Humboldt Univ, Berlin, Germany. Harvard Univ, Sch Med, Boston, MA USA. RP Lembcke, A (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,White Bldg,Room 270, Boston, MA 02114 USA. EM alexander.lembcke@gmx.de NR 53 TC 12 Z9 12 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD JAN PY 2006 VL 25 IS 1 BP 90 EP 98 DI 10.1016/j.healun.2005.02.025 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA 002KL UT WOS:000234610200014 PM 16399536 ER PT J AU Jassal, DS Hassan, A Buth, KJ Neilan, TG Koilpillai, C Hirsch, GM AF Jassal, DS Hassan, A Buth, KJ Neilan, TG Koilpillai, C Hirsch, GM TI Surgical management of infective endocarditis SO JOURNAL OF HEART VALVE DISEASE LA English DT Article ID MITRAL-VALVE ENDOCARDITIS; ECHOCARDIOGRAPHIC FINDINGS; MECHANICAL PROSTHESES; ACTIVE ENDOCARDITIS; REPLACEMENT; DIAGNOSIS; CRITERIA; COMPLICATIONS AB Background and aim of the study: Although retrospective reviews evaluating the surgical management of infective endocarditis (IE) have been conducted in Europe and in the USA, few data exist regarding management of the condition in Canada. The study aim was to evaluate the surgical management of individuals with culture-positive active IE at a Canadian tertiary care university hospital. Methods: A retrospective analysis was performed of 74 patients (53 males, 21 females; mean age 56 +/- 14 years) with a preoperative diagnosis of acute IE between 1995 and 2003 at the Queen Elizabeth 11 Health Sciences Centre, Halifax, Nova Scotia. Preoperative clinical variables evaluated included the Duke criteria for endocarditis, correlation between preoperative echocardiographic imaging and intraoperative findings, and postoperative morbidity and mortality. Results: Native valve endocarditis (NVE) was present in 60 patients, and prosthetic valve endocarditis (PVE) in 14. All patients met the Duke criteria for endocarditis. Correlation between preoperative transesophageal echocardiography (TEE) and surgical findings (vegetations 63%, abscesses 96%, leaflet perforation 100%) was superior when compared with preoperative transthoracic echocardiography (vegetations 43%, abscesses 75%, leaflet perforation 89%). There were low rates of postoperative morbidity (reoperation 8%, stroke 5%). Overall in-hospital mortality was 14% (seven NVE, 12%; three PVE, 21%). Conclusion: Herein is presented the largest and most current case series of patients treated surgically for active IE. The results demonstrate excellent agreement between preoperative TEE and intraoperative surgical findings in the current era of surgical management of this condition. C1 Dalhousie Univ, Dept Med, Cardiol Sect, Halifax, NS, Canada. Dalhousie Univ, Dept Surg, Sect Cardiac Surg, Halifax, NS B3H 4H2, Canada. Harvard Univ, Sch Med, Cardiol Sect, Cardiac Ultrasound Lab, Boston, MA USA. RP Jassal, DS (reprint author), Harvard Univ, Dept Cardiol, Cardiac Ultrasound Lab, Massachusetts Gen Hosp,Sch Med, VBK 508,55 Fruit St, Boston, MA 02114 USA. EM umjassal@hotmail.com NR 31 TC 5 Z9 6 U1 0 U2 0 PU I C R PUBLISHERS PI NORTHWOOD PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD HA6 2ET, ENGLAND SN 0966-8519 J9 J HEART VALVE DIS JI J. Heart Valve Dis. PD JAN PY 2006 VL 15 IS 1 BP 115 EP 121 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 002VG UT WOS:000234639300028 PM 16480022 ER PT J AU El-Serag, HB Siegel, AB Davila, JA Shaib, YH Cayton-Woody, M McBride, R McGlynn, KA AF El-Serag, HB Siegel, AB Davila, JA Shaib, YH Cayton-Woody, M McBride, R McGlynn, KA TI Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study SO JOURNAL OF HEPATOLOGY LA English DT Article DE outcomes; SEER-Medicare; resection; transplant; treatment; HCC ID SURVIVAL AB Background/Aims: There are several treatment alternatives available for patients diagnosed with hepatocellular carcinoma (HCC). Yet, neither the extent to which potentially curative or palliative therapy is used to treat HCC, nor the determinants of using such therapies are known. Further, it is unclear how effective different modalities are for treating HCC. Methods: We used the linked SEER-Medicare dataset to identify patients diagnosed with HCC between 1992 and 1999. We identified 2963 patients with continuous Medicare enrollment who were not enrolled in a Medicare-HMO. HCC treatments were categorized as potentially curative therapy (resection, transplant, local ablation), or palliative (trans-arterial chemoembolization (TACE), chemotherapy), and no therapy. Demographic (age, sex, race, geographic region), clinical (comorbidity, risk factors and severity of liver disease) and tumor factors (tumor size, extent of disease) were examined as potential determinants of therapy, as well as survival in univariate and multivariable analyses. Survival curves were also generated and compared among the different treatment modalities. Results: The median age at diagnosis was 74 years (range: 32-105), and most patients (91%) were older than 65 years. Approximately 68% were White, 10% Black, 4% Hispanic, 8% Asian, and 9% were of other race. Thirteen percent of the patients received potentially curative therapy (transplant 0.9%, resection 8.2%, local ablation 4.1%), 4% received TACE,57% received other palliative therapy, and 26% received no specific therapy. Only 34% of 513 patients with single lesions, and 34% of 143 patients with lesions < 3.0 cm received potentially curative therapy. However, 19.2% of patients with unfavorable tumor features (lesion > 10.0 cm) received such therapy. Among patients who received potentially curative therapy (n = 392), resection was the most common procedure (n = 243,62%) followed by local ablation (n = 122, 31%) and finally transplantation (n = 27, 7%). In regression analyses, geographic variations in the extent and type of curative therapy persisted after adjusting for demographic, clinical, and tumor features. Median overall survival was 104 days following HCC diagnosis with the longest survival in the transplant group (852 days) and the shortest survival in the group with no treatment (58 days). In the survival analysis, transplantation led to the longest survival, followed by resection. Neither ablation nor TACE yielded prolonged survival (3 year survival was less than 10%). Conclusions: In this predominantly 65 years and older Medicare population, there are marked geographic variations in the management of HCC that seem to be at least as important as clinical and tumor-related features in determining the extent and type of HCC therapy. There is underutilization of potentially curative therapy, even among those with favorable tumor features. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. C1 Baylor Coll Med, Sect Hlth Serv Res, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Gastroenterol Sect, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. Columbia Univ, Coll Phys & Surg, Div Canc Epidemiol & Genet, NCI,DHHS, New York, NY USA. Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA. Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY USA. Columbia Univ, Coll Phys & Surg, Mailman Sch Publ Hlth, New York, NY USA. RP El-Serag, HB (reprint author), Baylor Coll Med, Sect Hlth Serv Res, Houston Vet Affairs Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 13 TC 139 Z9 139 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PD JAN PY 2006 VL 44 IS 1 BP 158 EP 166 DI 10.1016/j.jhep.2005.10.002 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 000FG UT WOS:000234445700026 PM 16290309 ER PT J AU Chung, RT AF Chung, RT TI Assessment of efficacy of treatment in HCV: Infection and disease SO JOURNAL OF HEPATOLOGY LA English DT Article; Proceedings Paper CT 1st European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-Infected Patients CY MAR, 2005 CL Paris, FRANCE DE hepatitis C; HIV; treatment; assessment of response ID CHRONIC HEPATITIS-C; ALPHA-2A PLUS RIBAVIRIN; HUMAN-IMMUNODEFICIENCY-VIRUS; LIVER FIBROSIS; BIOCHEMICAL MARKERS; HIV; COINFECTION; PREDICT; TRIAL; INDEX AB The hepatitis C virus (HCV) lifecycle appears to be confined to the cytoplasm of hepatocytes. This has translated into the ability to produce sustained virological responses (SVRs) in a substantial proportion of HCV-infected people. Lower treatment responses and higher relapse rates in co-infection may be a consequence of HCV more frequently infecting difficult-to-access reservoirs such as peripheral blood mononuclear cells. However, the durability of sustained response appears to be minimally altered in co-infection. In light of these modest SVRs, and accelerated hepatic fibrosis progression among co-infected people, strategies to slow disease progression take on greater importance. In this context, histological response becomes an important endpoint in co-infection. Multicentre randomized trials of PEG-IFN and ribavirin demonstrate that assessment of histological responses either at the conclusion of therapy or 24 weeks after completion of therapy identify a number of patients who experience improvements in histological activity index in the absence of virological clearance. The prognostic value of serum markers of fibrosis in co-infection has not been validated, but this represents a particularly important area for development in co-infection in light of the probable need for more intensive histological sampling. Eventually, it is anticipated that genotype-phenotype correlations will permit selection of optimized antiviral regimens once virus specific enzymatic inhibitors have been approved. (c) 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. RP Chung, RT (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, GRJ 825, Boston, MA 02114 USA. EM rtchung@partners.org NR 19 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2006 VL 44 SU 1 BP S56 EP S59 DI 10.1016/j.jhep.2005.11.013 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 012MA UT WOS:000235342100013 PM 16343683 ER PT J AU Loggi, E Bihl, FK Chisholm, JV Testa, L Cursaro, C Biselli, M Pinna, AD Bernardi, M Brander, C Andreone, P AF Loggi, E. Bihl, F. K. Chisholm, J. V., III Testa, L. Cursaro, C. Biselli, M. Pinna, A. D. Bernardi, M. Brander, C. Andreone, P. TI Detectable HBV-specific T cell responses in liver transplant recipients: A comparison to chronic hepatitis B SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 26-30, 2006 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 Univ Bologna, Dipartimento Med Interna, Bologna, Italy. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02115 USA. Univ Bologna, Dipartimento Trapianti Fegato & Multiorgano, Bologna, Italy. RI Testa, Lilia/G-2451-2016 OI Testa, Lilia/0000-0003-1511-090X NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2006 VL 44 SU 2 MA 34 BP S15 EP S16 DI 10.1016/S0168-8278(06)80035-8 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 039SU UT WOS:000237328100035 ER PT J AU Landefeld, CS AF Landefeld, C. Seth TI Care of hospitalized older patients - Opportunities for hospital-based physicians SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article DE geriatric syndromes; geriatrics; healthcare improvement; hospital care; hospitalized older persons; patient safety; quality of care ID ADDITIONAL BASIC SCIENCE; RANDOMIZED CONTROLLED-TRIAL; CATHETER-RELATED BACTERIURIA; CLINICAL MEDICINE; FUNCTIONAL OUTCOMES; REGIONAL-VARIATIONS; ELDERLY PATIENTS; ADVERSE EVENTS; UNITED-STATES; HIP FRACTURE AB BACKGROUND: Half of patients admitted to hospital for reasons unrelated to childbirth are age 65 years or older. Nonetheless, few hospital-based physicians have received training in geriatric medicine, and few geriatricians practice in the hospital. This paper describes the state of the science of hospital care for older patients, and identifies opportunities and barriers to improving their care. METHODS: General medical journals from 1980 to the present were selectively reviewed to identify original articles on the treatment of specific diseases and syndromes on hospitalized persons age 65 years or older. Information was synthesized to describe the course of these patients during and after hospitalization, and to identify effective management strategies and gaps in knowledge. RESULTS: Older persons in hospitals pose substantial clinical challenges: they have high rates of cognitive impairment, delirium, disability, and difficulty walking, and they often require increased attention, longer lengths of stay, and higher hospital costs than younger patients with the same diagnoses. Disease-specific interventions have not been studied extensively in those older than 75 years. Multicomponent interventions can reduce short-term rates of disability and delirium without increasing costs, but they have not been widely disseminated. Interventions to treat or prevent other common conditions in hospitalized older patients have not been proven effective. CONCLUSIONS: Fundamental discoveries in the science of hospital medicine are needed to prevent or treat geriatric syndromes, to treat common diseases in the very old, and to put into practice what is known. Hospital-based physicians can address these gaps in knowledge and practice with geriatricians, building from their shared perspectives on the care of the aged in complex health systems. C1 [Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Landefeld, C. Seth] Univ Calif San Francisco, Ctr Aging, San Francisco, CA 94143 USA. [Landefeld, C. Seth] San Francisco VA Med Ctr, Qual Scholars Program, San Francisco, CA USA. [Landefeld, C. Seth] San Francisco VA Med Ctr, Geriatr & Extended Care Serv, San Francisco, CA USA. RP Landefeld, CS (reprint author), UCSF, Box 1265,Suite 380,3333 Calif St, San Francisco, CA 94118 USA. FU NIA NIH HHS [AG 00912, AG 10418] NR 68 TC 14 Z9 14 U1 2 U2 5 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD JAN-FEB PY 2006 VL 1 IS 1 BP 42 EP 47 DI 10.1002/jhm.11 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 291PQ UT WOS:000255209700009 PM 17219470 ER PT J AU von Boehmer, H AF von Boehmer, H TI Shaping the T cell repertoire (December 1, 2005) SO JOURNAL OF IMMUNOLOGY LA English DT Correction ID LY ANTIGENS; LYMPHOCYTES; THYMUS C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP von Boehmer, H (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM harald_von_boehmer@dfci.harvard.edu NR 6 TC 3 Z9 3 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2006 VL 176 IS 1 BP 3 EP 4 PG 2 WC Immunology SC Immunology GA 997QU UT WOS:000234262600001 PM 16365387 ER PT J AU Chen, CC Louie, S McCormick, BA Walker, WA Shi, HN AF Chen, CC Louie, S McCormick, BA Walker, WA Shi, HN TI Helminth-primed dendritic cells alter the host response to enteric bacterial infection SO JOURNAL OF IMMUNOLOGY LA English DT Article ID REGULATORY T-CELLS; CITROBACTER-RODENTIUM INFECTION; INDUCED COLITIS; MICROBIAL RECOGNITION; CONCURRENT INFECTION; COLONIC HYPERPLASIA; CYTOKINE RESPONSE; IMMUNE-RESPONSES; TH2 POLARIZATION; LEISHMANIA-MAJOR AB To examine whether intestinal helminth infection may be a risk factor for enteric bacterial infection, a murine model was established using the intestinal helminth Heligomosomoides polygyrus and a murine pathogen Citrobacter rodentium, which causes infectious colitis. Using this model we recently have shown that coinfection with the Th2-inducing H. polygyrus and C. rodentium promotes bacterial-associated disease and colitis. In this study, we expand our previous observations and examine the hypothesis that dendritic cells (DC) stimulated by helminth infection may play an important role in the regulation of the intestinal immune response to concurrent C rodentium infection as well as in the modulation of the bacterial pathogenesis. We show that H. polygyrus infection induces DC activation and IL-10 expression, and that adoptive transfer of parasite-primed DC significantly impairs host protection to C. rodentium infection, resulting in an enhanced bacterial infection and in the development of a more severe colonic injury. Furthermore, we demonstrate that adoptive transfer of parasite-primed IL-10-deficient DCs fails to result in the development of a significantly enhanced C. rodentium-mediated colitis. Similarly, when the DC IL-10 response was neutralized by anti-IL-10 mAb treatment in mice that received parasite-primed DC, no deleterious effect of the parasite-primed DC on the host intestinal response to C. rodentium was detected. Thus, our results provide evidence to indicate that the H. polygyrus- dependent modulation of the host response to concurrent C. rodentium infection involves IL-10-producing DCs. C1 Massachusetts Gen Hosp, Dept Pathol, Mucosal Immunol Lab, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. Chang Gung Univ, Taoyuan, Taiwan. Chang Gung Childrens Hosp, Taoyuan, Taiwan. RP Shi, HN (reprint author), Massachusetts Gen Hosp, Dept Pathol, Mucosal Immunol Lab, Bldg 114 16th St,Room 3504, Charlestown, MA 02129 USA. EM shiha@helix.mgh.harvard.edu FU NICHD NIH HHS [R01 HD031852, R01 HD31852]; NIDDK NIH HHS [K01 DK059996, KO1 DK059996, P01 DK-33506, P01 DK033506, P30 DK 40561, P30 DK040561, P30 DK040561-11, R01 DK070260, R01 DK70260] NR 57 TC 59 Z9 61 U1 1 U2 10 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2006 VL 176 IS 1 BP 472 EP 483 PG 12 WC Immunology SC Immunology GA 997QU UT WOS:000234262600054 PM 16365440 ER PT J AU Han, XZ Kawai, T Eastcott, JW Taubman, MA AF Han, XZ Kawai, T Eastcott, JW Taubman, MA TI Bacterial-responsive B lymphocytes induce periodontal bone resorption SO JOURNAL OF IMMUNOLOGY LA English DT Article ID CONGENITALLY ATHYMIC RATS; T-HELPER CELLS; OSTEOCLAST DIFFERENTIATION; PORPHYROMONAS-GINGIVALIS; ADOPTIVE TRANSFER; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; OSTEOPROTEGERIN LIGAND; INDEPENDENT ANTIGENS; HOST RESPONSES; DISEASE AB Host immune responses play a key role in periodontal diseases. We have found that B lymphocytes in human periodontal lesions bear abundant receptor activator of NF-kappa B ligand (RANKL), a major factor in the regulation of osteoclast differentiation. The purpose of this study was to evaluate Actinobacillus actinomycetemcomitans-responsive B lymphocytes in their level of RANKL expression and their effects on periodontal bone resorption. Congenitally athymic Rowett rats received injections of formalin-fixed A. actinomycetemeonzitans into the gingival papillae, and donor B cells from normal rats immunized with A. actinomycetemcomitans were transferred via tail vein injection. We demonstrated that B cells from A. actinomycetemcomitans-immunized animals had greater levels of RANKL expression and induced a significantly higher level of osteoclast differentiation from RAW 264.7 cells than did nonimmune B cells that were not Ag specific. This activity was eliminated by incubation with the RANKL decoy receptor osteoprotegerin fusion protein. A. actinoinycetemcomitans-binding B cell (ABB) and RANKL-expressing B cells were recovered from the gingival tissues of recipient rats transferred with ABB, but not from recipients of PBS nonimmune B cells or A. actinomyceteincoinitans nonbinding B cells. Also, recipients of ABB exhibited increased osteoclast formation on the alveolar bone surface and significant periodontal bone resorption. This effect was antagonized by injection of osteoprotegerin fusion protein into the local gingival tissues. In summary, this study suggests that B lymphocytes can contribute to increased periodontal bone resorption in the absence of T lymphocytes. This effect is associated with the up-regulation of RANKL expression. C1 Forsyth Inst, Dept Immunol, Boston, MA 02115 USA. RP Taubman, MA (reprint author), Forsyth Inst, Dept Immunol, 140 The Fenway, Boston, MA 02115 USA. EM mtaubman@forsyth.org FU NIDCR NIH HHS [R01 DE003420, DE-03420] NR 31 TC 71 Z9 73 U1 1 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2006 VL 176 IS 1 BP 625 EP 631 PG 7 WC Immunology SC Immunology GA 997QU UT WOS:000234262600072 PM 16365458 ER PT J AU Roberts, JD Niedzwiecki, D Carson, WE Chapman, PB Gajewski, TF Ernstoff, MS Hodi, FS Shea, C Leong, SP Johnson, J Zhang, DS Houghton, A Haluska, FG AF Roberts, JD Niedzwiecki, D Carson, WE Chapman, PB Gajewski, TF Ernstoff, MS Hodi, FS Shea, C Leong, SP Johnson, J Zhang, DS Houghton, A Haluska, FG CA Canc Leukemia Grp B TI Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma - Cancer and leukemia group B 509901 SO JOURNAL OF IMMUNOTHERAPY LA English DT Article DE melanoma; peptide vaccine; interleukin-2; phase II trial ID METASTATIC MELANOMA; CLINICAL-TRIALS; BONE-MARROW; THERAPY; TRANSPLANTATION; MALIGNANCIES AB High-dose interleukin-2 (IL-2) is the only approved immunologic therapy for advanced melanoma, but response rates are low and significant toxicities limit treatment to otherwise healthy patients. g209-2M is a nanopeptide engineered to mimic an epitope of the gp100 melanocyte differentiation protein that is recognized in a human leukocyte antigen (HLA)-restricted manner by melanoma tumor-infiltrating lymphocytes in some patients. Previous reports indicated that administration of the g209-2M peptide could induce g209-reactive circulating T cells in patients with melanoma and that the combination of g209-2M and high-dose IL-2 might be a more active treatment than high-dose IL-2 alone. Low-dose IL-2 is riot active but has significant biologic effects, and because of a different toxicity profile, it can be offered to most patients. The primary objective of this cooperative group phase 2 study was to determine the activity of the combination of g209-2M and low-dose IL-2 in advanced melanoma. Twenty-six HLA appropriate patients with advanced melanoma received subcutaneous g209-2M peptide once every 3 weeks and subcutaneous IL-2 (5 million IU/m(2)) daily for 5 days during the first and second weeks. Patients were monitored for tumor response, toxicity, and induction of g209-reactive circulating T cells. There were no objective responses. There were no toxic deaths and no grade 4 toxicities. More than half of the patients experienced some grade 2 toxicity and one quarter experienced grade 3 toxicity. There was no convincing evidence by enzyme-linked immunospot or tetramer analysis of induction of g209-reactive circulating T cells. The combination of g209-2M and low-dose IL-2 is safe and tolerable but inactive against advanced melanoma. Absence of evidence of immunization raises concerns for peptide-based immunization strategies with concurrent IL-2. C1 Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA. Canc & Leukemia Grp B, Ctr Stat, Durham, NC USA. Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Chicago, Med Ctr, Chicago, IL 60637 USA. Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Lebanon, NH USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Roberts, JD (reprint author), Virginia Commonwealth Univ, Massey Canc Ctr, POB 980037,401 Coll St, Richmond, VA 23298 USA. EM john.d.roberts@vcu.edu RI Carson, William/E-2846-2011 FU NCI NIH HHS [CA41287, CA12449, CA52764, CA60138, CA77651, CA77658, CA33601, CA32291, CA31946, CA04326] NR 18 TC 15 Z9 18 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1524-9557 J9 J IMMUNOTHER JI J. Immunother. PD JAN-FEB PY 2006 VL 29 IS 1 BP 95 EP 101 DI 10.1097/01.cji.0000195295.74104.ad PG 7 WC Oncology; Immunology; Medicine, Research & Experimental SC Oncology; Immunology; Research & Experimental Medicine GA 000UZ UT WOS:000234489200011 PM 16365605 ER PT J AU Glotzer, TV Daoud, EG Wyse, DG Singer, DE Holbrook, R Pruett, K Smith, K Hilker, CE AF Glotzer, TV Daoud, EG Wyse, DG Singer, DE Holbrook, R Pruett, K Smith, K Hilker, CE TI Rationale and design of a prospective study of the clinical significance of atrial arrhythmias detected by implanted device diagnostics: The TRENDS study SO JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY LA English DT Article DE atrial fibrillation; stroke; arrhythmia detection; continuous electrocardiographic monitoring; stroke risk factors ID RISK-FACTORS; FIBRILLATION; STROKE; PREDICTORS AB Background: Sustained atrial fibrillation (AF) is a common risk factor for stroke. While intermittent AF also appears to pose a substantial stroke risk, the quantitative relationship between the percentage of time spent in AF and stroke risk is poorly specified and "intermittent" AF is not the same as paroxysmal AF. Improved assessment of the impact of AF burden on stroke risk will allow more targeted and safer use of antithrombotic therapy. Methods and Results: The primary objective of this study is to determine if AT/AF (all device detected atrial tachyarrhythmias, including atrial flutter, atrial fibrillation, and atrial tachycardia) burden over a 30 day period is an independent predictor of the occurrence of ischemic stroke, transient ischemic attack (TIA) and/or systemic embolism in subjects not receiving anticoagulation therapy. TRENDS is a prospective, post-market, non-randomized, multicenter study designed to enroll 3100 subjects who have an independent Class I/II indication for cardiac rhythm device implantation and who have demographic features suggestive of an increased risk for thromboembolic complications related to AT/AF. All implanted devices will have the ability to collect long-term AT/AF burden trending data and will be equivalently programmed to ensure consistent data collection. All subjects will be followed with device interrogations every 3 months and clinic visits every 6 months for 1 year. Subjects with a documented history of AT/AF prior to enrollment and those who develop AT/AF during the 12-month follow-up will be followed until the last subject enrolled in the study has completed their 24-month follow-up. Conclusions: The results of the TRENDS study should help clarify the implications of data retrieved from an implantable device with regard to the risk for thromboembolic complications from atrial arrhythmias, even in the absence of symptoms. C1 Medtronic Inc, Minneapolis, MN 55432 USA. Hackensack Univ Med Plaza Electrophysiol Associat, Hackensack, NJ 07601 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Libin Cardiovasc Inst Alberta, Calgary, AB, Canada. Riverside Methodist Hosp, Midwest Res Fdn, Columbus, OH 43214 USA. Hackensack Univ, Med Ctr, Hackensack, NJ USA. RP Hilker, CE (reprint author), Medtronic Inc, Minneapolis, MN 55432 USA. EM TayaVG@aol.com; christopher.e.hilker@medtronic.com NR 22 TC 28 Z9 28 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1383-875X J9 J INTERV CARD ELECTR JI J. Interv. Card. Electrophysiol. PD JAN PY 2006 VL 15 IS 1 BP 9 EP 14 DI 10.1007/s10840-006-7622-y PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 039XH UT WOS:000237341000002 PM 16680544 ER PT J AU Baden, HP AF Baden, Howard P. TI One editor's look back at the JID SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02129 USA. RP Baden, HP (reprint author), Massachusetts Gen Hosp, Dept Dermatol, CBRC,13th St,Bldg 149, Boston, MA 02129 USA. EM hbaden@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JAN PY 2006 VL 126 IS 1 BP 7 EP 8 DI 10.1038/sj.jid.5700076 PG 2 WC Dermatology SC Dermatology GA 062KU UT WOS:000238943900003 ER PT J AU Goel, VK Lazar, AJF Warneke, CL Redston, MS Haluska, FG AF Goel, Vikas K. Lazar, Alexander J. F. Warneke, Carla L. Redston, Mark S. Haluska, Frank G. TI Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID MALIGNANT-MELANOMA; TUMOR PROGRESSION; PTEN/MMAC1 ALTERATIONS; FREQUENT EVENT; RAS MUTATIONS; CELL LINES; KINASE; IDENTIFICATION; ACTIVATION; EXPRESSION AB Frequent somatic mutation of v-raf murine sarcoma viral oncogene homolog B (BRAF), a downstream effector of the rat sarcoma oncogene (RAS) signaling pathway, is described in melanoma and other tumors. Our analysis of melanoma cell lines suggests that activating mutations in BRAF can occur simultaneously with inactivation of phosphatase and tensin homolog (PTEN), but neuroblastoma RAS (NRAS) mutations are not coincident. We determined the concurrent prevalence of mutations in BRAF and NRAS, and alteration of PTEN expression in 69 primary cutaneous melanomas. BRAF mutations were seen in 57% of cases. NRAS was mutated in 17% of samples, exclusively in exon 2. Two cases showed concurrent BRAF and NRAS mutations. Using immunohistochemistry, PTEN protein expression was lost or greatly reduced in 19% of tumors. Seven tumors with reduced PTEN yielded DNA amenable to sequencing, and three also showed mutation in BRAF but none in NRAS. In all, 11 (85%) of 13 tumors showing reduced PTEN expression were greater than 3.5mm thick, and the association of increasing Breslow thickness and loss or reduction of PTEN expression was statistically significant (P < 0.0001). Mutations in NRAS were not coincident with reduced PTEN expression, and the concurrent mutation of NRAS and BRAF was rare. C1 Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Melanoma Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA. RP Haluska, FG (reprint author), Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Melanoma Ctr, GRJ 1021,55 Fruit St, Boston, MA 02114 USA. EM Haluska.frank@mgh.harvard.edu RI Lazar, Alexander/A-3416-2008 OI Lazar, Alexander/0000-0002-6395-4499 FU NCI NIH HHS [1 RO1 CA 095798-01A2, P50 CA 93683-01]; NIAMS NIH HHS [P30 AR 042689] NR 31 TC 197 Z9 205 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JAN PY 2006 VL 126 IS 1 BP 154 EP 160 DI 10.1038/sj.jid.5700026 PG 7 WC Dermatology SC Dermatology GA 062KU UT WOS:000238943900026 PM 16417231 ER PT J AU Bogaert, Y Grippa, J Nemenoff, R Reusch, JEB AF Bogaert, Y Grippa, J Nemenoff, R Reusch, JEB TI Type 1 collagen regulates vascular smooth muscle cell phenotype by down-regulation of CREB and serum response factor through an Akt-dependent mechanism SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Denver VAMC, Denver, CO USA. Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 85 BP S94 EP S94 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500098 ER PT J AU Cordova, CA Said, BO McCarley, RW Baxter, MG Chiba, AA Strecker, RE AF Cordova, CA Said, BO McCarley, RW Baxter, MG Chiba, AA Strecker, RE TI Sleep deprivation in rats produces attentional impairments on a five-choice serial reaction time task SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Calif San Diego, Dept Cognit Sci, San Diego, CA USA. Univ Calif Irvine, Irvine Sch Med, Irvine, CA USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Boston VA Healthcare Syst, Boston, MA USA. Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England. NR 0 TC 0 Z9 0 U1 0 U2 2 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 76 BP S92 EP S92 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500089 ER PT J AU Gerchman, F Tong, J Utzschneider, KM McNeely, MJ Hull, RL Zraika, S Udayasankar, J Leonetti, DJ Boyko, EJ Fujimoto, WY Kahn, SE AF Gerchman, F Tong, J Utzschneider, KM McNeely, MJ Hull, RL Zraika, S Udayasankar, J Leonetti, DJ Boyko, EJ Fujimoto, WY Kahn, SE TI Increased visceral adiposity is associated with decreased glomerular filtration rate by a mechanism independent of glucose tolerance. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 156 BP S107 EP S107 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500169 ER PT J AU Goel, A Brooks-Worrell, B Palmer, JP AF Goel, A Brooks-Worrell, B Palmer, JP TI Assessment of regulatory T cells in phenotypic type 2 diabetes patients SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 305 BP S132 EP S132 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500318 ER PT J AU Heppe, D Gunter, J Pedler, M Reusch, JEB AF Heppe, D Gunter, J Pedler, M Reusch, JEB TI Vascular regulation of protein kinase in insulin resistance. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Denver VAMC, Denver, CO USA. Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 464 BP S159 EP S159 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500477 ER PT J AU Kao, KC Hong, S Taylor, CE Nouvong, A Masih, S Perell, KL Fang, MA AF Kao, KC Hong, S Taylor, CE Nouvong, A Masih, S Perell, KL Fang, MA TI Laterally wedged shoe inserts as an intervention for medial knee osteoarthritis SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Calif State Univ Fullerton, Dept Kinesiol & Hlth Sci, Fullerton, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 302 BP S132 EP S132 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500315 ER PT J AU Kulig, CC Beresford, TP Everson, XGT AF Kulig, CC Beresford, TP Everson, XGT TI Lack of detectable levels of fatty acid ethyl esters in plasma of abstinent liver transplant recipients. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Denver VA Med Ctr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 263 BP S125 EP S125 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500276 ER PT J AU Kurbanyan, K Lessell, S AF Kurbanyan, K Lessell, S TI A case of intracranial hypotension and cranial nerve VI palsy following chiropractic neck manipulation. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 180 BP S111 EP S111 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500193 ER PT J AU Njoku, CJ Patrick, KS Oates, JC AF Njoku, CJ Patrick, KS Oates, JC TI Urine F2-isoprostanes are reduced in lupus nephritis. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 247 BP S300 EP S300 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301501246 ER PT J AU Rome, ME Stella, SL Brecha, NC AF Rome, ME Stella, SL Brecha, NC TI Gamma-aminobutyric acid receptor physiology in cone bipolar cells of the mammalian retina. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 358 BP S141 EP S142 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500371 ER PT J AU Shimizu, T Shinmei, SS Fujikawa, DG AF Shimizu, T Shinmei, SS Fujikawa, DG TI Seizure-induced neuronal necrosis is a caspase-independent process. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 364 BP S143 EP S143 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500377 ER PT J AU Tong, J Utzschneider, KM Carr, DB Hull, RL Udayasankar, J Gerchman, F Zraika, S Knopp, RH Kahn, SE AF Tong, J Utzschneider, KM Carr, DB Hull, RL Udayasankar, J Gerchman, F Zraika, S Knopp, RH Kahn, SE TI Parasympathetic innervation may mediate the effect of age and gender on body fat distribution in humans. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 326 BP S136 EP S136 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500339 ER PT J AU Tylee, TS Cummings, DE AF Tylee, TS Cummings, DE TI Inhibition of hypothalamic protein kinase A signaling attenuates ghrelin-induced feeding in rats. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 319 BP S134 EP S135 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500332 ER PT J AU Tylee, TS Cummings, DE AF Tylee, TS Cummings, DE TI Inhibition of hypothalamic protein kinase A signaling attenuates ghrelin-induced feeding in rats SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 52 BP S88 EP S88 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500065 ER PT J AU Utzschneider, KM Tong, J Gerchman, F Udayasankar, J Montgomery, B Kahn, SE Puget, VA AF Utzschneider, KM Tong, J Gerchman, F Udayasankar, J Montgomery, B Kahn, SE Puget, VA TI The early insulin response during an oral glucose tolerance test exhibits marked day-to-day variability in free-living adults. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 155 BP S106 EP S106 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500168 ER PT J AU Wander, PL Raskind, MA Zabetian, CP Warren, DJ Kumata, J Peskind, ER AF Wander, PL Raskind, MA Zabetian, CP Warren, DJ Kumata, J Peskind, ER TI Prazosin improves nightmares and sleep disturbance and does not worsen daytime symptoms in posttraumatic stress disorder. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Washington, Sch Med, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA USA. Univ Washington, Dept Neurol, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Geriatr Ctr, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2006 VL 54 IS 1 SU S MA 511 BP S167 EP S167 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 011XH UT WOS:000235301500524 ER PT J AU Tseng, WYI Dou, JG Reese, TG Wedeen, VJ AF Tseng, WYI Dou, JG Reese, TG Wedeen, VJ TI Imaging myocardial fiber disarray and intramural strain hypokinesis in hypertrophic cardiomyopathy with MRI SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE MRI; hypertrophic cardiomyopathy; myocardium; disarray; dysfunction ID MAGNETIC-RESONANCE; IN-VIVO; MYOFIBER DISARRAY; DIFFUSION; DEFORMATION; DYSFUNCTION; FIBROSIS; STENOSIS; MOTION AB Purpose: To examine the relationship between myofiber disarray and myocardial hypokinesis in human hypertrophic cardiomyopathy (HCM) using noninvasive cardiac diffusion and strain MRI. Materials and Methods: Five patients with a diagnosis of HCM and five age-matched healthy volunteers were studied and compared. Cardiac diffusion MRI was applied to map in vivo myocardial fiber architecture. Cardiac strain MRI was applied to map myocardial motion. By acquiring registered diffusion and strain MRI images in vivo on both normal and HCM hearts, we investigated in HCM the relationship between myofiber disarray and systolic strain components, including radial, fiber, and cross-fiber strains, and sought to determine the mechanism behind disarray-related myocardial dysfunction in HCM. Results: Regionally disordered fiber orientation and reduced diffusion fractional anisotropy (FA) were found in HCM, demonstrating myofiber disarray. Intramural myocardial strain hypokinesis (reduced radial, fiber, an cross-fiber strains) was also observed in HCM in the same region, and was found to be correlated with FA. The correlation between FA and hypokinesis was found to be stronger in the cross-fiber direction (part of the passive myocardial function) compared to the fiber direction (part of the active myocardial function). This is consistent with the hypothesis that the principal feature of HCM is the reduction of myocardium passive compliance. The angle between principal shortening and fiber orientation was markedly disordered in HCM, indicating an abnormal transmural coupling. Conclusion: Myofiber disarray in HCM is correlated with abnormalities of both passive and active myocardial function, and the normal patterns of fiber shortening and wall thickening are deranged in HCM. C1 Massachusetts Gen Hosp, NMR Ctr, Boston, MA 02129 USA. Natl Taiwan Univ, Coll Med, Ctr Optoelect Biomed, Taipei 10764, Taiwan. RP Wedeen, VJ (reprint author), Massachusetts Gen Hosp, NMR Ctr, Bldg 149,13th ST MS 2301, Boston, MA 02129 USA. EM van@nmr.mgh.harvard.edu OI Tseng, Wen-Yih Isaac/0000-0002-2314-6868 FU NHLBI NIH HHS [1R01-HL56737] NR 24 TC 77 Z9 78 U1 0 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD JAN PY 2006 VL 23 IS 1 BP 1 EP 8 DI 10.1002/jmri.20473 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 000US UT WOS:000234488500001 PM 16331592 ER PT J AU Winterbottom, LM Fong, AM Benkstein, KL Liang, BB Snodgrass, LS Parks-Huitron, H AF Winterbottom, LM Fong, AM Benkstein, KL Liang, BB Snodgrass, LS Parks-Huitron, H TI Impact of a clinical pharmacy consult service on guideline adherence and management of gabapentin for neuropathic pain SO JOURNAL OF MANAGED CARE PHARMACY LA English DT Article DE gabapentin; neuropathic pain; clinical pharmacy; formulary management ID RANDOMIZED CONTROLLED-TRIAL; POSTHERPETIC NEURALGIA; DOUBLE-BLIND; DIABETIC-NEUROPATHY; DRUGS AB OBJECTIVE: Our objectives were to (1) determine whether a computerized clinical pharmacy approval and follow-up consult process for ordering new prescriptions for gabapentin for the treatment of neuropathic pain decreased the number of patients without documented treatment benefit while increasing follow-up and documentation of effectiveness, and (2) describe gabapentin use patterns at a Veterans Affairs (VA) Medical Center, including the use of first-line therapies prior to gabapentin therapy for neuropathic pain. METHODS: The clinical pharmacy intervention included review of (1) the indication for gabapentin; (2) the required use and failure or contraindication of 3 first-line therapies: nonsteroidal ant-inflammatory drugs (NSAIDs), tricyclic antidepressants (TCAs), and capsaicin cream; (3) the initial pain assessment; and (4) patient follow-up in 4 to 6 weeks, with repeat pain assessment. A retrospective chart review was performed for all patients who received a new prescription for gabapentin from October 2002 to April 2003 at the Portland VA Medical Center (PVAMC). The outcomes of interest for the provider group versus the clinical pharmacy managed group included follow-up at 6 weeks or less versus follow-up at more than 6 weeks, documentation of treatment benefit, how many of the 3 first-line therapies were tried before gabapentin, and whether the gabapentin therapy was discontinued. RESULTS: There were 237 patients who received a new prescription for gabapentin between October 2002 and April 2003. Of these gabapentin prescriptions, 61% (n=144) were prescribed for neuropathic pain. Of the new gabapentin prescriptions for neuropathic pain, 61% (n=88) were made from approved clinical pharmacy consults, 38% (n=54) were ordered without a clinical pharmacy consult, and 38% (n=2) were not included because the patient received the drug despite denial by the clinical pharmacy consult. The rate of follow-up to assess documentation of benefit of therapy with gabapentin was 87% (n=62) in the clinical pharmacy consult group compared with 51% (n=27) in the provider-managed group (chi(2) = 18.07, P < 0.001). Of the patients who were assessed by follow-up, 89% (n=55) of the clinical pharmacy consult group received follow-up within 6 weeks versus 52% (n=14) of the provider-managed group (X-2 = 12.63, P < 0.001). Compared with the patients managed by clinical pharmacists, 43% (n=23) of the gabapentin patients in the provider-managed group had no evidence of prior use of any of the 3 agents required by the gabapentin neuropathic pain guideline, 55% (n=29) had evidence of prior use of 1 or 2 first-line agents, and only 2% (n=1) had evidence of prior use of all 3 required first-line agents, versus 100% (n=71) of the patients managed by clinical pharmacy consult. There was no difference in the rate of continuation of gabapentin therapy in the group of patients who received clinical pharmacy consults (65%) compared with the provider-managed group (68%, chi(2)=0.11, P=0.718). Of the 148 pharmacy consults for new gabapentin prescriptions that were completed during the 7-month period from October 2002 through April 2003, 60 (40%) were denied, which resulted in the lack of gabapentin use in these 60 patients. CONCLUSIONS: A clinical pharmacy intervention as part of the management of a treatment guideline for appropriate gabapentin use promotes documentation of drug therapy effectiveness in neuropathic pain and prevention of gabapentin use prior to a trial with alternative first-line therapies. C1 Dept Vet Affairs Med Ctr, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Div Hosp & Specialty Med, Portland, OR USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. PVAMC, Portland Ctr Evaluat Clin Serv, Portland, OR USA. RP Winterbottom, LM (reprint author), Dept Vet Affairs Med Ctr, Portland, OR 97239 USA. EM lisa.winterbottom@med.va.gov NR 39 TC 2 Z9 2 U1 1 U2 5 PU ACADEMY MANAGED CARE PHARMACY PI ALEXANDRIA PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA SN 1083-4087 J9 J MANAG CARE PHARM JI J. Manag. Care Pharm. PD JAN-FEB PY 2006 VL 12 IS 1 BP 61 EP 69 PG 9 WC Health Care Sciences & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA 030BU UT WOS:000236609100005 PM 16420109 ER PT J AU Jones, SR Kopell, N AF Jones, SR Kopell, N TI Local network parameters can affect inter-network phase lags in central pattern generators SO JOURNAL OF MATHEMATICAL BIOLOGY LA English DT Article DE coupled oscillators; relaxation oscillations; inter-network phase lags; singular perturbation theory; dynamical systems ID ORDINARY DIFFERENTIAL-EQUATIONS; RELAXATION-OSCILLATORS; INVARIANT-MANIFOLDS; SWIMMERET; MOVEMENTS; RHYTHMS; NEURONS AB Weakly coupled phase oscillators and strongly coupled relaxation oscillators have different mechanisms for creating stable phase lags. Many oscillations in central pattern generators combine features of each type of coupling: local networks composed of strongly coupled relaxation oscillators are weakly coupled to similar local networks. This paper analyzes the phase lags produced by this combination of mechanisms and shows how the parameters of a local network, such as the decay time of inhibition, can affect the phase lags between the local networks. The analysis is motivated by the crayfish central pattern generator used for swimming, and uses techniques from geometrical singular perturbation theory. C1 Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. Boston Univ, Dept Math, Boston, MA 02215 USA. Boston Univ, Ctr BioDynam, Boston, MA 02215 USA. RP Jones, SR (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. EM srjones@nmr.mgh.harvard.edu NR 26 TC 6 Z9 6 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0303-6812 J9 J MATH BIOL JI J. Math. Biol. PD JAN PY 2006 VL 52 IS 1 BP 115 EP 140 DI 10.1007/s00285-005-0348-0 PG 26 WC Biology; Mathematical & Computational Biology SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology GA 995ZU UT WOS:000234145000006 PM 16195924 ER PT J AU Izard, J AF Izard, Jacques TI Cytoskeletal cytoplasmic filament ribbon of Treponema: A member of an intermediate-like filament protein family SO JOURNAL OF MOLECULAR MICROBIOLOGY AND BIOTECHNOLOGY LA English DT Article DE bacterial cytoskeleton; cell division; cytoplasmic filament; spirochete ID BACTERIAL-CELL-DIVISION; COILED-COIL PROTEIN; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; REPLICATION ORIGIN; GEN-NOV; CRYOELECTRON TOMOGRAPHY; CHROMOSOME SEGREGATION; REFRINGENS NICHOLS; DEFICIENT MUTANT AB Development of genetic systems for many bacterial genera, including Treponema, now allow the study of structures that are specific to certain pathogens. The cytoplasmic filament ribbon of treponemes that is involved in the cell division cycle has a unique organization. Cytoplasmic bridging proteins connect the filaments, maintaining the distance between them and providing the overall ribbon-like structure. The filaments are anchored by proteins associated with the inner membrane. Each filament is composed of a unique monomer, the cytoplasmic filament protein A (CfpA), with coiled-coils secondary structures. CfpA is part of a growing family of proteins that we propose to call bacterial intermediate-like filaments (BILF). Copyright (c) 2006 S. Karger AG, Basel. C1 Forsyth Inst, Boston, MA 02115 USA. RP Izard, J (reprint author), Forsyth Inst, 140 Fenway, Boston, MA 02115 USA. EM jizard@forsyth.org RI Izard, Jacques/A-6074-2012; OI Izard, Jacques/0000-0002-5904-5436 FU NCRR NIH HHS [RR01219]; NIAID NIH HHS [AI34354] NR 76 TC 13 Z9 14 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1464-1801 EI 1660-2412 J9 J MOL MICROB BIOTECH JI J. Mol. Microbiol. Biotechnol. PY 2006 VL 11 IS 3-5 BP 159 EP 166 DI 10.1159/000094052 PG 8 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 087VL UT WOS:000240770800005 PM 16983193 ER PT J AU Kovacs, I Lentini, KM Ingano, LM Kovacs, DM AF Kovacs, I Lentini, KM Ingano, LM Kovacs, DM TI Presenilin 1 forms aggresomal deposits in response to heat shock SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE Alzheimer's disease; aggregate; chaperone; dislocation; neurodegeneration ID TRANSMEMBRANE CONDUCTANCE REGULATOR; UBIQUITIN-PROTEASOME PATHWAY; FAMILIAL ALZHEIMERS-DISEASE; PROTEIN-DEGRADATION; ALPHA-SYNUCLEIN; GAMMA-SECRETASE; MUTANT; CELLS; AGGREGATION; EXPRESSION AB Aggresomes have been described as cytoplasmic membrane protein aggregates that are induced by proteasome inhibition or overexpression of certain proteins. Here, we characterized aggresomes formed by the Alzheimer's disease-associated presenilin 1 (PSI) protein. Proteasome inhibition induced accumulation of PSI in the endoplasmic reticulum (ER) and retrotranslocation of the protein from the ER membrane into the cytoplasm. Aggresomes formed by PSI modified the ER structure whereas proteasomes were inhibited. Therefore, clear visual identification of PSI aggresomes required removal of the proteasome inhibitor followed by hours of recovery to redistribute the ER throughout the cells. Aggresomes formed by PSI did not potentiate or attenuate apoptotic cell death induced by staurosporine treatment. Selective presence of the heat-shock proteins Hsp70 and HDJ-2/HSDJ, but not Hsp90, in aggresomes suggested chaperone-mediated transport of PSI into these structures. Because proteasome inhibition and heat shock are both known to induce expression of heat shock proteins, we also demonstrated that heat shock alone was sufficient to induce PSI aggresome formation and Hsp70 expression. These results indicate that aggresome formation by PSI is chaperone-mediated and can be induced in response to heat-shock stress, a common cellular event in neurodegenerative diseases. Malfunctioning of the proteasome or heat-shock stress response in the brains of patients affected by Alzheimer's disease may lead to the accumulation of stable aggresomes of PSI, perhaps contributing to neurodegeneration. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurobiol Dis Lab,Genet & Aging Res Unit,MIND, Charlestown, MA USA. RP Kovacs, DM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurobiol Dis Lab,Genet & Aging Res Unit,MIND, Charlestown, MA USA. EM dora_kovacs@hms.harvard.edu NR 51 TC 9 Z9 9 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PY 2006 VL 29 IS 1 BP 9 EP 19 DI 10.1385/JMN/29:01:9 PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 048FQ UT WOS:000237933400002 PM 16757805 ER PT J AU Couture, SM Roberts, DL Penn, DL Cather, C Otto, MW Goff, D AF Couture, SM Roberts, DL Penn, DL Cather, C Otto, MW Goff, D TI Do baseline client characteristics predict the therapeutic alliance in the treatment of schizophrenia? SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE alliance; psychosocial treatment; schizophrenia ID COGNITIVE-BEHAVIORAL THERAPY; NEGATIVE SYNDROME SCALE; WORKING ALLIANCE; INPATIENT TREATMENT; CASE-MANAGEMENT; SOCIAL SUPPORT; PSYCHOTHERAPY; SYMPTOMS; PROGRAM; VALIDATION AB This study examined clinical predictors of client and therapist alliance ratings early in therapy, the relationship between client and therapist alliance ratings, and the psychometric properties of the Working Alliance Inventory in individuals with schizophrenia receiving manual-based treatment. Assessment of clinical symptoms and social functioning were conducted at baseline, and alliance ratings were obtained at 5 weeks. The Working Alliance Inventory had high internal consistency, but there were low correlations between client and therapist ratings. Results also indicated that social functioning and the activation and autistic preoccupation factors on the Positive and Negative Syndrome Scale were significant predictors of therapists' alliance ratings. There were no significant relationships between clinical predictors and clients' therapeutic alliance ratings. The findings indicate that client interpersonal factors are significant predictors of the therapist-rated alliance in the treatment of schizophrenia. Low correlations between clients' and therapists' ratings of the alliance should be examined in future research. C1 Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Penn, DL (reprint author), Univ N Carolina, Dept Psychol, CB 3270, Chapel Hill, NC 27599 USA. NR 42 TC 47 Z9 47 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD JAN PY 2006 VL 194 IS 1 BP 10 EP 14 DI 10.1097/01.nmd.0000195315.39196.52 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 002KN UT WOS:000234610400002 PM 16462549 ER PT J AU Pinel, S Chastagner, P Merlin, JL Marchal, C Taghian, A Barberi-Heyob, M AF Pinel, S Chastagner, P Merlin, JL Marchal, C Taghian, A Barberi-Heyob, M TI Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE concomitant chemoradiation; human malignant glioma xenografts; overall treatment time; radiotherapy; topotecan ID SQUAMOUS-CELL CARCINOMA; TOPOISOMERASE-I INHIBITOR; RANDOMIZED MULTICENTER TRIAL; PLUS CRANIAL RADIATION; IONIZING-RADIATION; NUDE-MICE; CONVENTIONAL RADIOTHERAPY; FRACTIONATED-IRRADIATION; GLIOBLASTOMA-MULTIFORME; PHASE-I AB Purpose: Several studies reported that prolongation of overall treatment time of fractionated radiotherapy reduces the chance of tumor control. In the present study, we hypothesize that combining topotecan with irradiation could compensate for this detrimental time effect on the radioresponse. Therefore, we investigated the efficiency of different schedules of topotecan (TPT), radiotherapy (RT) or concomitant combination TPT + RT. Methods and Materials: Experiments were performed in two human high-grade glioma xenograft models (U87 and GBM Nan1). TPT and RT were delivered at a total dose of 3 mg/kg and 40 Gy, respectively. For the TPT + RT groups, TPT was injected 5 min before radiation. Total radiation doses were delivered in 5, 10, 20, or 30 fractions over 1, 2, 4, or 6 weeks, respectively. The efficiency of TPT, RT, and TPT + RT was evaluated by tumor growth delay (TGD). Results: At this low total dose, and independent of the schedule, no efficacy was found in TPT-treated glioma xenografts. Conversely, radiotherapy-induced antitumor effect decreased with prolongation of treatment time. For TPT + RT combination, antitumor activity was not influenced by schedule, and tumor response was always comparable to those measured for the shortest and the most efficient irradiation schedule (i.e. 1 week). When treatment was delivered over 4 or 6 weeks in U87 glioma xenografts, therapeutic enhancement ratios reached 2.6 and 3.7, respectively. This indicated that the interaction between ionizing radiation and topotecan was synergistic. Conclusion: The present study demonstrated that concomitant topotecan can compensate for the detrimental effect of treatment time protraction on radiotherapy efficacy in two malignant glioma xenografts. C1 Ctr Alexis Vautrin, Lab Rech Oncol, Vandoeuvre Les Nancy, France. Massachusetts Gen Hosp, Dept Radiat Therapy, Boston, MA 02114 USA. Ctr Alexis Vautrin, Dept Radiotherapie, Vandoeuvre Les Nancy, France. CHU, Dept Pediat Oncol, Vandoeuvre Les Nancy, France. CNRS UHP INPL, CRAN UMR7039, Ctr Alexis Vautrin, Lab Rec, Vandoeuvre Les Nancy, France. RP Pinel, S (reprint author), Ctr Alexis Vautrin, Lab Rech Oncol, Vandoeuvre Les Nancy, France. EM pinel.sophie@tiscali.fr NR 46 TC 7 Z9 7 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2006 VL 76 IS 1 BP 31 EP 38 DI 10.1007/s11060-005-3666-6 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 001RG UT WOS:000234553400004 PM 16311843 ER PT J AU Baehring, JM Piepmeier, J Duncan, C Ogle, E Kim, J Liebsch, N AF Baehring, JM Piepmeier, J Duncan, C Ogle, E Kim, J Liebsch, N TI Chondrosarcoma of the skull base SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article C1 Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA. Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA. Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Baehring, JM (reprint author), Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2006 VL 76 IS 1 BP 49 EP 49 DI 10.1007/s11060-005-5981-3 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 001RG UT WOS:000234553400006 PM 16402277 ER PT J AU Signore, AP Weng, ZF Hastings, T Van Laar, AD Liang, QH Lee, YJ Chen, J AF Signore, AP Weng, ZF Hastings, T Van Laar, AD Liang, QH Lee, YJ Chen, J TI Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE neuroprotection; Parkinson's disease; serinethreonine kinase ( Akt); substantia nigra pars compacta ID ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; PARKINSONS-DISEASE; IN-VIVO; CEREBRAL-ISCHEMIA; SUBSTANTIA-NIGRA; SIGNAL-TRANSDUCTION; NEUROTROPHIC FACTOR; BRAIN-INJURY; KINASE-B AB Parkinson's disease (PD) is a neurodegenerative disorder characterized by the death of midbrain dopaminergic neurons. In the present study, erythropoietin, a trophic factor that has both hematopoietic and neural protective characteristics, was investigated for its capacity to protect dopaminergic neurons in experimental Parkinson's disease. Using both the dopaminergic cell line, MN9D, and primary dopamine neurons, we show that erythropoietin (1-3 U/mL) is neuroprotective against the dopaminergic neurotoxin, 6-hydroxydopamine. Protection was mediated by the erythropoietin receptor, as neutralizing anti-erythropoietin receptor antibody abrogated the protection. Activation of Akt/protein kinase B (PKB), via the phosphoinositide 3-kinase pathway, is a critical mechanism in erythropoietin-induced protection, while activation of extracellular signal-regulated kinase (ERK)1/2 contributes only moderately. Indeed, transfection of constitutively active Akt/PKB into dopaminergic cells was sufficient to protect against cell death. Furthermore, erythropoietin diminished markers of apoptosis in MN9D cells, including caspase 9 and caspase 3 activation and internucleosomal DNA fragmentation, suggesting that erythropoietin interferes with the apoptosis-execution process. When erythropoietin was administered to mice unilaterally lesioned with 6-hydroxydopamine, it prevented the loss of nigral dopaminergic neurons and maintained striatal catecholamine levels for at least 8 weeks. Erythropoietin-treated mice also had significantly reduced behavioral asymmetries. These studies suggest that erythropoietin can be an effective neuroprotective agent for dopaminergic neurons, and may be useful in reversing behavioral deficits associated with Parkinson's disease. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Inst Neurodegenerat Disorders, Pittsburgh, PA 15213 USA. Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507,Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu FU NINDS NIH HHS [NS44178, NS44076, NS45048, NS43802] NR 66 TC 53 Z9 61 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD JAN PY 2006 VL 96 IS 2 BP 428 EP 443 DI 10.1111/j.1471-4159.2005.03587.x PG 16 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 994JX UT WOS:000234029100013 PM 16336625 ER PT J AU Deckersbach, T Dougherty, DD Rauch, SL AF Deckersbach, T Dougherty, DD Rauch, SL TI Functional imaging of mood and anxiety disorders SO JOURNAL OF NEUROIMAGING LA English DT Review DE neuroimaging; cognitive neuroscience; affective neuroscience; functional magnetic resonance imaging; position emission tomography; mood disorders; anxiety disorders ID OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL-BLOOD-FLOW; ANTERIOR CINGULATE CORTEX; GLUCOSE METABOLIC RATES; PROLONGED GLUCOCORTICOID EXPOSURE; PROCESSING RESOURCE DEFICIT; PET SYMPTOM PROVOCATION; CHILDHOOD SEXUAL-ABUSE AB Neuroimaging research has emerged as a valuable tool in shaping our understanding of the pathophysiology of psychiatric disorders. We review functional neuroimaging findings pertaining to mood disorders (major depression, bipolar disorders) as well as selected anxiety disorders (posttraumatic stress disorder [PTSD] and obsessive-compulsive disorder [OCD]). C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Deckersbach, T (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Bldg 149,13th St,2nd Floor, Charlestown, MA 02129 USA. EM tdeckersbach@partners.org NR 130 TC 51 Z9 53 U1 16 U2 26 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1051-2284 J9 J NEUROIMAGING JI J. Neuroimaging PD JAN PY 2006 VL 16 IS 1 BP 1 EP 10 DI 10.1177/1051228405001474 PG 10 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 011YX UT WOS:000235306500001 PM 16483270 ER PT J AU Mendez, MF McMurtray, A Chen, AK Shapira, JS Mishkin, F Miller, BL AF Mendez, MF McMurtray, A Chen, AK Shapira, JS Mishkin, F Miller, BL TI Functional neuroimaging and presenting psychiatric features in frontotemporal dementia SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID ALZHEIMERS-DISEASE; PICKS-DISEASE; NEUROPSYCHIATRIC FEATURES; LOBAR DEGENERATION; SEMANTIC DEMENTIA; TEMPORAL VARIANTS; FRONTAL VARIANT; SOCIAL-BEHAVIOR; CRITERIA; DYSFUNCTION AB Background: Frontotemporal dementia (FTD) is a behavioural syndrome caused by degeneration of the frontal and anterior temporal lobes. Behavioural disturbances include psychiatric features. Whether patients with FTD present with psychiatric features varies with the initial neuroanatomical variability of FTD. Objective: To identify presenting psychiatric changes not part of diagnostic criteria of FTD and contrast them with the degree of hemispheric asymmetry and frontal and temporal hypoperfusion on single photon emission computed tomography ( SPECT) imaging. Methods: 74 patients who met consensus criteria for FTD were evaluated at a two year follow up. All had brain SPECT on initial presentation. Results of an FTD psychiatric checklist were contrasted with ratings of regional hypoperfusion. Results: The regions of predominant hypoperfusion did not correlate with differences on FTD demographic variables but were associated with presenting psychiatric features. Dysthymia and anxiety were associated with right temporal hypoperfusion. "Moria'' or frivolous behaviour also occurred with temporal lobe changes, especially on the right. The only significant frontal lobe feature was the presence of a peculiar physical bearing in association with right frontal hypoperfusion. Conclusions: Patients with FTD may present with psychiatric changes distinct from the behavioural diagnostic criteria for this disorder. Early temporal involvement is associated with frivolous behaviour and right temporal involvement is associated with emotional disturbances. In contrast, those with right frontal disease may present with alterations in non-verbal behaviour. C1 VA Greater Los Angeles Healthcare, Neurobehav, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Harbor UCLA Med Ctr, Los Angeles, CA USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare, Neurobehav, 116AF,Bldg 500,3S,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU NIA NIH HHS [P01 AG019724, AG19724-01] NR 37 TC 46 Z9 46 U1 1 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD JAN PY 2006 VL 77 IS 1 BP 4 EP 7 DI 10.1136/jnnp.2005.072496 PG 4 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA 997EJ UT WOS:000234227500004 PM 16043457 ER PT J AU Kleinschmidt-DeMasters, BK Rojiani, AM Filley, CM AF Kleinschmidt-DeMasters, BK Rojiani, AM Filley, CM TI Central and extrapontine myelinolysis: Then... and now SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Review DE alcoholism; central pontine myelinolysis; extrapontine myelinolysis; hyponatremia; lateral pontine myelinolysis; osmotic demyelination; pathogenesis; white matter ID CENTRAL PONTINE MYELINOLYSIS; ELECTROLYTE-INDUCED DEMYELINATION; CENTRAL-NERVOUS-SYSTEM; LIVER-TRANSPLANT RECIPIENTS; RAPID CORRECTION; SERUM SODIUM; OSMOTIC MYELINOLYSIS; PITUITARY SURGERY; ORGANIC OSMOLYTES; MR FINDINGS AB In this review, we emphasize neuropathologic and neurobehavioral aspects of central Pontine and extrapontine myclinolysis (CPM/EPM), also known as the osmotic demyelination syndrome. The literature is reviewed from the time of the initial report in 1959 and from key developments that have occurred more recently. Particular consideration is given to pathogenic mechanisms as revealed by recent animal studies. The role of white matter Pathology in neurobehavioral dysfunction is also considered. The "then" and "now" of CPM and EPM tell 2 different stories. Yet, in many respects, this expansion of information over the past nearly 50 years simply represents a continuum, as well as recognition, of the vast gaps that still persist in our understanding of this disorder. C1 Univ Colorado, Ctr Hlth Sci, Dept Pathol, Denver, CO 80262 USA. Univ Colorado, Ctr Hlth Sci, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Ctr Hlth Sci, Dept Neurosurg, Denver, CO 80262 USA. Denver Vet Affairs med Ctr, Denver, CO USA. Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL USA. Univ S Florida, Dept Pathol & Neuropathol, Tampa, FL USA. RP Kleinschmidt-DeMasters, BK (reprint author), Univ Colorado, Ctr Hlth Sci, Dept Pathol, B-216,4200 E 9th Ave, Denver, CO 80262 USA. EM bk.demasters@uchsc.edu NR 96 TC 52 Z9 59 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD JAN PY 2006 VL 65 IS 1 BP 1 EP 11 DI 10.1097/01.jnen.0000196131.72302.68 PG 11 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 005PQ UT WOS:000234836700001 PM 16410743 ER PT J AU Bemelmans, AP Husson, I Jaquet, M Mallet, J Kosofsky, BE Gressens, P AF Bemelmans, AP Husson, I Jaquet, M Mallet, J Kosofsky, BE Gressens, P TI Lentiviral-mediated gene transfer of brain-derived neurotrophic factor is neuroprotective in a mouse model of neonatal excitotoxic challenge SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE BDNF; lentivirus; gene transfer; excitotoxicity; NMDA; periventricular leukomalacia; cerebral palsy; neuroprotection ID CENTRAL-NERVOUS-SYSTEM; EXCITATORY AMINO-ACIDS; PERIVENTRICULAR WHITE-MATTER; IN-VIVO; STRIATAL NEURONS; AMPA RECEPTORS; DNA FLAP; EXPRESSION; INJURY; TRANSDUCTION AB Excitotoxicity may be a critical factor in the formation of brain lesions associated with cerebral palsy. When injected into the murine neopallium at postnatal day 5, the glutamatergic analog N-methyl-D-aspartate (NMDA) produces transcortical neuronal death and periventricular white matter cysts, which mimic brain damage observed in human term and preterm neonates at risk for developing cerebral palsy. We previously showed that intracerebral injection of brain-derived neurotrophic factor (BDNF) was neuroprotective in this model. Because BDNF does not easily cross the blood-brain barrier, alternative strategies to avoid repeated intracerebral injections of BDNF should be tested, particularly when the goal of such translational research is ultimately to achieve clinical application. The goal of the present study was to assess the protective role of lentiviral-mediated gene transfer of BDNF against excitotoxic lesions induced by NMDA in newborn mice. We first assessed the biological activity of BDNF gene transfer in vitro and determined the efficiency of gene transfer in our in vivo model. We next administered the BDNF-expressing vector by intracerebral injection in neonatal mice, 3 days before inducing NMDA lesions. When compared with a control green fluorescent protein-expressing lentiviral vector, administration of BDNF-expressing vector induced a significant protection of the periventricular white matter and cortical plate against the NMDA-mediated insult. Intraventricular delivery of the BDNF-expressing lentiviral vector was more efficient in terms of neuroprotection than the intraparenchymal route. Altogether, the present study shows that viral-mediated gene transfer of BDNF to newborn mouse brain is feasible and affords significant neuroprotection against an excitotoxic insult. (c) 2005 Wiley-Liss, Inc. C1 Hop Ophtalm Jules Gonin, Unite Therapie Gen & Biol Cellules Souches, CH-1000 Lausanne 7, Switzerland. Hop La Pitie Salpetriere, CNRS, UMR 7091, Batiment CERVI, Paris, France. INSERM, U676, Paris, France. Univ Paris 07, Fac Med Denis Diderot, IFR 02, Paris, France. Hop Robert Debre, AP HP, Serv Neuropediat, F-75019 Paris, France. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. RP Bemelmans, AP (reprint author), Hop Ophtalm Jules Gonin, Unite Therapie Gen & Biol Cellules Souches, Ave France 15,Case Postale 133, CH-1000 Lausanne 7, Switzerland. EM alexis.bemelmans@ophtal.vd.ch OI Gressens, Pierre/0000-0002-0909-4221; Bemelmans, Alexis/0000-0001-7605-5225 NR 38 TC 23 Z9 24 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD JAN PY 2006 VL 83 IS 1 BP 50 EP 60 DI 10.1002/jnr.20704 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 003JJ UT WOS:000234677600006 PM 16299771 ER PT J AU Lima, MA Marzocchetti, A Autissier, P Tompkins, T Chen, Y Gordon, J Clifford, DB Gandhi, RT Berger, JR Koralnik, IJ AF Lima, Marco A. Marzocchetti, Angela Autissier, Patrick Tompkins, Troy Chen, Yiping Gordon, Jennifer Clifford, David B. Gandhi, Rajesh T. Berger, Joseph R. Koralnik, Igor J. TI Effector memory CD8+T lymphocytes control polyomavirus viremia, but not viruria, in HIV plus PML survivors SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 7th International Symposium on NeuroVirology CY MAY 31-JUN 03, 2006 CL Philadelphia, PA SP NIMH, NINDS, NIDA, Drexel Univ Coll Med, Inst Mol Med Infect Dis, Drexel Univ, Dept Microbiol Immunology, Office Dean, Temple Univ Sch Med, Sbarro Inst Canc Res & Mol Med, Natl Multiple Sclerosis Soc, Journal NeuroVirology C1 Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02115 USA. Fed Univ Rio De Janeiro, Sch Med, Rio De Janeiro, Brazil. Temple Univ, Sch Med, Ctr Neurovirol, Philadelphia, PA USA. Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA USA. Univ Kentucky, Coll Med, Dept Neurol, Lexington, KY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2006 VL 12 SU 1 MA P110 BP 46 EP 46 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 059US UT WOS:000238758300110 ER PT J AU Mohamed, FB Faro, SH Patel, S Gonzalez, C Hum, B Schwartzman, R AF Mohamed, Feroze B. Faro, Scott H. Patel, Sunil Gonzalez, Carlos Hum, Barbara Schwartzman, Robert TI Diffusion tensor magnetic resonance imaging in multiple sclerosis patients SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 7th International Symposium on NeuroVirology CY MAY 31-JUN 03, 2006 CL Philadelphia, PA SP NIMH, NINDS, NIDA, Drexel Univ Coll Med, Inst Mol Med Infect Dis, Drexel Univ, Dept Microbiol Immunology, Office Dean, Temple Univ Sch Med, Sbarro Inst Canc Res & Mol Med, Natl Multiple Sclerosis Soc, Journal NeuroVirology C1 Drexel Univ, Sch Biomed Engn, Philadelphia, PA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2006 VL 12 SU 1 MA P127 BP 54 EP 54 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 059US UT WOS:000238758300128 ER PT J AU Tyor, WR Rao, V Sas, A Bimonte, H Ranga, U Prasad, V AF Tyor, William R. Rao, Vasu Sas, Andrew Bimonte, Heather Ranga, Uday Prasad, Vinayaka TI Clade CHIV-1 encephalitis in SCID mice results in less cognitive dysfunction than clade B SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 7th International Symposium on NeuroVirology CY MAY 31-JUN 03, 2006 CL Philadelphia, PA SP NIMH, NINDS, NIDA, Drexel Univ Coll Med, Inst Mol Med Infect Dis, Drexel Univ, Dept Microbiol Immunology, Office Dean, Temple Univ Sch Med, Sbarro Inst Canc Res & Mol Med, Natl Multiple Sclerosis Soc, Journal NeuroVirology C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Charleston, SC USA. Albert Einstein Coll Med, Bronx, NY 10467 USA. Univ Arizona, Tempe, AZ USA. Jawaharlal Nehru Ctr Adv Sci Res, Bangalore, Karnataka, India. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2006 VL 12 SU 1 MA P195 BP 82 EP 82 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 059US UT WOS:000238758300196 ER PT J AU Ring, D Jupiter, JB AF Ring, D Jupiter, JB TI Operative treatment of osteochondral nonunion of the distal humerus SO JOURNAL OF ORTHOPAEDIC TRAUMA LA English DT Article DE osteochondral nonunion articular fracture osteonecrosis ID ARTICULAR FRACTURES; ELBOW; ARTHROPLASTY; CARTILAGE; RABBIT; PART AB Three patients with ununited osteochondral fracture fragments of the distal humerus (2 anterior capitellum and trochlea; 1 posterior trochlea) who had debridement and realignment of the nonunion, autogenous cancellous bone graft, and internal fixation an average of 6 (range, 5-8) months after injury were Studied. The pre-operative arc of elbow flexion was 80 degrees, 35 degrees, and 25 degrees. All 3 fractures healed Without implant related complications or osteonecrosis. At 28, 27, and 46 months after the index procedure for nonunion, the patients had 95 degrees, 90 degrees, and 115 degrees arcs of elbow flexion. The scores on the Mayo Elbow Performance Index were 80, 80, and 95 (2 good, 1 excellent). Based on this limited experience, it seems that operative treatment of ununited osteochondral fracture fragments can achieve union without osteonecrosis. Attempts to improve the function of the native elbow rather than salvage the situation with interpositional or prosthetic arthroplasty are worthwhile. C1 Massachusetts Gen Hosp, Dept Orthopaed Surg, Hand Surg Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Hand Surg Serv, ACC 525 15 Parkman St, Boston, MA 02114 USA. EM dring@partners.org NR 17 TC 9 Z9 10 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-5339 J9 J ORTHOP TRAUMA JI J. Orthop. Trauma PD JAN PY 2006 VL 20 IS 1 BP 56 EP 59 DI 10.1097/01.bot.0000164595.81477.b5 PG 4 WC Orthopedics; Sport Sciences SC Orthopedics; Sport Sciences GA 014QP UT WOS:000235495200011 PM 16424812 ER PT J AU Christianson, MA Schwartz, MW Suzuki, N AF Christianson, Matthew A. Schwartz, Michael W. Suzuki, Norman TI Determinants of insulin availability in parenteral nutrition solutions SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article ID ADSORPTION; INFUSION AB Background: Management of hyperglycemia in patients receiving parenteral nutrition (PN) often includes the addition of regular insulin to the PN solution. A literature review has shown insulin availability in such solutions to range from 10% to 95%. This discrepancy iri availability may be due to differences in the composition of the PN solution, the final concentration of insulin, or the assay method used to determine insulin concentrations. The purpose of this study was to evaluate insulin recovery from a standard PN solution used at our medical center. Methods: Solutions were manually prepared in our pharmacy according to standard practice. Multivitamins and trace elements were added to 1 of 2 L of solution each day. Each of 3 simulated patients received 2 L of solution per day for 3 consecutive days. Samples from each bottle were drawn at baseline, 1 hour after the start of infusion, and 1 hour before the end of infusion and were subsequently analyzed for immunoreactive insulin levels by radioimmunoassay. Results: Recovery of insulin from solutions containing multivitamins and trace elements was much greater (95%) than from those without (5%). Conclusions: The presence of multivitamins and trace elements is a major determinant of insulin availability in PN solutions. Additional research is necessary to determine the mechanism mediating this effect and to assess its clinical significance. C1 VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Serv Pharm, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Harborview Med Ctr, Seattle, WA USA. RP Christianson, MA (reprint author), VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Serv Pharm, S-119Phar,1660 S Columbian Way, Seattle, WA 98108 USA. EM matthew.christianson@med.va.gov RI Schwartz, Michael/H-9950-2012 NR 12 TC 5 Z9 7 U1 1 U2 2 PU AMER SOC PARENTERAL & ENTERAL NUTRITION PI SILVER SPRING PA 8630 FENTON STREET SUITE 412, SILVER SPRING, MD 20910 USA SN 0148-6071 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD JAN-FEB PY 2006 VL 30 IS 1 BP 6 EP 9 DI 10.1177/014860710603000106 PG 4 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 195WR UT WOS:000248443500003 PM 16387892 ER PT J AU Juppner, H Bastepe, M AF Juppner, H Bastepe, M TI Different mutations within or upstream of the GNAS locus cause distinct forms of pseudohypoparathyroidism SO JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM LA English DT Article; Proceedings Paper CT International Meeting on G(s)Alpha Related Diseases - McCune-Albright Syndrome-Pseudohypoparathyroidism CY DEC, 2004 CL Turin, ITALY SP EAMAS DE pseudohypoparathyroidism (PHP); PHP type Ia (PHP-Ia); pseudo-PHP (pPHP); PHP type Ib (PHP-Ib); progressive osseous heteroplasia (POH); alpha-subunit of stimulatory G protein (G,(s)alpha); syntaxin 16 (STX16) ID ALBRIGHT HEREDITARY OSTEODYSTROPHY; IMPRINTING CONTROL ELEMENT; STIMULATORY G-PROTEIN; GENE; IB; DELETION; REGION; DEFECT AB The term pseudohypoparathyroidism (PHP) refers to different disorders that are caused by mutations within GNAS or upstream of this complex genetic locus. GNAS gives rise to several different transcripts, including G(s)alpha (alpha-subunit of the heterotrimeric stimulatory G protein), XL alpha s (extra-large variant of G(s)alpha), and several additional sense and antisense transcripts. The complexity of the GNAS locus is furthermore reflected by a parent-specific methylation pattern of most of its different promoters. PHP can be divided into two major groups, PHP type Ia (PHP-Ia) and PHP type Ib (PHP-Ib). PHP-Ia is caused by heterozygous mutations affecting one of the 13 GNAS exons encoding G(alpha)s. In contrast, PHP-Ib is caused by heterozygous deletions within STX16, the gene encoding syntaxin 16, which is located more than 220 kb upstream of GNAS, or by deletions within GNAS involving exon NESP55 and two of the antisense exons. In either form of PHP, hormonal resistance develops only after maternal inheritance of the mutation, while paternal inheritance of the same molecular defect is not associated with endocrine abnormalities. In most familial cases of PHP-Ib, there is a loss of exon A/B methylation combined with active A/B transcription from both parental alleles, which leads to suppression of G(s)alpha transcription in the proximal renal tubules and, therefore, PTH resistance. C1 Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Juppner, H (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Their 5, Boston, MA 02114 USA. EM hjueppner@partners.org NR 25 TC 20 Z9 20 U1 0 U2 0 PU FREUND PUBLISHING HOUSE LTD PI TEL AVIV PA PO BOX 35010, TEL AVIV 61350, ISRAEL SN 0334-018X J9 J PEDIATR ENDOCR MET JI J. Pediatr. Endocrinol. Metab. PY 2006 VL 19 SU 2 BP 641 EP 646 PG 6 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA 054YJ UT WOS:000238414200014 PM 16789629 ER PT J AU Kunisaki, SM Fuchs, JR Kaviani, A Oh, JT LaVan, DA Vacanti, JP Wilson, JM Fauza, DO AF Kunisaki, SM Fuchs, JR Kaviani, A Oh, JT LaVan, DA Vacanti, JP Wilson, JM Fauza, DO TI Diaphragmatic repair through fetal tissue engineering: a comparison between mesenchymal amniocyte- and myoblast-based constructs SO JOURNAL OF PEDIATRIC SURGERY LA English DT Article; Proceedings Paper CT 36th Annual Meeting of the American-Pediatric-Surgical-Association CY MAY, 2005 CL Phoenix, AZ SP Amer Pediat Surg Assoc DE congenital diaphragmatic hernia; tissue engineering; amniotic fluid; skeletal muscle; diaphragm; congenital anomalies; birth defects; fetus; fetal; prenatal; neonatal ID AMNIOTIC-FLUID; IN-VITRO; HERNIA; RECONSTRUCTION; MUSCLE AB Purpose: We have previously shown that fetal tissue engineering is a preferred alternative to diaphragmatic repair in a large animal model. This study was aimed at comparing diaphragmatic constructs seeded with mesenchymal ammocytes and fetal myoblasts in this model. Methods: Neonatal lambs (n = 14) underwent repair of an experimental diaphragmatic defect with (mesenchymal ammocytes m group 1 and fetal myoblasts in group 2) or as an acellular graft (group 3). At 1 to 12 months postoperatively, implants were harvested for multiple analyses. Results: Repair failure (reherniation or eventration) was significantly higher in group 3 than in groups 1 and 2, with no difference between groups 1 and 2. Seeded fetal myoblasts quickly lost their myogenic phenotype in vivo. All grafts contained cells with a fibroblastic-myofibroblastic profile. Elastin concentrations and both modular and ultimate tensile strengths were significantly higher in group 1 than in groups 2 and 3. There were no differences in glycosaminoglycans and type I collagen levels among the groups. Conclusions: Diaphragmatic repair with a mesenchymal amniocyte-based engineered tendon leads to improved structural outcomes when compared with equivalent fetal myoblast-based and acellular grafts. The amniotic fluid is a preferred cell source for tissue-engineered diaphragmatic reconstruction. (c) 2006 Elsevier Inc. All rights reserved. C1 Childrens Hosp, Dept Surg, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Childrens Hosp, Adv Fetal Care Ctr, Boston, MA 02115 USA. MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Fauza, DO (reprint author), Childrens Hosp, Dept Surg, Fegan 3, Boston, MA 02115 USA. EM dario.fauza@childrens.harvard.edu RI LaVan, David/C-3943-2012 OI LaVan, David/0000-0002-1952-0028 FU NIDDK NIH HHS [DK065406-02] NR 23 TC 54 Z9 60 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0022-3468 J9 J PEDIATR SURG JI J. Pediatr. Surg. PD JAN PY 2006 VL 41 IS 1 BP 34 EP 39 DI 10.1016/j.jpedsurg.2005.10.011 PG 6 WC Pediatrics; Surgery SC Pediatrics; Surgery GA 010JZ UT WOS:000235189400008 PM 16410104 ER PT J AU Cebrat, M Bartosz-Bechowski, H Kluczyk, A Lisowski, M Stefanowicz, P Staszewska, A Picur, B Ruchala, P Micewicz, E Woznica, I Zimecki, M Szewczuk, Z AF Cebrat, M. Bartosz-Bechowski, H. Kluczyk, A. Lisowski, M. Stefanowicz, P. Staszewska, A. Picur, B. Ruchala, P. Micewicz, E. Woznica, I. Zimecki, M. Szewczuk, Z. TI Search for immunosuppressants with enhanced bioavailability based on the sequences of cyclolinopeptide A, CLX and ubiquitin SO JOURNAL OF PEPTIDE SCIENCE LA English DT Meeting Abstract C1 Univ Wroclaw, Fac Chem, PL-50138 Wroclaw, Poland. Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Harvard Univ, Childrens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA. Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA. Polish Acad Sci, Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland. RI Stefanowicz, Piotr/A-4373-2009; Cebrat, Marek/G-9754-2011 OI Cebrat, Marek/0000-0003-4975-4025 NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1075-2617 J9 J PEPT SCI JI J. Pept. Sci. PY 2006 VL 12 SU S BP 235 EP 235 PG 1 WC Biochemistry & Molecular Biology; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 075SN UT WOS:000239905600605 ER PT J AU Raymond, JR Gelasco, AK Turner, JH AF Raymond, J. R. Gelasco, A. K. Turner, J. H. TI Calmodulin interacts with and modulates 5-HT1a and 5-HT2a receptors SO JOURNAL OF PHARMACOLOGICAL SCIENCES LA English DT Meeting Abstract CT 6th IUPHAR Satellite Meeting on Serotonin CY JUN 27-30, 2006 CL Hokkaido Univ, Sapporo, JAPAN SP Serotonin Club HO Hokkaido Univ DE 5-HT/serotonin; calmodulin; phosphorylation; G protein C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JAPANESE PHARMACOLOGICAL SOC PI KYOTO PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN SN 1347-8613 J9 J PHARMACOL SCI JI J. Pharmacol. Sci. PY 2006 VL 101 SU 1 BP 58 EP 58 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 059UU UT WOS:000238758500056 ER PT J AU Morse, L Stashenko, P Battaglino, R AF Morse, L. Stashenko, P. Battaglino, R. TI Serotonin (5-HT) increases and prolongs p38 MAPK activation in osteoclasts SO JOURNAL OF PHARMACOLOGICAL SCIENCES LA English DT Meeting Abstract CT 6th IUPHAR Satellite Meeting on Serotonin CY JUN 27-30, 2006 CL Hokkaido Univ, Sapporo, JAPAN SP Serotonin Club HO Hokkaido Univ DE serotonin; osteoclast; RANKL; p38; MAPK C1 Harvard Univ, Sch Med, Forsyth Inst, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JAPANESE PHARMACOLOGICAL SOC PI KYOTO PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN SN 1347-8613 J9 J PHARMACOL SCI JI J. Pharmacol. Sci. PY 2006 VL 101 SU 1 BP 64 EP 64 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 059UU UT WOS:000238758500061 ER PT J AU Montoya, A Price, BH Menear, M Lepage, M AF Montoya, A Price, BH Menear, M Lepage, M TI Brain imaging and cognitive dysfunctions in Huntington's disease SO JOURNAL OF PSYCHIATRY & NEUROSCIENCE LA English DT Review DE brain imaging; cognition; functional neuroimaging; Huntington disease; structural neuroimaging ID CEREBRAL-BLOOD-FLOW; BASAL GANGLIA VOLUME; CORTICOSTRIATAL CIRCUITS; SUBCORTICAL DEMENTIA; TRINUCLEOTIDE REPEAT; COMPUTED-TOMOGRAPHY; SCAN INVESTIGATIONS; MEMORY FUNCTION; FUNCTIONAL MRI; PET AB Recent decades have seen tremendous growth in our understanding of the cognitive dysfunctions observed in Huntington's disease (HD). Advances in neuroimaging have contributed greatly to this growth. We reviewed the role that structural and functional neuroimaging techniques have played in elucidating the cerebral bases of the cognitive deficits associated with HD. We conducted a computer-based search using PubMed and PsycINFO databases to retrieve studies of patients with HD published between 1965 and December 2004 that reported measures on cognitive tasks and used neuroimaging techniques. Structural neuroimaging has provided important evidence of morphological brain changes in HD. Striatal and cortical atrophy are the most common findings, and they correlate with cognitive deficits in attention, working memory and executive functions. Functional studies have also demonstrated correlations between striatal dysfunction and cognitive performance. Striatal hypoperfusion and decreased glucose utilization correlate with executive dysfunction. Hypometabolism also occurs throughout the cerebral cortex and correlates with performance on recognition memory, language and perceptual tests. Measures of presynaptic and postsynaptic dopamine biochemistry have also correlated with measurements of episodic memory, speed of processing and executive functioning. Aided by the results of numerous neuroimaging studies, it is becoming increasingly clear that cognitive deficits in HD involve abnormal connectivity between the basal ganglia and cortical areas. In the future, neuroimaging techniques may shed the most light on the pathophysiology of HD by defining neurodegenerative disease phenotypes as a valuable tool for knowing when patients become "symptomatic," having been in a gene-positive presymptomatic state, and as a biomarker in following the disease, thereby providing a prospect for improved patient care. C1 McGill Univ, Res Ctr, Brain Imaging Grp, Douglas Hosp, Montreal, PQ H4H 1R3, Canada. McLean Hosp, Dept Neurol, Boston, MA USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Lepage, M (reprint author), McGill Univ, Res Ctr, Brain Imaging Grp, Douglas Hosp, 6875 LaSalle Blvd, Montreal, PQ H4H 1R3, Canada. EM martin.lepage@mcgill.ca NR 67 TC 117 Z9 123 U1 2 U2 15 PU CMA MEDIA INC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA SN 1180-4882 J9 J PSYCHIATR NEUROSCI JI J. Psychiatry Neurosci. PD JAN PY 2006 VL 31 IS 1 BP 21 EP 29 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 998YL UT WOS:000234355700003 PM 16496032 ER PT J AU Farrelly, N Dibben, C Hunt, N AF Farrelly, N Dibben, C Hunt, N TI Current management of bipolar affective disorder: Is it reflective of the BAP guidelines? SO JOURNAL OF PSYCHOPHARMACOLOGY LA English DT Article DE bipolar disorder; mania; depression; evidence-based guidelines; clinical practice ID LITHIUM; ANTIDEPRESSANTS; NONADHERENCE; DEPRESSION; EFFICACY AB In October 2003 the British Association of Psychopharmacology (BAP) published evidence-based guidelines on the management of bipolar disorder. The aim of this study was to assess whether the guidelines could provide the basis for examining clinical decisions and the extent to which practice accords with these guidelines. Case notes of out patients with bipolar disorder were reviewed. Demographic details, and treatment recommendations were determined. The management of affective episodes was evaluated and compared with BAP guidelines. In 84 subjects, 224 affective episodes were identified. Treatment was consistent with BAP guidelines in 72% of episodes. Mania was more likely to be managed in accordance with guidelines than depression or mixed episodes. The use of antidepressant medication was the most likely intervention to deviate from recommendations. Reasons for treatments at odds with the guidelines were identified. Our study demonstrates that clinical practice among a range of psychiatrists broadly reflects the guidelines that have been issued by the British Association of Psychopharmacotogy (BAP). The BAP guidelines offer a practical and auditable basis for the short- and Long-term treatment of bipolar affective disorder. C1 Fulbourne Hosp, Cambridge CB1 5EF, England. Massachusetts Gen Hosp, Harvard Bipolar Clin, Boston, MA 02114 USA. Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA. RP Hunt, N (reprint author), Fulbourne Hosp, George McKenzie House, Cambridge CB1 5EF, England. EM Neil.Hunt@cambsmh.nhs.uk NR 13 TC 11 Z9 11 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0269-8811 J9 J PSYCHOPHARMACOL JI J. Psychopharmacol. PD JAN PY 2006 VL 20 IS 1 BP 128 EP 131 DI 10.1177/0269881105056999 PG 4 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 014AN UT WOS:000235451200018 PM 16174680 ER PT J AU Shen, BJ Myers, HF McCreary, CP AF Shen, BJ Myers, HF McCreary, CP TI Psychosocial predictors of cardiac rehabilitation quality-of-life outcomes SO JOURNAL OF PSYCHOSOMATIC RESEARCH LA English DT Article DE cardiac rehabilitation; coronary heart disease; hostility; quality of life; social support; depression ID CORONARY-HEART-DISEASE; COOK-MEDLEY HOSTILITY; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; SOCIAL SUPPORT; DEPRESSIVE SYMPTOMS; CONSTRUCT-VALIDITY; NEGATIVE EMOTIONS; FUNCTIONAL STATUS; HEALTH AB This study investigated hostility, social support, coping, depression, and their contributions to concurrent and posttreatment quality of life (QoL) among a group of patients participating in a 6-week cardiac rehabilitation program. Method: Both direct and mediational relationships among psychosocial factors, QoL baseline, and QoL outcome were examined using structural equation modeling analysis, while age, education, and severity of illness (risk for future event) were controlled. Results: The final model was well supported (chi(2)=64.88, df=56, P >.05; CFI=.99, RMSEA=.04). Results indicated that baseline QoL, hostility, and depressive symptom severity directly and independently predicted QoL outcome, while depression and hostility were also associated with baseline QoL. Hostility, social support, and maladaptive coping also contributed to baseline and follow-up QoL by their associations with depression. Conclusion: Psychosocial characteristics were interrelated, and they predicted postrehabilitation QoL outcome directly or indirectly through depression symptom severity (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Greater Los Angeles VA Hlth Ctr, Los Angeles, CA USA. RP Shen, BJ (reprint author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA. EM bshen@miami.edu NR 60 TC 27 Z9 29 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3999 J9 J PSYCHOSOM RES JI J. Psychosomat. Res. PD JAN PY 2006 VL 60 IS 1 BP 3 EP 11 DI 10.1016/j.jpsychores.2005.06.069 PG 9 WC Psychiatry SC Psychiatry GA 012DH UT WOS:000235317900002 PM 16380304 ER PT J AU Rigotti, NA AF Rigotti, NA TI Increasing smoking cessation at the population level: Thinking outside the box SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Editorial Material C1 Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 01773 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. RP Rigotti, NA (reprint author), Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, 50 Stanford St, Boston, MA 01773 USA. EM nrigotti@partners.org NR 7 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD JAN-FEB PY 2006 VL 12 IS 1 BP 3 EP 5 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 999FY UT WOS:000234375500002 PM 16340507 ER PT J AU Turner, AP Martin, C Williams, RM Goudreau, K Bowen, JD Hatzakis, M Whitham, RH Bourdette, DN Walker, L Haselkorn, JK AF Turner, Aaron P. Martin, Christine Williams, Rhonda M. Goudreau, Kelly Bowen, James D. Hatzakis, Michael, Jr. Whitham, Ruth H. Bourdette, Dennis N. Walker, Lynne Haselkorn, Jodie K. TI Exploring educational needs of multiple sclerosis care providers: Results of a care-provider survey SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE cognition; depression; disease-modifying agents; education; fatigue; multiple sclerosis; multiple sclerosis diagnosis; pain; sexual function; spasticity ID CONTINUING MEDICAL-EDUCATION AB Our objective was to survey experienced multiple sclerosis (MS) care providers, determine their ongoing professional educational needs, and develop future education programs. We asked providers across a variety of disciplines to identify the areas in which clinical consultation and continuing medical education (CME) would most improve their ability to provide care to individuals with MS; their preferred education modalities; and their confidence in providing care related to disease-modifying agents (DMAs), fatigue, depression, spasticity, and bladder management. At a national meeting of MS professionals, 152 MS care providers completed a self-report survey that was designed for this cross-sectional cohort study. Areas of greatest interest for clinical consultation and CME were identical and included cognition, fatigue, DMA use, spasticity, pain, sex, diagnosis of MS, and depression. Participants expressed a preference for live and interactive CME modalities. Confidence in providing specific disease-related care sometimes differed between Veterans Health Administration (VHA) and non-VHA providers. The results indicate that clinical consultations and CME should be targeted to the topics of greatest interest identified by providers and delivered in a live or interactive modality whenever possible. C1 VA Puget Sound Hlth Care Syst, Rehabil Care Serv S117, Dept Vet Affairs, Seattle, WA 98108 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Univ Maryland, Dept Neurol, College Pk, MD 20742 USA. VAMC, Baltimore, MD USA. VAMC, Portland, OR USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv S117, Dept Vet Affairs, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@med.va.gov OI Turner, Aaron/0000-0001-6897-8003 NR 15 TC 2 Z9 2 U1 0 U2 0 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD JAN-FEB PY 2006 VL 43 IS 1 BP 25 EP 33 DI 10.1682/JRRD.2004.11.0139 PG 9 WC Rehabilitation SC Rehabilitation GA 060SI UT WOS:000238821500004 PM 16847769 ER PT J AU Wallin, MT Wilken, JA Turner, AP Williams, RM Kane, R AF Wallin, Mitchell T. Wilken, Jeffrey A. Turner, Aaron P. Williams, Rhonda M. Kane, Robert TI Depression and multiple sclerosis: Review of a lethal combination SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE assessment; depression; morbidity; mortality; multiple sclerosis; outcome; prevention; review; suicide; treatment ID QUALITY-OF-LIFE; EXPRESSIVE GROUP-PSYCHOTHERAPY; COGNITIVE-BEHAVIOR THERAPY; RANDOMIZED CLINICAL-TRIAL; BRAIN MRI LESIONS; MAJOR DEPRESSION; SOCIAL SUPPORT; INTERFERON-BETA; PRIMARY-CARE; MULTIDIMENSIONAL ASSESSMENT AB Depression is the most frequent psychiatric disorder in multiple sclerosis (MS) patients. The etiology of depression is multifactorial and likely associated with psychosocial stress, focal demyelinating lesions, and immune dysfunction. Proper diagnosis and severity assessment are critical prior to initiation of therapy. Patients with suicidal ideation should be referred for immediate psychiatric consultation and be closely monitored. While more therapeutic trials for depression in MS are needed, MS patients have been shown to respond to current antidepressant medications and psychotherapy. Unfortunately, patients with MS and major depression or suicidal thoughts are often underassessed and therefore not diagnosed. Unlike other aspects of MS, depression is treatable. Early intervention in depression can prevent declines in quality of life and even death from suicide. This article reviews the unique features, assessment, and treatment of depression in MS. MS care providers should vigilantly assess depression and suicide risk in their patients. C1 Dept Vet Affairs Med Ctr, Neurol Serv 127, Washington, DC 20422 USA. Georgetown Univ, Dept Neurol, Washington, DC USA. Maryland VA Healthcare Syst, Multiple Sclerosis Ctr Excellence E, Baltimore, MD USA. Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. VA Puget Sound Hlth Care Syst, MSCoE W, Seattle, WA USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Wallin, MT (reprint author), Dept Vet Affairs Med Ctr, Neurol Serv 127, 50 Irving St NW, Washington, DC 20422 USA. EM mitchell.wallin@med.va.gov OI Turner, Aaron/0000-0001-6897-8003 NR 137 TC 38 Z9 41 U1 1 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD JAN-FEB PY 2006 VL 43 IS 1 BP 45 EP 61 DI 10.1682/JRRD.2004.09.0117 PG 17 WC Rehabilitation SC Rehabilitation GA 060SI UT WOS:000238821500006 PM 16847771 ER PT J AU Lovera, J Bagert, B Smoot, KH Wild, K Frank, R Bogardus, K Oken, BS Whitham, RH Bourdette, DN AF Lovera, Jesus Bagert, Bridget Smoot, Kyle H. Wild, Katherine Frank, Rachel Bogardus, Kristin Oken, Barry S. Whitham, Ruth H. Bourdette, Dennis N. TI Correlations of Perceived Deficits Questionnaire of Multiple Sclerosis Quality of Life Inventory with Beck Depression Inventory and neuropsychological tests SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE Beck Depression Inventory; California Verbal Learning Test; cognition disorders; depression; multiple sclerosis; neuropsychological tests; Paced Auditory Serial Addition Test; Perceived Deficits Questionnaire; quality of life; questionnaires ID COGNITIVE DYSFUNCTION; PERFORMANCE; METAMEMORY; IMPAIRMENT AB The Perceived Deficits Questionnaire (PDQ) is a part of the Multiple Sclerosis (MS) Quality of Life Inventory that assesses self-perceived cognitive difficulties. We used baseline data from 49 MS subjects participating in a clinical trial to evaluate the correlation of the PDQ with two measures of cognitive impairment, the Paced Auditory Serial Addition Test (PASAT) and the California Verbal Learning Test, 2nd edition (CVLT-II), total score, and one measure of depression, the Beek Depression Inventory-Amended (BDI-IA). The PDQ correlated significantly (r - 0.42; 95% confidence interval [CI], 0.15 to 0.62; p = 0.003) with the BDI-IA scores but not with either the PASAT (r = - 0.22; 95% Cl, - 0.48 to 0.06; p = 0.2) or the CVLT-II total (r = - 0. 17; 95% CI, -0.43 to 0. 12; p = 0.25). A subset of 38 of these subjects who scored worse than 0.5 standard deviation below the mean on the PASAT or CVLT-II received a more extensive neuropsychological battery of tests. No significant correlations were found between any of these tests and the PDQ. These results suggest that self-perceived cognitive dysfunction relates more to depression than to objective cognitive dysfunction. C1 Portland VA Med Ctr, Dept Vet Affairs Multiple Sclerosis Ctr Excellenc, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Neurol, Sch Med, Portland, OR 97201 USA. Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Cambridge, MA 02138 USA. RP Lovera, J (reprint author), Portland VA Med Ctr, Dept Vet Affairs Multiple Sclerosis Ctr Excellenc, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM loveraj@ohsu.edu RI Bagert, Bridget/A-5499-2011 FU NCCIH NIH HHS [P50 AT00066-01] NR 24 TC 28 Z9 28 U1 1 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD JAN-FEB PY 2006 VL 43 IS 1 BP 73 EP 82 DI 10.1682/JRRD.2004.09.0118 PG 10 WC Rehabilitation SC Rehabilitation GA 060SI UT WOS:000238821500008 PM 16847773 ER PT J AU Campbell, DG Turner, AP Williams, RM Hatzakis, M Bowen, JD Rodriquez, A Haselkorn, JK AF Campbell, Duncan G. Turner, Aaron P. Williams, Rhonda M. Hatzakis, Michael, Jr. Bowen, James D. Rodriquez, Arthur Haselkorn, Jodie K. TI Complementary and alternative medicine use in veterans with multiple sclerosis: Prevalence and demographic associations SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE acupuncture; alternative medicine; chiropractic treatment; complementary therapies; herbal medications; logistic model; massage therapy; multiple sclerosis; naturopathy; traditional healthcare ID UNITED-STATES; MILITARY VETERANS; MENTAL-DISORDERS; NATIONAL-SURVEY; PRIMARY-CARE; THERAPIES; PATTERNS; GUIDELINES; UTILITY; MS AB The present study explored complementary and alternative medicine (CAM) use in veterans with multiple sclerosis (MS). We administered self-report questionnaires to 451 veterans who received healthcare from Veterans Health Administration facilities. CAM use among veterans with MS was widespread; 37% of respondents reported current or past use. Roughly 33% of CAM users reported using multiple interventions, and 40% of respondents desired interventions that they were not already using. Logistic regression suggested that CAM use was more likely among participants with graduate-level education, poor self-reported health over the past year, and a progressive relapsing MS subtype. Participants who used traditional medical services were also more likely to use CAM, which suggests that CAM services are used in addition to, as opposed to in place of, traditional services. As others have proposed, these results suggest that care providers who work with persons with MS would be well served to understand, routinely screen for, and make use of CAM when appropriate. C1 VA Puget Sound Healthcare Syst, Rehabil Care Serv, Seattle, WA 98108 USA. Dept Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. VA Puget Sound Healthcare Syst, Div Neurol, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. RP Turner, AP (reprint author), VA Puget Sound Healthcare Syst, Rehabil Care Serv, S-117,1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@med.va.gov OI Turner, Aaron/0000-0001-6897-8003 NR 37 TC 18 Z9 18 U1 4 U2 8 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD JAN-FEB PY 2006 VL 43 IS 1 BP 99 EP 109 DI 10.1682/JRRD.2004.08.0110 PG 11 WC Rehabilitation SC Rehabilitation GA 060SI UT WOS:000238821500011 PM 16847776 ER PT J AU Wallen, ES Mulloy, KB AF Wallen, Erik S. Mulloy, Karen B. TI Computer-based training for safety: Comparing methods with older and younger workers SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE computer-based teaming; adult teaming; occupational safety and health training; aging; multimedia ID COGNITIVE LOAD THEORY; ADULT AGE-DIFFERENCES; WORKING-MEMORY; SPLIT-ATTENTION; TEXT; PERFORMANCE; INFORMATION; EFFICIENCY; TASK AB Introduction: Computer-based safety training is becoming more common and is being delivered to an increasingly aging workforce. Aging results in a number of changes that make it more difficult to learn from certain types of computer-based training. Instructional designs derived from cognitive teaming theories may overcome some of these difficulties. Methods: Three versions of computer-based respiratory safety training were shown to older and younger workers who then took a high and a low level teaming test. Results: Younger workers did better overall. Both older and younger workers did best with the version containing text with pictures and audio narration. Discussion: Computer-based training with pictures and audio narration may be beneficial for workers over 45 years of age. Impact on Industry: Computer-based safety training has advantages but workers of different ages may benefit differently. Computer-based safety programs should be designed and selected based on their ability to effectively train older as well as younger learners. (c) 2006 National Safety Council and Elsevier Ltd. All rights reserved. C1 Univ New Mexico 1, Dept Internal Med, Albuquerque, NM 87131 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Mulloy, KB (reprint author), Univ New Mexico 1, Dept Internal Med, MSC10-5550, Albuquerque, NM 87131 USA. EM kmulloy@salud.unm.edu NR 51 TC 14 Z9 15 U1 4 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PY 2006 VL 37 IS 5 BP 461 EP 467 DI 10.1016/j.jsr.2006.08.003 PG 7 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 123FF UT WOS:000243281000005 PM 17137597 ER PT J AU Cooper, RA AF Cooper, RA TI James J. Peters Memorial Lecture - Carrying the torch: A call to build on the progress of the past 25 years SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Editorial Material ID SPINAL-CORD-INJURY; REHABILITATION; MEDICINE C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R1, Pittsburgh, PA 15206 USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R1, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper+@pitt.edu NR 17 TC 2 Z9 2 U1 0 U2 0 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2006 VL 29 IS 1 BP 5 EP 9 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 027KG UT WOS:000236413900003 PM 16572559 ER PT J AU Cooper, RA AF Cooper, RA TI Wheelchair standards: It's all about quality assurance and evidence-based practice SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Editorial Material ID ELECTRIC-POWERED WHEELCHAIRS; ANSI/RESNA STANDARDS; DURABILITY C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R1, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Bioengn & Phys Med & Rehabil, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R1, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu NR 12 TC 8 Z9 8 U1 0 U2 0 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2006 VL 29 IS 2 BP 93 EP 94 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 044BW UT WOS:000237648100002 PM 16739552 ER PT J AU Waites, KB Canupp, KC Roper, JF Camp, SM Chen, YY AF Waites, Ken B. Canupp, Kay C. Roper, James F. Camp, Susan M. Chen, Yuying TI Evaluation of 3 methods of bladder irrigation to treat bacteriuria in persons with neurogenic bladder SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE neurogenic bladder; spinal cord injuries; bacteriuria; urinary tract infection; irrigation; acetic acid; neomycin-polymyxin ID SPINAL-CORD-INJURY; URINARY-TRACT-INFECTION; INTERMITTENT CATHETERIZATION; INDWELLING CATHETERS; CIPROFLOXACIN; PROPHYLAXIS; PREVENTION; LESION AB Background/Objective: We conducted a randomized, double-blind comparison of twice daily bladder irrigation using 1 of 3 different solutions in community-residing persons with neurogenic bladder who used indwelling catheters to evaluate efficacy in treatment of bacteriuria. Methods: Eighty-nine persons with bacteriuria were randomized to irrigate their bladders twice daily for 8 weeks with 30 mL of (a) sterile saline, (b) acetic acid, or (c) neomycin-polymyxin solution. Urinalysis, cultures, and antimicrobial susceptibility tests were performed at baseline and weeks 2, 4, and 8 to determine the extent to which each of the solutions affected numbers and types of bacteria, urinary pH, urinary leukocytes, and generation of antimicrobial-resistant organisms. Results: Bladder irrigation was well tolerated with the exception of 3 participants who had bladder spasms. None of the 3 irrigants had a detectable effect on the degree of bacteriuria or pyuria in 52 persons who completed the study protocol. A significant increase in urinary pH occurred in all 3 groups. No significant development of resistance to oral antimicrobials beyond what was observed at baseline was detected. Conclusions: Bladder irrigation was generally well tolerated for 8 weeks. No advantages were detected for neomycin-polymyxin or acetic acid over saline in terms of reducing the urinary bacterial load and inflammation. We cannot recommend bladder irrigation as a means of treatment for bacteriuria in persons with neurogenic bladder. C1 Univ Alabama, Dept Pathol, Birmingham, AL 35249 USA. Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA. Birmingham Vet Affairs Med Ctr, Phys Med & Rehabil Serv, Birmingham, AL USA. RP Waites, KB (reprint author), Univ Alabama, Dept Pathol, WP 230,619 19th St S, Birmingham, AL 35249 USA. EM waites@path.uab.edu NR 24 TC 18 Z9 18 U1 2 U2 3 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2006 VL 29 IS 3 BP 217 EP 226 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 060SH UT WOS:000238821400007 PM 16859225 ER PT J AU LaVela, SL Weaver, FM Goldstein, B Chen, K Miskevics, S Rajan, S Gater, DR AF LaVela, Sherri L. Weaver, Frances M. Goldstein, Barry Chen, Ke Miskevics, Scott Rajan, Suparna Gater, David R., Jr. TI Diabetes mellitus in individuals with spinal cord injury or disorder SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE spinal cord injuries; diabetes mellitus; self-care; Behavioral Factor Surveillance System; prevalence; veterans affairs ID VETERANS; COMPLICATIONS; POPULATION; OUTCOMES; ALCOHOL; DISEASE AB Background/Objective: To examine diabetes prevalence, care, complications, and characteristics of veterans with a spinal cord injury or disorder (SCI/D). Methods: A national survey of veterans with an SCI/D was conducted using Behavioral Risk Factor Surveillance System (BRFSS) survey questions. Data were compared with national Centers for Disease Control and Prevention BRFSS data for veteran and nonveteran general populations. Results: Overall prevalence of diabetes in individuals with an SCI/D was 20% (3 times higher than in the general population). Veterans with an SCI/D and veterans, in general, had a higher prevalence of diabetes across all age groups; however, those with an SCI/D who were 45 to 59 years of age had a higher prevalence than other veterans. One fourth of the persons with an SCI/D and diabetes reported that diabetes affected their eyes or that they had retinopathy (25%), and 41% had foot sores that took more than 4 weeks to heal. More veterans, both with (63%) and without an SCI/D (60%), took a class on how to manage their diabetes than the general population (50%). Veterans with an SCI/D and diabetes were more likely to report other chronic conditions and poorer quality of life than those without diabetes. Conclusions: Diabetes prevalence is greater among veterans with an SCI/D compared with the civilian population, but is similar to that of other veterans, although it may occur at a younger age in those with an SCI/D. Veterans with an SCI/D and diabetes reported more comorbidities, more slow-healing foot sores, and poorer quality of life than those without diabetes. Efforts to prevent diabetes and to provide early intervention in persons with SCI/D are needed. C1 Vet Affairs Edward Hines Jr Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Midw Ctr Hlth Serv & Policy Res, Dept Vet Affairs, Hines, IL 60141 USA. Univ Illinois, Sch Publ Hlth, Ctr Res Hlth & Aging, Chicago, IL USA. Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Chicago, IL 60611 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. VA Ann Arbor Healthcare Syst, Dept Vet Affairs, Ann Arbor, MI USA. RP LaVela, SL (reprint author), Vet Affairs Edward Hines Jr Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Midw Ctr Hlth Serv & Policy Res, Dept Vet Affairs, POB 5000 151H, Hines, IL 60141 USA. EM Sherri.LaVela@va.gov RI Gater, David/F-3418-2011 OI Gater, David/0000-0002-6714-619X NR 36 TC 33 Z9 33 U1 1 U2 2 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2006 VL 29 IS 4 BP 387 EP 395 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 092ZV UT WOS:000241137800005 PM 17044389 ER PT J AU Kilbourne, AM Salloum, I Dausey, D Cornelius, JR Conigliaro, J Xu, XY Pincus, HA AF Kilbourne, AM Salloum, I Dausey, D Cornelius, JR Conigliaro, J Xu, XY Pincus, HA TI Quality of care for substance use disorders in patients with serious mental illness SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE mental disorders; substance use disorders; psychotic disorders; quality of care; quality indicators AB We assessed the quality of care for substance use disorders (SUDs) among 8,083 patients diagnosed with serious mental illness from the VA mid-Atlantic region. Using data from the National Patient Care Database (2001-2002), we assessed the percentage of patients receiving a diagnosis of SUD, percentage beginning SUD treatment 14 days or earlier after diagnosis, and percentage receiving continued SUD care 30 days or less. Overall, 1,559 (19.3%) were diagnosed with an SUD. Of the 1,559, 966 (62.0%) initiated treatment and 847 (54.3%) received continued care. Although patients diagnosed with bipolar disorder were more likely to receive a diagnosis of SUD than those diagnosed with schizophrenia or schizoaffective disorder (22.7%, 18.9%, and 17.7%, respectively; chi(2) = 26.02, df = 2, p < .001), they were less likely to initiate (49.1%, 70.7%, and 68.6%, respectively; chi(2) = 59.29, df = 2, p < .001) or continue treatment (39.9%, 63.2%, and 62.2%, respectively; chi(2) = 72.25, df = 2, p < .001). Greater efforts are needed to diagnose and treat SUDs in patients with serious mental illness, particularly for those with bipolar disorder. (c) 2006 Elsevier Inc. All rights reserved. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. Univ Pittsburgh, RAND, Hlth Inst, Pittsburgh, PA 15213 USA. Univ Kentucky, Med Ctr, Lexington, KY USA. RP Kilbourne, AM (reprint author), VA Pittsburgh Ctr Hlth Equ Res & Promot, 151-C,Univ Dr C, Pittsburgh, PA 15240 USA. EM amy.kilbourne@med.va.gov FU NIAAA NIH HHS [R01 AA 11292, R21 AA 014396] NR 11 TC 7 Z9 7 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JAN PY 2006 VL 30 IS 1 BP 73 EP 77 DI 10.1016/j.jsat.2005.10.003 PG 5 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 007KC UT WOS:000234966700007 PM 16377454 ER PT J AU Samii, A Ryan-Dykes, P Tsukuda, RA Zink, C Franks, R Nichol, WP AF Samii, A Ryan-Dykes, P Tsukuda, RA Zink, C Franks, R Nichol, WP TI Telemedicine for delivery of health care in Parkinson's disease SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article AB We have used telemedicine at the Seattle Veterans Administration Medical Center to deliver follow-up care to patients with Parkinson's disease (PD). Patients were located at eight facilities which were 67-2400 km from the medical centre. Each facility had videoconferencing equipment (connected by Internet Protocol at 384 kbit/s), and computer terminals that could access the patient's electronic medical record. Over a three-year period, we used telemedicine for 100 follow-up visits on 34 PD patients. Visits lasted 30-60 min. Patients and providers were satisfied with the use of the technology. Savings amounted to approximately 1500 attendant travel hours, 100,000 travel kilometres, and US$37,000 in travel and lodging costs. For the first 82 telemedicine visits, the video quality was inadequate for scoring all components of the motor Unified Parkinson Disease Rating Scale (UPDRS). For the last 18 visits, a different videoconferencing unit produced better video quality, which was satisfactory for motor UPDRS measurements, except for components that required physical contact with the patient (rigidity and retropulsion testing). Our experience shows that telemedicine can be used effectively for follow-up visits with selected PD patients who are unable to travel. C1 VAPSHCS, Dept Neurol, Seattle, WA 98108 USA. VAPSHCS, Seattle PADRECC, Seattle, WA 98108 USA. Portland VA Med Ctr, Portland PADRECC, Portland, OR USA. VA Puget Sound Hlth Care Syst, Clin Informat, Seattle, WA USA. RP Samii, A (reprint author), VAPSHCS, Dept Neurol, Mailstop 127,1660 S Columbian Way, Seattle, WA 98108 USA. EM asamii@u.washington.edu NR 5 TC 32 Z9 32 U1 0 U2 5 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2006 VL 12 IS 1 BP 16 EP 18 DI 10.1258/135763306775321371 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 011AF UT WOS:000235239300003 PM 16438773 ER PT J AU Qureshi, AA Brandling-Bennett, HA Giberti, S McClure, D Halpern, EF Kvedar, JC AF Qureshi, AA Brandling-Bennett, HA Giberti, S McClure, D Halpern, EF Kvedar, JC TI Evaluation of digital skin images submitted by patients who received practical training or an online tutorial SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID TELEDERMATOLOGY AB We evaluated the ability of subjects to capture and submit teledermatology images with a digital camera. We also examined whether participants who received individual training sessions would capture better-quality images than participants who were provided only with self-training. Fifty participants were randomized between inperson training and self-training via an online tutorial. The majority of participants were young, well educated women. Two dermatologists reading the images for quality indicators had high agreement that digital images acquired were of high quality: images were well framed, appropriately bright, in focus and did not have a shadow. There was moderate agreement on diagnosis-related indicators, such as the presence or absence of pustules or papules and acne versus rosacea. There was no difference in the image-quality attributes between participants personally trained and those trained with the online tutorial. Subjects participating in this study were able to acquire images of good quality, irrespective of whether they received practical training or used an online tutorial. C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA USA. Partners Telemed, Boston, MA USA. Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA USA. RP Qureshi, AA (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, 45 Francis St,221L, Boston, MA 02115 USA. EM aqureshi@portners.org NR 7 TC 11 Z9 11 U1 1 U2 3 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2006 VL 12 IS 2 BP 79 EP 82 DI 10.1258/135763306776084392 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 028CG UT WOS:000236462800006 PM 16539754 ER PT J AU Stoddard, FJ Saxe, G Ronfeldt, H Drake, JE Burns, J Edgren, C Sheridan, R AF Stoddard, FJ Saxe, G Ronfeldt, H Drake, JE Burns, J Edgren, C Sheridan, R TI Acute stress symptoms in young children with burns SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE early childhood; pain; acute stress; burns; parent stress ID POSTTRAUMATIC-STRESS; EARLY-CHILDHOOD; DISORDER; PTSD; TRAUMA AB Objective: Posttraumatic stress disorder symptoms are a focus of much research with older children, but little research has been conducted with young children, who account for about 50% of all pediatric burn injuries. This is a 3-year study of 12- to 48-month-old acutely burned children to assess acute traumatic stress outcomes. The aims were to (1) assess the prevalence of acute traumatic stress symptoms and (2) develop a model of risk factors for these symptoms in these children. Method: Acute stress symptoms were measured using the Posttraumatic Stress Disorder Semi-Structured Interview and Observational Record for Infants and Young Children. Children's responses were then assessed, including behavior and physiological measures for developmental/functional consequences. A path analysis strategy was used to build a model of risk factors. Risk factors assessed in this model included observed pain (Visual Analogue Scale), parent symptoms (Stanford Acute Stress Reaction Questionnaire), and magnitude of trauma (total body surface area burned). Results: Of the 64 subjects meeting inclusion criteria, 52 subjects agreed to participate. These children were highly symptomatic; almost 30% of these children had acute stress symptoms. A path analysis model yielded two independent pathways to acute stress symptoms: (1) from the size of the burn to the mean pulse rate in the hospital to acute stress symptoms and (2) from the child's pain to the parents' stress symptoms to acute stress symptoms. This model accounted for 39% of the variance of acute stress symptoms and yielded excellent fit indexes. Conclusions: A high percentage of acute stress symptoms were identified in young children with burns. A model of risk factors, including the size of the burn, pain, pulse rate, and parents' symptoms, was identified. C1 Shriners Burn Hosp, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. Boston Univ, Med Ctr, Natl Child Traumat Stress Network, Boston, MA 02215 USA. Shriners Burn Hosp, Dept Surg, Boston, MA 02114 USA. RP Stoddard, FJ (reprint author), Shriners Burn Hosp, Dept Psychiat, 51 Blossom St, Boston, MA 02114 USA. EM fstoddard@partners.org OI Saxe, Glenn/0000-0002-4756-1169 NR 32 TC 60 Z9 60 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD JAN PY 2006 VL 45 IS 1 BP 87 EP 93 DI 10.1097/01.chi.0000184934.71917.3a PG 7 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 997BY UT WOS:000234221200011 PM 16327585 ER PT J AU Schouten, R AF Schouten, R TI Commentary: Psychiatric advance directives as tools for enhancing treatment of the mentally ill SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Editorial Material ID LIVING WILL; SCHIAVO,TERRI AB In this issue of the journal, Swanson et al. explore the demand for and utilization of psychiatric advance directives (PADs), and discuss some of the barriers to their greater acceptance. This author suggests that PADs may be more widely accepted and utilized if they are viewed as tools for maximizing individual autonomy, with an emphasis on optimizing rather than merely restricting care. C1 Harvard Univ, Sch Med, Boston, MA 02115 USA. Massachusetts Gen Hosp, Law & Psychiat Serv, Boston, MA 02114 USA. RP Schouten, R (reprint author), 55 Fruit St, Boston, MA 02114 USA. EM rschouten@partners.org NR 8 TC 4 Z9 4 U1 0 U2 2 PU AMER ACAD PSYCHIATRY LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2006 VL 34 IS 1 BP 58 EP 60 PG 3 WC Law; Psychiatry SC Government & Law; Psychiatry GA 028ZL UT WOS:000236527200009 PM 16585235 ER PT J AU Jaskille, A Koustova, E Rhee, P Britten-Webb, J Chen, HZ Valeri, CR Kirkpatrick, JR Alam, HB AF Jaskille, A Koustova, E Rhee, P Britten-Webb, J Chen, HZ Valeri, CR Kirkpatrick, JR Alam, HB TI Hepatic apoptosis after hemorrhagic shock in rats can be reduced through modifications of conventional Ringer's solution SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID PROGRAMMED CELL-DEATH; PULMONARY APOPTOSIS; FLUID RESUSCITATION; GROWTH-FACTOR; SURVIVAL; PHOSPHORYLATION; PYRUVATE; LIVER; ACTIVATION; MECHANISMS AB BACKGROUND: Resuscitation with racemic lactated Ringer's solution induces cellular apoptosis. This study was conducted to determine if the elimination of D-lactate isomer would attenuate apoptosis in the liver, and to investigate the possible mechanisms. STUDY DESIGN: Sprague Dawley rats (n = 30, 5 per group) were subjected to modified volume-controlled hemorrhage and randomized to the following groups: no hemorrhage (sham); no resuscitation (NR); resuscitation with racemic lactated Ringer's (DL-LR); L-isomer LR (L-LR); ketone (beta-hydroxybuturate) Ringer's (KR); or pyruvate Ringer's (PR). Animals were sacrificed 2 hours later and expressions of proapoptotic proteins (BAD), antiapoptotic (bcl-2) proteins, and poly-ADP ribose polymerase (PARP) cleavage in liver were analyzed by Western blotting. Contribution of the phosphatidylinositol 3-kinase/serine/threonine kinase (PI3k/Akt) pathway was assessed by measuring total and phosphorylated PI3K, Akt, BAD, and endothelial nitric oxide synthase (eNOS) proteins. The terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay was used to detect the apoptotic cells. Liver ATP levels were measured using a luciferase reaction assay. RESULTS: Hemorrhage significantly decreased the hepatic ATP level and resuscitation improved it, but it returned to normal only in the L-isomer lactated Ringer's and ketone Ringer's groups. Expression of proapoptotic proteins was significantly lower in the pyruvate Ringer's and ketone Ringer's groups; L-isomer lactated Ringer's and pyruvate Ringer's resuscitation significantly increased bcl-2 expression. Poly-ADP ribose polymerase fragmentation and total number of apoptotic cells were significantly increased in the racemic lactated Ringer's group. There was no significant induction of Akt activity or changes in phosphorylated BAD, Akt, or eNOS levels. CONCLUSIONS: Resuscitation with racemic lactated Ringer's induces hepatic apoptosis, which is decreased if the D-isomer of lactate is eliminated. Apoptosis is reduced even more when lactate is substituted with beta-hydroxybutyrate or pyruvate. The beneficial effects are not through improvements in the energy status or activation of the PI3K/Akt pathway. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA. Washington Hosp Ctr, Washington, DC 20010 USA. USN, Blood Res Lab, Washington, DC 20375 USA. RP Alam, HB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Ste 810, Boston, MA 02114 USA. NR 50 TC 23 Z9 23 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD JAN PY 2006 VL 202 IS 1 BP 25 EP 35 DI 10.1016/j.jamcollsurg.2005.08.027 PG 11 WC Surgery SC Surgery GA 042VM UT WOS:000237558700004 PM 16377494 ER PT J AU Banerji, A Clark, S Afilalo, M Blanda, MP Cydulka, RK Camargo, CA AF Banerji, A Clark, S Afilalo, M Blanda, MP Cydulka, RK Camargo, CA TI Prospective multicenter study of acute asthma in younger versus older adults presenting to the emergency department SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE asthma; age; bronchodilation; inhaled corticosteroids ID OBSTRUCTIVE PULMONARY-DISEASE; INHALED CORTICOSTEROIDS; DRUG-THERAPY; INFLAMMATION; PREVENTION; HEALTH; READMISSION; POPULATION; PATTERNS; AIRWAYS AB OBJECTIVES: To describe acute asthma in younger versus older adults presenting to the emergency department (ED). DESIGN: Prospective cohort study. Asthmatic adults were divided into three age groups: 18 to 34, 35 to 54, and 55 and older. The analysis was restricted to never smokers and smokers with fewer than 10 pack-years. SETTING: ED. PARTICIPANTS: Two thousand sixty-four patients aged 18 and older with a physician diagnosis of asthma. MEASUREMENTS: Medications and peak expiratory flow. RESULTS: There were 1,158 (56%) subjects aged 18 to 34; 777 (37%) aged 35 to 54; and 129 (6%) aged 55 and older. Older patients were most likely to have a primary care provider (65%, 74%, and 91%, respectively; P < .001); most were not taking inhaled corticosteroids (39%, 55%, and 48%, respectively; P <.001). Older patients reported fewer ED visits for asthma (2, 2, and 1, respectively; P=.001) but were more likely to report asthma hospitalization (24%, 31%, and 37%, respectively; P <.001). All groups had severe exacerbations (initial percentage predicted peak flow: 47, 47, and 47, respectively; P=.50), but older patients were least likely to report severe symptoms (72%, 79%, and 67%, respectively; P=.001). Older patients did not respond as well to bronchodilators, even after controlling for other demographic factors, markers of asthma severity, and ED management (change between initial and final peak expiratory flow, using subjects aged 18 to 34 as reference: aged 35-54, beta=-0.7 (95% CI=-9.4-8.0); aged >= 55, beta=-18.4 (-31.9 to -4.9)). The smaller change in peak expiratory flow contributed most to older patients' greater likelihood of hospitalization. CONCLUSION: Older asthma patients were less responsive to emergency bronchodilation. This may reflect chronic undertreatment with inhaled corticosteroids. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Rheumatol Allergy & Immunol, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. Sir Mortimer B Davis Jewish Hosp, Dept Emergency Med, Montreal, PQ H3T 1E2, Canada. Summa Hlth Syst, Dept Emergency Med, Akron, OH USA. MetroHlth Med Ctr, Dept Emergency Med, Cleveland, OH USA. RP Camargo, CA (reprint author), Massachusetts Gen Hosp, EMNet Coordinating Ctr, 326 Cambridge St,Suite 410, Boston, MA 02114 USA. EM ccamargo@partners.org FU NHLBI NIH HHS [HL63841]; NIEHS NIH HHS [T32 ES07069] NR 36 TC 30 Z9 31 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2006 VL 54 IS 1 BP 48 EP 55 DI 10.1111/j.1532-5415.2005.00563.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 999QF UT WOS:000234404300007 PM 16420197 ER PT J AU Morales, K Wittink, M Datto, C DiFilippo, S Cary, M TenHave, T Katz, IR AF Morales, K Wittink, M Datto, C DiFilippo, S Cary, M TenHave, T Katz, IR TI Simvastatin causes changes in affective processes in elderly volunteers SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE simvastatin; cholesterol; affect; depression; diaries ID LOW SERUM-CHOLESTEROL; QUALITY-OF-LIFE; COA REDUCTASE INHIBITORS; DEPRESSIVE SYMPTOMS; MENTAL-DISORDER; HEART-DISEASE; STATINS; PREVALENCE; METABOLISM; MORTALITY AB OBJECTIVES: To test for simvastatin-induced changes in affect and affective processes in elderly volunteers. DESIGN: Randomized, clinical trial. SETTING: The Geriatric Behavioral Psychopharmacology Laboratory at the University of Pennsylvania. PARTICIPANTS: Eighty older volunteers, average age 70, with high normal/mildly elevated serum cholesterol. INTERVENTION: Simvastatin up to 20 mg/d or placebo for 15 weeks. MEASUREMENTS: Daily diary records of positive and negative affects and of events and biweekly measures of depressive symptoms. Affect ratings were obtained using the Lawton positive and negative affect scales; independent raters coded the valences of events. RESULTS: Thirty-one of 39 subjects assigned to placebo and 33 of 41 receiving simvastatin completed the study. During biweekly assessments, four subjects on simvastatin and one on placebo experienced depressive symptoms, as manifest by Center for Epidemiological Studies Depression scale scores greater than 16 (exact P=.36). Diary data demonstrated significant effects on affective processes. For positive affect, there was a significant medication-by-time interaction that reflected decreases in positive affect in subjects receiving simvastatin, greatest in those patients whose final total cholesterol levels were below 148 mg/dL. For negative affect, there were significant medication-by-event, and medication-by-event-by-time interactions, reflecting a time-limited increase in the apparent effect of negative events. CONCLUSION: Simvastatin has statistically significant effects on affect and affective processes in elderly volunteers. The decrease in positive affect may be significant clinically and relevant to the quality of life of many patients. C1 Univ Penn, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Ctr Biostat & Epidemiol, Philadelphia, PA 19104 USA. Univ Penn, Dept Family Practice & Community Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia Dept, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Katz, IR (reprint author), Univ Penn, Sect Geriatr Psychiat, 3535 Market St,Room 3001, Philadelphia, PA 19104 USA. EM katzi@mail.med.upenn.edu FU NIMH NIH HHS [R01 MH58349, P30 MH66270] NR 49 TC 24 Z9 26 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2006 VL 54 IS 1 BP 70 EP 76 DI 10.1111/j.1532-5412.2005.00542.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 999QF UT WOS:000234404300010 PM 16420200 ER PT J AU Shea, S Weinstock, RS Starren, J Teresi, J Plamas, W Field, L Morin, P Goland, R Izquierdo, RE Wolff, IT Ashraf, M Hilliman, C Silver, S Meyer, S Holmes, D Petkova, E Capps, L Lantigua, RA AF Shea, S Weinstock, RS Starren, J Teresi, J Plamas, W Field, L Morin, P Goland, R Izquierdo, RE Wolff, IT Ashraf, M Hilliman, C Silver, S Meyer, S Holmes, D Petkova, E Capps, L Lantigua, RA CA IDEATel Consortium TI A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID COLUMBIA-UNIVERSITY INFORMATICS; MICROVASCULAR COMPLICATIONS; ELECTRONIC COMMUNICATION; CARDIOVASCULAR-DISEASE; INTENSIVE THERAPY; GLYCEMIC CONTROL; IDEATEL PROJECT; WEIGHT-LOSS; CHOLESTEROL; TECHNOLOGY AB Background: Telemedicine is a promising but largely unproven technology for providing case management services to patients with chronic conditions who experience barriers to access to care or a high burden of illness. Methods: The authors conducted a randomized, controlled trial comparing telemedicine case management to usual care, with blinding of those obtaining outcome data, in 1,665 Medicare recipients with diabetes, aged 55 years or greater, and living in federally designated medically underserved areas of New York State. The primary endpoints were HgbA1c, blood pressure, and low-density lipoprotein (LDL) cholesterol levels. Results: In the intervention group (n = 844), mean HgbA1c improved over one year from 7.35% to 6.97% and from 8.35% to 7.42% in the subgroup with baseline HgbA1c >= 7% (n = 353). In the usual care group (n = 821) mean HgbA1c improved over one year from 7.42% to 7.17%. Adjusted net reductions (one-year minus baseline mean values in each group, compared between groups) favoring the intervention were as follows: HgbA1c, 0.18% (p = 0.006), systolic and diastolic blood pressure, 3.4 (p = 0.001) and 1.9 mm Hg (p < 0.001), and LDL cholesterol, 9.5 mg/dL (p < 0.001). In the subgroup with baseline HgbA1c >= 7%, net adjusted reduction in HgbA1c favoring the intervention group was 0.32% (p = 0.002). Mean LDL cholesterol level in the intervention group at one year was 95.7 mg/dL. The intervention effects were similar in magnitude in the subgroups living in New York City and upstate New York. Conclusion: Telemedicine case management improved glycemic control, blood pressure levels, and total and LDL cholesterol levels at one year of follow-up. C1 Columbia Univ, Dept Med, New York, NY USA. Columbia Univ, Dept Biomed Informat, New York, NY USA. Columbia Univ, Dept Radiol, New York, NY USA. Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY USA. Columbia Univ, Joseph Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. Columbia Univ, Joseph Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. SUNY Upstate Med Univ, Joslin Diabet Ctr, Syracuse, NY USA. SUNY Upstate Med Univ, Div Endocrinol Diabet & Metab, Syracuse, NY USA. VA Med Ctr, Dept Vet Affairs, Syracuse, NY USA. Hebrew Home Aged, Div Res, Bronx, NY USA. Columbia Univ, Stroud Ctr, New York, NY USA. New York State Psychiat Inst & Hosp, New York, NY 10032 USA. SUNY Upstate Med Univ, Dept Family Med, Syracuse, NY USA. Harlem Hosp Med Ctr, Dept Med, New York, NY USA. RP Shea, S (reprint author), Div Gen Med, 630 W 168th St, New York, NY 10032 USA. EM ss35@columbia.edu OI Petkova, Eva/0000-0001-5129-9442 NR 74 TC 149 Z9 151 U1 2 U2 25 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD JAN-FEB PY 2006 VL 13 IS 1 BP 40 EP 51 DI 10.1197/jamia.M1917 PG 12 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA 004AI UT WOS:000234724000007 PM 16221935 ER PT J AU Lasko, TA Atlas, SJ Barry, MJ Chueh, HC AF Lasko, TA Atlas, SJ Barry, MJ Chueh, HC TI Automated identification of a physician's primary patients SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID OPERATING CHARACTERISTIC CURVES; DENOMINATOR PROBLEM; AREAS AB Objective: To develop and validate an automated method for determining the set of patients for whom a given primary care physician holds overall clinical responsibility. Design: The study included all adult patients (16,185) seen at least once in an ambulatory setting during a three-year period by 18 primary care physicians in ten practices. The physicians indicated whether they considered themselves to be the physician primarily responsible for the overall clinical care of each visiting patient. Statistical models were constructed to predict the physicians' designations using predictor variables derived from electronically available appointment schedules and demographic information. Measurements: Predictive accuracy was assessed primarily using the area under the receiver-operating characteristic curve (AUC), and secondarily using positive predictive value (PPV) and sensitivity. Results: A minimal set of six variables was identified as predictive of the physicians' designations. The constructed model had a median AUC for individual physicians of 0.92 (interquartile interval: 0.90 - 0.96), a PPV of 0.94 (interquartile interval: 0.87 - 0.95), and a sensitivity of 0.95 (interquartile interval: 0.87 - 0.97). Conclusion: A statistical model using a minimal set of commonly available electronic data can accurately predict the set of patients for whom a physician holds primary clinical responsibility. Further research examining the generalization of the model to other settings would be valuable. C1 Brigham & Womens Hosp, Decis Syst Grp, Boston, MA USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA USA. MIT, Comp Sci & Artif Intelligence Lab, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Div Gen Med, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Clin Epidemiol Unit, Boston, MA USA. RP Lasko, TA (reprint author), MIT, CSAIL, 32 Vassar St,32-252, Cambridge, MA 02139 USA. EM tlasko@mit.edu FU NLM NIH HHS [2T15LM07092-1] NR 25 TC 10 Z9 10 U1 1 U2 1 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD JAN-FEB PY 2006 VL 13 IS 1 BP 74 EP 79 DI 10.1197/jamia.M1876 PG 6 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 004AI UT WOS:000234724000011 PM 16221940 ER PT J AU Weingart, SN Rind, D Tofias, Z Sands, DZ AF Weingart, SN Rind, D Tofias, Z Sands, DZ TI Who uses the patient Internet portal? The PatientSite experience SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article AB Objective: Although the patient Internet portal is a potentially transformative technology there is little scientific information about the demographic and clinical characteristics of portal enrollees and the features that they access. Design: We describe two pilot studies of a comprehensive Internet portal called PatientSite. These pilots include a prospective one-year cohort study of all patients who enrolled in April 2003 and a case-control study in 2004 of enrollees and nonenrollees at two hospital-based primary care practices. Measurements: The cohort study tracked patient enrollment and features in PatientSite that enrollees accessed, such as laboratory and radiology results, prescription renewals, appointment requests, managed care referrals, and clinical messaging. The case-control study used medical record review to compare the demographic and clinical characteristics of 100 randomly selected PatientSite enrollees and 100 nonenrollees. Results: PatientSite use grew steadily after its introduction. New enrollees logged in most frequently in the first month, but 26% to 77% of the cohort continued to access the portal at least monthly They most often examined laboratory and radiology results and sent clinical messages to their providers. PatientSite enrollees were younger and more affluent and had fewer medical problems than nonenrollees. Conclusion: Expanding the use of patient portals will require an understanding of obstacles that prevent access for those who might benefit most from this technology. C1 Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Stoneman Ctr Qual Improvement, Div Gen Med & Primary Care, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. ZixCorp, Dallas, TX USA. RP Weingart, SN (reprint author), Dana Farber Canc Inst, Ctr Patient Safety, 44 Binney St, Boston, MA 02115 USA. EM saul_weingart@dfci.hanard.edu FU AHRQ HHS [1 K08 HS 11644] NR 14 TC 106 Z9 106 U1 1 U2 10 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD JAN-FEB PY 2006 VL 13 IS 1 BP 91 EP 95 DI 10.1197/jamia.M1833 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 004AI UT WOS:000234724000013 PM 16221943 ER PT J AU Barnhill, JG Fye, CL Williams, DW Reda, DJ Harris, CL Clegg, DO AF Barnhill, Jamie G. Fye, Carol L. Williams, David W. Reda, Domenic J. Harris, Crystal L. Clegg, Daniel O. TI Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION LA English DT Article DE dietary supplements; chondroitin; glucosamine/chondroitin arthritis intervention trial; osteoarthritis; product selection AB Objective: To select a high-quality chondroitin dosage form and/ or an appropriate source of sodium chondroitin for the National Institutes of Health's Glucosamine/ Chondroitin Arthritis Intervention Trial ( GAIT). Design: Controlled experimental trials. Setting: Laboratory. Patients or Participants: Not applicable. Interventions: Commercially available chondroitin products were reviewed, and purified sodium chondroitin from two suppliers was evaluated through tests ( infrared and near-infrared identification, moisture content, pH, optical rotation, color and clarity of aqueous solutions prepared from the powders, protein contamination, total residue following ignition and nitrogen content, determination of sodium chondroitin molecular weight, disaccharide analysis, and measurement of chondroitin, sodium, and total glycosaminoglycan content) and an onsite supplier audit. Main Outcome Measures: Purity, potency, and quality of sodium chondroitin powders. Results: No commercially available chondroitin product was deemed appropriate for use in GAIT. Samples of sodium chondroitin powder from two suppliers exhibited similar disaccharide and glycosaminoglycan content. Each contained approximately 2% hyaluronic acid and 8%-9% unsulfated disaccharide. Potency was inconsistent across groups, which might have resulted from different analytical methods and choice of reference standard. Mean potency obtained by five separate methods ranged from 82.2% to 95.5% for one supplier, 92.5% to 110.1% for another, and 95.1% to 112.5% for a commercially obtained reference standard. Critical issues raised by the results include choice of reference standard, selection of assay method, and the consistent appearance of an unidentifiable contaminant present in all three lots from one supplier. Conclusion: This blinded study determined methods to identify acceptable agents and provided results, which, in addition to regulatory compliance supplier audits, formed the basis for chondroitin product selection in GAIT. C1 US Dept Vet Affairs, Biopharmaceut Pharmacokinet Lab Sect, Cooperat Studies Program, Clin Res Pharm Coordinating Ctr, Albuquerque, NM USA. Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA. SMART, Good Clin Practice Review Grp, VA Cooperat Studies Program, Albuquerque, NM USA. Glucosamine Chondroitin Arthritis Intervent Trail, Hines, IL USA. Coordinating Ctr, VA Cooperat Studies Program, Hines, IL USA. Clin Res Pharm Coordinating Ctr, Biopharmaceut Pharmacokinet Lab, VA Cooperat Studies Program, Albuquerque, NM 87106 USA. Univ Utah, Sch Med, Div Rheumatol, Salt Lake City, UT USA. RP Barnhill, JG (reprint author), Clin Res Pharm Coordinating Ctr, Biopharmaceut Pharmacokinet Lab, VA Cooperat Studies Program, 2401 Ctr Ave,SE, Albuquerque, NM 87106 USA. EM jamie.barnhill@csp.research.med.va.gov FU NIAMS NIH HHS [AR92236] NR 13 TC 24 Z9 25 U1 0 U2 6 PU AMER PHARMACEUTICAL ASSOC PI WASHINGTON PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037 USA SN 1544-3191 J9 J AM PHARM ASSOC JI J. Am. Pharm. Assoc. PD JAN-FEB PY 2006 VL 46 IS 1 BP 14 EP 24 DI 10.1331/154434506775268616 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA V43YX UT WOS:000202971500006 PM 16529337 ER PT J AU Shlipak, MG Fyr, CLW Chertow, GM Harris, TB Kritchevsky, SB Tylavsky, FA Satterfield, S Cummings, SR Newman, AB Fried, LF AF Shlipak, Michael G. Fyr, Christina L. Wassel Chertow, Glenn M. Harris, Tamara B. Kritchevsky, Stephen B. Tylavsky, Frances A. Satterfield, Suzanne Cummings, Steven R. Newman, Anne B. Fried, Linda F. TI Cystatin C and mortality risk in the elderly: The health, aging, and body composition study SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; CORONARY-HEART-DISEASE; EARLY RENAL IMPAIRMENT; OLDER-ADULTS; KIDNEY-FUNCTION; CARDIOVASCULAR EVENTS; CLINICAL EVALUATION; MARKER; INSUFFICIENCY; CREATININE AB Kidney dysfunction is known to decrease life expectancy in the elderly. Cystatin C is a novel biomarker of kidney function that may have prognostic utility in older adults. The association of cystatin C with mortality was evaluated in a biracial cohort of black and white ambulatory elderly and compared with that of serum creatinine concentrations. The Health, Aging and Body Composition study is a cohort of well-functioning elderly that was designed to evaluate longitudinal changes in weight, body composition, and function. A total of 3075 participants who were aged 70 to 79 yr and had no disability were recruited at sites in Memphis, TN, and Pittsburgh, PA, between April 1997 and June 1998 with a follow-up of 6 yr. At entry, the mean cystatin C was 1.05 mg/L and the mean creatinine was 1.06 mg/dl. After 6 yr of follow-up, 557 participants had died. The mortality rates in each ascending cystatin C quintile were 1.7, 2.7, 2.9, 3.1, and 5.4%/yr. After adjustment for demographic risk factors, comorbid health conditions, and inflammatory biomarkers (C-reactive protein, IL-6. and TNF-alpha), each quintile of cystatin C was significantly associated with increased mortality risk compared with the lowest: Hazard ratios (HR; 95% confidence intervals) quintile 1, -1.0 (referent); quintile 2, -1.74 (1.21 to 2.50); quintile 3, -1.51 (1.05 to 2.18); quintile 4, -1.49 (1.04 to 2.13); and quintile 5, -2.18 (1.53 to 3.10). These associations did not differ by gender or race. Results were consistent for cardiovascular and other-cause mortality, but not cancer mortality. Creatinine quintiles were not associated with mortality after multivariate adjustment (HR: 1.0 [referent], 1.00 [0.72 to 1.39], 0.95 [0.68 to 1.32], 1.11 [0.79 to 1.57], 1.16 [0.86 to 1.58]). Cystatin C is a strong, independent risk factor for mortality in the elderly. Future studies should investigate whether cystatin C has a role in clinical medicine. C1 Univ Calif San Francisco, Gen Internal Med Sect, VA Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA. Wake Forest Bowman Gray Sch Med, J Paul Sticht Ctr Aging & Rehabil, Winston Salem, NC USA. Univ Tennessee, Dept Prevent Med, Memphis, TN 38163 USA. Calif Pacific Med Ctr, Inst Res, San Francisco, CA USA. Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Shlipak, MG (reprint author), Univ Calif San Francisco, Gen Internal Med Sect, VA Med Ctr, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM shlip@itsa.ucsf.edu RI Newman, Anne/C-6408-2013; OI Newman, Anne/0000-0002-0106-1150; Kritchevsky, Stephen/0000-0003-3336-6781 FU NHLBI NIH HHS [R01 HL073208-01]; NIA NIH HHS [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106] NR 27 TC 137 Z9 141 U1 0 U2 4 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2006 VL 17 IS 1 BP 254 EP 261 DI 10.1681/ASN.2005050545 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 106SB UT WOS:000242120000032 PM 16267155 ER PT J AU Wierenga, CE Maher, LM Moore, AB White, KD McGregor, K Soltysik, DA Peck, KK Gopinath, KS Singletary, F Gonzalez-Rothi, LJ Briggs, RW Crosson, B AF Wierenga, CE Maher, LM Moore, AB White, KD McGregor, K Soltysik, DA Peck, KK Gopinath, KS Singletary, F Gonzalez-Rothi, LJ Briggs, RW Crosson, B TI Neural substrates of syntactic mapping treatment: An fMRI study of two cases SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE neuroplasticity; rehabilitation; aphasia; functional neuroimaging; linguistics; cerebrovascular accident ID EVENT-RELATED FMRI; TEMPORAL-SPATIAL STRATEGY; THEMATIC ROLE ASSIGNMENT; SENTENCE COMPREHENSION; SPEECH PRODUCTION; BRAIN PLASTICITY; BROCAS AREA; POSTSTROKE APHASIA; TREATMENT PROGRAM; RIGHT-HEMISPHERE AB Two patients (G01, J02) with chronic nonfluent aphasia and sentence production deficits received syntactic mapping treatment to improve sentence production. The patients had dramatically different outcomes in that improved syntax production generalized to nontreatment tasks for G01, but not for JO2. To learn how treatment influenced the neural substrates for syntax production, both patients underwent pre- and posttreatment functional magnetic resonance imaging (fMRI) of sentence generation. G01 showed more robust activity posttreatment than pretreatment in Broca's area; ventral temporal activity decreased slightly from pre- to posttreatment. Comparison of J02's pretreatment and posttreatment images revealed little change, although activity was more diffuse pre- than posttreatment. Findings suggest that for G01, rehabilitation led to engagement of an area (Broca's area) used minimally during the pretreatment scan, whereas for J02, rehabilitation may have led to more efficient use of areas already involved in sentence generation during the pretreatment scan. fMRI findings are discussed in the context of sentence-production outcome and generalization. C1 Univ Florida, Hlth Sci Ctr, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA. Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr, Dept Vet Affairs Rehabil Res & Dev, Gainesville, FL USA. Univ Florida, Dept Neurol, Gainesville, FL 32611 USA. Univ Florida, Dept Radiol & Nucl Med, Gainesville, FL 32611 USA. Univ Florida, Dept Psychol, Gainesville, FL 32611 USA. Univ Florida, Dept Radiol, Gainesville, FL 32611 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Crosson, B (reprint author), Univ Florida, Hlth Sci Ctr, Dept Clin & Hlth Psychol, Box 100165, Gainesville, FL 32610 USA. EM bcrosson@phhp.ufl.edu RI Crosson, Bruce/L-3128-2013; Maher, Lynn/L-7074-2015; OI SOLTYSIK, DAVID/0000-0002-6597-5226; McGregor, Keith/0000-0003-3654-351X FU NIDCD NIH HHS [P50-DC03888] NR 76 TC 18 Z9 20 U1 3 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD JAN PY 2006 VL 12 IS 1 BP 132 EP 146 DI 10.1017/S135561770606019X PG 15 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 012BS UT WOS:000235313800016 PM 16433953 ER PT J AU Loeken, MR AF Loeken, MR TI Advances in understanding the molecular causes of diabetes-induced birth defects SO JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION LA English DT Review DE diabetic embryopathy; diabetic pregnancy; neural tube defect; Pax3; p53 ID NEURAL-TUBE DEFECTS; PROTEIN-KINASE-C; HIGH GLUCOSE; RAT EMBRYOS; VITAMIN-E; CONGENITAL-MALFORMATIONS; OXIDATIVE STRESS; GENE-EXPRESSION; PAX-3 GENE; CARDIOVASCULAR MALFORMATIONS AB OBJECTIVE: To review the current understanding of the molecular causes of birth defects resulting from diabetic pregnancy, with a focus on neural tube defects. METHODS: A mouse model of diabetic pregnancy is described, in which embryo gene expression associated with neural tube defects is examined. Chemical, physiologic, or genetic manipulations are employed to elucidate critical pathways affected by increased glucose metabolism, and how abnormal gene expression disrupts neural tube closure. RESULTS: Increased glucose delivery to embryos, or activation of pathways that are stimulated by high glucose, such as the hexosamine biosynthetic pathway or hypoxia, increase oxidative stress in embryos, inhibit expression of Pax3, a gene that encodes a transcription factor that is required for neural tube closure, and increase neural tube defects. Conversely, blocking these pathways, or providing the antioxidants, reduced glutathione or vitamin E, suppress the adverse effects of excess glucose. Pax3 decreases steady-state levels of the p53 tumor-suppressor protein, such that when Pax3 is deficient, p53 protein increases, leading to increased neuroepithelial apoptosis prior to completion of neural tube closure. Embryos that lack both functional Pax3 protein and p53 do not display neuroepithelial apoptosis or neural tube defects. CONCLUSIONS: Excess glucose metabolism by embryos resulting from maternal hyperglycemia disturbs a complex network of biochemical pathways, leading to oxidative stress. Oxidative stress inhibits expression of genes, such as Pax3, which control essential developmental processes. Pax3 protein is required during neural tube development to suppress p53-dependent cell death and consequent abortion of neural tube closure, but is not required to control expression of genes that direct neural tube closure. Impaired embryo gene expression resulting from oxidative stress, and consequent apoptosis or disturbed organogenesis, may be a general mechanism to explain diabetic embryopathy. C1 Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Dev & Stem Cell Biol,Dept Med, Boston, MA 02215 USA. RP Loeken, MR (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Dev & Stem Cell Biol,Dept Med, 1 Joslin Pl, Boston, MA 02215 USA. EM mary.loeken@joslin.harvard.edu OI Loeken, Mary/0000-0002-8056-9816 NR 84 TC 54 Z9 59 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1071-5576 J9 J SOC GYNECOL INVEST JI J. Soc. Gynecol. Invest. PD JAN PY 2006 VL 13 IS 1 BP 2 EP 10 DI 10.1016/j.jsgi.2005.09.007 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 001ZX UT WOS:000234582300002 PM 16303321 ER PT J AU Inaba, K McKenney, M Munera, F de Moya, M Lopez, PP Schulman, CI Habib, FA AF Inaba, K McKenney, M Munera, F de Moya, M Lopez, PP Schulman, CI Habib, FA TI Cystogram follow-up in the management of traumatic bladder disruption SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 64th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma CY SEP 22, 2005 CL Atlanta, GA SP Amer Assoc Surg Trauma DE bladder; wounds and injuries; radiography; diagnostic imaging; computed tomography; X-ray ID RUPTURE AB Background. The utility of obtaining a routine cystogram after the repair of intraperitoneal bladder disruption before urethral catheter removal is unknown. This study was designed to examine whether follow-up cystogram evaluation after traumatic bladder disruption affected the clinical management of these injuries. We hypothesized that routine cystograms, after operative repair of intraperitoneal bladder disruptions, provide no clinically useful information and may be eliminated in the management of these injuries. Methods. Our prospectively collected trauma database was retrospectively reviewed for all ICD-9 867.0 and 867.1 coded bladder injuries over a 6-year period ending in June 2004. Demographics, clinical injury data, detailed operative records, and imaging studies were reviewed for each patient. Bladder injuries were categorized as intraperitoneal (IP) or extraperitoneal (EP) bladder disruptions based on imaging results and operative exploration. Patients with IP injuries were further subdivided into those with "simple" dome disruptions or through-and-through penetrating injuries and "complex" injuries involving the trigone or ureter reimplantation. All patients sustaining isolated ureteric or urethral injury were excluded from further analysis. Results: In all, 20,647 trauma patients were screened for bladder injury. Out of this group, there were 50 IP (47 simple, 3 complex) and 37 EP injuries available for analysis. All IP injuries underwent operative repair. Eight of the IP injuries (all simple) had no postoperative cystogram and all were doing well at 1- to 4-week follow-up. The remaining 42 patients underwent a postoperative cystogram at 15.3 +/- 7.3 days (range 7 to 36 days). All simple IP injuries had a negative postoperative cystogram. The only positive study was in one of the three complex IP injuries. In the EP group, 21.6% had positive cystograms requiring further follow-up and intervention. Conclusions: Patients sustaining extraperitoneal and complex intraperitoneal bladder disruptions require routine cystogram follow-up. In those patients undergoing repair of a simple intraperitoneal bladder disruption, however, routine follow-up cystograms did not affect clinical management. Further prospective evaluation to determine the optimal timing of catheter removal in this patient population is warranted. C1 Univ So Calif, Los Angeles Cty Med Ctr, Div Trauma & Surg Crit Care, Los Angeles, CA 90033 USA. Univ Miami, Div Trauma & Crit Care, Miami, FL 33152 USA. Univ Miami, Div Emergency Radiol, Ryder Trauma Ctr, Miami, FL 33152 USA. Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. RP Inaba, K (reprint author), Univ So Calif, Los Angeles Cty Med Ctr, Div Trauma & Surg Crit Care, 1200 N State St 10-750, Los Angeles, CA 90033 USA. EM kinaba@surgery.usc.edu NR 12 TC 9 Z9 9 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-6061 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD JAN PY 2006 VL 60 IS 1 BP 23 EP 27 DI 10.1097/01.ta.0000200096.44452.8a PG 5 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 008UN UT WOS:000235066300006 PM 16456432 ER PT J AU Ayuste, EC Chen, HZ Koustova, E Rhee, P Ahuja, N Chen, Z Valeri, CR Spaniolas, K Mehrani, T Alam, HB AF Ayuste, EC Chen, HZ Koustova, E Rhee, P Ahuja, N Chen, Z Valeri, CR Spaniolas, K Mehrani, T Alam, HB TI Hepatic and pulmonary apoptosis after hemorrhagic shock in swine can be reduced through modifications of conventional Ringer's solution SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 64th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma CY SEP 22, 2005 CL Atlanta, GA SP Amer Assoc Surg Trauma DE hemorrhage; liver; lung; swine; apoptosis; metabolism; cytokines; resuscitation; Ringers solutions; ketone ID ADHESION MOLECULE-1 EXPRESSION; OPERATION-IRAQI-FREEDOM; PROGRAMMED CELL-DEATH; FLUID RESUSCITATION; NEUTROPHIL ACTIVATION; RAT MODEL; PYRUVATE; MECHANISMS; SYSTEM; EXPERIENCE AB Background: cytotoxic properties of racemic (D-,L-isomers) lactated Ringer's solution detected in vitro and in small animal experiments, have not been confirmed in large animal models. Our hypothesis was that in a clinically relevant large animal model of hemorrhage, resuscitation with racemic lactated Ringer's solution would induce cellular apoptosis, which can be attenuated by elimination of D-lactate. Methods: Yorkshire swine (n = 49, weight 40-58 kg) were subjected to uncontrolled (iliac arterial and venous injuries) and controlled hemorrhage, totaling 40% of estimated blood volume. They were randomized (n = 7/group) to control groups, which consisted of (1) no hemorrhage (NH), (2) no resuscitation (NR), or resuscitation groups, which consisted of (3) 0.9% saline (NS), (4) racemic lactated Ringer's (DL-LR), (5) L-isomer lactated Ringer's (L-LR), (6) Ketone Ringer's (KR), (7) 6% hetastarch in 0.9% saline (Hespan). KR was identical to LR except for equimolar substitution of lactate with beta-hydroxybutyrate. Resuscitation was performed in three phases, simulating (1) prehospital, (2) operative, (3) postoperative/recovery periods. Arterial blood gasses, circulating cytokines (TNF-alpha, IL-1, -6, -10), and markers of organ injury were serially measured. Metabolic activity of brain, and liver, was measured with microdialysis. Four hours postinjury, organs were harvested for Western blotting, ELISA, TUNEL assay, and immunohistochemistry. Results: All resuscitation strategies restored blood pressure, but clearance of lactic acidosis was impeded following DL-LR resuscitation. Metabolic activity decreased during shock and improved with resuscitation, without any significant inter-group differences. Levels of cytokines in circulation were similar, but tissue levels of TNF in liver and lung increased six- and three-folds (p < 0.05) in NR group. In liver, all resuscitation strategies significantly decreased TNF levels compared with the NR group, but in the lung resuscitation with lactated Ringer (DL and L isomers) failed to decrease tissue TNF levels. DL-LR resuscitation also increased apoptosis (p < 0.05) in liver and lung, which was not seen after resuscitation with other solutions. Conclusions: In this large animal model of hemorrhagic shock, resuscitation with conventional (racemic) LR solution increased apoptotic cell death in liver and lung. This effect can be prevented by simple elimination Of D-lactate from the Ringer's solution. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. Univ Philippines, Philippine Gen Hosp, Med Ctr, Manila, Philippines. Washington Hosp Ctr, Washington, DC 20010 USA. USN, Blood Res Lab, Boston, MA USA. RP Alam, HB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM hbalam@partners.org NR 43 TC 44 Z9 46 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-6061 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD JAN PY 2006 VL 60 IS 1 BP 52 EP 62 DI 10.1097/01.ta.0000200156.05397.0b PG 11 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 008UN UT WOS:000235066300014 PM 16456436 ER PT J AU Alam, HB Rhee, P Honma, K Chen, HZ Ayuste, EC Lin, T Toruno, K Mehrani, T Engel, C Chen, Z AF Alam, HB Rhee, P Honma, K Chen, HZ Ayuste, EC Lin, T Toruno, K Mehrani, T Engel, C Chen, Z TI Does the rate of rewarming from profound hypothermic arrest influence the outcome in a swine model of lethal hemorrhage? SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma CY SEP 29-OCT 02, 2004 CL Maui, HI SP Amer Assoc Surg Trauma DE hypothermia; warming rate; suspended animation; uncontrolled hemorrhage; vascular injuries; thoracotomy; organ preservation; neurologic function; survival ID PROLONGS SURVIVAL-TIME; CEREBRAL BLOOD-FLOW; CARDIAC-ARREST; CIRCULATORY ARREST; BRAIN-DAMAGE; TRAUMATIC EXSANGUINATION; CARDIOPULMONARY BYPASS; MODERATE HYPOTHERMIA; SUSPENDED ANIMATION; MILD HYPOTHERMIA AB Background. Rapid induction of profound hypothermic arrest (suspended animation) can provide valuable time for the repair of complex injuries and improve survival. The optimal rate for re-warming from a state of profound hypothermia is unknown. This experiment was designed to test the impact of different warming rates on outcome in a swine model of lethal hemorrhage from complex vascular injuries. Methods: Uncontrolled lethal hemorrhage was induced in 40 swine (80-120 lbs) by creating an iliac artery and vein injury, followed 30 minutes later (simulating transport time) by laceration of the descending thoracic aorta. Through a thoracotomy approach, a catheter was placed in the aorta and hyperkalemic organ preservation solution was infused on cardiopulmonary bypass to rapidly (2 degrees C/min) induce profound (10 degrees C) hypothermia. Vascular injuries were repaired during 60 minutes of hypothermic arrest. The 4 groups (n = 10/group) included normothermic controls (NC) where core temperature was maintained between 36 to 37 degrees C, and re-warming from profound hypothermia at rates of. 0.25 degrees C/min (slow), 0.5 degrees C/min (medium), or 1 degrees C/min (fast). Hyperkalemia was reversed during the hypothermic arrest period, and blood was infused for resuscitation during re-warming. After discontinuation of cardiopulmonary bypass, the animals were recovered and monitored for 6 weeks for neurologic deficits, cognitive function (learning new skills), and organ dysfunction. Detailed examination of brains was performed at 6 weeks. Results: All the normothermic animals died, whereas survival rates for slow, medium and fast re-warming from hypothermic arrest were 50, 90, and 30%, respectively (p < 0.05 slow and medium warming versus normothermic control, p < 0.05 medium versus fast re-warming). All the surviving animals were neurologically intact, displayed normal learning capacity, and had no long-term organ dysfunction. Conclusions: Rapid induction of hypothermic arrest maintains viability of brain during repair of lethal vascular injuries. Long-term survival is influenced by the rate of reversal of hypothermia. C1 Harvard Univ, Div Trauma Emergency Surg & Surg Crit Care, Massachusetts Gen Hosp, Dept Surg,Med Sch, Boston, MA 02114 USA. Uniformed Serv Univ Hlth Sci, Trauma Res & Readiness Inst Surg, Bethesda, MD 20814 USA. Los Angeles Cty Univ So Calif Med Ctr, Los Angeles, CA USA. RP Alam, HB (reprint author), Harvard Univ, Div Trauma Emergency Surg & Surg Crit Care, Massachusetts Gen Hosp, Dept Surg,Med Sch, 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM hbalam@partners.org FU NHLBI NIH HHS [R01 HL 71698] NR 56 TC 55 Z9 60 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-6061 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD JAN PY 2006 VL 60 IS 1 BP 134 EP 144 DI 10.1097/01.ta.0000198469.95292.ec PG 11 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 008UN UT WOS:000235066300029 PM 16456447 ER PT J AU Conhaim, RL Watson, KE Heisey, DM Leverson, GE Harms, BA AF Conhaim, RL Watson, KE Heisey, DM Leverson, GE Harms, BA TI Hemorrhage causes interalveolar perfusion maldistribution in the lungs of anesthetized rats SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma CY SEP 29-OCT 02, 2004 CL Maui, HI SP Amer Assoc Surg Trauma DE blood loss; pulmonary blood flow; pulmonary microcirculation; dispersion index analysis; perfusion heterogeneity ID INJURY; MICROVESSELS AB Background: Lung injury often occurs following hemorrhage and we hypothesized that this might be due to the effects of hemorrhage on perfusion distribution among alveoli. To test this, we measured interalveolar perfusion distribution in anesthetized, spontaneously breathing rats subjected to blood losses of 0%, 10%, 20%, or 30% of calculated blood volume Methods: We measured interalveolar perfusion distribution by analyzing trapping patterns of 4-mu m diameter fluorescent latex particles infused into the pulmonary circulation. The particles (2 X 10(8)) were infused I hour after each animal had been bled, and the lungs were then removed and air-dried. Using a confocal fluorescence microscope, we collected images of the particles in eight sections of each lung. Each image encompassed 3,360 x 3,360 x 100 mu m (approximately 5,000 alveoli), and included 3-4,000 particles. Particle distributions in the images were measured using the method of dispersion index (DI) analysis. A DI value of zero corresponds to a statistically random distribution; the more DI exceeds zero, the more the distribution is clustered or inhomogenous Results: The largest DI values for the four groups were: 0%, 0.69 +/- 0.41; 10%, 0.57 +/- 0.58; 20%, 0.72 +/- 0.34; 30%, 1.38 +/- 0.41. The 30% blood loss group had a max DI value approximately twofold greater than those of the other three (P < 0.0001). Conclusions. Our results suggest that interalveolar perfusion distribution becomes markedly maldistributed at blood losses of 30%. This contributes to ventilation-perfusion mismatching, and may be a precipitating event for lung injury following hemorrhage. C1 Univ Wisconsin, Sch Med, Dept Surg, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Conhaim, RL (reprint author), Univ Wisconsin, Sch Med, Dept Surg, BX3236,600 Highland Ave, Madison, WI 53792 USA. EM conhaim@surgery.wisc.edu NR 16 TC 9 Z9 9 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-6061 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD JAN PY 2006 VL 60 IS 1 BP 158 EP 162 DI 10.1097/01.ta.0000203110.03258.d0 PG 5 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 008UN UT WOS:000235066300034 PM 16456450 ER PT J AU Mazzucco, D Spector, M AF Mazzucco, D Spector, M TI Contact area as a critical determinant in the tribology of metal-on-polyethylene total joint arthroplasty SO JOURNAL OF TRIBOLOGY-TRANSACTIONS OF THE ASME LA English DT Article ID MOLECULAR-WEIGHT POLYETHYLENE; TOTAL HIP-REPLACEMENT; MULTIDIRECTIONAL MOTION; PRESSURE-DEPENDENCE; WEAR SIMULATION; FEMORAL HEADS; UHMWPE; LUBRICANT; ROUGHNESS; FRICTION AB The effects of contact area and contact stress oil friction and wear of polyethylene-metal articulation were evaluated using a bidirectional pin-on-disk apparatus. A doubling of the contact area underfixed loading conditions led to a 50% increase in the coefficient of friction and a doubling of the wear rate. There appeared to be a relationship between the increase in wear rate and the increase in the coefficient of friction. A model was developed to explain the mechanism by which engagement of asperities results in the increasing wear rate with increasing contact area despite the decreased stress. C1 Exponent Failure Anal Associates, Philadelphia, PA 19104 USA. VA Boston Healthcare Syst, Boston, MA 02130 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA. RP Mazzucco, D (reprint author), Exponent Failure Anal Associates, 3401 Market St,Suite 300, Philadelphia, PA 19104 USA. EM dmazzucco@exponent.com NR 32 TC 7 Z9 7 U1 2 U2 7 PU ASME-AMER SOC MECHANICAL ENG PI NEW YORK PA THREE PARK AVE, NEW YORK, NY 10016-5990 USA SN 0742-4787 J9 J TRIBOL-T ASME JI J. Tribol.-Trans. ASME PD JAN PY 2006 VL 128 IS 1 BP 113 EP 121 DI 10.1115/1.2114930 PG 9 WC Engineering, Mechanical SC Engineering GA 004LB UT WOS:000234753200013 ER PT J AU Greene, KL Elkin, EP Karapetian, A DuChane, J Carroll, PR Kane, CJ AF Greene, KL Elkin, EP Karapetian, A DuChane, J Carroll, PR Kane, CJ CA Capsure Investigators TI Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: Results from CAPSURE SO JOURNAL OF UROLOGY LA English DT Article DE prostatic neoplasms; biopsy; recurrence; prostatectomy ID POSITIVE SURGICAL MARGINS; BEAM RADIATION-THERAPY; NEEDLE-BIOPSY; ANTIGEN RECURRENCE; PATHOLOGICAL STAGE; SEARCH DATABASE; CANCER; CORES; PERCENTAGE; DISEASE AB Purpose: Prostate cancer biopsy information is important for patient risk assessment. Although the number and extent of positive biopsies have been used to predict recurrence, the impact of positive biopsy location and contiguity is less clear. We compared the ability of positive prostate biopsy location and pattern with number and percent positive biopsies to predict recurrence after RP. Materials and Methods: From CaPSURE we identified 2,037 men treated with RP from 1992 to 2002 for whom detailed biopsy information and 2 or more followup PSA values were available. Treatment failure was defined as 2 consecutive PSA values of 0.2 ng/ml or higher, or a second treatment delivered more than 6 months after RP. Biopsy tumor volume (number and percent positive sites), location of disease (anatomical site, laterality), and contiguity of positive biopsies were entered into Cox proportional hazards models to predict risk of disease recurrence while controlling for Gleason grade, PSA and T stage. Results: Higher number and percent of positive biopsy cores were associated with prostate cancer recurrence, risk stratification category and Gleason grade, p < 0.0001, HR 1.09 (Cl 1.02 to 1.16) and 1.01 (CI 1.00 to 1.01), respectively. Number of biopsy cores taken, laterality, contiguity and positive biopsy location were not associated with disease recurrence. Conclusions: The number and the percentage of biopsies positive for cancer correlated with treatment failure after radical prostatectomy. Contiguity, laterality and location were not associated with recurrence. C1 Univ Calif San Francisco, Dept Urol, Ctr Comprehens Canc, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. TAP Pharmaceut Prod Inc, Lake Forest, IL USA. RP Kane, CJ (reprint author), Univ Calif San Francisco, Dept Urol, Ctr Comprehens Canc, 1600 Divisadero St,Rm A631, San Francisco, CA 94143 USA. EM ckane@urol.ucsf.edu FU PHS HHS [P50 C89520] NR 20 TC 18 Z9 18 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2006 VL 175 IS 1 BP 125 EP 129 DI 10.1016/S0022-5347(05)00009-1 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 994AD UT WOS:000234001100030 PM 16406887 ER PT J AU Beer, TM Bland, LB Bussiere, JR Neiss, MB Wersinger, EM Garzotto, M Ryan, CW Janowsky, JS AF Beer, TM Bland, LB Bussiere, JR Neiss, MB Wersinger, EM Garzotto, M Ryan, CW Janowsky, JS TI Testosterone loss and estradiol administration modify memory in men SO JOURNAL OF UROLOGY LA English DT Article DE prostatic neoplasms; estradiol; testosterone; memory ID PROSTATE-CANCER; COGNITIVE FUNCTION; OLDER MEN; WORKING-MEMORY; ESTROGEN; SUPPRESSION; PERFORMANCE; CARCINOMA; HORMONES; THERAPY AB Purpose: Little is known about the effect of androgen deprivation therapy on the brain despite the fact that sex steroid receptors are abundant in cortical brain regions that mediate memory and other cognitive functions. We characterized the impact of androgen deprivation and of subsequent estradiol therapy on the long-term and working memory of patients with prostate cancer. Materials and Methods: Long-term memory (immediate and delayed paragraph recall tests), working memory (SOP and Trails tests) and Profile of Mood States were assessed at baseline and 4 weeks later in 18 patients with androgen independent prostate cancer beginning second line hormonal therapy with transdermal estradiol 0.6 mg/24 hours. The same assessments were performed in 2 age matched control groups of 18 patients with prostate cancer undergoing androgen deprivation continuing on hormonal therapy and 17 community dwelling healthy men. Results: Immediate and delayed verbal memory were significantly worse in patients with prostate cancer on androgen deprivation than in age matched healthy controls. In addition, men with prostate cancer took more time to complete the Trails A task, indicating slower processing speed, but did not differ significantly from healthy controls in working memory tasks. In individual repeated measures analyses, verbal memory performance improved with estradiol therapy but did not change in the 2 control groups. Conclusions: Sex steroid loss and replacement have effects on specific cognitive processes in older men. Furthermore, estrogen has the potential to reverse the neurotoxic effects on memory performance caused by androgen deprivation. C1 Oregon Hlth Sci Univ, Div Hematol & Med Oncol, Dept Med, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Div Urol, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Beer, TM (reprint author), Oregon Hlth Sci Univ, Div Hematol & Med Oncol, Dept Med, Mail Code CR145,3181 SW San Jackson Pk Rd, Portland, OR 97239 USA. EM beert@ohsu.edu FU NCRR NIH HHS [5 M01 RR00334, 5 M01 RR00334-33S2]; NIA NIH HHS [AG18843]; PHS HHS [03-3839-504384] NR 20 TC 62 Z9 63 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2006 VL 175 IS 1 BP 130 EP 135 DI 10.1016/S0022-5347(05)00049-2 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 994AD UT WOS:000234001100032 PM 16406889 ER PT J AU Smith, MR Boyce, SP Moyneur, E Duh, MS Raut, MK Brandman, J AF Smith, MR Boyce, SP Moyneur, E Duh, MS Raut, MK Brandman, J TI Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; bone and bones; gonadorelin; fractures ID ANDROGEN-DEPRIVATION THERAPY; BONE-MINERAL DENSITY; CARCINOMA; MEN; OSTEOPOROSIS; ORCHIECTOMY; DIAGNOSIS AB Purpose: We assessed the relationship between GnRH agonists and the risk of clinical fractures in men with prostate cancer. Materials and Methods: Using a database of medical claims from 16 large American companies we identified a study group of 3,779 men with prostate cancer who received treatment with a GnRH agonist and a control group of 8,341 with prostate cancer who were not treated with a GnRH agonist. Men with I or more medical claims for bone metastases were excluded. The rates of any clinical fracture, hip fracture and vertebral fracture were compared between the groups. Results: The rate of any fracture was 7.91/100 vs 6.55/100 person-years at risk in men who received vs did not receive a GnRH agonist (relative risk 1.21, 95% CI 1.09 to 1.34). The rates of hip fracture (relative risk 1.76, 95% CI 1.33 to 2.33) and vertebral fracture (relative risk 1.18, 95% CI 0.94 to 1.48) were also higher in men who received a GnRH agonist. GnRH agonist treatment was independently associated with fracture risk on multivariate analyses. Conclusions: GnRH agonists increase the risk of clinical fracture in men with prostate cancer. C1 Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA. Analysis Grp Inc, Boston, MA USA. Novartis Pharmaceut Corp, E Hanover, NJ USA. RP Smith, MR (reprint author), Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Cox 640,100 Blossom St, Boston, MA 02114 USA. EM smith.matthew@mgh.harvard.edu NR 15 TC 112 Z9 117 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2006 VL 175 IS 1 BP 136 EP 139 DI 10.1016/S0022-5347(05)00033-9 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 994AD UT WOS:000234001100033 PM 16406890 ER PT J AU Burgio, KL Goode, PS Urban, DA Umlauf, MG Locher, JL Bueschen, A Redden, DT AF Burgio, KL Goode, PS Urban, DA Umlauf, MG Locher, JL Bueschen, A Redden, DT TI Preoperative biofeedback assisted behavioral training to decrease post-prostatectomy incontinence: A randomized, controlled trial SO JOURNAL OF UROLOGY LA English DT Article DE bladder; urinary incontinence; biofeedback (psychology); prostatectomy; pelvic floor ID QUALITY-OF-LIFE; LOCALIZED PROSTATE-CANCER; RADICAL PROSTATECTOMY; URINARY-INCONTINENCE; MEN; RELIABILITY; INVENTORY; OUTCOMES; WOMEN AB Purpose: We tested the effectiveness of preoperative biofeedback assisted behavioral training for decreasing the duration and severity of incontinence, and improving quality of life in the 6 months following radical prostatectomy. Materials and Methods: We performed a prospective, randomized, controlled trial comparing preoperative behavioral training to usual care. The volunteer sample included 125 men 53 to 68 years old who elected radical prostatectomy for prostate cancer. Patients were stratified according to age and tumor differentiation, and randomized to 1 preoperative session of biofeedback assisted behavioral training plus daily home exercise or a usual care control condition, consisting of simple postoperative instructions to interrupt the urinary stream. The main outcome measurements were duration of incontinence (time to continence), as derived from bladder diaries, incontinence severity (the proportion with severe/continual leakage), pad use, Incontinence Impact Questionnaire, psychological distress (Hopkins Symptom Checklist) and health related quality of life (Medical Outcomes Study Short Form Health Survey). Results: Preoperative behavioral training significantly decreased time to continence (p = 0.03) and the proportion of patients with severe/continual leakage at the 6-month end point (5.9% vs 19.6%, p = 0.04). There were also significant differences between the groups for self-reported urine loss with coughing (22.0% vs 51.1%, p = 0.003), sneezing (26.0% vs 48.9%, p = 0.02) and getting up from lying down (14.0% vs 31.9%, p = 0.04). No differences were found on return to work and usual activities or quality of life measures. Conclusions: Preoperative behavioral training can hasten the recovery of urine control and decrease the severity of incontinence following radical prostatectomy. C1 Univ Alabama, Sch Med, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs Med Ctr, Birmingham, AL USA. Univ Alabama, Sch Med, Dept Med, Birmingham, AL USA. Univ Alabama, Sch Med, Dept Surg, Birmingham, AL USA. Univ Alabama, Sch Med, Ctr Aging, Birmingham, AL USA. Univ Alabama, Sch Med, Sch Nursing, Birmingham, AL USA. Univ Alabama, Sch Med, Sch Publ Hlth, Birmingham, AL USA. RP Burgio, KL (reprint author), Birmingham Vet Affairs Med Ctr, GRECC, 11G,700 19th St S, Birmingham, AL 35233 USA. EM kburgio@aging.uab.edu FU NIDDK NIH HHS [R01 DK50283] NR 20 TC 78 Z9 81 U1 0 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2006 VL 175 IS 1 BP 196 EP 201 DI 10.1016/S0022-5347(05)00047-9 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 994AD UT WOS:000234001100053 PM 16406909 ER PT J AU Campo-Ruiz, V Lauwers, GY Anderson, RR Delgado-Baeza, E Gonzalez, S AF Campo-Ruiz, V Lauwers, GY Anderson, RR Delgado-Baeza, E Gonzalez, S TI Novel virtual biopsy of the kidney with near infrared, reflectance confocal microscopy: A pilot study in vivo and ex vivo SO JOURNAL OF UROLOGY LA English DT Article DE kidney; microscopy; confocal; lasers; rats; Wistar; anatomy ID RENAL BIOPSY; SEGMENTATION; HISTOLOGY; TISSUE AB Purpose: Current diagnostic strategies for the kidney combine noninvasive imaging techniques with invasive procedures such as needle biopsy. However, renal needle biopsy is not devoid of risks, such as bleeding or infection. Additionally, histology studies are limited to ex vivo morphology and processing induces tissue artifacts, is time-consuming and limits the performance of further studies. Near infrared, reflectance CM is a novel technique that allows high resolution optical sectioning through intact tissues without using any exogenous fluorescent stains. Contrast between structures is based on the natural differences in refractivity. In this pilot study we assessed the usefulness of CM in the study of the kidney in vivo and ex vivo. Materials and Methods: Kidneys of live rats were imaged with CM. Contrast in images is based on native properties of the tissue upon being shone with a near infrared laser. By convention hyperrefractile structures are seen as white and hyporefractile structures are seen as black. CM imaging planes varied along the x, y and z axes of space. Images of live kidney were compared with those from ex vivo CM imaging and standard histology procedures. Results: The tubules, glomeruli, vessels and interstitium were readily identified, revealing intracellular detail. Differences between the kidney in vivo and ex vivo were also observed. Experimental contrast agents further highlighted the nuclei. Conclusions: CM is a useful noninvasive imaging technique that is an adjunct to current techniques for 3-dimensional study of the kidney in vivo and ex vivo. Future technical developments will provide key applications during surgical intervention, transplantation and rapid tissue assessment. C1 Harvard Univ, Massachusetts Gen Hosp, Wellman Labs Photomed, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Gastrointestinal Pathol Serv, Dept Pathol, Boston, MA 02114 USA. Univ Autonoma Madrid, Sch Med, Dept Morphol Histol, Madrid, Spain. RP Gonzalez, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Wellman Labs Photomed, Boston, MA 02114 USA. NR 16 TC 9 Z9 10 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2006 VL 175 IS 1 BP 327 EP 336 DI 10.1016/S0022-5347(05)00008-X PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 994AD UT WOS:000234001100082 PM 16406937 ER PT J AU Lo, WK vanSonnenberg, E Shankar, S Morrison, PR Silverman, SG Tuncali, K Rabin, M AF Lo, WK vanSonnenberg, E Shankar, S Morrison, PR Silverman, SG Tuncali, K Rabin, M TI Percutaneous CT-guided radiofrequency ablation of symptomatic bilateral adrenal metastases in a single session SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID TUMORS; CARCINOMA; INJECTION; ADENOMA AB Percutaneous computed tomography (CT)-guided radiofrequency (RF) ablation has been used in the palliative treatment of symptomatic bilateral adrenal tumors, often with each tumor addressed separately over the course of multiple treatment sessions. In the present case, a 71-year-old man with a diagnosis of lung cancer and painful bilateral metastases to the adrenal glands underwent percutaneous CT-guided RF thermal ablation of both adrenal masses in a single session (left adrenal mass, 4.7 cm; right adrenal mass, 4.3 cm), without occurrence of blood pressure instability or other acute complications. Measurement of plasma levels of cortisol, adrenocorticotropic hormone (ACTH), and glucose before and after RF ablation revealed transient changes that suggested preservation of endocrine feedback mechanisms. The patient experienced marked relief in pain bilaterally. By 5 days after the procedure, cortisol, ACTH, and glucose levels returned to preprocedural levels. On further follow-up at 6 months, the patient noted a lack of endocrine sequelae and continued pain relief. C1 Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. RP vanSonnenberg, E (reprint author), St Josephs Hosp, Dept Radiol, 350 W Thomas Rd, Phoenix, AZ 85013 USA. EM eric.vansonnenberg@chw.edu NR 15 TC 26 Z9 27 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD JAN PY 2006 VL 17 IS 1 BP 175 EP 179 DI 10.1097/01.RVI.0000188748.51764.CE PG 5 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 028VV UT WOS:000236517800022 PM 16415149 ER PT J AU von Andrian, UH AF von Andrian, U. H. TI In vivo visualization of adaptive immune responses SO JOURNAL OF VASCULAR RESEARCH LA English DT Meeting Abstract CT 24th Conference of the European-Society-for-Microcirculation CY AUG 30-SEP 02, 2006 CL Amsterdam, NETHERLANDS SP European Soc Microcirculat C1 Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2006 VL 43 SU 1 BP 20 EP 20 PG 1 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 087JT UT WOS:000240739400052 ER PT J AU Moretti, A Caron, L Lam, JT Qyang, Y Yunfu, S Evans, S Chien, KR Laugwitz, KL AF Moretti, A. Caron, L. Lam, J. T. Qyang, Y. Yunfu, S. Evans, S. Chien, K. R. Laugwitz, K. -L. TI Diversification of endothelial, cardiac, and smooth muscle cell lineages via multipotency of individual isl1+/Nkx2.5+/flk1+ primordial cardiovascular stem cells SO JOURNAL OF VASCULAR RESEARCH LA English DT Meeting Abstract CT Annual Meeting of the German-Society-for-Microcirculation-and-Vascular-Biology CY OCT 12-14, 2006 CL Minich, GERMANY SP German Soc Microcirculat & Vasc Biol C1 Tech Univ Munich, Klinikum Rechts Isar, Med Klin 1, D-8000 Munich, Germany. Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA USA. UCSD Inst Mol Med, La Jolla, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2006 VL 43 IS 6 BP 533 EP 534 PG 2 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 102WZ UT WOS:000241845400007 ER PT J AU Bruehl, MLV Antl, M Konrad, I Eigelsperger, C Werner, M Wilm, M Hofmann, F Schlossmann, J Massberg, S AF Bruehl, M. L. v. Antl, M. Konrad, I. Eigelsperger, C. Werner, M. Wilm, M. Hofmann, F. Schlossmann, J. Massberg, S. TI IRAG-phosphorylation conveys NO/cGMP-dependent inhibition of platelet/vessel wall interaction in vivo SO JOURNAL OF VASCULAR RESEARCH LA English DT Meeting Abstract CT Annual Meeting of the German-Society-for-Microcirculation-and-Vascular-Biology CY OCT 12-14, 2006 CL Minich, GERMANY SP German Soc Microcirculat & Vasc Biol C1 Tech Univ Munich, Med Klin 1, MRI & DHM, D-8000 Munich, Germany. Tech Univ Munich, Inst Pharmacol & Toxicol, D-8000 Munich, Germany. EMBL, Prot & Peptide Grp, Heidelberg, Germany. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, CBR Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2006 VL 43 IS 6 BP 573 EP 574 PG 2 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 102WZ UT WOS:000241845400119 ER PT J AU Schurzinger, K Lorenz, M Stark, K Kerstan, S Orschiedt, L Jennen, L Walch, A Massberg, S AF Schuerzinger, K. Lorenz, M. Stark, K. Kerstan, S. Orschiedt, L. Jennen, L. Walch, A. Massberg, S. TI A critical role of platelets in the postnatal closure of the ductus arteriosus botalli SO JOURNAL OF VASCULAR RESEARCH LA English DT Meeting Abstract CT Annual Meeting of the German-Society-for-Microcirculation-and-Vascular-Biology CY OCT 12-14, 2006 CL Minich, GERMANY SP German Soc Microcirculat & Vasc Biol C1 Tech Univ Munich, Med Klin, MRI DHM, Munich, Germany. GSF, Munich, Germany. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, CBR Inst, Boston, MA 02115 USA. RI Walch, Axel/B-4554-2012 OI Walch, Axel/0000-0001-5578-4023 NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2006 VL 43 IS 6 BP 577 EP 577 PG 1 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 102WZ UT WOS:000241845400128 ER PT J AU Clouse, WD Brewster, DC AF Clouse, WD Brewster, DC TI Graft-enteric erosion with fungal septic emboli SO JOURNAL OF VASCULAR SURGERY LA English DT Article C1 Wilford Hall USAF Med Ctr, Div Vasc Surg, Lackland AFB, TX 78236 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Vasc Surg, Boston, MA USA. RP Clouse, WD (reprint author), Wilford Hall USAF Med Ctr, Div Vasc Surg, Lackland AFB, TX 78236 USA. EM dcbrewster@partners.org NR 3 TC 0 Z9 0 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2006 VL 43 IS 1 BP 184 EP 184 DI 10.1016/j.jvs.2004.08.043 PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 003CQ UT WOS:000234659600038 PM 16414410 ER PT J AU Peterka, RJ Wall, C Kentala, E AF Peterka, Robert J. Wall, Conrad, III Kentala, Erna TI Determining the effectiveness of a vibrotactile balance prosthesis SO JOURNAL OF VESTIBULAR RESEARCH-EQUILIBRIUM & ORIENTATION LA English DT Article DE vestibular; balance prosthesis; posture; orientation; vibrotactile; human ID HUMAN POSTURAL CONTROL; VESTIBULAR DEFICITS; STIMULATION; PROTOTYPE AB We present a quantitative method for characterizing the effectiveness of a balance prosthesis based on tactile vibrators. The balance prosthesis used an array of 12 tactile vibrators (tactors) placed on the anterior and posterior surfaces of the torso to provide body orientation feedback related to the angular position and velocity of anterior-posterior body sway. Body sway was evoked in subjects with normal sensory function and in vestibular loss subjects by rotating the support surface upon which a test subject stood with eyes closed. Tests were performed both with (tactor trials) and without (control trials) the prosthesis activated. Several amplitudes of support surface stimulation were presented with each stimulus following a pseudorandom motion profile. For each stimulus amplitude, a transfer function analysis characterized the amplitude (gain) and timing (phase) of body sway evoked by the support surface stimulus over a frequency range of 0.017 to 2.2 Hz. A comparison of transfer function results from the control trials of normal subjects with results from tactor trials of vestibular loss subjects provided a quantitative measure of the effectiveness of the balance prosthesis in substituting for missing vestibular information. Although this method was illustrated using a specific balance prosthesis, the method is general and could be applied to balance prostheses that utilize other technology. C1 Oregon Hlth & Sci Univ, Inst Neurol Sci, Beaverton, OR 97006 USA. Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. Univ Helsinki Hosp, Helsinki, Finland. RP Peterka, RJ (reprint author), Oregon Hlth & Sci Univ, Inst Neurol Sci, OHSU W Campus,Bldg 1,505 NW 185th Ave, Beaverton, OR 97006 USA. EM peterkar@ohsu.edu FU NIA NIH HHS [AG017960]; NIDCD NIH HHS [DC6201] NR 16 TC 29 Z9 29 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0957-4271 J9 J VESTIBUL RES-EQUIL JI J. Vestib. Res.-Equilib. Orientat. PY 2006 VL 16 IS 1-2 BP 45 EP 56 PG 12 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 091RO UT WOS:000241046200005 PM 16917168 ER PT J AU Williams, BR Baker, PS Allman, RM Roseman, JM AF Williams, Beverly Rosa Baker, Patricia Sawyer Allman, Richard M. Roseman, Jeffrey M. TI The feminization of bereavement among community-dwelling older adults SO JOURNAL OF WOMEN & AGING LA English DT Article DE bereavement; feminization; older adults ID WOMENS HEALTH; DEPRESSIVE SYMPTOMS; PARENTAL BEREAVEMENT; GENDER-DIFFERENCES; PHYSICAL-ACTIVITY; SOCIAL NETWORKS; LIFE SPOUSAL; WIDOWHOOD; SUPPORT; MEN AB We examined gender differences in frequency and sociodemographic predictors of spousal, non-spousal family, and friendship bereavement events among community-dwelling older adults using data from the UAB Study of Aging. Analysis involved a 30-month observation period of 893 subjects. There were significant differences between women and men for all types of loss. Significant differences were also found in the sociodemographic predictors of loss between and within gender categories. This study revealed the extent to which older women disproportionately bear the burden of loss and points to the need for greater attention to bereavement as a women's issue. C1 Birningham VA Med Ctr, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL 35233 USA. Univ Alabama, Ctr Aging, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. Univ Alabama, Dept Med, Div Gerontol & Geriatr Med, Birmingham, AL 35294 USA. Univ Alabama, Dept Epidemiol, Birmingham, AL 35294 USA. RP Williams, BR (reprint author), Birningham VA Med Ctr, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, GRECC 11G,700 19th St S, Birmingham, AL 35233 USA. EM bwilliams@aging.uab.edu; pbaker@uab.edu; rallman@uab.edu; bush@uab.edu FU NIA NIH HHS [R01 AG015062, R01 AG15062] NR 50 TC 11 Z9 11 U1 3 U2 5 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 0895-2841 J9 J WOMEN AGING JI J. Women Aging PY 2006 VL 18 IS 3 BP 3 EP 18 DI 10.1300/J074v18n03_02 PG 16 WC Gerontology; Women's Studies SC Geriatrics & Gerontology; Women's Studies GA 106PS UT WOS:000242113800002 PM 17000616 ER PT J AU Steiner, M Pearlstein, T Cohen, LS Endicott, J Kornstein, SG Roberts, C Roberts, DL Yonkers, K AF Steiner, M Pearlstein, T Cohen, LS Endicott, J Kornstein, SG Roberts, C Roberts, DL Yonkers, K TI Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs SO JOURNAL OF WOMENS HEALTH LA English DT Article ID PREMENSTRUAL DYSPHORIC DISORDER; SEROTONIN-REUPTAKE INHIBITORS; PAROXETINE CONTROLLED-RELEASE; RANDOMIZED-CONTROLLED-TRIAL; PHASE SERTRALINE TREATMENT; LUTEAL-PHASE; DOUBLE-BLIND; SEEKING BEHAVIOR; CLINICAL-TRIAL; PRIMARY-CARE AB The hallmark feature of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) is the predictable, cyclic nature of symptoms or distinct on/offness that begins in the late luteal phase of the menstrual cycle and remits shortly after the onset of menstruation. PMDD is distinguished from PMS by the severity of symptoms, predominance of mood symptoms, and role dysfunction, particularly in personal relationships and marital/family domains. Several treatment modalities are beneficial in PMDD and severe PMS, but the selective serotonin reuptake inhibitors (SSRIs) have emerged as first-line therapy. The SSRIs can be administered continuously throughout the entire month, intermittently from ovulation to the onset of menstruation, or semi-intermittently with dosage increases during the late luteal phase. These guidelines present practical treatment algorithms for the use of SSRIs in women with pure PMDD or severe PMS, PMDD and underlying subsyndromal clinical features of mood or anxiety, or premenstrual exacerbation of a mood/anxiety disorder. C1 McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 4A6, Canada. McMaster Univ, Dept Obstet & Gynecol, Hamilton, ON L8N 4A6, Canada. St Josephs Hosp, Womens Hlth Concerns Clin, Hamilton, ON, Canada. Women & Infants Hosp Rhode Isl, Brown Med Sch, Dept Psychiat & Human Behavior, Providence, RI USA. Massachusetts Gen Hosp, Clin Res Program, Boston, MA USA. Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. New York State Psychiat Inst & Hosp, Dept Res Assesment & Training, New York, NY USA. Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA. Virginia Commonwealth Univ, Dept Obstet & Gynecol, Richmond, VA USA. Emory Univ, Sch Med, Dept Internal Med, Atlanta, GA USA. Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA USA. Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Steiner, M (reprint author), McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 4A6, Canada. EM mst@mcmaster.ca RI Steiner, Meir /B-2121-2016 NR 70 TC 49 Z9 52 U1 3 U2 8 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD JAN PY 2006 VL 15 IS 1 BP 57 EP 69 DI 10.1089/jwh.2006.15.57 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 007RY UT WOS:000234988500010 PM 16417420 ER PT J AU Andress, DL AF Andress, DL TI Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation SO KIDNEY INTERNATIONAL LA English DT Review DE vitamin D; vitamin D receptor activation; chronic kidney disease; cardiovascular disease ID CHRONIC-RENAL-FAILURE; SMOOTH-MUSCLE-CELLS; CD4(+) T-CELLS; CORONARY-ARTERY CALCIFICATION; CHRONIC-HEMODIALYSIS PATIENTS; BONE MORPHOGENETIC PROTEIN-2; HORMONE-RELATED PEPTIDE; VASCULAR CALCIFICATION; PARATHYROID-HORMONE; SECONDARY HYPERPARATHYROIDISM AB Hyperparathyroidism occurs in most patients during the progression of chronic kidney disease (CKD) and one of its initiating events, reduced serum levels of 1,25-dihydroxyvitamin D, results from a decrease in renal 1 alpha hydroxylase activity, which converts 25-hydroxyvitamin D to its activated form. The combination of persistently high parathyroid hormone (PTH) and low 1,25-dihydroxyvitamin D is associated with bone loss, cardiovascular disease, immune suppression and increased mortality in patients with end-stage kidney failure. Recent studies in dialysis patients suggest that paricalcitol, a selective activator of the vitamin D receptor (VDR), is associated with a more favorable efficacy to side effect profile than calcitriol, with less morbidity and better survival. One hypothesis derived from such studies suggests that systemic activation of VDRs may have direct effects on the cardiovascular system to decrease mortality in CKD. Although current guidelines for regulating serum calcium, phosphate and PTH recommend specific interventions at the various stages of CKD to prevent or postpone irreversible parathyroid disease and decrease cardiovascular morbidity and mortality, emerging data suggest that vitamin D therapy may prolong survival in this patient population by mechanisms that are independent of calcium, phosphate and PTH. It is suggested that a re-evaluation of current treatment recommendations is needed and that future research should focus on mechanisms that distinguish potential tissue specific benefits of selective VDR activators in patients with CKD. C1 Univ Washington, VA Puget Sound Hlth Care Syst, Div Nephrol, Dept Med, Seattle, WA 98108 USA. RP Andress, DL (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Div Nephrol, Dept Med, Mailstop 111A,1660 S Columbian Way, Seattle, WA 98108 USA. EM dandress@u.washington.edu NR 117 TC 198 Z9 211 U1 1 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2006 VL 69 IS 1 BP 33 EP 43 DI 10.1038/sj.ki.5000045 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 999JX UT WOS:000234386700016 PM 16374421 ER PT J AU Chow, FY Nikolic-Paterson, DJ Ozols, E Atkins, RC Rollin, BJ Tesch, GH AF Chow, FY Nikolic-Paterson, DJ Ozols, E Atkins, RC Rollin, BJ Tesch, GH TI Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice SO KIDNEY INTERNATIONAL LA English DT Article DE diabetic nephropathy; streptozotocin; macrophage; renal injury; monocyte chemoattractant protein-1; inducible nitric oxide synthase ID MACROPHAGES; NEPHROPATHY; GLOMERULOSCLEROSIS; ACTIVATION; DISEASE; RATS AB Diabetic nephropathy involves a renal inflammatory response induced by the diabetic milieu. Macrophages accumulate in diabetic kidneys in association with the local upregulation of monocyte chemoattractant protein-1 ( MCP-1); however, the contribution of macrophages to renal injury and the importance of MCP-1 to their accrual are unclear. Therefore, we examined the progression of streptozotocin (STZ)-induced diabetic nephropathy in mice deficient in MCP-1 in order to explore the role of MCP-1-mediated macrophage accumulation in the development of diabetic kidney damage. Renal pathology was examined at 2, 8, 12 and 18 weeks after STZ treatment in MCP-1 intact (+/+) and deficient (-/-) mice with equivalent blood glucose and hemoglobin A1c levels. In MCP-1(+/+) mice, the development of diabetic nephropathy was associated with increased kidney MCP-1 production, which occurred mostly in tubules, consistent with our in vitro finding that elements of the diabetic milieu ( high glucose and advanced glycation end products) directly stimulate tubular MCP-1 secretion. Diabetes of 18 weeks resulted in albuminuria and elevated plasma creatinine in MCP-1(+/+) mice, but these aspects of renal injury were largely suppressed in MCP-1(-/-) mice. Protection from nephropathy in diabetic MCP-1(-/-) mice was associated with marked reductions in glomerular and interstitial macrophage accumulation, histological damage and renal fibrosis. Diabetic MCP- 1(+/+) mice also had a smaller proportion of kidney macrophages expressing markers of activation (inducible nitric oxide synthase or sialoadhesin) compared to diabetic MCP- 1( +/+) mice. In conclusion, our study demonstrates that MCP-1-mediated macrophage accumulation and activation plays a critical role in the development of STZ-induced mouse diabetic nephropathy. C1 Monash Med Ctr, Dept Nephrol, Clayton, Vic 3168, Australia. Monash Univ, Monash Med Ctr, Dept Med, Clayton, Vic 3168, Australia. Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA. RP Tesch, GH (reprint author), Monash Med Ctr, Dept Nephrol, 246 Clayton Rd, Clayton, Vic 3168, Australia. EM gtesch@hotmail.com RI Tesch, Greg/I-1444-2013 OI Tesch, Greg/0000-0002-6137-3092 NR 14 TC 244 Z9 270 U1 1 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2006 VL 69 IS 1 BP 73 EP 80 DI 10.1038/sj.ki.5000014 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 999JX UT WOS:000234386700021 PM 16374426 ER PT J AU Krolewski, AS Poznik, GD Placha, G Canani, L Dunn, J Walker, W Smiles, A Krolewski, B Fogarty, DG Moczulski, D Araki, S Makita, Y Ng, DPK Rogus, J Duggirala, R Rich, SS Warram, JH AF Krolewski, AS Poznik, GD Placha, G Canani, L Dunn, J Walker, W Smiles, A Krolewski, B Fogarty, DG Moczulski, D Araki, S Makita, Y Ng, DPK Rogus, J Duggirala, R Rich, SS Warram, JH TI A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes SO KIDNEY INTERNATIONAL LA English DT Article DE genetics of diabetic nephropathy; QTL for urinary albumin excretion; variance components linkage analysis; QTLs on chromosomes 5q; 7q and 22q ID RENAL-DISEASE; NEPHROPATHY; POLYMORPHISM; SUSCEPTIBILITY; FAMILIES; RISK; MICROALBUMINURIA; PROGRESSION; COMPLICATIONS; DETERMINANTS AB The main hallmark of diabetic nephropathy is elevation in urinary albumin excretion. We performed a genome-wide linkage scan in 63 extended families with multiple members with type II diabetes. Urinary albumin excretion, measured as the albumin-to-creatinine ratio (ACR), was determined in 426 diabetic and 431 nondiabetic relatives who were genotyped for 383 markers. The data were analyzed using variance components linkage analysis. Heritability (h(2)) of ACR was significant in diabetic (h(2) = 0.23, P = 0.0007), and nondiabetic (h(2) = 0.39, P = 0.0001) relatives. There was no significant difference in genetic variance of ACR between diabetic and nondiabetic relatives (P = 0.16), and the genetic correlation (r(G) = 0.64) for ACR between these two groups was not different from 1 (P = 0.12). These results suggested that similar genes contribute to variation in ACR in diabetic and nondiabetic relatives. This hypothesis was supported further by the linkage results. Support for linkage to ACR was suggestive in diabetic relatives and became significant in all relatives for chromosome 22q (logarithm of odds, LOD = 3.7) and chromosome 7q (LOD = 3.1). When analyses were restricted to 59 Caucasian families, support for linkage in all relatives increased and became significant for 5q (LOD = 3.4). In conclusion, genes on chromosomes 22q, 5q and 7q may contribute to variation in urinary albumin excretion in diabetic and nondiabetic individuals. C1 Harvard Univ, Sch Med, Joslin Diabet Ctr, Res Div,Sect Genet & Epidemiol, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. SW Fdn Biomed Res, San Antonio, TX 78284 USA. Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA. RP Krolewski, AS (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Res Div,Sect Genet & Epidemiol, 1 Joslin Pl, Boston, MA 02215 USA. EM andrzej.krolewski@joslin.harvard.edu RI Fogarty, Damian/A-8925-2011; Canani, Luis/G-9686-2012 OI Canani, Luis/0000-0002-1813-4491 FU NIDDK NIH HHS [DK47475, DK58549, DK67638] NR 41 TC 73 Z9 77 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2006 VL 69 IS 1 BP 129 EP 136 DI 10.1038/sj.ki.5000023 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 999JX UT WOS:000234386700028 PM 16374433 ER PT J AU Park, SE DeFrate, LE Suggs, JF Gill, TJ Rubash, HE Li, G AF Park, SE DeFrate, LE Suggs, JF Gill, TJ Rubash, HE Li, G TI The change in length of the medial and lateral collateral ligaments during in vivo knee flexion (vol 12, pg 377, 2005) SO KNEE LA English DT Correction ID POSTERIOR CRUCIATE LIGAMENT; ANTERIOR CRUCIATE; SUPPORTING STRUCTURES; TENSION PATTERN; FLEXED KNEE; STRAIN; INJURY; INSTABILITY; STABILITY; VALGUS AB The collateral ligaments of the knee are important in maintaining knee stability. However, little data has been reported on the in vivo function of the collateral ligaments. The objective of this study was to investigate the change in length of different fiber bundles of the medial collateral ligament (MCL), deep fibers of the MCL (DMCL) and the lateral collateral ligament (LCL) during in vivo knee flexion. The knees of five healthy subjects were scanned using magnetic resonance imaging. These images were used to create three-dimensional models of the tibia and femur, including the insertions of the collateral ligaments. The MCL, DMCL, and LCL were each divided into three equal portions: an anterior bundle, a middle bundle and a posterior bundle. Next, the subjects were imaged from two orthogonal directions using fluoroscopy while performing a quasi-static lunge from 0 degrees to 90 degrees of flexion. The models and fluoroscopic images were then used to reproduce the in vivo motion of the knee. From these models, the length of each bundle of each ligament was measured as a function of flexion. The length of the anterior bundle of the MCL did not change significantly with flexion. The length of the posterior bundle of the MCL consistently decreased with flexion (p < 0.05). The change in length of the DMCL with flexion was similar to the trend observed for the MCL. The length of the anterior bundle of the LCL increased with flexion and the length of the posterior bundle decreased with flexion. These data indicate that the collateral ligaments do not elongate uniformly as the knee is flexed, with different bundles becoming taut and slack. These data may help to provide a better understanding of the in vivo function of the collateral ligaments and be used to improve surgical reconstructions of the collateral ligaments. Furthermore, the data suggest that the different roles of various portions of the collateral ligaments along the flexion path should be considered before releasing the collateral ligaments during knee arthroplasty. (c) 2005 Elsevier B.V. All rights reserved. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Bioengn Lab, Boston, MA 02114 USA. MIT, Dept Mech Engn, Boston, MA 02114 USA. RP Li, G (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Bioengn Lab, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA. EM gli1@partners.org NR 35 TC 4 Z9 4 U1 2 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0968-0160 J9 KNEE JI Knee PD JAN PY 2006 VL 13 IS 1 BP 76 EP 82 DI 10.1016/j.knee.2005.09.005 PG 7 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 005UZ UT WOS:000234850800019 ER PT J AU Thornburg, KL Bagby, SP Giraud, GD AF Thornburg, Kent L. Bagby, Susan P. Giraud, George D. BE Neill, JD TI Maternal Adaptation to Pregnancy SO KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON LA English DT Article; Book Chapter ID GLOMERULAR-FILTRATION-RATE; INTERSTITIAL HYDROSTATIC-PRESSURE; BASAL METABOLIC-RATE; ANGIOTENSIN-ALDOSTERONE SYSTEM; INSTRUMENTED CONSCIOUS RATS; ATRIAL-NATRIURETIC-PEPTIDE; PLASMA-VOLUME EXPANSION; ADULT-BLOOD PRESSURE; GRAVID ANIMAL-MODELS; RENAL HEMODYNAMICS C1 [Thornburg, Kent L.; Giraud, George D.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Heart Res Ctr, Portland, OR 97201 USA. [Thornburg, Kent L.; Bagby, Susan P.; Giraud, George D.] Oregon Hlth & Sci Univ, Dept Med, Heart Res Ctr, Portland, OR 97201 USA. [Giraud, George D.] Portland VA Med Ctr, Portland, OR USA. RP Thornburg, KL (reprint author), Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Heart Res Ctr, Portland, OR 97201 USA. OI Thornburg, Kent/0000-0002-5561-4785 NR 220 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-053527-2 PY 2006 BP 2899 EP 2923 PG 25 WC Reproductive Biology SC Reproductive Biology GA BCW96 UT WOS:000311804003004 ER PT J AU Sethu, P Sin, A Toner, M AF Sethu, P Sin, A Toner, M TI Microfluidic diffusive filter for apheresis (leukapheresis) SO LAB ON A CHIP LA English DT Article ID MICROFABRICATED ELECTRODES; BLOOD; SEPARATION AB Apheresis is a procedure used to fractionate whole blood into its individual components. Following fractionation, the desired component is isolated and the remaining blood in many cases is returned to the donor. Leukapheresis is one type of apheresis where leukocytes (white blood cells) are selectively removed. This procedure is commonly used for blood transfusions to remove donor leukocytes from being transferred to the recipient. Apheresis also has several therapeutic applications. In this manuscript we discuss the design, fabrication and testing of a continuous flow diffusive filter, fabricated using simple soft lithographic techniques for depletion of leukocytes. This device employs micro sieves that exploit the size and shape difference between the different cell types to obtain depletion of leukocytes from whole blood. Currently, conventional apheresis methods like centrifugation or fiber mesh filtration are commonly used. A theoretical model was developed to determine the optimal shape of the diffuser to ensure that the volumetric flow through individual sieve elements is equal. This device was designed to serve as a passive device that does not require any external manipulation. Results show that for the given device design, isolation of similar to 50% of the inlet erythrocytes ( red blood cells), along with depletion of >97% of the inlet leukocytes is possible at a flow rate of 5 mu l min(-1). Simple modifications to the geometry and dimensions of the sieves can be made to obtain isolation of plasma. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Surg Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA. Shriners Hosp Children, Boston, MA 02114 USA. RP Sethu, P (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Surg Serv, Boston, MA 02114 USA. EM spalania@sbi.org; asin@partners.org; mtoner@sbi.org FU NIBIB NIH HHS [P41 EB002503] NR 12 TC 94 Z9 97 U1 5 U2 43 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2006 VL 6 IS 1 BP 83 EP 89 DI 10.1039/b512049g PG 7 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 014UR UT WOS:000235506300010 PM 16372073 ER PT J AU Hull, MJ Nazarian, RM Wheeler, AE Black-Schaffer, WS Mark, EJ AF Hull, MJ Nazarian, RM Wheeler, AE Black-Schaffer, WS Mark, EJ TI Survey of 160 internal medicine and pathology resident physicians on the importance and acquisition of autopsies SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 9 BP 6A EP 6A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600010 ER PT J AU Deshpande, V Nielsen, GP Mankin, HJ Rosenberg, AE AF Deshpande, V Nielsen, GP Mankin, HJ Rosenberg, AE TI Intraosseous benign notochord cell tumors (BNCT): Further evidence supporting a relationship to chordoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 31 BP 10A EP 10A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600032 ER PT J AU Chan, MM Lu, X Iglehart, JD Miron, PL AF Chan, MM Lu, X Iglehart, JD Miron, PL TI Gene expression profiling of NMU-induced rat mammary tumors: A model of human breast cancer progression SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 95 BP 23A EP 23A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600096 ER PT J AU Bongiovanni, M Bloom, L Krane, JF Powers, CN Hintermann, S Pache, JC Faquin, WC AF Bongiovanni, M Bloom, L Krane, JF Powers, CN Hintermann, S Pache, JC Faquin, WC TI Cytomorphologic features of poorly differentiated thyroid carcinoma: A statistical analysis of 35 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Hop Cantonal Univ Geneva, Geneva, Switzerland. Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Virginia Commonwealth Univ, Richmond, VA 23284 USA. CYPA Lab, Lausanne, Switzerland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 234 BP 53A EP 54A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600234 ER PT J AU Brachtel, EF Iafrate, AJ Mark, EJ Deshpande, V AF Brachtel, EF Iafrate, AJ Mark, EJ Deshpande, V TI Epidermal growth factor receptor (EGFR) mutations in lung carcinomas are associated with distinct cytomorphological features SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 235 BP 54A EP 54A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600235 ER PT J AU Chandan, VS Faquin, WC Wilbur, D Khurana, KK AF Chandan, VS Faquin, WC Wilbur, D Khurana, KK TI Immunolocalization of CD57 and GLUT-1 in cell blocks: Role in fine needle aspiration diagnosis of papillary thyroid carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 SUNY Upstate Med Univ, Syracuse, NY USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 237 BP 54A EP 54A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600237 ER PT J AU Eichhorn, JH Buckner, L Buckner, SB Beech, DP Crothers, BA Wilbur, DC AF Eichhorn, JH Buckner, L Buckner, SB Beech, DP Crothers, BA Wilbur, DC TI Internet-based gynecologic telecytology with remote automated image selection: Results of a first-phase development trial SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Walter Reed Army Med Ctr, Washington, DC 20307 USA. Natl Naval Med Res Inst, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 245 BP 56A EP 56A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600245 ER PT J AU Ko V Nanji, SS Tambouret, RH Wilbur, DC AF Ko, V Nanji, SS Tambouret, RH Wilbur, DC TI Testing for HPV as an objective measure for quality assurance in gynecologic cytology: Positive rates in equivocal and abnormal specimens SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 272 BP 62A EP 62A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600272 ER PT J AU Ko V Tambouret, RH Kuebler, D Black-Schaffer, WS Wilbur, DC AF Ko, V Tambouret, RH Kuebler, D Black-Schaffer, WS Wilbur, DC TI Validation of HPV testing using hybrid capture II with the Surepath collection method SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 271 BP 62A EP 62A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600271 ER PT J AU Michaels, PJ Rollins, SE Bounds, BC Brugge, WR Pitman, MB AF Michaels, PJ Rollins, SE Bounds, BC Brugge, WR Pitman, MB TI Cyst fluid analysis and endoscopic features aid in the preoperative grading of intraductal papillary mucinous neoplasms of the pancreas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 293 BP 66A EP 67A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600293 ER PT J AU Nagle, JA Eichhorn, JH Crothers, BA Wilbur, DC AF Nagle, JA Eichhorn, JH Crothers, BA Wilbur, DC TI Determination of specimen adequacy and the presence of transformation zone component using an automated Internet-based telecytology system for cervical cytology SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Walter Reed Army Med Ctr, Washington, DC 20307 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 295 BP 67A EP 67A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600295 ER PT J AU Nanji, SS Eichhorn, JJ Crothers, BA Wilbur, DC AF Nanji, SS Eichhorn, JJ Crothers, BA Wilbur, DC TI Determining the effective cervical cytology triage point using an automated Internet-based telecytology system with hierarchical image review SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Walter Reed Army Med Ctr, Washington, DC 20307 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 296 BP 67A EP 67A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600296 ER PT J AU Shah, SS Chandan, VS Wilbur, DC Khurana, KK AF Shah, SS Chandan, VS Wilbur, DC Khurana, KK TI GFAP and CD57 immunolocalization in cell block preparations is a useful adjunct in the diagnosis of pleomorphic adenoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 SUNY Upstate Med Univ, Syracuse, NY USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 317 BP 72A EP 72A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600317 ER PT J AU Chaudhry, IH Zembowicz, A AF Chaudhry, IH Zembowicz, A TI Adnexal clear cell carcinoma with comedonecrosis: Clinicopathological analysis of 12 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Leeds Gen Infirm, Leeds, W Yorkshire, England. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 343 BP 77A EP 77A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600343 ER PT J AU Doeden, KS Mihm, MC Detmar, M Dadras, SS AF Doeden, KS Mihm, MC Detmar, M Dadras, SS TI LYVE-1 and D2-40, two lymphatic specific markers, increase detection of lymphatic invasion in cutaneous melanoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Stanford Univ, Med Ctr, Stanford, CA 94305 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Swiss Fed Inst Technol, Zurich, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 BP 80A EP 80A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600355 ER PT J AU Dahia, PL Powers, JF Alvarado-Cabrero, I Ehsani, SA Albores-Saavedra, J Tischler, AS AF Dahia, PL Powers, JF Alvarado-Cabrero, I Ehsani, SA Albores-Saavedra, J Tischler, AS TI Expression of Notch3 protein in "high altitude paragangliomas" SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Tufts New England Med Ctr, Boston, MA USA. IMSS, Oncol Hosp, Mexico City, DF, Mexico. LSU, Ctr Hlth Sci, Shreveport, LA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 413 BP 91A EP 92A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600413 ER PT J AU Belsley, NA Mino-Kenudson, M Ban, S Park, DY Ochiai, A Kato, Y Muzikansky, A Deshpande, V Shimizu, M Vieth, M Lauwers, GY AF Belsley, NA Mino-Kenudson, M Ban, S Park, DY Ochiai, A Kato, Y Muzikansky, A Deshpande, V Shimizu, M Vieth, M Lauwers, GY TI Endoscopic mucosal resection does not improve lingering differences in the evaluation of gastric neoplasia between eastern and western pathologists SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Saitama Med Sch, Moroyama, Saitama 35004, Japan. Natl Canc Hosp E, Chiba, Japan. Canc Inst Hosp, Tokyo, Japan. Klinikum Bayreuth, Bayreuth, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 464 BP 102A EP 102A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600464 ER PT J AU Bronner, MP Walker, E Burgart, L Goldblum, JR Greenson, JK Haber, M Hart, J Lauwers, G Lazenby, A Lewin, D Robert, M Washington, K Montgomery, E AF Bronner, MP Walker, E Burgart, L Goldblum, JR Greenson, JK Haber, M Hart, J Lauwers, G Lazenby, A Lewin, D Robert, M Washington, K Montgomery, E TI Diagnostic accuracy in ulcerative colitis neoplasia SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Cleveland Clin, Cleveland, OH 44106 USA. Mayo Clin, Rochester, MN 55905 USA. Univ Chicago, Chicago, IL 60637 USA. Med Coll Penn & Hahnemann Univ, Philadelphia, PA 19102 USA. Harvard Univ, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. Yale Univ, New Haven, CT 06520 USA. Vanderbilt Univ, Nashville, TN 37240 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 468 BP 103A EP 103A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600468 ER PT J AU Deshpande, V Chicano, SL Selig, MK Mino-Kenudson, M Colvin, RB Lauwers, GY AF Deshpande, V Chicano, SL Selig, MK Mino-Kenudson, M Colvin, RB Lauwers, GY TI Autoimmune pancreatitis: A systemic IgG4 immune complex mediated disease SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 482 BP 106A EP 106A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600482 ER PT J AU Farraye, FA Andrews, CW Shah, SA Becker, JM Bleday, R Ashley, S Hodin, R Eisenberg, M Berger, BM Odze, RD AF Farraye, FA Andrews, CW Shah, SA Becker, JM Bleday, R Ashley, S Hodin, R Eisenberg, M Berger, BM Odze, RD TI Analysis of DNA mutations in stool is a novel method to detect neoplasia in patients with inflammatory bowel disease SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Boston Med Ctr, Boston, MA USA. Brown Univ, Providence, RI 02912 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Lab Corp Amer, Res Triangle Pk, NC USA. Exact Sci, Marlborough, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 486 BP 107A EP 107A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600486 ER PT J AU Farris, AB Srivastava, A Misdraji, J Lauwers, GY Mino-Kenudson, M AF Farris, AB Srivastava, A Misdraji, J Lauwers, GY Mino-Kenudson, M TI Sessile serrated polyp/adenoma: Challenging discrimination from other colonic polyps SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 487 BP 107A EP 108A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600487 ER PT J AU Mino-Kenudosn, M Ban, S Deshpande V Shimizu, M Lauwers, GY AF Mino-Kenudosn, M Ban, S Deshpande, V Shimizu, M Lauwers, GY TI Buried dysplasia and early adenocarcinoma arising in Barrett Esophagus (BE) after photodynamic therapy (PDT): Not uncommon findings SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Saitama Med Sch, Moroyama, Saitama, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 516 BP 114A EP 114A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600516 ER PT J AU Mino-Kenudson, M Ohana, M Ban, S Deshpande V Shimizu, M Lauwers, GY AF Mino-Kenudson, M Ohana, M Ban, S Deshpande, V Shimizu, M Lauwers, GY TI Barrett esophagus associated neoplasms treated by photodynamic therapy: Determination of limiting factors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Saitama Med Sch, Moroyama, Saitama, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 517 BP 114A EP 114A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600517 ER PT J AU Mitsuhashi, T Lauwers, GY Ban, S Mino-Kenudson, M Shimizu, Y Ogawa, F Shimizu, M AF Mitsuhashi, T Lauwers, GY Ban, S Mino-Kenudson, M Shimizu, Y Ogawa, F Shimizu, M TI Post-gastric EMR surveillance biopsies: Evaluation of mucosal changes and recognition of potential mimics of residual adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Tohoku Univ, Grad Sch Med Sci, Sendai, Miyagi 980, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Saitama Med Sch, Moroyama, Saitama, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 518 BP 114A EP 114A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600518 ER PT J AU Ogino, S Brahnandan, M Cantor, M Namgyal, C Kawasaki, T Kirkner, G AF Ogino, S Brahnandan, M Cantor, M Namgyal, C Kawasaki, T Kirkner, G TI Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 523 BP 115A EP 116A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600523 ER PT J AU Ogino, S Cantor, M Kawasaki, T Brahmandam, M Weisenberger, DJ Laird, PW Loda, M Fuchs, CS AF Ogino, S Cantor, M Kawasaki, T Brahmandam, M Weisenberger, DJ Laird, PW Loda, M Fuchs, CS TI Quantitative DNA methylation analysis determines CpG island methylator phenotype (CIMP) as a distinct subtype of colorectal cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ So Calif, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 524 BP 116A EP 116A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600524 ER PT J AU Srivastava, A Misdraji, J Lauwers, GY Graeme-Cook, F Odze, RD AF Srivastava, A Misdraji, J Lauwers, GY Graeme-Cook, F Odze, RD TI Goblet cell tumors of the appendix: An immunohistochemical and outcome analysis of 63 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 546 BP 120A EP 120A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207600545 ER PT J AU Abreu-e-Lima, P Sadow, PM Nakamura, E Kaelin, WG Nose, V AF Abreu-e-Lima, P Sadow, PM Nakamura, E Kaelin, WG Nose, V TI Clusterin expression differentiates wild Type-VHL from VHL-Defective sporadic clear cell renal cell carcinomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Howard Hughes Med Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 576 BP 126A EP 127A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601010 ER PT J AU He, W Dahl, DM McDougal, I Wu, CL AF He, W Dahl, DM McDougal, I Wu, CL TI Laparoscopic versus open radical prostatectomy: Analysis of 1000 cases at Massachusetts General Hospital SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 BP 141A EP 141A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601080 ER PT J AU Perner, SR Hofer, MD Li, H Kuefer, R Gschwend, J Hautmann, R Moeller, P Rubin, MA AF Perner, SR Hofer, MD Li, H Kuefer, R Gschwend, J Hautmann, R Moeller, P Rubin, MA TI Prostate-specific membrane antigen (PSMA) expression as a predictor of prostate cancer progression SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Hosp Ulm, Ulm, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 715 BP 155A EP 155A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601149 ER PT J AU de Leval, L Waltregny, D Dupuis, LM Boniver, J Oliva, E AF de Leval, L Waltregny, D Dupuis, LM Boniver, J Oliva, E TI Uterine tumors resembling ovarian sex-cord tumors: A study of 14 cases showing a diverse phenotypic profile SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 CHU Sart Tilman, Liege, Belgium. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 812 BP 176A EP 176A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601246 ER PT J AU Hauptmann, S Schmidt, H Bilkenroth, U Kobel, M Czernobilsky, B Roth, L McCluggage, G Scully, RE Oliva, E AF Hauptmann, S Schmidt, H Bilkenroth, U Kobel, M Czernobilsky, B Roth, L McCluggage, G Scully, RE Oliva, E TI Small cell carcinoma of the ovary of the hypercalcemic type: A highly aggressive neoplasm without CGH aberrations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Univ Halle Wittenberg, Halle, Saale, Germany. Patho Lab Ltd, Ness Ziona, Israel. Indiana Univ, Med Ctr, Indianapolis, IN 46204 USA. Royal Grp Hosp Trusts, Belfast, Antrim, North Ireland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 836 BP 181A EP 181A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601270 ER PT J AU Hristov, AC Vang, R Young, RH Seidman, JD Ronnett, BM AF Hristov, AC Vang, R Young, RH Seidman, JD Ronnett, BM TI Ovarian metastases of appendiceal tumors with goblet cell carcinoid-like features: Limited expression of neuroendocrine markers and clinicopathologic features of aggressive invasive carcinoma support designation as adenocarcinoma rather than goblet cell carcinoid tumor SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Washington Hosp Ctr, Washington, DC 20010 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 838 BP 181A EP 181A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601272 ER PT J AU Lopez-Varela, E Fuller, AF Orsulic, S Miao, J Parks, KU Oliva, E AF Lopez-Varela, E Fuller, AF Orsulic, S Miao, J Parks, KU Oliva, E TI Hepsin expression in surface epithelial carcinomas of the ovary. An immunohistochemical tissue microarray analysis of 70 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 870 BP 188A EP 188A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601304 ER PT J AU McCluggage, WG Young, RH AF McCluggage, WG Young, RH TI Paraganglioma of the ovary: Three cases of an extremely rare primary ovarian neoplasm, including two exhibiting inhibin positivity SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Royal Grp Hosp Trust, Belfast, Antrim, North Ireland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 875 BP 189A EP 189A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601309 ER PT J AU Oliva, E de Leval, L De Cenninck, C Augenbron V Soslow, RA Herens, C AF Oliva, E de Leval, L De Cenninck, C Augenbron, V Soslow, RA Herens, C TI Interphase FISH detection of JAZF1-JJAZ1 gene fusion in endometrial stromal tumors with smooth muscle differentiation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. CHU Sart Tilman, Liege, Belgium. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 883 BP 191A EP 191A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601317 ER PT J AU Oliva, E Wang, WL Branton, P Logani, S Zannoni, GF Linkov I Asher, M Soslow, RA AF Oliva, E Wang, WL Branton, P Logani, S Zannoni, GF Linkov, I Asher, M Soslow, RA TI Expression of melanocytic ("PEComa") markers in smooth muscle tumors of the uterus: An immunohistochemcial analyisis of 86 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Inova Fairfax Hosp, Falls Church, VA USA. Emory Univ, Atlanta, GA 30322 USA. Univ Cattolica Rome, Rome, Italy. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 884 BP 191A EP 191A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601318 ER PT J AU Silva, EG Young, RH AF Silva, EG Young, RH TI The spectrum of clear cells in endometrioid neoplasms (other than secretory type) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 915 BP 197A EP 197A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601349 ER PT J AU Soslow, RA Ali, A Negron, E Linkov I Asher, M Oliva, E AF Soslow, RA Ali, A Negron, E Linkov, I Asher, M Oliva, E TI Mullerian adenosarcomas: An immunophenotypic analysis of 35 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 918 BP 197A EP 198A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601352 ER PT J AU Staats, PN Clement, PB Young, RH AF Staats, PN Clement, PB Young, RH TI Primary adenocarcinoma (other than clear cell type) of the vagina: A clinicopathologic study of 31 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Vancouver Gen Hosp, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 921 BP 198A EP 198A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601355 ER PT J AU Turbiner, J Sanchez, C Sarrio, D Moreno, G Franceschetti, I Palacios, J Oliva, E AF Turbiner, J Sanchez, C Sarrio, D Moreno, G Franceschetti, I Palacios, J Oliva, E TI Pathogenetic pathways in ovarian endometrioid adenocarcinoma: A molecular study of 29 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. CNIO, Madrid, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 926 BP 199A EP 199A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601360 ER PT J AU Wang, WL Soslow, RA Zannoni, GF Branton, P Nonaka, D Oliva, E AF Wang, WL Soslow, RA Zannoni, GF Branton, P Nonaka, D Oliva, E TI The utility of tumor cell necrosis in the diagnosis of primary leiomyosarcoma of the uterus: An analysis of 77 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Catholic Univ Rome, Rome, Italy. Inova Fairfax Hosp, Falls Church, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 932 BP 201A EP 201A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601366 ER PT J AU Chen, X Cesarman, E Hyjek, E Kaplan, LD Scadden, DT Chadburn, A AF Chen, X Cesarman, E Hyjek, E Kaplan, LD Scadden, DT Chadburn, A TI FOXP1 expression in AIDS-associated diffuse large B-cell lymphoma (DLBCL): Correlation with prognostic parameters in patients from AIDS malignancies consortium trial 010 SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Cornell Univ, Weill Med Coll, New York, NY USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1016 BP 219A EP 219A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601450 ER PT J AU Ferry, JA Fung, C Zukerberg, L Hasserjian, R Harris, NL AF Ferry, JA Fung, C Zukerberg, L Hasserjian, R Harris, NL TI Lymphoma of the ocular adnexa: A study of 353 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1045 BP 225A EP 225A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601479 ER PT J AU Gupta, R Hasserjian, RP Rezuke, WN DiGiuseppe, JA Hunt, JP AF Gupta, R Hasserjian, RP Rezuke, WN DiGiuseppe, JA Hunt, JP TI Percentage hematogones by flow cytometric analysis is lower in patients with myelodysplastic syndrome than in cytopenic patients without myelodysplastic syndrome SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Baystate Med Ctr, Springfield, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Hartford Hosp, Hartford, CT 06115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1062 BP 229A EP 229A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601496 ER PT J AU Gupta, R Johari V Hasserjian, R AF Gupta, R Johari, V Hasserjian, R TI Myelodysplastic syndrome with isolated del(20q): A distinct clinicopathologic entity? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Baystate Med Ctr, Springfield, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1063 BP 229A EP 229A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601497 ER PT J AU Rahemtullah, A Rezk, S Wang, SA Hasserjian, RP AF Rahemtullah, A Rezk, S Wang, SA Hasserjian, RP TI Aberrant expression of CD5 and CD10 in hairy cell leukemia: Correlation with clinical presentation and outcome SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Univ Massachusetts, Mem Med Ctr, Worcester, MA 01605 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1125 BP 242A EP 243A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601559 ER PT J AU Rodig, SJ Abramson, JS Pinkus, GS Shipp, MA Kutok, JL AF Rodig, SJ Abramson, JS Pinkus, GS Shipp, MA Kutok, JL TI Evaluation of CD52 expression in hematopoietic neoplasms by standard immunohistochemistry: Implications for the expanded use of alemtuzumab (CAMPATH-1H) in the treatment of hematologic malignancies SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1132 BP 244A EP 244A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601566 ER PT J AU Rodig, SJ Savage, KJ Harris, NL Shipp, MA Hsi, ED Gascoyne, RD Kutok, JL AF Rodig, SJ Savage, KJ Harris, NL Shipp, MA Hsi, ED Gascoyne, RD Kutok, JL TI Expression of TRAF1 and nuclear C-rel distinguishes primary mediastinal large B cell lymphoma from nodal diffuse large B cell lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1133 BP 244A EP 244A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601567 ER PT J AU Seliem, RM Wang, WL Hasserjian, RP Ferry, JA Harris, NL Zukerberg, LR AF Seliem, RM Wang, WL Hasserjian, RP Ferry, JA Harris, NL Zukerberg, LR TI CD30 positive cells in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): A clinicopathologic evaluation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1140 BP 246A EP 246A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207601574 ER PT J AU Chicano, SL Cornell, LD Selig, MK Collins, AB McCluskey, RT Colvin, RB AF Chicano, SL Cornell, LD Selig, MK Collins, AB McCluskey, RT Colvin, RB TI Distinctive ultrastructural features of chronic allograft glomerulopaithy: New formation of circumferential glomerular basement membrane SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1207 BP 260A EP 261A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207602055 ER PT J AU Cornell, LD Chicano, SL Deshpande, V Collins, AB Selig, MK Lauwers, GY Colvin, RB AF Cornell, LD Chicano, SL Deshpande, V Collins, AB Selig, MK Lauwers, GY Colvin, RB TI IgG4 immune-complex tubulointerstitial nephritis associated with autoimmune pancreatitis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1208 BP 261A EP 261A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207602056 ER PT J AU Rotman, SC Smith, RN Kawai, T Della Pelle, P Cosimi, AB Colvin, RB AF Rotman, SC Smith, RN Kawai, T Della Pelle, P Cosimi, AB Colvin, RB TI Detection of T regulatory cells expressing Foxp3 in renal allografts: Potential pathogenetic and diagnostic implications SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1228 BP 265A EP 265A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207602076 ER PT J AU Chu, GC Bardeesy, N Aguirre, AJ Redston, MS DePinho, RA AF Chu, GC Bardeesy, N Aguirre, AJ Redston, MS DePinho, RA TI p53 and p6(Ink4a) constrain progression of pancreatic adenocarcinoma in the mouse: Correlations between genotype and histologic phenotype SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1258 BP 271A EP 271A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207602106 ER PT J AU Mino-Kenudson, M Ban, S Deshpande, V Sakurai, T Kuroda, M Shimizu, M Lauwers, GY AF Mino-Kenudson, M Ban, S Deshpande, V Sakurai, T Kuroda, M Shimizu, M Lauwers, GY TI Mucinous cystic neoplasm: Unique ovarian stroma but heterogeneous epithelial lining SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Saitama Med Sch, Saitama, Japan. Kyoto Univ Hosp, Kyoto 606, Japan. Fujita Hlth Univ, Sch Med, Aichi, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1286 BP 277A EP 277A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207602134 ER PT J AU Suh, N Liapis, H Misdraji, J Brunt, EM Wang, HL AF Suh, N Liapis, H Misdraji, J Brunt, EM Wang, HL TI Epstein-Barr virus hepatitis: Diagnostic value of immunohistochemistry, in situ hybridization and polymerase chain reaction on liver biopsy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Washington Univ, St Louis, MO USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. St Louis Univ, St Louis, MO 63103 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1301 BP 280A EP 280A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207602149 ER PT J AU Coon, D Roberts, D Kradin, R AF Coon, D Roberts, D Kradin, R TI Differential epithelial expression of sonic hedge hog and foxfl1 in interstial pneumonias SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1425 BP 306A EP 306A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207602273 ER PT J AU Matsubara, O Imazeki, N Okochi, Y Nakatani, Y Mark, EJ AF Matsubara, O Imazeki, N Okochi, Y Nakatani, Y Mark, EJ TI Distribution, density and morphology of Langerhans' cells in the lung: Relationship to lung development, pulmonary fibrosis and smoking SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1458 BP 313A EP 313A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207602306 ER PT J AU Matsubara, O Imazeki, N Nakatani, Y Mark, F AF Matsubara, O Imazeki, N Nakatani, Y Mark, F TI Role of lymphangiogenesis in repair and remodeling of the lung after acute lung injury SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Coll Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1459 BP 313A EP 313A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207602307 ER PT J AU Balis, UJ AF Balis, UJ TI Real-time region-of-interest-based image database query and differential diagnosis generation utilizing third-generation vector quantization techniques in concert with N-Space Voronoi mapping SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1513 BP 324A EP 324A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207602361 ER PT J AU Tholouli, E Divizio, D O'Connell, F Twomey, D Levenson, R Hoyland, JA Liu-Yin, JA Lee, CA Golub, TR Loda, M Byers, RJ AF Tholouli, E Divizio, D O'Connell, F Twomey, D Levenson, R Hoyland, JA Liu-Yin, JA Lee, CA Golub, TR Loda, M Byers, RJ TI In-situ gene expression profiling in clinical samples by quantum dot based multiplex hybridization SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Manchester Royal Infirm, Manchester M13 9WL, Lancs, England. Univ Manchester, Manchester, Lancs, England. Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. MIT, Boston, MA USA. CRI, Woburn, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2006 VL 86 SU 1 MA 1562 BP 335A EP 335A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 996WY UT WOS:000234207602410 ER PT J AU Hofstetter, J Suckow, MA Hickman, DL AF Hofstetter, John Suckow, Mark A. Hickman, Debra L. BE Suckow, MA Weisbroth, SH Franklin, CL TI Morphophysiology SO LABORATORY RAT, 2ND EDITION SE American College of Laboratory Animal Medicine Series LA English DT Article; Book Chapter ID TASTE BUD DISTRIBUTION; MINOR SALIVARY-GLANDS; PRECORNEAL TEAR FILM; BROWN ADIPOSE-TISSUE; AGE-RELATED-CHANGES; ALBINO-RAT; SKELETAL-MUSCLE; POSTNATAL-DEVELOPMENT; INTRAOCULAR-PRESSURE; SURFACE AREA C1 [Hofstetter, John] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Hickman, Debra L.] Portland VA Med Ctr, Portland, OR 97239 USA. [Suckow, Mark A.] Univ Notre Dame, Freiman Life Sci Ctr 400, Notre Dame, IN 46556 USA. RP Hofstetter, J (reprint author), Indiana Univ Sch Med, 1120 South Dr,Fesler Hall 302, Indianapolis, IN 46202 USA. OI Suckow, Mark/0000-0001-7317-697X NR 215 TC 9 Z9 9 U1 1 U2 3 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-045432-0 J9 AM COLL LAB PY 2006 BP 93 EP 125 DI 10.1016/B978-012074903-4/50007-8 PG 33 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA BCT73 UT WOS:000311378400006 ER PT J AU Titone, DA Koh, CK Kjelgaard, MM Bruce, S Speer, SR Wingfield, A AF Titone, Debra A. Koh, Christine K. Kjelgaard, Margaret M. Bruce, Stephanie Speer, Shari R. Wingfield, Arthur TI Age-related impairments in the revision of syntactic misanalyses: Effects of prosody SO LANGUAGE AND SPEECH LA English DT Article DE aging; prosody; syntactic ambiguity resolution ID MOVING-WINDOW TECHNIQUE; TIME-COMPRESSED SPEECH; OLDER-ADULTS; SENTENCE COMPREHENSION; LANGUAGE COMPREHENSION; AMBIGUOUS SENTENCES; WORKING-MEMORY; YOUNG; INTERFERENCE; ALLOCATION AB Two experiments examined whether young and older adults differ in comprehending sentences that contain temporary syntactic closure ambiguities. Experiment I examined age-related differences using the Auditory Moving Window (AMW) task, in which sentences were presented in a segment-by-segment self-paced fashion. Experiment 2 examined age-related differences using a sentence recall task, in which sentences were presented in their entirety. Sentences were constructed to have cooperating prosody (i.e., where prosody is consistent with the syntactic boundaries), baseline prosody (i.e., where prosody is ambiguous in the syntactically ambiguous region), and conflicting prosody (i.e., where cross-splicing relocates the prosodic phrase break at a misleading point in syntactic structure). The results showed that both young and older adults make comparable use of prosodic information to interpret temporary syntactic ambiguities, although younger adults may make use of this information more quickly than older adults. In addition, older adults appeared to be less able than young adults to revise initial syntactic misinterpretations caused by conflicting prosodic information. These results are interpreted with respect to age-related impairments in the allocation of working memory resources and inefficient inhibitory function during spoken language processing. C1 McGill Univ, Dept Psychol, Montreal, PQ H3A 1B1, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Ohio State Univ, Columbus, OH 43210 USA. Brandeis Univ, Waltham, MA 02254 USA. RP Titone, DA (reprint author), McGill Univ, Dept Psychol, 1205 Dr Penfield Ave, Montreal, PQ H3A 1B1, Canada. EM dtitone@psych.mcgill.ca FU NIA NIH HHS [AG04517] NR 54 TC 12 Z9 12 U1 1 U2 6 PU KINGSTON PRESS SERVICES LTD PI MIDDLESEX PA 43, DERWENT RD, WHITTON TWICKENHAM, MIDDLESEX TW2 7HQ, ENGLAND SN 0023-8309 J9 LANG SPEECH JI Lang. Speech PY 2006 VL 49 BP 75 EP 99 PN 1 PG 25 WC Audiology & Speech-Language Pathology; Linguistics; Psychology, Experimental SC Audiology & Speech-Language Pathology; Linguistics; Psychology GA 073MR UT WOS:000239747800005 PM 16922063 ER PT J AU Strasswimmer, J Grande, DJ AF Strasswimmer, J Grande, DJ TI Do pulsed lasers produce an effective photodynamic therapy response? SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE photodynamic therapy; pulsed dye laser; intense pulsed light; dermatology; skin; aminolevulinic acid; flashlamp; skin ID ACTINIC KERATOSES; LIGHT AB Background: Photodynamic therapy (PDT) in dermatology is traditionally performed with topical aminolevulinic acid (ALA) and continuous-wave (CW) illumination with blue or red light. Recently, several authors have reported success with laser and other pulsed-light sources for PDT. While the clinical benefits on sun-exposed skin are apparent, no study has demonstrated that the pulsed light sources are responsible for the observed response. Study Design: A placebo-controlled study of two pulsed light sources previously reported for PDT: the pulsed dye laser (PDL) or broadband flashlamp filtered intense pulsed light (IPL). Sun-hidden skin was prepared with microdermabrasion and acetone scrub followed by ALA under occlusion. Laser or IPL was delivered under conditions previously reported to produce a clinical response. Control areas were exposed to standardized CW blue light or to no light. A second control area was prepared and received light and the ALA vehicle. Results: IPL and PDL demonstrated a faint dose-response effect on PDT activation, but were less potent than a smaller fluence of CW blue light. Ambient light activated ALA-treated skin. Conclusion: Both IPL and PDL are capable of activation of PDT but produce dramatically less PDT reaction than the standard CW blue-light broadband source. Physicians desiring a robust PDT response might select CW sources over pulsed sources. Ambient light may activate a PDT reaction. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. Harvard Univ, Sch Med, Dept Dermatol, Boston, MA USA. Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA. Myst Valley Dermatol, Medford, MA USA. RP Strasswimmer, J (reprint author), 4600 Ingraham Highway, Coral Gables, FL 33133 USA. EM strasswimmer@hotmail.com OI strasswimmer, john/0000-0002-5790-2633 NR 10 TC 27 Z9 28 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD JAN PY 2006 VL 38 IS 1 BP 22 EP 25 DI 10.1002/lsm.20277 PG 4 WC Dermatology; Surgery SC Dermatology; Surgery GA 009YN UT WOS:000235149600003 PM 16392149 ER PT J AU Lee, H Kang, HW Teichman, JMH Oh, J Welch, AJ AF Lee, H Kang, HW Teichman, JMH Oh, J Welch, AJ TI Urinary calculus fragmentation during Ho : YAG and Er : YAG lithotripsy SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE lithotripsy; calculus; kidney stone; Ho : YAG laser; Er : YAG laser; fragmentation; ablation ID GERMANIUM/SILICA OPTICAL-FIBERS; LASER LITHOTRIPSY; ERBIUM-YAG; HOLMIUM LASER; EFFICIENCY VARIES; PULSE DURATION; ABLATION; TISSUE; RADIATION; DELIVERY AB Background and Objectives: We tested Ho:YAG and Er:YAG laser ablation of human urinary calculi to determine if Er:YAG is a more efficient lithotripsy device. Study Design/Materials and Methods: Ablation efficiency of Ho:YAG and Er:YAG lasers was tested at varying energy settings, ranging from the damage threshold to clinical energy setting associated with Ho:YAG laser. Stones of known composition (calcium oxalate monohydrate (COM), cystine, and uric acid (UA)) were irradiated. Crater width, depth, and ablation volumes were determined using an optical coherence tomography (OCT). Results: For all stones and energy settings, the Er:YAG laser produced deeper craters and larger ablation volumes than Ho:YAG laser. The Ho:YAG laser created wider craters during the multiple pulse process and the shape of craters was irregular. Conclusions: The Er:YAG laser is more efficient than the Ho:YAG laser for lithotripsy. The deeper craters produced by the Er:YAG laser is attributed to the high absorption of energy at its wavelength. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. Univ Texas, Dept Biomed Engn, Austin, TX 78712 USA. St Pauls Hosp, Dept Surg, Div Urol, Vancouver, BC V6Z 1Y6, Canada. RP Lee, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, BHX 630,50 Blossom St, Boston, MA 02114 USA. EM hlee14@partners.org NR 42 TC 30 Z9 34 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD JAN PY 2006 VL 38 IS 1 BP 39 EP 51 DI 10.1002/lsm.20258 PG 13 WC Dermatology; Surgery SC Dermatology; Surgery GA 009YN UT WOS:000235149600006 PM 16292771 ER PT J AU Salomatina, E Anderson, RR Yaroslavsky, AN AF Salomatina, E Anderson, RR Yaroslavsky, AN TI Scattering provides contrast for the detection of nonmelanoma skin cancer SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 23 BP 9 EP 9 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900024 ER PT J AU Laubach, HJ Manstein, D AF Laubach, HJ Manstein, D TI Histological evaluation of minimally invasive radiofrequency exposure SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 28 BP 10 EP 10 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900029 ER PT J AU Laubach, HJ Barthe, PG Makin, IRS Slayton, MH Manstein, D AF Laubach, HJ Barthe, PG Makin, IRS Slayton, MH Manstein, D TI Confined thermal damage with Intense Ultrasound (IUS) SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. ULThera LLC, Mesa, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 43 BP 15 EP 15 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900044 ER PT J AU Shawgo, RS Kundakovic, L Farinelli, W Echague, AV Tannous, Z Morello, AP Mathiowitz, E Anderson, RR Flotte, TJ AF Shawgo, RS Kundakovic, L Farinelli, W Echague, AV Tannous, Z Morello, AP Mathiowitz, E Anderson, RR Flotte, TJ TI In vivo evaluation of pigments engineered for removal SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brown Univ, Providence, RI 02912 USA. Freedom 2 LLC, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 54 BP 18 EP 18 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900052 ER PT J AU White, WM Laubauch, HJ Makin, IRS Slayton, MH Barthe, PG Gliklich, R AF White, WM Laubauch, HJ Makin, IRS Slayton, MH Barthe, PG Gliklich, R TI Selective trancutaneous delivery of energy to facial subdermal tissues using the ultrasound therapy system SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. MGH, Wellman Labs Photomed, Boston, MA USA. ULThera LLC, Mesa, AZ USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 113 BP 37 EP 37 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900111 ER PT J AU Gagnon, DA Manstein, D AF Gagnon, DA Manstein, D TI The nurse's changing role in dermatologic laser medicine SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 128 BP 41 EP 41 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900122 ER PT J AU Akst, LM Kohler, JB Burns, JA Broadhurst, MS Anderson, RR Zeitels, SM AF Akst, LM Kohler, JB Burns, JA Broadhurst, MS Anderson, RR Zeitels, SM TI Soft-tissue effects of pulsed-KTP laser on excised calf vocal folds SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Massachusetts Gen Hosp, Ctr Laryngeal Surg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Wellman Labs Photomed, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 152 BP 46 EP 46 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900139 ER PT J AU Broadhurst, MS Kobler, JB Akst, LM Burns, JA Anderson, RR Zeitels, SM AF Broadhurst, MS Kobler, JB Akst, LM Burns, JA Anderson, RR Zeitels, SM TI Effects of 585 nm pulsed-dye-ilaser (PDL) settings on vessel ablation in the avian chorioallantoic membrane (CAM): Implications for vocal-fold mucosal photoangiolysis SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Massachusetts Gen Hosp, Ctr Laryngeal Surg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Wellman Labs Photomed, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 157 BP 47 EP 47 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900144 ER PT J AU Burns, JA Kohler, JB Akst, LM Broadhurst, MS Anderson, RR Zeitels, SM AF Burns, JA Kohler, JB Akst, LM Broadhurst, MS Anderson, RR Zeitels, SM TI Thermal effects of thulium and carbon dioxide lasers on excised calf vocal folds SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Massachusetts Gen Hosp, Ctr Laryngeal Surg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Wellman Labs Photomed, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 158 BP 48 EP 48 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900145 ER PT J AU Laubach, HJ Astner, S Paithankar, DY Lipton, JC Manstein, D AF Laubach, HJ Astner, S Paithankar, DY Lipton, JC Manstein, D TI Evaluation of sebum output after 1,450 nm diode laser (Smoothbeam (R)) treatment SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA USA. Candela Corp, Wayland, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 254 BP 74 EP 74 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900226 ER PT J AU Petri, M Manstein, D AF Petri, M Manstein, D TI Hair distribution pattern with relevance for optical hair removal SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 268 BP 79 EP 79 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900240 ER PT J AU Pandolfino, T Laubach, HJ Gagnon, D Manstein, D AF Pandolfino, T Laubach, HJ Gagnon, D Manstein, D TI CO2 laser induced ablative micropatterns in skin SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 279 BP 82 EP 82 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900251 ER PT J AU Echague, AV Avram, M AF Echague, AV Avram, M TI High frequency ultrasound for cellulite imaging SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Candela Corp, Wayland, MA USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 280 BP 83 EP 83 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900252 ER PT J AU Demidova, TN Herman, IN Hamblin, MR AF Demidova, TN Herman, IN Hamblin, MR TI Low level light stimulates wound healing in mice SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Laser-Medicine-and-Surgery CY APR 05-09, 2006 CL Boston, MA SP Amer Soc Laser Med & Surg C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2006 SU 18 MA 295 BP 88 EP 88 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 027JY UT WOS:000236412900267 ER PT B AU Mietzner, SM Stout, JE Shannon, JL Yu, VL Wareing, DR AF Mietzner, Sue M. Stout, Janet E. Shannon, Jaclynn L. Yu, Victor L. Wareing, David R. BE Cianciotto, NP Kwaik, YA Edelstein, PH Fields, BS Geary, DF Harrison, TG Joseph, CA Ratcliff, RM Stout, JE Swanson, MS TI Evaluation of the dynal biotech Legionella immunomagnetic separation method versus conventional culture for the isolation of Legionella pneumophila serogroup 1 from water samples SO LEGIONELLA: STATE OF THE ART 30 YEARS AFTER ITS RECOGNITION LA English DT Proceedings Paper CT 6th International Conference on Legionella CY OCT 16-20, 2005 CL Chicago, IL ID NOSOCOMIAL LEGIONNAIRES-DISEASE; SYSTEMS C1 VA Pittsburgh Healthcare Syst, Dept Infect Dis, Pittsburgh, PA 15240 USA. RP Mietzner, SM (reprint author), VA Pittsburgh Healthcare Syst, Dept Infect Dis, Pittsburgh, PA 15240 USA. NR 6 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-390-1 PY 2006 BP 449 EP 452 PG 4 WC Infectious Diseases SC Infectious Diseases GA BFS09 UT WOS:000244175400107 ER PT B AU Stout, JE AF Stout, Janet E. BE Cianciotto, NP Kwaik, YA Edelstein, PH Fields, BS Geary, DF Harrison, TG Joseph, CA Ratcliff, RM Stout, JE Swanson, MS TI Controlling Legionella in hospital water systems: Facts versus folklore SO LEGIONELLA: STATE OF THE ART 30 YEARS AFTER ITS RECOGNITION LA English DT Proceedings Paper CT 6th International Conference on Legionella CY OCT 16-20, 2005 CL Chicago, IL ID NOSOCOMIAL LEGIONNAIRES-DISEASE; ENVIRONMENTAL CULTURES; POTABLE WATER; DISINFECTION; PREVENTION; PNEUMOPHILA; CATALONIA; BACTERIA; EFFICACY; SPAIN C1 VA Pittsburgh Healthcare Syst, Dept Infect Dis, Pittsburgh, PA 15240 USA. RP Stout, JE (reprint author), VA Pittsburgh Healthcare Syst, Dept Infect Dis, Pittsburgh, PA 15240 USA. NR 31 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-390-1 PY 2006 BP 469 EP 472 PG 4 WC Infectious Diseases SC Infectious Diseases GA BFS09 UT WOS:000244175400113 ER PT J AU Scott, BL Sandmaier, BM Storer, B Maris, MB Sorror, ML Maloney, DG Chauncey, TR Storb, R Deeg, HJ AF Scott, BL Sandmaier, BM Storer, B Maris, MB Sorror, ML Maloney, DG Chauncey, TR Storb, R Deeg, HJ TI Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis SO LEUKEMIA LA English DT Article DE myelodysplastic syndrome; hemopoietic cell transplantation; nonmyeloablative transplantation; secondary leukemia ID HEMATOPOIETIC-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; GRAFT-VERSUS-LEUKEMIA; HEMATOLOGIC MALIGNANCIES; UNRELATED DONORS; THERAPY; ENGRAFTMENT; DISEASES; OLDER; HCT AB Transplant outcome was analyzed in 150 patients with myelo-dysplastic syndrome (MDS) or acute myelogenous leukemia transformed from MDS (tAML) conditioned with nonmyeloablative or myeloablative regimens. A total of 38 patients received nonmyeloablative regimens of 2Gy total body irradiation alone (n = 2) or with fludarabine (n = 36), 90mg/m(2). A total of 112 patients received a myeloablative regimen of busulfan, 16 mg/kg ( targeted to 800-900 ng/ml), and cyclophosphamide 120 mg/kg. Nonmyeloablative patients were older ( median age 62 vs 52 years, P < 0.001), more frequently had progressed to tAML ( 53 vs 31%, P = 0.06), had higher risk disease by the International Prognostic Scoring System ( 53 vs 30%, P = 0.004), had higher transplant specific comorbidity indices ( 68 vs 42%, P = 0.01) and more frequently had durable complete responses to induction chemotherapy ( 58 vs 14%). Three-year overall survival (27%/48% ( P = 0.56)), progression-free survival (28%/44%, ( P = 0.60)), and nonrelapse mortality (41%/34%, ( P = 0.94)) did not differ significantly between nonmyeloblative/ myeloablative conditioning. Overall (HR = 0.9, P = 0.84) and progression-free survivals (HR = 1, P = 0.93) were similar for patients with chemotherapy-induced remissions irrespective of conditioning intensity. Graft vs leukemia effects may be more important than conditioning intensity in preventing progression in patients in chemotherapy-induced remissions at the time of transplantation. Randomized prospective studies are needed to further address the optimal choice of transplant conditioning intensity in myeloid neoplasms. C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Deeg, HJ (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. EM jdeeg@fhcrc.org FU NCI NIH HHS [CA15704, CA18029, CA78902, P01 CA078902]; NHLBI NIH HHS [HL36444] NR 15 TC 148 Z9 152 U1 2 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD JAN PY 2006 VL 20 IS 1 BP 128 EP 135 DI 10.1038/sj.leu.2404010 PG 8 WC Oncology; Hematology SC Oncology; Hematology GA 993LW UT WOS:000233956600018 PM 16270037 ER PT J AU Medoff, BD Luster, AD AF Medoff, Benjamin D. Luster, Andrew D. BE Detrick, B Hamilton, RG Folds, JD TI Chemokine and Chemokine Receptor Analysis SO MANUAL OF MOLECULAR AND CLINICAL LABORATORY IMMUNOLOGY, 7TH EDITION LA English DT Article; Book Chapter ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; BRONCHIOLITIS OBLITERANS SYNDROME; NEUTROPHIL-ACTIVATING PEPTIDE-78; ALLOGENEIC CELLULAR INTERACTIONS; RHEUMATOID-ARTHRITIS SYNOVIUM; CARDIAC ALLOGRAFT-REJECTION; ADJUVANT-INDUCED ARTHRITIS; NECROSIS-FACTOR-ALPHA; FUNCTION IN-VIVO C1 [Medoff, Benjamin D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA 02114 USA. [Medoff, Benjamin D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Luster, Andrew D.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Charlestown, MA 02129 USA. RP Medoff, BD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA 02114 USA. NR 144 TC 0 Z9 1 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-364-2 PY 2006 BP 371 EP 384 PG 14 WC Immunology SC Immunology GA BOX98 UT WOS:000277993100043 ER PT J AU Collins, AB Colvin, RB Nousari, CH Anhalt, GJ AF Collins, A. Bernard Colvin, Robert B. Nousari, Carlos H. Anhalt, Grant J. BE Detrick, B Hamilton, RG Folds, JD TI Immunofluorescence Methods in the Diagnosis of Renal and Skin Diseases SO MANUAL OF MOLECULAR AND CLINICAL LABORATORY IMMUNOLOGY, 7TH EDITION LA English DT Article; Book Chapter ID LINKED-IMMUNOSORBENT-ASSAY; EPIDERMOLYSIS-BULLOSA-ACQUISITA; ANTI-BP180 AUTOANTIBODIES; PERITUBULAR CAPILLARIES; FLUORESCENT-ANTIBODY; ALLOGRAFT REJECTION; HUMORAL REJECTION; C4D DEPOSITS; PEMPHIGUS; MICROSCOPY C1 [Collins, A. Bernard; Colvin, Robert B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Collins, A. Bernard; Colvin, Robert B.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Anhalt, Grant J.] Johns Hopkins Sch Med, Dept Dermatol, Baltimore, MD 21205 USA. [Nousari, Carlos H.] DermPath Diagnost S Florida, Inst Immunofluorescence, Miami, FL 33069 USA. [Nousari, Carlos H.] Univ Miami, Dept Dermatol, Miami, FL 33069 USA. RP Collins, AB (reprint author), Massachusetts Gen Hosp, Dept Pathol, 32 Fruit St, Boston, MA 02114 USA. NR 62 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-364-2 PY 2006 BP 414 EP + PG 12 WC Immunology SC Immunology GA BOX98 UT WOS:000277993100049 ER PT J AU Collins, AB Colvin, RB AF Collins, A. Bernard Colvin, Robert B. BE Detrick, B Hamilton, RG Folds, JD TI Kidney and Lung Disease Mediated by Anti-Glomerular Basement Membrane Antibodies: Detection by Western Blot Analysis SO MANUAL OF MOLECULAR AND CLINICAL LABORATORY IMMUNOLOGY, 7TH EDITION LA English DT Article; Book Chapter ID RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; ANTI-GBM ANTIBODIES; ALPORT SYNDROME; GOODPASTURES-SYNDROME; IV COLLAGEN; HEREDITARY NEPHRITIS; GENE; AUTOANTIBODIES; CHAIN; ALLOANTIBODIES C1 [Collins, A. Bernard; Colvin, Robert B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Collins, A. Bernard; Colvin, Robert B.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Collins, AB (reprint author), Massachusetts Gen Hosp, Dept Pathol, 32 Fruit St, Boston, MA 02114 USA. NR 42 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-364-2 PY 2006 BP 1110 EP 1115 PG 6 WC Immunology SC Immunology GA BOX98 UT WOS:000277993100126 ER PT S AU Hamblin, MR Demidova, TN AF Hamblin, Michael R. Demidova, Tatiana N. BE Hamblin, MR Waynant, RW Anders, J TI Mechanisms of low level light therapy - art. no. 614001 SO Mechanisms for Low Light Therapy SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Mechanisms for Low-Light Therapy CY JAN 22-24, 2006 CL San Jose, CA SP SPIE DE biostimulation; low level laser therapy; wound healing; biomodulation; cold laser; action spectra ID HELIUM-NEON LASER; CYTOCHROME-C-OXIDASE; CARPAL-TUNNEL-SYNDROME; RAT-LIVER MITOCHONDRIA; CELLS IN-VITRO; PERIPHERAL-NERVE; PROMOTES REGENERATION; FUNCTIONAL RECOVERY; NITRIC-OXIDE; IRRADIATION AB The use of low levels of visible or near infrared light for reducing pain, inflammation and edema, promoting healing of wounds, deeper tissues and nerves, and preventing tissue damage has been known for almost forty years since the invention of lasers. Originally thought to be a peculiar property of laser light (soft or cold lasers), the subject has now broadened to include photobiomodulation and photobiostimulation using non-coherent light. Despite many reports of positive findings from experiments conducted in vitro, in animal models and in randomized controlled clinical trials, LLLT remains controversial. This likely is due to two main reasons; firstly the biochemical mechanisms underlying the positive effects are incompletely understood, and secondly the complexity of rationally choosing amongst a large number of illumination parameters such as wavelength, fluence, power density, pulse structure and treatment timing has led to the publication of a number of negative studies as well as many positive ones. In particular a biphasic dose response has been frequently observed where low levels of light have a much better effect than higher levels. This introductory review will cover some of the proposed cellular chromophores responsible for the effect of visible light on mammalian cells, including cytochrome c oxidase (with absorption peaks in the near infrared) and photoactive porphyrins. Mitochondria are thought to be a likely site for the initial effects of light, leading to increased ATP production, modulation of reactive oxygen species and induction of transcription factors. These effects in turn lead to increased cell proliferation and migration (particularly by fibroblasts), modulation in levels of cytokines, growth factors and inflammatory mediators, and increased tissue oxygenation. The results of these biochemical and cellular changes in animals and patients include such benefits as increased healing in chronic wounds, improvements in sports injuries and carpal tunnel syndrome, pain reduction in arthritis and neuropathies, and amelioration of damage after heart attacks, stroke, nerve injury and retinal toxicity. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02115 USA. RP Hamblin, MR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02115 USA. OI Hamblin, Michael/0000-0001-6431-4605 NR 67 TC 32 Z9 32 U1 2 U2 18 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-6183-0 J9 P SOC PHOTO-OPT INS PY 2006 VL 6140 BP 14001 EP 14001 AR 614001 DI 10.1117/12.646294 PG 12 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BEL12 UT WOS:000237683400001 ER PT S AU Demidova, TN Herman, IM Salomatina, EV Yaroslavsky, AN Hamblin, MR AF Demidova, Tatiana N. Herman, Ira M. Salomatina, Elena V. Yaroslavsky, Anna N. Hamblin, Michael R. BE Hamblin, MR Waynant, RW Anders, J TI Wound healing stimulation in mice by low-level light - art. no. 61400C SO Mechanisms for Low Light Therapy SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Mechanisms for Low-Light Therapy CY JAN 22-24, 2006 CL San Jose, CA SP SPIE DE biostimulation; low level light therapy; excisional wound healing; biomodulation; cold laser ID HELIUM-NEON LASER; MYOFIBROBLASTS; IRRADIATION; FIBROBLASTS; THERAPY; CONTRACTION; DIODE; BLIND AB It has been known for many years that low levels of laser or non-coherent light (LLLT) accelerate some phases of wound healing. LLLT can stimulate fibroblast and keratinocyte proliferation and migration. It is thought to work via light absorption by mitochondrial chromophores leading to an increase in ATP, reactive oxygen species and consequent gene transcription. However, despite many reports about the positive effects of LLLT on wound healing, its use remains controversial. Our laboratory has developed a model of a full thickness excisional wound in mice that allows quantitative and reproducible light dose healing response curves to be generated. We have found a biphasic dose response curve with a maximum positive effect at 2 J/cm(2) of 635-nm light and successively lower beneficial effects from 3-25 J/cm(2), the effect is diminished at doses below 2J/cm(2) and gradually reaches control healing levels. At light doses above 25 J/cm2 healing is actually worse than controls. The two most effective wavelengths of light were found to be 635 and 820-nm. We found no difference between filtered 635 +/- 15-nm light from a lamp and 633-nm light from a HeNe laser. The strain and age of the mouse affected the magnitude of the effect. Light treated wounds start to contract after illumination while control wounds initially expand for the first 24 hours. Our hypothesis is that a single brief light exposure soon after wounding affects fibroblast cells in the margins of the wound. Cells may be induced to proliferate, migrate and assume a myofibroblast phenotype. Our future work will be focused on understanding the mechanisms underlying effects of light on wound healing processes. C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Demidova, TN (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. OI Hamblin, Michael/0000-0001-6431-4605 NR 25 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-6183-0 J9 P SOC PHOTO-OPT INS PY 2006 VL 6140 BP C1400 EP C1400 AR 61400C DI 10.1117/12.646310 PG 9 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BEL12 UT WOS:000237683400010 ER PT J AU Murray, JP Liotti, M Ingmundson, PT Mayberg, HS Pu, YL Zamarripa, F Liu, YJ Woldorff, MG Gao, JH Fox, PT AF Murray, JP Liotti, M Ingmundson, PT Mayberg, HS Pu, YL Zamarripa, F Liu, YJ Woldorff, MG Gao, JH Fox, PT TI Children's brain Activations while viewing televised violence revealed by fMRI SO MEDIA PSYCHOLOGY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; FACIAL EXPRESSIONS; HUMAN AMYGDALA; RIGHT-HEMISPHERE; EMOTION; RETRIEVAL; RECOGNITION; ATTENTION; MEMORY; PET AB Though social and behavioral effects of TV violence have been studied extensively, the brain systems involved in TV violence viewing in children are, at present, not known. In this study, 8 children viewed televised violent and nonviolent video sequences while brain activity was measured with functional magnetic resonance imaging. Both violent and nonviolent viewing activated regions involved in visual motion, visual object and scenes, and auditory listening. However, viewing TV violence selectively recruited a network of right hemisphere regions including precuneus, posterior cingulate, amygdala, inferior parietal, and prefrontal and premotor cortex. Bilateral activations were apparent in hippocampus, parahippo-campus, and pulvinar. TV violence viewing transiently recruits a network of brain regions involved in the regulation of emotion, arousal and attention, episodic memory encoding and retrieval, and motor programming. This pattern of brain activations may explain the behavioral effects observed in many studies, especially the finding that children who are frequent viewers of TV violence are more likely to behave aggressively. Such extensive viewing may result in a large number of aggressive scripts stored in long-term memory in the posterior cingulate, which facilitates rapid recall of aggressive scenes that serve as a guide for overt social behavior. C1 Kansas State Univ, Sch Family Studies & Human Serv, Manhattan, KS 66506 USA. Harvard Univ, Childrens Hosp, Sch Med, Mind Sci Fdn, Boston, MA 02115 USA. Harvard Univ, Childrens Hosp, Sch Med, Ctr Media & Child Hlth, Boston, MA 02115 USA. Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. Emory Univ, Sch Med, Atlanta, GA 30322 USA. Univ Chicago, Sch Med, Chicago, IL 60637 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. Univ Florida, Sch Med, Gainesville, FL 32611 USA. Duke Univ, Durham, NC 27706 USA. RP Murray, JP (reprint author), Kansas State Univ, Sch Family Studies & Human Serv, Manhattan, KS 66506 USA. EM jpm@ksu.edu RI Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 NR 56 TC 25 Z9 25 U1 0 U2 14 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1521-3269 EI 1532-785X J9 MEDIA PSYCHOL JI Media Psychol. PY 2006 VL 8 IS 1 BP 25 EP 37 DI 10.1207/S1532785XMEP0801_3 PG 15 WC Communication; Film, Radio, Television; Psychology, Applied SC Communication; Film, Radio & Television; Psychology GA 012PZ UT WOS:000235352800003 ER PT J AU Zheng, H Yucel, R Ayanian, JZ Zaslavsky, AM AF Zheng, H Yucel, R Ayanian, JZ Zaslavsky, AM TI Profiling providers on use of adjuvant chemotherapy by combining cancer registry and medical record data SO MEDICAL CARE LA English DT Article DE profiling; provider quality; cancer; Bayesian methods; cancer registries ID QUALITY-OF-CARE; COLORECTAL-CANCER; OUTCOMES RESEARCH; LINKAGE; ISSUES AB Purpose: Treatment information collected by cancer registries can be used to monitor the provision of guideline-recommended chemotherapy to colorectal cancer patients. Incomplete information may bias comparisons of these rates. We developed statistical methods that combine data from a registry and physicians' records to assess hospital quality. Data: From California Cancer Registry data, we selected all patients (n = 12,594) newly diagnosed with stage III colon cancer or stage 11 or III rectal cancer from 428 hospitals during the years 1994 to 1998. To assess rates and predictors of underreporting of chemotherapy, we surveyed physicians treating 1449 of these patients from 98 hospitals during the years 1996 to 1997. Methods: Using Bayesian statistical models, we imputed unobserved treatments. We studied the impact of underreporting on provider profiling by comparing rankings, estimates, and credible intervals based only on registry data to those incorporating physician survey data. Results: Analyses that account for incompleteness of reporting yielded wider credible intervals for provider profiles than those that ignored such incompleteness. Among the 109 (25%) hospitals in the highest quartile of chemotherapy rates according to the registry data, 16 were not so classified when incomplete reporting was taken into account. With the more comprehensive model, 12 hospitals could be identified that ranked in the top quartile with probability > 0.90. Conclusion: Estimates of adjusted hospital chemotherapy rates based solely on cancer registry data overstate the precision of assessments of hospital quality. Using additional information from a physician survey and applying rigorous statistical models, better inferences can be drawn about provider quality. C1 Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. Massachusetts Gen Hosp, Div Epidemiol & Outcomes Res, Partners AIDS Res Ctr, Boston, MA 02114 USA. Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Biostat & Epidemiol, Amherst, MA USA. Brigham & Womens Hosp, Dept Med, Div Gen Med, Boston, MA 02115 USA. RP Zaslavsky, AM (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM zaslavsk@hcp.med.harvard.edu FU AHRQ HHS [R01 HS09869]; NCI NIH HHS [U01 CA93344, U01 CA93324] NR 23 TC 13 Z9 14 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2006 VL 44 IS 1 BP 1 EP 7 DI 10.1097/01.mlr.0000188910.88374.11 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 998TN UT WOS:000234342600001 PM 16365606 ER PT J AU Johnson, ML Pietz, K Battleman, DS Beyth, RJ AF Johnson, ML Pietz, K Battleman, DS Beyth, RJ TI Therapeutic goal attainment in patients with hypertension and dyslipidemia SO MEDICAL CARE LA English DT Article ID DENSITY-LIPOPROTEIN-CHOLESTEROL; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIALS; DIABETES-MELLITUS; CLINICAL-PRACTICE; HEART-DISEASE; RISK-FACTORS; GUIDELINES; MANAGEMENT AB Background: Recent guidelines emphasize the need to assess and treat overall risk for cardiovascular disease through the concomitant management of multiple risk factors. We sought to ascertain treatment patterns and attainment of therapeutic goals in patients with isolated and concomitant hypertension and dyslipidemia, both with and without diabetes mellitus (DM) and symptomatic cardiovascular disease. Methods: Inception cohorts of more than 41,000 newly diagnosed hypertension and dyslipidemia patients from 6 medical centers of the south-central Veterans Affairs health care system were evaluated. Treatment patterns and goal attainment for low-density lipoprotein cholesterol (LDL-C; Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults guidelines: < 160, < 130, or <= 100 mg/dL depending on risk factors) and blood pressure (BP; Joint National Committee 6: < 140/90 or < 130/85 mm Hg depending on risk factors) were measured at I year. Separate analyses were conducted in patients with and without DM and symptomatic cardiovascular disease. Results: Treatment rates in patients with and without DM and symptomatic disease ranged from 46.6% to 71.3% in patients with hypertension only, from 31.5% to 64.1% in patients with dyslipidemia only, and from 64.3% to 91.3% in patients with both conditions. Among asymptomatic patients, 40.6% of nondiabetics and 20.6% of patients with DM with isolated hypertension reached BP targets. Attainment of LDL-C goals was slightly higher and reached 52.8% among patients with DM with concomitant hypertension. Among symptomatic patients, attainment of all goals was < 40% for all groups. The proportion of asymptomatic patients with concomitant disease reaching goal for both BP and LDL-C was 24.4% among nondiabetics and 15.4% among patients with DM; these proportions decreased to 13.6% and 13.4% respectively, among patients with symptomatic cardiovascular disease. Conclusions: The majority of patients were receiving pharmacological treatment of hypertension and dyslipidemia, yet attainment of therapeutic goals was generally < 50%. Further work is needed to determine factors related to improvement in management and outcomes of patients with multiple cardiovascular risk factors. C1 VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA USA. Univ Florida, Rehabil Outcomes Res Ctr, NF SG Vet Hlth Syst, Gainesville, FL 32611 USA. Univ Florida, Div Geriatr, Gainesville, FL USA. Pfizer Inc, Pfizer Global Outcomes Res, New York, NY USA. RP Johnson, ML (reprint author), VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mjohnson@bcm.tmc.edu NR 34 TC 32 Z9 33 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2006 VL 44 IS 1 BP 39 EP 46 DI 10.1097/01.mlr.0000188982.25397.37 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 998TN UT WOS:000234342600006 PM 16365611 ER PT J AU Ferris, TG Kuhthau, K Ausiello, J Perrin, J Kahn, R AF Ferris, TG Kuhthau, K Ausiello, J Perrin, J Kahn, R TI Are minority children the last to benefit from a new technology? Technology diffusion and inhaled corticosteriods for asthma SO MEDICAL CARE LA English DT Article DE technology diffusion; quality of care; asthma; children; inhaled steroids; bronchodilators; race/ethnicity; disparities ID HMOS GO BAD; CHILDHOOD ASTHMA; MANAGEMENT-PRACTICES; 2 PARTS; CARE; HOSPITALIZATION; QUALITY; BUDESONIDE; MEDICATION; EMERGENCY AB Background: Racial and ethnic disparities in health and health care have been well documented, but few studies have addressed how disparities may change over time. Objective: We sought to determine the change in relative rates over time of corticosteroid metered dose inhaler (MDI) use in minority and nonminority populations with asthma. Design and Setting: We used a cross-sectional survey for 5 periods of 2 years' each (1989-1990, 1991-1992, 1993-1994, 1995-1996, 1997-1998) using the National Ambulatory Medical Care Surveys (NAMCS). Participants: A total of 3671 visits by adults and children with asthma to U.S. office-based physicians comprised our sample. Main Outcome Measure: We sought to measure differences in inhaled corticosteroid use for minority and nonminority adults and children controlling for gender, specialty, U.S. region, and type of insurance. Results: Minority patients with asthma were less than half as likely as nominority patients to have had a steroid MDI prescribed during 1989-1990. By 1995-1996, minority and nonminority patients with asthma were equally likely to have had a steroid MDI prescribed. Although differences between black and white patients resolved, differences between white and Hispanic patients persisted even after adjusting for insurance. Children initially were less likely than adults with asthma to have steroid MDI prescribed, and this difference persisted. Minority children had the greatest delay in adoption of steroid MDIs. Conclusion: Steroid MDIs diffused into minority and nonminority adult and child populations at different rates. C1 Harvard Univ, Sch Med, Boston, MA 02138 USA. Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Policy, Boston, MA USA. Cincinnati Childrens Med Ctr, Div Gen Pediat, Cincinnati, OH USA. RP Ferris, TG (reprint author), MGH Partners Inst Hlth Policy, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM tferris@partners.org NR 35 TC 33 Z9 33 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2006 VL 44 IS 1 BP 81 EP 86 DI 10.1097/01.mlr.0000188914.47033.cd PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 998TN UT WOS:000234342600011 PM 16365616 ER PT J AU Mendez, MF AF Mendez, MF TI What frontotemporal dementia reveals about the neurobiological basis of morality SO MEDICAL HYPOTHESES LA English DT Article ID ANTISOCIAL PERSONALITY-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; FRONTAL-LOBE DAMAGE; PREFRONTAL CORTEX; ACQUIRED SOCIOPATHY; SOCIAL COGNITION; DECISION-MAKING; CRIMINAL BEHAVIOR; TEMPORAL VARIANT; BRAIN AB There is evidence that moral behavior is a product of evolution and an innate aspect of the human brain. Functional magnetic resonance studies in normals, investigations of psychopaths, and acquired sociopathy from brain lesions suggest a neurobiology of moral behavior. Reports of sociopathy among patients with frontotemporal dementia (FTD) have provided a further opportunity to clarify the neurobiology of morality. They confirm a morality network that includes the ventromedial frontal cortex, the orbitofrontal cortex, and the amygdalae. The right ventromedial region is critical for the emotional tagging of moral situations, the orbitofrontal cortex responds to social cues and mitigates impulsive reactions, and the amygdalae are necessary for threat detection and moral learning. Alterations in moral behavior in FTD may result from a loss of the emotional label of moral dilemmas, coupled with disinhibited responses. More investigations are needed to fully understand how the brain mediates moral or ethical behavior. (c) 2006 Elsevier Ltd. All rights reserved. C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, Dept Neurol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. RP Mendez, MF (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, Dept Neurol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu NR 84 TC 29 Z9 29 U1 5 U2 13 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PY 2006 VL 67 IS 2 BP 411 EP 418 DI 10.1016/j.mehy.2006.01.048 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 057WD UT WOS:000238625000039 PM 16540253 ER PT J AU Deisboeck, TS Guiot, C Delsanto, PP Pugno, N AF Deisboeck, Thomas S. Guiot, Caterina Delsanto, Pier Paolo Pugno, Nicola TI Does cancer growth depend on surface extension? SO MEDICAL HYPOTHESES LA English DT Article ID TUMOR VASCULAR ARCHITECTURE; MODEL; ANGIOGENESIS; INVASION; LAWS AB We argue that volumetric growth dynamics of a solid cancer depend on the tumor system's overall surface extension. While this at first may seem evident, to our knowledge, so far no theoretical argument has been presented explaining this relationship explicitly. In here, we therefore develop a conceptual framework based on the so-called 'universal scaling law' and then support our conjecture through evaluation with experimental data. Our concept suggests not only that cancer tissue invasion operates with relatively few and thin branches of mobile cells but also that this overall tumor surface expansion, and the diffusion of nutrients that it enables, can nourish the tumor prior to the impact of neovascularization. (c) 2006 Elsevier Ltd. All rights reserved. C1 Massachusetts Gen Hosp East, Harvard MIT HST Athinoula A Martinos Ctr Biomed I, Complex Biosyst Modeling Lab, Charlestown, MA 02129 USA. Univ Turin, Dip Neurosci, Turin, Italy. Univ Turin, CNISM, Sez Turin, Turin, Italy. Politecn Torino, Dipartimento Fis, Turin, Italy. Politecn Torino, Dip Ingn Strutturale, Turin, Italy. RP Deisboeck, TS (reprint author), Massachusetts Gen Hosp East, Harvard MIT HST Athinoula A Martinos Ctr Biomed I, Complex Biosyst Modeling Lab, 2301,Bldg 149,13th St, Charlestown, MA 02129 USA. EM deisboec@helix.mgh.harvard.edu RI guiot, caterina/C-6708-2009; Pugno, Nicola/C-2289-2014; OI guiot, caterina/0000-0001-8529-1625 FU NCI NIH HHS [CA 085139, CA 113004] NR 15 TC 9 Z9 9 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PY 2006 VL 67 IS 6 BP 1338 EP 1341 DI 10.1016/j.mehy.2006.05.029 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 112XL UT WOS:000242561200015 PM 16828232 ER PT S AU Estepar, RSJ Stylopoulos, N Ellis, RE Samset, E Westin, CF Thompson, C Vosburgh, K AF Estepar, Raul San Jose Stylopoulos, Nicholas Ellis, Randy E. Samset, Eigil Westin, Carl-Fredrik Thompson, Christopher Vosburgh, Kirby BE Larsen, R Nielsen, M Sporring, J TI Towards scarless surgery: An endoscopic-ultrasound navigation system for transgastric access procedures SO MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2006, PT 1 SE LECTURE NOTES IN COMPUTER SCIENCE LA English DT Article; Proceedings Paper CT 9th International Conference on Computing and Computer-Assisted Intervention CY OCT 01-06, 2006 CL Copenhagen, DENMARK SP AstraZeneca, Ctr Clin & Basic Res, Claron, Elsevier, GE, Medtronic, No Digital Inc, Siemens Corp Res, Springer, Visiopharm AB Scarless surgery is a new and very promising technique that can mark a new era in surgical procedures. We have created and validated a navigation system for endoscopic and transgastric access interventions in in vivo pilot studies. The system provides augmented visual feedback and additional contextual information by establishing a correspondence between the real time endoscopic ultrasound image and a preoperative CT volume using rigid registration. The system enhances the operator's ability to interpret the ultrasound image reducing the mental burden used in probe placement. Our analysis shows that rigid registration is accurate enough to help physicians in endoscopic abdominal surgery where, by using preoperative data for context and real-time imaging for targeting, distortions that limit the use of only preoperative data can be overcome. C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. CIMIT, Boston, MA USA. RP Estepar, RSJ (reprint author), Brigham & Womens Hosp, Boston, MA 02115 USA. EM rjosest@bwh.harvard.edu; nstylopoulos@partners.org; ellis@bwh.harvard.edu; samset@bwh.harvard.edu; westin@bwh.harvard.edu; ccthompson@partners.org; kvosburgh@partners.org NR 10 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 3-540-44707-5 J9 LECT NOTES COMPUT SC PY 2006 VL 4190 BP 445 EP 453 PG 9 WC Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging GA BFF18 UT WOS:000241556300055 ER PT S AU Manzke, R Reddy, VY Dalal, S Hanekamp, A Rasche, V Chan, RC AF Manzke, Robert Reddy, Vivek Y. Dalal, Sandeep Hanekamp, Annemarie Rasche, Volker Chan, Raymond C. BE Larsen, R Nielsen, M Sporring, J TI Intra-operative volume imaging of the left atrium and pulmonary veins with rotational X-ray angiography SO MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2006, PT 1 SE LECTURE NOTES IN COMPUTER SCIENCE LA English DT Article; Proceedings Paper CT 9th International Conference on Computing and Computer-Assisted Intervention CY OCT 01-06, 2006 CL Copenhagen, DENMARK SP AstraZeneca, Ctr Clin & Basic Res, Claron, Elsevier, GE, Medtronic, No Digital Inc, Siemens Corp Res, Springer, Visiopharm ID FIBRILLATION AB Complex electrophysiology (EP) procedures, such as catheter-based ablation in the left atrium and pulmonary veins (LAPV) for treatment of atrial fibrillation, require knowledge of heart chamber anatomy. Electroanatomical mapping (EAM) is typically used to define cardiac structures by combining electromagnetic spatial catheter localization with surface models which interpolate the anatomy between EAM point locations in 3D. Recently, the incorporation of pre-operative volumetric CT or MR data sets has allowed for more detailed maps of LAPV anatomy to be used intra-operatively. Preoperative data sets are however a rough guide since they can be acquired several days to weeks prior to EP intervention. Due to positional and physiological changes, the intra-operative cardiac anatomy can be different from that depicted in the pre-operative data. We present a novel application of contrast-enhanced rotational X-ray imaging for CT-like reconstruction of 3D LAPV anatomy during the intervention itself. We perform two selective contrast-enhanced rotational acquisitions and reconstruct CT-like volumes with 3D filtered back projection. Two volumes depicting the left and right portions of the LAPV are registered and fused. The combined data sets are then visualized and segmented intra-procedurally to provide anatomical data and surface models for intervention guidance. Our results from animal and human experiments indicate that the anatomical information from intra-operative CT-like reconstructions compares favorably with pre-acquired CT data and can be of sufficient quality for intra-operative guidance. C1 Philips Res N Amer, Clin Sites Res, Briarcliff Manor, NY USA. Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Expt Electrophysiol Lab, Boston, MA 02114 USA. Univ Clin Ulm, Ulm, Germany. RP Manzke, R (reprint author), Philips Res N Amer, Clin Sites Res, 345 Scarborough Rd, Briarcliff Manor, NY USA. EM robert.manzke@philips.com OI Rasche, Volker/0000-0001-8844-3583 NR 7 TC 9 Z9 9 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 3-540-44707-5 J9 LECT NOTES COMPUT SC PY 2006 VL 4190 BP 604 EP 611 PG 8 WC Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging GA BFF18 UT WOS:000241556300074 ER PT S AU Niethammer, M Bouix, S Westin, CF Shenton, ME AF Niethammer, Marc Bouix, Sylvain Westin, Carl-Fredrik Shenton, Martha E. BE Larsen, R Nielsen, M Sporring, J TI Fiber bundle estimation and parameterization SO MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2006, PT 2 SE LECTURE NOTES IN COMPUTER SCIENCE LA English DT Article; Proceedings Paper CT 9th International Conference on Computing and Computer-Assisted Intervention CY OCT 01-06, 2006 CL Copenhagen, DENMARK SP AstraZeneca, Ctr Clin & Basic Res, Claron, Elsevier, GE, Medtronic, No Digital Inc, Siemens Corp Res, Springer, Visiopharm AB Individual white matter fibers cannot be resolved by current magnetic resonance (MR) technology. Many fibers of a fiber bundle will pass through an individual volume element (voxel). Individual visualized fiber tracts are thus the result of interpolation on a relatively coarse voxel grid, and an infinite number of them may be generated in a given volume by interpolation. This paper aims at creating a level set representation of a fiber bundle to describe this apparent continuum of fibers. It further introduces a coordinate system warped to the fiber bundle geometry, allowing for the definition of geometrically meaningful fiber bundle measures. C1 Harvard Univ, Sch Med, Psychiat Neuroimaging Lab, Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Lab Math Imaging, Brigham & Womens Hosp, Boston, MA 02115 USA. VA Boston Healthcare Syst, Neurosci Lab, Brockton, MA USA. RP Niethammer, M (reprint author), Harvard Univ, Sch Med, Psychiat Neuroimaging Lab, Brigham & Womens Hosp, Boston, MA 02115 USA. EM marc@bwh.harvard.edu; sylvain@bwh.harvard.edu; westin@bwh.harvard.edu; shenton@bwh.harvard.edu NR 11 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 3-540-44727-X J9 LECT NOTES COMPUT SC PY 2006 VL 4191 BP 252 EP 259 PG 8 WC Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging GA BFF19 UT WOS:000241556700031 ER PT S AU Bullitt, E Lin, NU Ewend, MG Zeng, DL Winer, EP Carey, LA Smith, JK AF Bullitt, Elizabeth Lin, Nancy U. Ewend, Matthew G. Zeng, Donglin Winer, Eric P. Carey, Lisa A. Smith, J. Keith BE Larsen, R Nielsen, M Sporring, J TI Tumor therapeutic response and vessel tortuosity: Preliminary report in metastatic breast cancer SO MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2006, PT 2 SE LECTURE NOTES IN COMPUTER SCIENCE LA English DT Article; Proceedings Paper CT 9th International Conference on Computing and Computer-Assisted Intervention CY OCT 01-06, 2006 CL Copenhagen, DENMARK SP AstraZeneca, Ctr Clin & Basic Res, Claron, Elsevier, GE, Medtronic, No Digital Inc, Siemens Corp Res, Springer, Visiopharm ID MALIGNANT GLIOMA; VASCULATURE AB No current non-invasive method is capable of assessing the efficacy of brain tumor therapy early during treatment. We outline an approach that evaluates tumor activity via statistical analysis of vessel shape using vessels segmented from MRA. This report is the first to describe the changes in vessel shape that occur during treatment of metastatic brain tumors as assessed by sequential MRA. In this preliminary study of 16 patients undergoing treatment for metastatic breast cancer we conclude that vessel shape may predict tumor response several months in advance of traditional methods. C1 Univ N Carolina, CASILab, Chapel Hill, NC 27599 USA. Harvard Univ, Dana Farber Canc Ctr, Boston, MA 02115 USA. RP Bullitt, E (reprint author), Univ N Carolina, CASILab, CB 7062, Chapel Hill, NC 27599 USA. EM bullitt@bios.unc.edu; Nancy_Lin@dfci.harvard.edu; ewend@bios.unc.edu; dzeng@bios.unc.edu; Eric_Winer@dfci.harvard.edu; carey@med.unc.edu; jksmith@med.unc.edu OI Smith, J Keith/0000-0001-7588-3520 NR 15 TC 8 Z9 8 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 3-540-44727-X J9 LECT NOTES COMPUT SC PY 2006 VL 4191 BP 561 EP 568 PG 8 WC Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging GA BFF19 UT WOS:000241556700069 ER PT S AU Cai, WL Nappi, J Zalis, ME Harris, GJ Yoshida, H AF Cai, Wenli Nappi, Janne Zalis, Micheal E. Harris, Gordon J. Yoshida, Hiroyuki BE Reinhardt, JM Pluim, JPW TI Digital bowel cleansing for computer-aided detection of polyps in fecal-tagging CT colonography - art. no. 614422 SO Medical Imaging 2006: Image Processing, Pts 1-3 SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Medical Imaging 2006 Conference CY FEB 12-14, 2006 CL San Diego, CA SP SPIE DE computer-aided diagnosis; X-ray and CT; abdominal ID COLORECTAL-CANCER; CONVENTIONAL COLONOSCOPY; VIRTUAL COLONOSCOPY; PREFERENCES; ADULTS AB Digital bowel cleansing (DBC) is an emerging method for segmentation of fecal materials, which are tagged by an Xray-opaque oral contrast agent in CT colonography (CTC) images, effectively removing them for digital cleansing of the colon. Existing DBC approaches tend to use simple thresholding-based methods for the removal of tagged fecal materials; however, because of the pseudo-enhancement of polyps caused by the surrounding tagged fecal materials, such methods tend erroneously to remove a part of or the entire polyps submerged in these materials. In this study, we developed a novel DBC method that preserves the soft-tissue structures submerged in or partially covered by tagged fecal materials. In our approach, submerged soft-tissue structures are characterized by their local shape signatures that are calculated based on the eigenvalues of a Hessian matrix. A structure-enhancement function is formulated for enhancing of the soft-tissue structures, and the values of the function are integrated into the speed function of a level set method to delineate the submerged soft-tissue structures while removing the tagged fecal materials. In an analysis of 10 submerged polyps, our new DBC method was shown to delineate polyps better than was possible with our previously reported cleansing method based on thresholding. Application of our computer-aided detection (CAD) scheme showed that the use of the new DBS method substantially reduced the number of false-positive detections compared with those of our previous, thresholding-based method. C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Cai, WL (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. NR 16 TC 1 Z9 1 U1 0 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-6423-6 J9 P SOC PHOTO-OPT INS PY 2006 VL 6144 BP 14422 EP 14422 AR 614422 DI 10.1117/12.654168 PN 1-3 PG 9 WC Computer Science, Interdisciplinary Applications; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BEL75 UT WOS:000238033300073 ER PT S AU Cai, WL Dachille, F Harris, GJ Yoshida, H AF Cai, Wenli Dachille, Frank Harris, Gordon J. Yoshida, Hiroyuki BE Reinhardt, JM Pluim, JPW TI Vesselness propagation - A fast interactive vessel structure segmentation method - art. no. 614447 SO Medical Imaging 2006: Image Processing, Pts 1-3 SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Medical Imaging 2006 Conference CY FEB 12-14, 2006 CL San Diego, CA SP SPIE DE image processing; vessel segmentation; computed tomographic angiography ID ROW CT; IMAGES AB With the rapid development of multi-detector computed tomography (MDCT), resulting in increasing temporal and spatial resolution of data sets, clinical use of computed tomographic angiography (CTA) is rapidly increasing. Analysis of vascular structures is much needed in CTA images; however, the basis of the analysis, vessel segmentation, can still be a challenging problem. In this paper, we present a fast interactive method for CTA vessel segmentation, called vesselness propagation. This method is a two-step procedure, with a pre-processing step and an interactive step. During the pre-processing step, a vesselness volume is computed by application of a CTA transfer function followed by a multiscale Hessian filtering. At the interactive stage, the propagation is controlled interactively in terms of the priority of the vesselness. This method was used successfully in many CTA applications such as the carotid artery, coronary artery, and peripheral arteries. It takes less than one minute for a user to segment the entire vascular structure. Thus, the proposed method provides an effective way of obtaining an overview of vascular structures. C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Cai, WL (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. NR 22 TC 0 Z9 0 U1 0 U2 2 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-6423-6 J9 P SOC PHOTO-OPT INS PY 2006 VL 6144 BP 14447 EP 14447 AR 614447 DI 10.1117/12.653637 PN 1-3 PG 9 WC Computer Science, Interdisciplinary Applications; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BEL75 UT WOS:000238033301069 ER PT S AU Nappi, J Frimmel, H Yoshida, H AF Nappi, Janne Frimmel, Hans Yoshida, Hiroyuki BE Reinhardt, JM Pluim, JPW TI Centerline-based colon segmentation for CAD of CT colonography - art. no. 61445H SO Medical Imaging 2006: Image Processing, Pts 1-3 SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Medical Imaging 2006 Conference CY FEB 12-14, 2006 CL San Diego, CA SP SPIE DE computer-aided diagnosis; x-ray and CT; abdominal ID COMPUTED TOMOGRAPHIC COLONOGRAPHY; POLYPS; REDUCTION; SCHEME AB We developed a fast centerline-based segmentation (CBS) algorithm for the extraction of colon in computer-aided detection (CAD) for CT colonography (CTC). CBS calculates local centerpoints along thresholded components of abdominal air, and connects the centerpoints iteratively to yield a colon centerline. A thick region encompassing the colonic wall is extracted by use of region-growing around the centerline. The resulting colonic wall is employed in our CAD scheme for the detection of polyps, in which polyps are detected within the wall by use of volumetric shape features. False-positive detections are reduced by use of a Bayesian neural network. The colon extraction accuracy of CBS was evaluated by use of 38 clinical CTC scans representing various preparation conditions. On average, CBS covered more than 96% of the visible region of colon with less than 1% extracolonic components in the extracted region. The polyp detection performance of the CAD scheme was evaluated by use of 121 clinical cases with 42 colonoscopy-confirmed polyps 5-25 mm. At a 93% by-polyp detection sensitivity for polyps >= 5 mm, a leave-one-patient-out evaluation yielded 1.4 false-positive polyp detections per CT scan. C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Nappi, J (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. NR 17 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-6423-6 J9 P SOC PHOTO-OPT INS PY 2006 VL 6144 BP H1445 EP H1445 AR 61445H DI 10.1117/12.653940 PN 1-3 PG 8 WC Computer Science, Interdisciplinary Applications; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BEL75 UT WOS:000238033302032 ER PT S AU Wu, T Liu, B Moore, R Kopans, D AF Wu, Tao Liu, Bob Moore, Richard Kopans, Daniel BE Flynn, MJ Hsieh, J TI Optimal acquisition techniques for digital breast tomosynthesis screening - art. no. 61425E SO Medical Imaging 2006: Physics of Medical Imaging, Pts 1-3 SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Medical Imaging 2006 Conference CY FEB 12-14, 2006 CL San Diego, CA SP SPIE DE tomosynthesis; digital mammography; x-ray imaging; acquisition technique optimization ID FILM MAMMOGRAPHY; PERFORMANCE AB A second-generation digital breast tomosynthesis system is used for a screening study comparing tomosynthesis with conventional two-view mammography with matched x-ray dose. The system acquires 15 projections of a breast at different angles using a digital detector. This work explores acquisition techniques that optimize the quality of projection images at low x-ray exposure. The system provides three target-filter combinations (Mo-Mo, Mo-Rh and Rh-Rh) and the recommended tube voltage range is from 25 to 40kVp. A thin disk was put on top of slabs of breast tissue equivalent materials (20 to 85mm). Contrast-to-noise ratio of the disk was measured from projections acquired with different kVp and target-filter combinations. The squared CNR normalized by average glandular dose was used to compare the quality/dose efficiency of different techniques. The optimal quality/dose efficiency was achieved as the detector entrance exposure was in the range of 5-30mR. Within this range, Mo-Mo gives the highest quality for 20mm; results are very close for 30mm; Rh-Rh is slightly better for 45mm and apparently better than others for 65 and 85mm. However, sufficient detector entrance exposure cannot be guaranteed for all cases due to the total dose limit and the system limit. For some cases, the detector is operated slightly off its optimal performance range. The kVp does not show an impact except for 85 mm, in which the quality/dose efficiency slightly increases at higher kVp. Rh-Rh is selected for > 40mm thickness; Mo-Mo is selected for 20mm thickness; and Mo-Rh is selected for 30 and 40mm. C1 Massachusetts Gen Hosp, Dept Radiol, Div Breast Imaging, Boston, MA 02114 USA. RP Wu, T (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Breast Imaging, WACC 240,RM 280,15 Parkman St, Boston, MA 02114 USA. NR 7 TC 4 Z9 4 U1 0 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-6185-7 J9 P SOC PHOTO-OPT INS PY 2006 VL 6142 BP E1425 EP E1425 AR 61425E DI 10.1117/12.652289 PN 1-3 PG 11 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BEL88 UT WOS:000238049700184 ER PT S AU Liu, B Wu, T Moore, RH Kopans, DB AF Liu, Bob Wu, Tao Moore, Richard H. Kopans, Daniel B. BE Flynn, MJ Hsieh, J TI Monte Carlo simulation of x-ray scatter based on patient model from digital breast tomosynthesis - art. no. 61421N SO Medical Imaging 2006: Physics of Medical Imaging, Pts 1-3 SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Medical Imaging 2006 Conference CY FEB 12-14, 2006 CL San Diego, CA SP SPIE DE digital mammography; tomosynthesis; Monte Carlo simulation; scatter correction ID MAMMOGRAPHY; GATE; PET AB We are developing a breast specific scatter correction method for digital beast tomosynthesis (DBT). The 3D breast volume was initially reconstructed from 15 projection images acquired from a GE prototype tomosynthesis system without correction of scatter. The voxel values were mapped to the tissue compositions using various segmentation schemes. This voxelized digital breast model was entered into a Monte Carlo package simulating the prototype tomosynthesis system. One billion photons were generated from the x-ray source for each projection in the simulation and images of scattered photons were obtained. A primary only projection image was then produced by subtracting the scatter image from the corresponding original projection image which contains contributions from the both primary photons and scatter photons. The scatter free projection images were then used to reconstruct the 3D breast using the same algorithm. Compared with the uncorrected 3D image, the x-ray attenuation coefficients represented by the scatter-corrected 3D image are closer to those derived from the measurement data. C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Liu, B (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. NR 14 TC 3 Z9 3 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-6185-7 J9 P SOC PHOTO-OPT INS PY 2006 VL 6142 BP N1421 EP N1421 AR 61421N DI 10.1117/12.650193 PN 1-3 PG 9 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BEL88 UT WOS:000238049700057 ER PT S AU Hillman, EMC Devor, A Dunn, AK Boas, DA AF Hillman, Elizabeth M. C. Devor, Anna Dunn, Andrew K. Boas, David A. BE Manduca, A Amini, AA TI Laminar optical tomography: high-resolution 3D functional imaging of superficial tissues - art. no. 61431M SO Medical Imaging 2006: Physiology, Function, and Structure from Medical Images Pts 1 and 2 SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Medical Imaging 2006 Conference CY FEB 12-14, 2006 CL San Diego, CA SP SPIE DE optical imaging; functional imaging; depth-resolved; brain; cortex; high-resolution; hemoglobin ID TURBID MEDIA; OXYGENATION; RAT AB Laminar Optical Tomography (LOT) is a new medical imaging modality for high-resolution, depth-resolved, functional imaging of superficial tissue such as rodent cortex, skin and the retina. LOT uses visible laser light to image to depths of > 2mm (far deeper than microscopy) and is highly sensitive to absorption and fluorescence contrast, enabling spectroscopic functional information such as hemoglobin oxygenation to be imaged with 100-200 micron resolution. LOT has been used to image the hemodynamic response to stimulus in the somatosensory cortex of rats. The resulting three-dimensional (3D) images through the depth of the cortex can be used to delineate the arterial, capillary and venous responses, revealing new information about the intricacies of the oxygenation and blood flow dynamics related to neuronal activation. Additional applications of LOT are being explored, including the integration of 3D Voltage Sensitive Dye fluorescence imaging. LOT imaging uses a system similar to a confocal microscope, quickly scanning a focused beam of light over the surface of the tissue (similar to 8Hz frame rate). Light is detected from both the focus of the scanning beam, and also at increasing distances from the beam's focus. This scattered light has penetrated more deeply into the tissue, and allows features at different depths to be distinguished. An algorithm that includes photon migration modeling of light scattering converts the raw data into 3D images. The motivation for functional optical imaging will be outlined, the basic principles of LOT imaging will be described, and the latest in-vivo results will be presented. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Hillman, EMC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, CNY 149,13th St, Charlestown, MA 02129 USA. RI Dunn, Andrew/I-9527-2014 NR 14 TC 6 Z9 6 U1 0 U2 2 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-6186-5 J9 P SOC PHOTO-OPT INS PY 2006 VL 6143 BP M1431 EP M1431 AR 61431M DI 10.1117/12.655876 PN 1-2 PG 14 WC Engineering, Biomedical; Physiology; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Physiology; Radiology, Nuclear Medicine & Medical Imaging GA BEK96 UT WOS:000237637000056 ER PT J AU El Fakhri, G Ouyang, J Zimmerman, RE Fischman, AJ Kijewski, MF AF El Fakhri, G Ouyang, J Zimmerman, RE Fischman, AJ Kijewski, MF TI Performance of a novel collimator for high-sensitivity brain SPECT SO MEDICAL PHYSICS LA English DT Article DE high-sensitivity brain SPECT; variable focusing collimator; estimation; and detection SNR ID DOPAMINE TRANSPORTER SITES; SELECTIVE LIGAND; ALTROPANE AB We assessed improvements in performance in detection and estimation tasks due to a novel brain single photon computed tomography collimator. Data were acquired on the CeraSPECT (TM) scanner using both new and standard collimators. The new variable focusing collimator SensOgrade (TM) samples the projections unequally, with central regions more heavily represented, to compensate for attenuation of counts from central brain structures. Furthermore, it utilizes more of the cylindrical crystal surface. Two phantom studies were performed. The first phantom was a 21-cm-diameter cylindrical background containing nine spheres ranging from 0.5 to 5 cm(3) in volume. Tc-99m sphere to background activity ratio was 10:1. Twenty-nine 10-min datasets were acquired with each collimator. The second phantom was the Radiology Support Devices (Long Beach, CA) striatal phantom with striatal-background ratios of 10:1 on the left and 5:1 on the right. Twenty-nine 4-min datasets were acquired with each collimator. Perfusion imaging using Tc-99m-HMPAO was also performed in three healthy volunteers using both collimators under identical simulations. Projections were reconstructed by filtered backprojection with an unwindowed ramp filter. The nonprewhitening matched filter signal-to-noise ratio (NPW-SNR) was computed as a surrogate for human performance in detecting spherical lesions. Sphere activity concentration, radius, and location coordinates were simultaneously estimated by fitting images to an assumed model using an iterative nonlinear algorithm. Resolution recovery was implicit in the estimation procedure, as the point spread function was incorporated into the model. NPW-SNR for sphere detection was 1.5 to 2 times greater with the new collimator; for the striatal phantom the improvement in SNR was 54%. The SNR for estimating sphere activity concentration improved by 46 to 89% for spheres located more than 5 ern from the phantom center. Images acquired with the standard collimator were too noisy in the central regions to allow estimation of sphere activity. In Tc-99m-HMPAO human studies, SNR was improved by 21 to 41 % in the cortex, 66% in the basal ganglia, and 74% in the thalamus. The new collimator leads to substantially improved detection and estimation performance throughout the brain. The higher sensitivity will be particularly important for dynamic imaging. (c) 2006 American Association of Physicists in Medicine. C1 Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02115 USA. RP El Fakhri, G (reprint author), Harvard Univ, Sch Med, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. EM elfakhri@bwh.harvard.edu FU NIBIB NIH HHS [R01-EB000802, R01-EB005876, R01 EB000802, R01-EB001989] NR 14 TC 4 Z9 4 U1 0 U2 4 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JAN PY 2006 VL 33 IS 1 BP 209 EP 215 DI 10.1118/1.2143140 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 004SI UT WOS:000234772100026 PM 16485427 ER PT J AU Dusek, JA Chang, BH Zaki, J Lazar, SW Deykin, A Stefano, GB Wohlhueter, AL Hibberd, PL Benson, H AF Dusek, JA Chang, BH Zaki, J Lazar, SW Deykin, A Stefano, GB Wohlhueter, AL Hibberd, PL Benson, H TI Association between oxygen consumption and nitric oxide production during the relaxation response SO MEDICAL SCIENCE MONITOR LA English DT Article DE relaxation response; fractional exhaled nitric oxide; volumetric oxygen consumption; stress ID PITUITARY-ADRENAL AXIS; BEHAVIORAL MEDICINE INTERVENTION; VASCULAR ENDOTHELIAL FUNCTION; SYMPATHETIC-NERVOUS-SYSTEM; CONTROLLED CLINICAL-TRIAL; DECREASED BLOOD-PRESSURE; ISCHEMIC-HEART-DISEASE; SLEEP-ONSET INSOMNIA; EXHALED AIR; DEPENDENT VASODILATION AB Background: Mind/body pracfices that elicit the relaxation response (RR) are currently practiced by over 30% of American adults. RR elicitation reduces volumetric oxygen consumption (VO2) from rest and counteracts the effects of stress, although the mechanisms mediating the RR remain unknown. This study was designed to investigate whether RR elicitation is mediated by nitric oxide (NO). We developed a method to quantify depth of RR using change in VO2 (slope) dufing RR elicitation. We evaluated whether depth of RR elicitation was correlated with changes in NO, as measured by percentage changes in fractional exhaled nitric oxide (FENO). Material/Methods: We conducted a randomized, controlled trial, in which 46 subjects were randomized to either 8-weeks of RR training using audiotapes (n=34) or 8-weeks of exposure to a control condition - receiving health-education by audiotapes (n=12). Prior to randomization, VO2 and FENO were measured while subjects listened to a control audiotape. Eight weeks later, VO2 and FENO were measured while the RR group listened to a RR-eliciting audiotape and the control group listened to a control audiotape. Results: Prior to receiving any training, there was no association between VO2 slope and F E NO. After training, there was an inverse correlation between VO2 slope and FENO in the RR group (r=-0.41, P=0.037, n=26), but not in the control group (r=0.12, P=0.78, n=8). Conclusions: Depth of RR elicitation was associated with increased concentrations of FENO after RR training. The RR may be mediated by NO helping to explain its clinical effects in stress-related disorders. C1 Mind Body Med Inst, Chestnut Hill, MA 02467 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA. Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Boston, MA 02215 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA. Tufts New England Med Ctr, Div Clin Res Resources, Boston, MA USA. RP Dusek, JA (reprint author), Mind Body Med Inst, 824 Boylston St, Chestnut Hill, MA 02467 USA. EM jdusek@bidmc.harvard.edu RI Lazar, Sara/G-3809-2012 OI Lazar, Sara/0000-0003-1126-8363 FU NCCIH NIH HHS [K01 AT 00694, R21 AT003425, K01 AT000694]; NCRR NIH HHS [M01 RR 000054, M01 RR 01032]; ODCDC CDC HHS [H75/CCH 119124, H75/CCH 123424] NR 100 TC 35 Z9 35 U1 1 U2 9 PU INT SCIENTIFIC LITERATURE, INC PI ALBERTSON PA 1125 WILLIS AVE, ALBERTSON, NY 11507 USA SN 1234-1010 J9 MED SCI MONITOR JI Med. Sci. Monitor PD JAN PY 2006 VL 12 IS 1 BP CR1 EP CR10 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 004GR UT WOS:000234740500007 PM 16369463 ER PT J AU Krivickas, LS Fielding, RA Murray, A Callahan, D Johansson, A Dorer, DJ Frontera, WR AF Krivickas, LS Fielding, RA Murray, A Callahan, D Johansson, A Dorer, DJ Frontera, WR TI Sex differences in single muscle fiber power in older adults SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE aging; contractile properties; myofiber; skeletal muscle ID SARCOMERE-LENGTH; CONTRACTILE FUNCTION; WOMEN; MEN; VELOCITY; STRENGTH; CALCIUM; FORCE; PERFORMANCE; CYCLE AB Purpose: This study was conducted to determine whether differences in power at the single muscle fiber level contribute to sex differences in whole muscle power production in the elderly. Methods: A total of 16 sedentary older persons (10 women, 6 men), mean age 72 yr, had percutaneous needle biopsy of musculus vastus lateralis. Chemically skinned single muscle fibers were activated with Ca2+ for maximal isometric force measurement (P.). The slack test was performed to determine maximal unloaded shortening velocity (V-o). Force-velocity and power curves were generated via a series of isotonic contractions, allowing measurement of peak power and specific power. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to determine myosin heavy chain composition of single muscle fibers. Whole muscle strength, velocity, and power were measured for knee extension and double leg press. Results: Men had greater whole muscle strength, power, and velocity compared with women. Studied were 274 type I and 33 type IIa single fibers. No significant sex differences were found for fiber size, P-o, specific force, V-o, power, or specific power in type I or IIa fibers. Conclusions: Single muscle fiber quality in older women is equivalent to that in older men and can not explain the differences seen in whole muscle strength, power, or function. C1 Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Boston Univ, Dept Hlth Sci, Sargeant Coll Hlth & Rehabil Sci, Boston, MA USA. Tufts Univ, Ctr Aging, Sarcopenia Lab, Jean Mayer USDA Human Nutr Res, Boston, MA USA. Massachusetts Gen Hosp, Biostat Ctr, Boston, MA USA. RP Krivickas, LS (reprint author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA. EM lkrivickas@partners.org FU NIA NIH HHS [AG-18844] NR 32 TC 15 Z9 15 U1 3 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD JAN PY 2006 VL 38 IS 1 BP 57 EP 63 DI 10.1249/01.mss.0000180357.58329.bl PG 7 WC Sport Sciences SC Sport Sciences GA 000LS UT WOS:000234464100010 PM 16394954 ER PT S AU Demirci, U Toner, M AF Demirci, U Toner, M GP IEEE TI Direct etch method for microfluidic channel and nano-height post fabrication by picoliter droplets SO MEMS 2006: 19TH IEEE INTERNATIONAL CONFERENCE ON MICRO ELECTRO MECHANICAL SYSTEMS, TECHNICAL DIGEST SE Proceedings IEEE Micro Electro Mechanical Systems LA English DT Proceedings Paper CT 19th IEEE International Conference on Micro Electro Mechanical Systems (MEMS 2006) CY JAN 22-26, 2006 CL Istanbul, TURKEY SP IEEE, Robot & Automat Soc AB Photolithography is an expensive and significant step in microfabrication. Approaches that Could change lithography could create impact on semiconductor and microelectromechanical systems fields. We demonstrate a droplet based direct etching method by ejecting etchant droplets at desired locations by using microdroplet ejector arrays. This method could be used for easy fabrication of poly(dimethylsiloxane) microfluidic channels; nanometer height post-like structures in microfluidic channels. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Shriners Hosp Children, Boston, MA 02115 USA. RP Harvard Univ, Sch Med, Massachusetts Gen Hosp, Shriners Hosp Children, Boston, MA 02115 USA. EM utkan@stanfordalumni.org; mtoner@sbi.org NR 11 TC 0 Z9 0 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1084-6999 BN 0-7803-9475-5 J9 PROC IEEE MICR ELECT PY 2006 BP 326 EP 329 PG 4 WC Engineering, Electrical & Electronic; Engineering, Mechanical; Instruments & Instrumentation SC Engineering; Instruments & Instrumentation GA BEE74 UT WOS:000236994500082 ER PT S AU Bohringer, KF Bilge, H Cheng, XH Ratner, B Takeuchi, S Fujita, H AF Bohringer, KF Bilge, H Cheng, XH Ratner, B Takeuchi, S Fujita, H GP IEEE TI INFRARED LIGHT INDUCED PATTERNING OF PROTEINS ON PPNIPAMTHERMORESPONSIVE THIN FILMS: A PROTEIN LASER PRINTER SO MEMS 2006: 19TH IEEE INTERNATIONAL CONFERENCE ON MICRO ELECTRO MECHANICAL SYSTEMS, TECHNICAL DIGEST SE Proceedings IEEE Micro Electro Mechanical Systems LA English DT Proceedings Paper CT 19th IEEE International Conference on Micro Electro Mechanical Systems (MEMS 2006) CY JAN 22-26, 2006 CL Istanbul, TURKEY SP IEEE, Robot & Automat Soc ID DIP-PEN NANOLITHOGRAPHY AB Controlled adsorption and patterning of proteins on a thin film of thermo-responsive plasma-deposited poly-N-isopro-pylacrylamide occurs in response to heating with a computer-controlled infrared laser beam, with pattern resolution in the single micrometer range and adsorption times within a few seconds. Deposition of multiple proteins in the same substrate region has been accomplished. Successful streptavidin-biotin and antibody-antigen binding indicates that protein function stays intact after proteins adsorb to the ppNI-PAM bio-polymer surface. C1 Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. Univ Tokyo, Inst Ind Sci, Tokyo 1138654, Japan. Massachusetts Gen Hosp, Boston, MA USA. Univ Washington, UWEB, Seattle, WA 98195 USA. RP Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. FU NIH Center of Excellence in Genomic Science and Technology [1-P50-HG002360-01] FX This work received support from by the NIH Center of Excellence in Genomic Science and Technology grant 1-P50-HG002360-01. NR 12 TC 0 Z9 0 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1084-6999 BN 0-7803-9475-5 J9 PROC IEEE MICR ELECT PY 2006 BP 530 EP 533 PG 4 WC Engineering, Electrical & Electronic; Engineering, Mechanical; Instruments & Instrumentation SC Engineering; Instruments & Instrumentation GA BEE74 UT WOS:000236994500133 ER PT J AU Shifren, JL AF Shifren, JL TI Is testosterone or estradiol the hormone of desire? A novel study of the effects of testosterone treatment and aromatase inhibition in postmenopausal women SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Editorial Material ID HYPOACTIVE SEXUAL DESIRE; ESTROGEN; DISORDER; BEHAVIOR C1 Massachusetts Gen Hosp, Vincent Obstet & Gynecol Serv, Boston, MA 02114 USA. RP Shifren, JL (reprint author), Massachusetts Gen Hosp, Vincent Obstet & Gynecol Serv, Boston, MA 02114 USA. NR 9 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD JAN-FEB PY 2006 VL 13 IS 1 BP 8 EP 9 DI 10.1097/01.gme.0000194820.69150.96 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 003NM UT WOS:000234688900004 PM 16607092 ER PT J AU Quackenbush, J AF Quackenbush, J. TI Computational approaches to analysis of DNA microarray data SO METHODS OF INFORMATION IN MEDICINE LA English DT Article DE DNA microarrays; computational clustering methods; classification of gene expression data; verification and validation of microarray result ID GENE-EXPRESSION DATA; PROBABILISTIC BOOLEAN NETWORKS; SELF-ORGANIZING MAPS; REGULATORY NETWORKS; TUMOR CLASSIFICATION; PATTERNS; CANCER; PLATFORMS; SCALE; VALIDATION AB Objectives: To review the current state of the art in computational methods for the analysis of DNA microarray data. Methods: The review considers methods of microarray data collection, transformation and representation, comparisons and predictions of gene expression from the data, their mechanistic analysis, related systems biology, and the application of clustering techniques. Results: Functional genomics approaches have greatly increased the rate at which data on biological systems is generated, leading to corresponding challenges in analyzing the data through advanced computational techniques. The paper compares and contrasts the application of computational clustering for discovery, comparison, and prediction of gene expression classes, together with their evaluation and relation to mechanistic ana lyses of biological systems. Conclusion: Methods for assaying gene expression levels by DNA microarray experiments produce considerably more data than other techniques, and require a wide variety of computational techniques for identifying patterns of expression that may he biologically significant. These will have to he verified and validated by comparison to results from other methods, integrated with other systems data, and provide the feedback for further experimentation for testing mechanistic or other biological hypotheses. C1 Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Quackenbush, J (reprint author), Dana Farber Canc Inst, Dept Biostat, Mayer 232 44 Binney St, Boston, MA 02115 USA. EM johnq@jimmy.harvard.edu NR 67 TC 23 Z9 23 U1 1 U2 7 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 0026-1270 J9 METHOD INFORM MED JI Methods Inf. Med. PY 2006 VL 45 SU 1 BP 91 EP 103 PG 13 WC Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics SC Computer Science; Health Care Sciences & Services; Medical Informatics GA 116AP UT WOS:000242775200018 ER PT J AU Setubal, JC Reis, M Matsunaga, J Haake, DA AF Setubal, JC Reis, M Matsunaga, J Haake, DA TI Lipoprotein computational prediction in spirochaetal genomes 10.1099/mic.0.28317-0 SO MICROBIOLOGY-SGM LA English DT Article ID SURFACE-EXPOSED LIPOPROTEIN; LYME-DISEASE SPIROCHETE; BORRELIA-BURGDORFERI; BACTERIAL LIPOPROTEINS; ESCHERICHIA-COLI; TREPONEMA-PALLIDUM; SEQUENCE-ANALYSIS; SIGNAL PEPTIDES; PROTEIN; PATHOGENESIS AB Lipoproteins are of great interest in understanding the molecular pathogenesis of spirochaetes. Because spirochaete lipobox sequences exhibit more plasticity than those of other bacteria, application of existing prediction algorithms to emerging sequence data has been problematic. In this paper a novel lipoprotein prediction algorithm is described, designated SpLip, constructed as a hybrid of a lipobox weight matrix approach supplemented by a set of lipoprotein signal peptide rules allowing for conservative amino acid substitutions. Both the weight matrix and the rules are based on a training set of 28 experimentally verified spirochaetal lipoproteins. The performance of the SpLip algorithm was compared to that of the hidden Markov model-based LipoP program and the rules-based algorithm Psort for all predicted protein-coding genes of Leptospira interrogans sv. Copenhageni, L. interrogans sv. Lai, Borrelia burgdorferi, Borrelia garinii, Treponema pallidum and Treponema denticola. Psort sensitivity (13-35 %) was considerably less than that of SpLip (93-100 %) or LipoP (50-84 %) due in part to the requirement of Psort for Ala or Gly at the -1 position, a rule based on E. coli lipoproteins. The percentage of false-positive lipoprotein predictions by the LipoP algorithm (8-30 %) was greater than that of SpLip (0-1 %) or Psort (4-27 %), due in part to the lack of rules in LipoP excluding unprecedented amino acids such as Lys and Arg in the -1 position. This analysis revealed a higher number of predicted spirochaetal lipoproteins than was previously known. The improved performance of the SpLip algorithm provides a more accurate prediction of the complete lipoprotein repertoire of spirochaetes. The hybrid approach of supplementing weight matrix scoring with rules based on knowledge of protein secretion biochemistry may be a general strategy for development of improved prediction algorithms. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. Virginia Tech, Virginia Bioinformat Inst, Blacksburg, VA 24060 USA. Univ Estadual Campinas, Lab Bioinformat, Inst Computac, BR-13084071 Campinas, SP, Brazil. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Haake, DA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. EM dhaake@ucla.edu RI Setubal, Joao/C-7305-2012; Reis, Marcelo/K-4075-2012 OI Setubal, Joao/0000-0001-9174-2816; Reis, Marcelo/0000-0002-3754-9115 FU NIAID NIH HHS [AI-34431, R01 AI034431, R01 AI034431-09, R21 AI034431, R29 AI034431] NR 36 TC 112 Z9 115 U1 0 U2 4 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1350-0872 J9 MICROBIOL-SGM JI Microbiology-(UK) PD JAN PY 2006 VL 152 BP 113 EP 121 DI 10.1099/mic.0.28317-0 PN 1 PG 9 WC Microbiology SC Microbiology GA 004HA UT WOS:000234741400013 PM 16385121 ER PT J AU Thompson, SK Chang, EY Jobe, BA AF Thompson, SK Chang, EY Jobe, BA TI Clinical review: Healing in gastrointestinal anastomoses, Part I SO MICROSURGERY LA English DT Review ID EXPERIMENTAL COLONIC ANASTOMOSES; MECHANICAL BOWEL PREPARATION; EXPERIMENTAL INTESTINAL ANASTOMOSES; ACUTE WOUND FAILURE; COLLAGEN-SYNTHESIS; COLORECTAL SURGERY; BREAKING STRENGTH; BURSTING STRENGTH; RATS; RESECTION AB Gastrointestinal healing is a topic rarely reviewed in the literature, yet it is of paramount importance to the surgeon. Failure of anastomotic healing may lead to life-threatening complications, additional surgical procedures, increased length of stay, increased cost, long-term disability, and reduced quality of life for the patient. The goal of this article is to review the biological response to wounded tissue, to outline discrete differences between skin and gastrointestinal healing, to discuss local and systemic factors important to gastrointestinal healing, and to compare methods of measuring collagen content and strength of the newly formed anastomosis. Part II of this review will focus on techniques and therapies available to optimize anastornotic healing. (c) 2006 Wiley-Liss, Inc. C1 Portland VA Med Ctr, P3GS Surg Serv, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA. RP Jobe, BA (reprint author), Portland VA Med Ctr, P3GS Surg Serv, POB 1034, Portland, OR 97207 USA. EM jobeb@ohsu.edu NR 27 TC 67 Z9 72 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0738-1085 J9 MICROSURG JI Microsurgery PY 2006 VL 26 IS 3 BP 131 EP 136 DI 10.1002/micr.20197 PG 6 WC Surgery SC Surgery GA 030UN UT WOS:000236660500002 PM 16518804 ER PT J AU Enestvedt, CK Thompson, SK Chang, EY Jobe, BA AF Enestvedt, CK Thompson, SK Chang, EY Jobe, BA TI Clinical review: Healing in gastrointestinal anastomoses, Part II SO MICROSURGERY LA English DT Review ID ENDOTHELIAL GROWTH-FACTOR; ADDITIONAL MICROVASCULAR ANASTOMOSIS; INTRATHORACIC ESOPHAGEAL-CARCINOMA; LASER-DOPPLER FLOWMETRY; GASTRIC TUBE; BLOOD-FLOW; PREOPERATIVE EMBOLIZATION; INTESTINAL ANASTOMOSES; INDUCED ANGIOGENESIS; COLON INTERPOSITION AB Complications arising from gastrointestinal anastomosis failures are a major source of morbidity and mortality. This review examines the effects of local blood flow on anastomotic healing, and discusses strategies for improving perfusion. Disruption of blood supply plays a significant role in the development of anastornotic leakage. Several methods have been suggested to improve perfusion. Omental pedicles have been employed as buttresses to promote angiogenesis, but efficacy in preventing anastornotic dehiscence has not been established. The administration of exogenous pharmacologic agents (such as vascular endothelial growth factor) is another potential strategy, although the oncological safety of this approach has been questioned. Two techniques which show promise in reducing anastornotic leakage rates include the vascular augmentation of grafts at risk for ischemia (supercharging) and ischemic conditioning (utilizing the delay phenomenon). Further studies of these strategies are needed to establish their efficacy and safety for routine use in gastrointestinal anastomoses. (c) 2006 Wiley-Liss, Inc. C1 Portland VA Med Ctr, P3GS Surg Serv, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA. RP Jobe, BA (reprint author), Portland VA Med Ctr, P3GS Surg Serv, POB 1034, Portland, OR 97207 USA. EM jobeb@ohsu.edu NR 49 TC 25 Z9 30 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0738-1085 J9 MICROSURG JI Microsurgery PY 2006 VL 26 IS 3 BP 137 EP 143 DI 10.1002/micr.20198 PG 7 WC Surgery SC Surgery GA 030UN UT WOS:000236660500003 PM 16518802 ER PT J AU McCarthy, D Blumenthal, D AF McCarthy, D Blumenthal, D TI Stories from the sharp end: Case studies in safety improvement SO MILBANK QUARTERLY LA English DT Article DE patient safety; quality of care; organizational culture; delivery of health care ID MEDICAL EMERGENCY TEAM; PATIENT-CENTERED CARE; QUALITY; ERROR; PERFORMANCE; HOSPITALS; SYSTEMS; COMMUNICATION; RELIABILITY; INFECTIONS AB Motivated by pressure and a wish to improve, health care organizations are implementing programs to improve patient safety. This article describes six natural experiments in health care safety that show where the safety field is heading and opportunities for and barriers to improvement. All these programs identified organizational culture change as critical to making patients safer, differing chiefly in their methods of creating a patient safety culture. Their goal is a safety culture that promotes continuing innovation and improvement, transcending whatever particular safety methodology is used. Policymakers could help stimulate a culture of safety by linking regulatory goals to safety culture expectations, sponsoring voluntary learning collaborations, rewarding safety improvements, better using publicly reported data, encouraging consumer involvement, and supporting research and education. C1 Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. RP Blumenthal, D (reprint author), Massachusetts Gen Hosp, Inst Hlth Policy, 50 Staniford St,9th Floor,Suite 901, Boston, MA 02114 USA. EM dblumenthal@partners.org NR 86 TC 22 Z9 22 U1 1 U2 9 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0887-378X J9 MILBANK Q JI Milbank Q. PY 2006 VL 84 IS 1 BP 165 EP 200 DI 10.1111/j.1468-0009.2006.00442.x PG 36 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 020FI UT WOS:000235893400007 PM 16529572 ER PT J AU Sherman, SE Joseph, AM Yano, EM Simon, BF Arikian, N Rubenstein, LV Parkerton, P Mittman, BS AF Sherman, SE Joseph, AM Yano, EM Simon, BF Arikian, N Rubenstein, LV Parkerton, P Mittman, BS TI Assessing the institutional approach to implementing smoking cessation practice guidelines in veterans health administration facilities SO MILITARY MEDICINE LA English DT Article ID PRIMARY-CARE; QUALITY AB National smoking cessation guidelines include recommended strategies for providers and health care organizations, but they offer little guidance on how to structure care. We conducted a cross-sectional survey at 40 Veterans Health Administration facilities, to describe the structure of smoking cessation care, to assess adherence to national guidelines, and to assess facilities' preferred approach to providing smoking cessation treatment. We categorized sites as those using a primary care approach (most smokers treated by the primary care provider) versus a specialty approach (medication restricted to smoking cessation clinics, to which most patients were referred). Nearly all sites reported systematic screening for smoking and counseling of smokers, usually by both nursing staff members and the primary care provider. Most sites used a specialty approach, restricting medication access to smokers attending a cessation program. Future research should evaluate whether this approach provides adequate access and responsiveness to patient preferences for the full population of smokers in primary care. C1 Vet Adm Greater Los Angeles Healthcare Syst, Vet Adm Hlth Serv Res & Dev, Ctr Excellence Study Healthcare Provider Behav, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. Vet Adm Med Ctr, Ctr Chron Dis Outcome Res, Vet Integrated Serv Network 13, Minneapolis, MN 55417 USA. Univ Minnesota, Dept Med, Minneapolis, MN 55417 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90095 USA. RAND Corp, Santa Monica, CA 90407 USA. RP Sherman, SE (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Vet Adm Hlth Serv Res & Dev, Ctr Excellence Study Healthcare Provider Behav, Sepulveda, CA 91343 USA. NR 22 TC 15 Z9 15 U1 2 U2 2 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD JAN PY 2006 VL 171 IS 1 BP 80 EP 87 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 019JV UT WOS:000235832300018 PM 16532880 ER PT J AU King, LA King, DW Vogt, DS Knight, J Samper, RE AF King, Lynda A. King, Daniel W. Vogt, Dawne S. Knight, Jeffrey Samper, Rita E. TI Deployment risk and resilience inventory: A collection of measures for studying deployment-related experiences of military personnel and veterans SO MILITARY PSYCHOLOGY LA English DT Review ID POSTTRAUMATIC-STRESS-DISORDER; GULF-WAR VETERANS; MALE VIETNAM VETERANS; SOCIAL SUPPORT; PSYCHOMETRIC PROPERTIES; CONTENT VALIDITY; DESERT-STORM; PSYCHOLOGICAL-ASSESSMENT; COMBAT EXPOSURE; NATIONAL SAMPLE AB This article describes the development of an inventory to assess key psychosocial risk and resilience factors for military personnel and veterans deployed to war zones or other hazardous environments. Part I details the definition and operationalization of the 14 constructs: 2 predeployment factors (e.g., childhood family environment), 10 deployment or war-zone factors (e.g., concerns about life and family disruptions, deployment social support, combat experiences), and 2 postdeployment factors (e.g., postdeployment stressors). In Parts 2 and 3, data from 2 separate national samples of Gulf War veterans were used to refine item sets and establish estimates of internal consistency reliability. Part 4 employed a 3rd new national sample of Gulf War veterans to document evidence for validity in terms of relations with mental and physical health. C1 Boston Univ, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02215 USA. Boston Univ, Dept Psychol, Boston, MA 02215 USA. Boston Univ, Dept Psychiat, Boston, MA 02215 USA. RP King, LA (reprint author), VA Boston Healthcare Syst 116B 5, 150 S Hungtinton Ave, Boston, MA 02130 USA. EM lking@bu.edu NR 103 TC 248 Z9 250 U1 4 U2 28 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA SN 0899-5605 J9 MIL PSYCHOL JI Milit. Psychol. PY 2006 VL 18 IS 2 BP 89 EP 120 DI 10.1207/s15327876mp1802_1 PG 32 WC Psychology, Multidisciplinary SC Psychology GA 073GP UT WOS:000239731300001 ER PT J AU Thompson, SM Cai, X Dinocourt, C Nestor, MW AF Thompson, Scott M. Cai, Xiang Dinocourt, Celine Nestor, Michael W. BE Pitkanen, A Schwartzkroin, PA Moshe, SL TI The Use of Brain Slice Cultures for the Study of Epilepsy SO MODELS OF SEIZURES AND EPILEPSY LA English DT Article; Book Chapter ID HIPPOCAMPUS IN-VITRO; EXCITATORY SYNAPTIC-TRANSMISSION; TEMPORAL-LOBE EPILEPSY; LONG-TERM POTENTIATION; SEIZURE-LIKE ACTIVITY; SEMLIKI-FOREST-VIRUS; CA1 PYRAMIDAL CELLS; RAT HIPPOCAMPUS; EPILEPTIFORM ACTIVITY; ORGANOTYPIC CULTURES C1 [Thompson, Scott M.] Univ Calif Los Angeles, W Los Angeles VA Med Ctr, Los Angeles, CA 90024 USA. [Cai, Xiang; Dinocourt, Celine; Nestor, Michael W.] Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA. RP Thompson, SM (reprint author), Univ Calif Los Angeles, W Los Angeles VA Med Ctr, Los Angeles, CA 90024 USA. NR 99 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-045702-4 PY 2006 BP 45 EP 58 DI 10.1016/B978-012088554-1/50007-4 PG 14 WC Neurosciences SC Neurosciences & Neurology GA BCT46 UT WOS:000311355400007 ER PT J AU Mazarati, AM Thompson, KW Suchomelova, L Sankar, R Shirasaka, Y Nissinen, J Pitkanen, A Bertram, E Wasterlain, CG AF Mazarati, Andrey M. Thompson, Kerry W. Suchomelova, Lucie Sankar, Raman Shirasaka, Yukiyoshi Nissinen, Jari Pitkanen, Asla Bertram, Edward Wasterlain, Claude G. BE Pitkanen, A Schwartzkroin, PA Moshe, SL TI Status Epilepticus: Electrical Stimulation Models SO MODELS OF SEIZURES AND EPILEPSY LA English DT Article; Book Chapter ID SUSTAINING STATUS EPILEPTICUS; LIMBIC STATUS EPILEPTICUS; TEMPORAL-LOBE EPILEPSY; DEEP PREPYRIFORM CORTEX; SPONTANEOUS SEIZURES; ANTIEPILEPTIC DRUGS; DEVELOPING BRAIN; NEURONAL DEATH; ANIMAL-MODELS; RAT MODEL C1 [Mazarati, Andrey M.; Thompson, Kerry W.; Suchomelova, Lucie; Shirasaka, Yukiyoshi] Univ Calif Los Angeles, W Los Angeles VA Med Ctr, Los Angeles, CA 90095 USA. [Bertram, Edward] Univ Virginia, Dept Neurol, Charlottesville, VA USA. [Nissinen, Jari; Pitkanen, Asla] Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, FIN-70211 Kuopio, Finland. [Sankar, Raman] Univ Calif Los Angeles, Brain Res Inst, Dept Neurol, Los Angeles, CA 90024 USA. [Sankar, Raman] Univ Calif Los Angeles, Brain Res Inst, Dept Pediat, Los Angeles, CA 90024 USA. RP Mazarati, AM (reprint author), Univ Calif Los Angeles, W Los Angeles VA Med Ctr, Los Angeles, CA 90095 USA. NR 70 TC 10 Z9 10 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-045702-4 PY 2006 BP 449 EP 464 DI 10.1016/B978-012088554-1/50038-4 PG 16 WC Neurosciences SC Neurosciences & Neurology GA BCT46 UT WOS:000311355400038 ER PT J AU Hull, MJ Nazarian, RM Wheeler, AE Black-Schaffer, WS Mark, EJ AF Hull, MJ Nazarian, RM Wheeler, AE Black-Schaffer, WS Mark, EJ TI Survey of 160 internal medicine and pathology resident physicians on the importance and acquisition of autopsies SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 9 BP 6A EP 6A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500010 ER PT J AU Deshpande, V Nielsen, GP Mankin, HJ Rosenberg, AE AF Deshpande, V Nielsen, GP Mankin, HJ Rosenberg, AE TI Intraosseous benign notochord cell tumors (BNCT): Further evidence supporting a relationship to chordoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 31 BP 10A EP 10A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500032 ER PT J AU Chan, MM Lu, X Iglehart, JD Miron, PL AF Chan, MM Lu, X Iglehart, JD Miron, PL TI Gene expression profiling of NMU-induced rat mammary tumors: A model of human breast cancer progression SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 95 BP 23A EP 23A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500096 ER PT J AU Bongiovanni, M Bloom, L Krane, JF Powers, CN Hintermann, S Pache, JC Faquin, WC AF Bongiovanni, M Bloom, L Krane, JF Powers, CN Hintermann, S Pache, JC Faquin, WC TI Cytomorphologic features of poorly differentiated thyroid carcinoma: A statistical analysis of 35 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Hop Univ Geneva, Geneva, Switzerland. Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Virginia Commonwealth Univ, Richmond, VA USA. CYPA Lab, Lausanne, Switzerland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 234 BP 53A EP 54A PG 2 WC Pathology SC Pathology GA 995IR UT WOS:000234094500234 ER PT J AU Brachtel, EF Iafrate, AJ Mark, EJ Deshpande, V AF Brachtel, EF Iafrate, AJ Mark, EJ Deshpande, V TI Epidermal growth factor receptor (EGFR) mutations in lung carcinomas are associated with distinct cytomorphological features SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 235 BP 54A EP 54A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500235 ER PT J AU Chandan, VS Faquin, WC Wilber, D Khurana, KK AF Chandan, VS Faquin, WC Wilber, D Khurana, KK TI Immunolocalization of CD57 and GLUT-1 in cell blocks: Role in fine needle aspiration diagnosis of papillary thyroid carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 SUNY, Upstate Med Univ, Syracuse, NY USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 237 BP 54A EP 54A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500237 ER PT J AU Eichhorn, JH Buckner, L Buckner, SB Beech, DP Crothers, BA Wilbur, DC AF Eichhorn, JH Buckner, L Buckner, SB Beech, DP Crothers, BA Wilbur, DC TI Internet-based gynecologic telecytology with remote automated image selection: Results of a first-phase development trial SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Walter Reed Army Med Ctr, Washington, DC 20307 USA. Natl Naval Med Res Inst, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 245 BP 56A EP 56A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500245 ER PT J AU Green, LK AF Green, LK TI Granulomatous inflammation in cytopathology: A review of 154 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Houston VAMC, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 257 BP 58A EP 58A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500257 ER PT J AU Ogino, S Brahmandam, M Cantor, M Namgyal, C Kawasaki, T Kirkner, G Meyerhardt, JA Loda, M Fuchs, CS AF Ogino, S Brahmandam, M Cantor, M Namgyal, C Kawasaki, T Kirkner, G Meyerhardt, JA Loda, M Fuchs, CS TI Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component SO MODERN PATHOLOGY LA English DT Article DE BRAF; colon cancer; COX2; fatty acid synthase; MSI; mucinous; signet ring cell ID FATTY-ACID SYNTHASE; MISMATCH-REPAIR; COLON-CANCER; MICROSATELLITE INSTABILITY; PROGNOSTIC INDICATOR; ANTITUMOR-ACTIVITY; PROSTATE-CANCER; EXPRESSION; PROTEIN; CYCLOOXYGENASE-2 AB Signet ring cell carcinoma and mucinous carcinoma are distinct subtypes of colorectal adenocarcinoma. The morphologic and molecular spectra of colorectal carcinomas with various signet ring cell components and colorectal carcinomas with various mucinous components, compared to non-mucinous adenocarcinomas, have not been examined. The study groups consisted of 39 carcinomas with various signet ring cell components ('the signet group'), 167 carcinomas with various mucinous components ('the mucinous group'), and 457 nonmucinous adenocarcinoma. We visually estimated the amounts of signet ring cell and mucinous components in tumors, and subclassified the signet and mucinous groups according to the amount of each component (<= 19, 20 - 49, and >= 50%). We sequenced BRAF and KRAS, analyzed for microsatellite instability (MSI) and 18q loss of heterozygosity (LOH), and performed immunohistochemistry for TP53, cyclooxygenase-2 (COX2), MLH1, O-6-methylguanine DNA methyltransferase (MGMT), p16 (CDKN2A), and fatty acid synthase (FASN). Signet ring cell carcinoma (>= 50% signet ring cell tumors) and <= 49% signet ring cell tumors showed similar molecular features. Except for MSI and MGMT, >= 50% mucinous tumors and <= 49% mucinous tumors also showed similar molecular features. BRAF mutations, MSI, and MLH1 loss were more frequent in both the signet and mucinous groups than nonmucinous carcinoma. More frequent KRAS mutations and less frequent p16 loss and TP53 positivity were observed in the mucinous group than nonmucinous carcinoma. 18q LOH and COX2 overexpression were less common in the signet group than nonmucinous carcinoma. FASN levels were highest in the mucinous group, followed by nonmucinous carcinoma, and lowest in the signet group. In conclusion, a minor (<= 49%) signet ring cell or mucinous component in colorectal carcinoma suggests molecular features similar to >= 50% signet ring cell or mucinous carcinoma, respectively. Signet ring cell carcinoma and mucinous carcinoma are related subtypes of colorectal adenocarcinoma, but have molecular features distinct from each other. C1 Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. RP Ogino, S (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. EM shuji_ogino@dfci.harvard.edu FU NCI NIH HHS [P01 CA55075-13, P01 CA87969-03] NR 43 TC 112 Z9 119 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 IS 1 BP 59 EP 68 DI 10.1038/modpathol.3800482 PG 10 WC Pathology SC Pathology GA 995YB UT WOS:000234140000007 PM 16118624 ER PT J AU Kasuganti, D Green, L Reddy, VB Kluskens, L Gattuso, P AF Kasuganti, D Green, L Reddy, VB Kluskens, L Gattuso, P TI Hematologic malignancies involving body cavities: Diagnostic and prognostic implications in 116 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Rush Univ, Med Ctr, Chicago, IL 60612 USA. Houston VAMC, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 267 BP 61A EP 61A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500267 ER PT J AU Ko V Nanji, SS Tambouret, RH Wilbur, DC AF Ko, V Nanji, SS Tambouret, RH Wilbur, DC TI Testing for HPV as an objective measure for quality assurance in gynecologic cytology: Positive rates in equivocal and abnormal specimens SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 272 BP 62A EP 62A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500272 ER PT J AU Ko V Tambouret, RH Kuebler, D Black-Schaffer, WS Wilbur, DC AF Ko, V Tambouret, RH Kuebler, D Black-Schaffer, WS Wilbur, DC TI Validation of HPV testing using Hybrid Capture II with the Surepath collection method SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 271 BP 62A EP 62A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500271 ER PT J AU Michaels, PJ Rollins, SE Bounds, BC Brugge, WR Pitman, MB AF Michaels, PJ Rollins, SE Bounds, BC Brugge, WR Pitman, MB TI Cyst fluid analysis and endoscopic features aid in the preoperative grading of intraductal papillary mucinous neoplasms of the pancreas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 293 BP 66A EP 67A PG 2 WC Pathology SC Pathology GA 995IR UT WOS:000234094500293 ER PT J AU Nagle, JA Eichhorn, JH Crothers, BA Wilbur, DC AF Nagle, JA Eichhorn, JH Crothers, BA Wilbur, DC TI Determination of specimen adequacy and the presence of transformation zone component using an automated Internet-based telecytology system for cervical cytology SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Walter Reed Army Med Ctr, Washington, DC 20307 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 295 BP 67A EP 67A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500295 ER PT J AU Nanji, SS Eichhorn, JH Crothers, BA Wilbur, DC AF Nanji, SS Eichhorn, JH Crothers, BA Wilbur, DC TI Determining the effective cervical cytology triage point using an automated Internet-based telecytology system with hierarchical image review SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Walter Reed Army Med Ctr, Washington, DC 20307 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 296 BP 67A EP 67A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500296 ER PT J AU Shah, SS Chandan, VS Wilbur, DC Khurana, KK AF Shah, SS Chandan, VS Wilbur, DC Khurana, KK TI GFAP and CD57 immunolocalization in cell block preparations is a useful adjunct in the diagnosis of pleomorphic adenoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 SUNY Syracuse, Upstate Med Univ, Syracuse, NY USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 317 BP 72A EP 72A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500317 ER PT J AU Chaudhry, IH Zembowicz, A AF Chaudhry, IH Zembowicz, A TI Adnexal clear cell carcinoma with comedonecrosis: Clinicopathological analysis of 12 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Leeds Gen Infirm, Leeds, W Yorkshire, England. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 343 BP 77A EP 77A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500343 ER PT J AU Doeden, KS Mihm, MC Detmar, M Dadras, SS AF Doeden, KS Mihm, MC Detmar, M Dadras, SS TI LYVE-1 and D2-40, two lymphatic specific markers, increase detection of lymphatic invasion in cutaneous melanoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Stanford Univ, Med Ctr, Stanford, CA 94305 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Swiss Fed Inst Technol, Zurich, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 355 BP 80A EP 80A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500355 ER PT J AU Dahia, PL Powers, JF Alvarado-Cabrero, I Ehsani, SA Albores-Saavedra, J Tischler, AS AF Dahia, PL Powers, JF Alvarado-Cabrero, I Ehsani, SA Albores-Saavedra, J Tischler, AS TI Expression of Notch3 protein in "high altitude paragangliomas" SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Tufts New England Med Ctr, Boston, MA USA. IMSS, Oncol Hosp, Mexico City, DF, Mexico. LSU, Hlth Sci Ctr, Shreveport, LA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 413 BP 91A EP 92A PG 2 WC Pathology SC Pathology GA 995IR UT WOS:000234094500413 ER PT J AU Bronner, MP Walker, E Burgart, L Goldblum, JR Greenson, JK Haber, M Hart, J Lauwers, G Lazenby, A Lewin, D Robert, M Washington, K Montgomery, E AF Bronner, MP Walker, E Burgart, L Goldblum, JR Greenson, JK Haber, M Hart, J Lauwers, G Lazenby, A Lewin, D Robert, M Washington, K Montgomery, E TI Diagnostic accuracy in ulcerative colitis neoplasia SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Cleveland Clin, Cleveland, OH 44106 USA. Mayo Clin, Rochester, MN USA. Univ Michigan, Ann Arbor, MI 48109 USA. MCP Hahnemann, Philadelphia, PA USA. Univ Chicago, Chicago, IL 60637 USA. Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA. Univ Alabama, Tuscaloosa, AL 35487 USA. Med Univ S Carolina, Charleston, SC 29425 USA. Yale Univ, New Haven, CT 06520 USA. Vanderbilt Univ, Nashville, TN USA. Johns Hopkins Univ, Baltimore, MD 21218 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 468 BP 103A EP 103A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500468 ER PT J AU Deshpande, V Chicano, SL Selig, MK Mino-Kenudson, M Colvin, RB Lauwers, GY AF Deshpande, V Chicano, SL Selig, MK Mino-Kenudson, M Colvin, RB Lauwers, GY TI Autoimmune pancreatitis: A systemic IgG4 immune complex mediated disease SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 482 BP 106A EP 106A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500482 ER PT J AU Farraye, FA Andrews, CW Shah, SA Becker, JM Bleday, R Ashley, S Hodin, R Eisenberg, M Berger, BM Odze, RD AF Farraye, FA Andrews, CW Shah, SA Becker, JM Bleday, R Ashley, S Hodin, R Eisenberg, M Berger, BM Odze, RD TI Analysis of DNA mutations in stool is a novel method to detect neoplasia in patients with inflammatory bowel disease SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Boston Med Ctr, Boston, MA USA. Brown Univ, Providence, RI 02912 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Lab Corp Amer, Res Triangle Pk, NC USA. Exact Sci, Marlborough, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 486 BP 107A EP 107A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500486 ER PT J AU Farris, AB Srivastava, A Misdraji, J Lauwers, GY Mino-Kenudson, M AF Farris, AB Srivastava, A Misdraji, J Lauwers, GY Mino-Kenudson, M TI Sessile serrated polyp/adenoma: Challenging discrimination from other colonic polyps SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 487 BP 107A EP 108A PG 2 WC Pathology SC Pathology GA 995IR UT WOS:000234094500487 ER PT J AU Mino-Kenudosn, M Ban, S Deshpande V Shimizu, M Lauwers, GY AF Mino-Kenudosn, M Ban, S Deshpande, V Shimizu, M Lauwers, GY TI Buried dysplasia and early adenocarcinoma arising in Barrett esophagus (BE) after photodynamic therapy (PDT): Not uncommon findings SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Saitama Med Sch, Moroyama, Saitama 35004, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 516 BP 114A EP 114A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500516 ER PT J AU Mino-Kenudson, M Ohana, M Ban, S Deshpande V Shimizu, M Lauwers, GY AF Mino-Kenudson, M Ohana, M Ban, S Deshpande, V Shimizu, M Lauwers, GY TI Barrett Esophagus associated neoplasms treated by photodynamic therapy: Determination of limiting factors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Saitama Med Sch, Moroyama, Saitama 35004, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 517 BP 114A EP 114A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500517 ER PT J AU Mitsuhashi, T Lauwers, GY Ban, S Mino-Kenudson, M Shimizu, Y Ogawa, F Shimizu, M AF Mitsuhashi, T Lauwers, GY Ban, S Mino-Kenudson, M Shimizu, Y Ogawa, F Shimizu, M TI Post-gastric EMR surveillance biopsies: Evaluation of mucosal changes and recognition of potential mimics of residual adenocarcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Tohoku Univ, Grad Sch Med Sci, Sendai, Miyagi 980, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Saitama Med Sch, Moroyama, Saitama 35004, Japan. RI Mitsuhashi, Tomoko/A-6996-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 518 BP 114A EP 114A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500518 ER PT J AU Ogino, S Brahmandam, M Cantor, M Namgyal, C Kawasaki, T Kirkner, G Meyerhardt, J Loda, M Fuchs, CS AF Ogino, S Brahmandam, M Cantor, M Namgyal, C Kawasaki, T Kirkner, G Meyerhardt, J Loda, M Fuchs, CS TI Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 8 Z9 8 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 523 BP 115A EP 116A PG 2 WC Pathology SC Pathology GA 995IR UT WOS:000234094500523 ER PT J AU Ogino, S Cantor, M Kawasaki, T Brahmandam, M Weisenberger, DJ Laird, PW Loda, M Fuchs, CS AF Ogino, S Cantor, M Kawasaki, T Brahmandam, M Weisenberger, DJ Laird, PW Loda, M Fuchs, CS TI Quantitative DNA methylation analysis determines CpG island methylation phenotype (CIMP) as a distinct subtype of colorectal cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ So Calif, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 524 BP 116A EP 116A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500524 ER PT J AU Srivastava, A Misdraji, J Lauwers, GY Graeme-Cook, F Odze, RD AF Srivastava, A Misdraji, J Lauwers, GY Graeme-Cook, F Odze, RD TI Goblet cell tumors of the appendix: An immunohistochemical and outcome analysis of 63 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 545 BP 120A EP 120A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094500545 ER PT J AU Abreu-e-Lima, P Sadow, PM Nakamura, E Kaelin, WG Nose, V AF Abreu-e-Lima, P Sadow, PM Nakamura, E Kaelin, WG Nose, V TI Clusterin expression differentiates wild type-VHL from VHL-defective sporadic clear cell renal cell carcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Howard Hughes Med Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 576 BP 126A EP 127A PG 2 WC Pathology SC Pathology GA 995IR UT WOS:000234094501015 ER PT J AU He, W Dahl, DM McDougal, WS Wu, CL AF He, W Dahl, DM McDougal, WS Wu, CL TI Laparoscopic versus open radical prostatectomy: Analysis of 1000 cases at Massachusetts General Hospital SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 646 BP 141A EP 141A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501085 ER PT J AU Perner, SR Hofer, MD Li, H Kuefer, R Gschwend, J Hautmann, R Moeller, P Rubin, MA AF Perner, SR Hofer, MD Li, H Kuefer, R Gschwend, J Hautmann, R Moeller, P Rubin, MA TI Prostate-specific membrane antigen (PSMA) expression as a predictor of prostate cancer progression SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Hosp Ulm, Ulm, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 715 BP 155A EP 155A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501154 ER PT J AU de Leval, L Waltregny, D Dupuis, LM Boniver, J Oliva, E AF de Leval, L Waltregny, D Dupuis, LM Boniver, J Oliva, E TI Uterine tumors resembling ovarian sex-cord tumors: A study of 14 cases showing a diverse phenotypic profile SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 CHU Sart Tilman, B-4000 Liege, Belgium. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 812 BP 176A EP 176A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501251 ER PT J AU Hauptmann, S Schmidt, H Bilkenroth, U Kobel, M Czernobilsky, B Roth, L McCluggage, G Scully, RE Oliva, E AF Hauptmann, S Schmidt, H Bilkenroth, U Kobel, M Czernobilsky, B Roth, L McCluggage, G Scully, RE Oliva, E TI Small cell carcinoma of the ovary of the hypercalcemic type: A highly aggressive neoplasm without CGH aberrations SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Univ Halle Wittenberg, Halle Saale, Saale, Germany. Patho Lab Ltd, Ness Ziona, Israel. Indiana Univ, Med Ctr, Indianapolis, IN USA. Royal Grp Hosp Trusts, Belfast, Antrim, North Ireland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 836 BP 181A EP 181A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501275 ER PT J AU Hristov, AC Vang, R Young, RH Seidman, JD Ronnett, BM AF Hristov, AC Vang, R Young, RH Seidman, JD Ronnett, BM TI Ovarian metastases of appendiceal tumors with goblet cell carcinoid-like features: Limited expression of neuroendocrine markers and clinicopathologic features of aggressive invasive carcinoma support designation as adenocarcinoma rather than goblet cell carcinoid tumor SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Washington Hosp Ctr, Washington, DC 20010 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 838 BP 181A EP 181A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501277 ER PT J AU Lopez-Varela, E Fuller, AF Orsulic, S Miao, J Parks, KU Oliva, E AF Lopez-Varela, E Fuller, AF Orsulic, S Miao, J Parks, KU Oliva, E TI Hepsin expression in surface epithelial carcinomas of the ovary. An immunohistochemical tissue microarray analysis of 70 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 870 BP 188A EP 188A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501309 ER PT J AU McCluggage, WG Young, RH AF McCluggage, WG Young, RH TI Paraganglioma of the ovary: Three cases of an extremely rare primary ovarian neoplasm, including two exhibiting inhibin positivity SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Royal Grp Hosp Trust, Belfast, Antrim, North Ireland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 875 BP 189A EP 189A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501314 ER PT J AU Oliva, E Wang, WL Branton, P Logani, S Zannoni, GF Linkov I Asher, M Soslow, RA AF Oliva, E Wang, WL Branton, P Logani, S Zannoni, GF Linkov, I Asher, M Soslow, RA TI Expression of Melanocytic ("PEComa") markers in smooth muscle tumors of the uterus: An immunohistochemcial analyisis of 86 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Inova Fairfax Hosp, Falls Church, VA USA. Emory Univ, Atlanta, GA 30322 USA. Univ Cattolica, Rome, Italy. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 884 BP 191A EP 191A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501323 ER PT J AU Oliva, E de Leval, L De Ceuninck, C Augenbron V Soslow, RA Herens, C AF Oliva, E de Leval, L De Ceuninck, C Augenbron, V Soslow, RA Herens, C TI Interphase FISH detection of JAZF1-JJAZ1 gene fusion in endometrial stromal tumors with smooth muscle differentiation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. CHU Sart Tilman, B-4000 Liege, Belgium. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 883 BP 191A EP 191A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501322 ER PT J AU Silva, EG Young, RH AF Silva, EG Young, RH TI The spectrum of clear cells in endometrioid neoplasms (other than secretory type) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 915 BP 197A EP 197A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501354 ER PT J AU Soslow, RA Ali, A Negron, E Linkov I Asher, M Oliva, E AF Soslow, RA Ali, A Negron, E Linkov, I Asher, M Oliva, E TI Mullerian adenosarcomas: An immunophenotypic analysis of 35 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 918 BP 197A EP 198A PG 2 WC Pathology SC Pathology GA 995IR UT WOS:000234094501357 ER PT J AU Staats, PN Clement, PB Young, RH AF Staats, PN Clement, PB Young, RH TI Primary adenocarcinoma (other than clear cell type) of the vagina: A clinicopathologic study of 31 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Vancouver Gen Hosp, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 921 BP 198A EP 198A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501360 ER PT J AU Turbiner, J Sanchez, C Sarrio, D Moreno, G Franceschetti, I Palacios, J Oliva, E AF Turbiner, J Sanchez, C Sarrio, D Moreno, G Franceschetti, I Palacios, J Oliva, E TI Pathogenetic pathways in ovarian endometrioid adenocarcinoma: A molecular study of 29 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. CNIO, Madrid, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 926 BP 199A EP 199A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501365 ER PT J AU Wang, WL Soslow, RA Zannoni, GF Branton, P Nonaka, D Oliva, E AF Wang, WL Soslow, RA Zannoni, GF Branton, P Nonaka, D Oliva, E TI The utility of tumor cell necrosis in the diagnosis of primary leiomyosarcoma of the uterus: An analysis of 77 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Cattolica, Rome, Italy. Inova Fairfax Hosp, Falls Church, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 932 BP 201A EP 201A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501371 ER PT J AU Chen, X Cesarman, E Hyjek, E Kaplan, LD Scadden, DT Chadburn, A AF Chen, X Cesarman, E Hyjek, E Kaplan, LD Scadden, DT Chadburn, A TI FOXP1 expression in AIDS-associated diffuse large B-cell lymphoma (DLBCL): Correlation with prognostic parameters in patients from AIDS malignancies consortium trial 010 SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Weill Cornell Med Coll, New York, NY USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1016 BP 219A EP 219A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501455 ER PT J AU Ferry, JA Fung, C Zukerberg, L Hasserjian, R Preffer, F Harris, NL AF Ferry, JA Fung, C Zukerberg, L Hasserjian, R Preffer, F Harris, NL TI Lymphoma of the ocular adnexa: A study of 353 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1045 BP 225A EP 225A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094501484 ER PT J AU Gupta, R Hasserjian, RP Rezuke, WN DiGiuseppe, JA Hunt, JP AF Gupta, R Hasserjian, RP Rezuke, WN DiGiuseppe, JA Hunt, JP TI Percentage hematogones by flow cytometric analysis is lower in patients with myelodysplastic syndrome than in cytopenic patients without myelodysplastic syndrome SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Baystate Med Ctr, Springfield, MA USA. Hartford Hosp, Hartford, CT 06115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1062 BP 229A EP 229A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502005 ER PT J AU Gupta, R Johari V Hasserjian, RP AF Gupta, R Johari, V Hasserjian, RP TI Myelodysplastic syndrome with isolated del(20q): A distinct clinicopathologic entity? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Baystate Med Ctr, Springfield, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1063 BP 229A EP 229A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502006 ER PT J AU Rahemtullah, A Rezk, S Wang, SA Hasserjian, RP AF Rahemtullah, A Rezk, S Wang, SA Hasserjian, RP TI Aberrant expression of CD5 and CD10 in hairy cell leukemia: Correlation with clinical presentation and outcome SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. UMass Mem Med Ctr, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1125 BP 242A EP 243A PG 2 WC Pathology SC Pathology GA 995IR UT WOS:000234094502068 ER PT J AU Rodig, SJ Abramson, JS Pinkus, GS Shipp, MA Kutok, JL AF Rodig, SJ Abramson, JS Pinkus, GS Shipp, MA Kutok, JL TI Evaluation of CD52 expression in hematopoietic neoplasms by standard immunohistochemistry: Implications for the expanded use of alemtuzumab (CAMPATH-1H) in the treatment of hematologic malignancies SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1132 BP 244A EP 244A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502075 ER PT J AU Rodig, SJ Savage, KJ Harris, NL Shipp, MA Hsi, ED Gascoyne, RD Kutok, JL AF Rodig, SJ Savage, KJ Harris, NL Shipp, MA Hsi, ED Gascoyne, RD Kutok, JL TI Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large B cell lymphoma from nodal diffuse large B cell lymphoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1133 BP 244A EP 244A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502076 ER PT J AU Seliem, RM Wang, WL Hasserjian, RP Ferry, JA Harris, NL Zukerberg, LR AF Seliem, RM Wang, WL Hasserjian, RP Ferry, JA Harris, NL Zukerberg, LR TI CD30 positive cells in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): A clinicopathologic evaluation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1140 BP 246A EP 246A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502083 ER PT J AU Chicano, SL Cornell, LD Selig, MK Collins, AB McCluskey, RT Colvin, RB AF Chicano, SL Cornell, LD Selig, MK Collins, AB McCluskey, RT Colvin, RB TI Distinctive ultrastructural features of chronic allograft glomerulopathy: New formation of circumferential glomerular basement membrane SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1207 BP 260A EP 261A PG 2 WC Pathology SC Pathology GA 995IR UT WOS:000234094502150 ER PT J AU Cornell, LD Chicano, SL Deshpande, V Collins, AB Selig, MK Lauwers, GY Colvin, RB AF Cornell, LD Chicano, SL Deshpande, V Collins, AB Selig, MK Lauwers, GY Colvin, RB TI IgG4 immune-complex tubulointerstitial nephritis associated with autoimmune pancreatitis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1208 BP 261A EP 261A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502151 ER PT J AU Rotman, SC Smith, RN Kawai, T Della Pelle, P Cosimi, AB Colvin, RB AF Rotman, SC Smith, RN Kawai, T Della Pelle, P Cosimi, AB Colvin, RB TI Detection of T regulatory cells expressing Foxp3 in renal allografts: Potential pathogenetic and diagnostic implications SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1228 BP 265A EP 265A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502171 ER PT J AU Chu, GC Bardeesy, N Aguirre, AJ Redston, MS DePinho, RA AF Chu, GC Bardeesy, N Aguirre, AJ Redston, MS DePinho, RA TI p53 and p16(Ink4a) constrain progression of pancreatic adenocarcinoma in the mouse: Correlations between genotype and histologic phenotype SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1258 BP 271A EP 271A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502201 ER PT J AU Mino-Kenudson, M Ban, S Deshpande, V Sakurai, T Kuroda, M Shimizu, M Lauwers, GY AF Mino-Kenudson, M Ban, S Deshpande, V Sakurai, T Kuroda, M Shimizu, M Lauwers, GY TI Mucinous cystic neoplasm: Unique ovarian stroma but heterogeneous epithelial lining SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Saitama Med Sch, Saitama, Japan. Kyoto Univ Hosp, Kyoto 606, Japan. Fujita Hlth Univ, Sch Med, Aichi, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1286 BP 277A EP 277A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502229 ER PT J AU Suh, N Liapis, H Misdraji, J Brunt, EM Wang, HL AF Suh, N Liapis, H Misdraji, J Brunt, EM Wang, HL TI Epstein-Barr virus hepatitis: Diagnostic value of immunohistochemistry, in situ hybridization and polymerase chain reaction on liver biopsy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Washington Univ, St Louis, MO USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. St Louis Univ, St Louis, MO 63103 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1301 BP 280A EP 280A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502244 ER PT J AU Coon, D Roberts, D Kradin, R AF Coon, D Roberts, D Kradin, R TI Differential epithelial expression of sonic hedge hog and Foxfi1 in interstial pneumonias SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1425 BP 306A EP 306A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502368 ER PT J AU Matsubara, O Imazeki, N Nakatani, Y Mark, EJ AF Matsubara, O Imazeki, N Nakatani, Y Mark, EJ TI Role of lymphangiogenesis in repair and remodeling of the lung after acute lung injury SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Med Coll, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1459 BP 313A EP 313A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502402 ER PT J AU Matsubara, O Imazeki, N Okochi, Y Nakatani, Y Mark, EJ AF Matsubara, O Imazeki, N Okochi, Y Nakatani, Y Mark, EJ TI Distribution, density and morphology of Langerhans' cells in the lung: Relationship to lung development, pulmonary fibrosis and smoking SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1458 BP 313A EP 313A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502401 ER PT J AU Balis, UJ AF Balis, UJ TI Real-time region-of-interest-based image database query and differential diagnosis generation utilizing third-generation Vector Quantization techniques in concert with N-space Voronoi mapping SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1513 BP 324A EP 324A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502456 ER PT J AU Tholouli, E Divizio, D O'Connell, F Twomey, D Levenson, R Hoyland, JA Liu-Yin, JA Lee, CA Golub, TR Loda, M Byers, RJ AF Tholouli, E Divizio, D O'Connell, F Twomey, D Levenson, R Hoyland, JA Liu-Yin, JA Lee, CA Golub, TR Loda, M Byers, RJ TI In-situ gene expression profiling in clinical samples by quantum dot based multiplex hybridization SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 11-17, 2006 CL Atlanta, GA SP US & Canadian Acad Pathol C1 Manchester Royal Infirm, Manchester M13 9WL, Lancs, England. Univ Manchester, Manchester, Lancs, England. Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. MIT, Boston, MA USA. CRI, Woburn, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2006 VL 19 SU 1 MA 1562 BP 335A EP 335A PG 1 WC Pathology SC Pathology GA 995IR UT WOS:000234094502505 ER PT J AU Buttery, S Yoshida, S Pellman, D AF Buttery, S. Yoshida, S. Pellman, D. TI Yeast Formins Bni1 and Bnr1 Utilize Different Modes of Cortical Interaction during the Assembly of Actin Cables SO MOLECULAR BIOLOGY OF THE CELL LA English DT Meeting Abstract C1 [Buttery, S.; Yoshida, S.; Pellman, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 J9 MOL BIOL CELL JI Mol. Biol. Cell PY 2006 VL 17 PG 1 WC Cell Biology SC Cell Biology GA V05MS UT WOS:000207130700335 ER PT J AU Cai, X Lietha, D Karginov, AV Rajfur, Z Jacobson, K Hahn, KM Eck, MJ Schaller, MD AF Cai, X. Lietha, D. Karginov, A. V. Rajfur, Z. Jacobson, K. Hahn, K. M. Eck, M. J. Schaller, M. D. TI Visualizing the Spatial and Temporal Regulation of FAK Activity in Living Cells SO MOLECULAR BIOLOGY OF THE CELL LA English DT Meeting Abstract C1 [Cai, X.; Rajfur, Z.; Jacobson, K.; Schaller, M. D.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC USA. [Lietha, D.; Eck, M. J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Karginov, A. V.; Hahn, K. M.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA. [Jacobson, K.; Hahn, K. M.; Schaller, M. D.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Schaller, M. D.] Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC USA. RI Rajfur, Zenon/H-2506-2013; Lietha, Daniel/L-8041-2014 OI Lietha, Daniel/0000-0002-6133-6486 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 J9 MOL BIOL CELL JI Mol. Biol. Cell PY 2006 VL 17 PG 1 WC Cell Biology SC Cell Biology GA V05MS UT WOS:000207130700359 ER PT J AU Huang, S Bustos, R Munagala, ID Benz, EJ AF Huang, S. Bustos, R. Munagala, I. D. Benz, E. J. TI Interaction of Protein 4.1R and Actin Stabilizes E-cadherin-dependent Intercellular Adhesion in Epithelial Adherens Junctions SO MOLECULAR BIOLOGY OF THE CELL LA English DT Meeting Abstract C1 [Huang, S.; Bustos, R.; Munagala, I. D.; Benz, E. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 J9 MOL BIOL CELL JI Mol. Biol. Cell PY 2006 VL 17 PG 1 WC Cell Biology SC Cell Biology GA V05MS UT WOS:000207130700375 ER PT J AU Mahon, MJ Bonacci, TM Divieti, P Smrcka, AV AF Mahon, MJ Bonacci, TM Divieti, P Smrcka, AV TI A docking site for G protein beta gamma subunits on the parathyroid hormone 1 receptor supports signaling through multiple pathways SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID HORMONE (PTH)/PTH-RELATED PEPTIDE; 3RD INTRACELLULAR LOOP; CYCLIC-AMP PRODUCTION; PHOSPHOLIPASE-C-BETA; OPOSSUM KIDNEY-CELLS; PERTUSSIS TOXIN; COUPLED RECEPTORS; ADENYLYL-CYCLASE; TERMINAL REGION; G-ALPHA AB The G protein-coupled receptor for PTH and PTH-related protein ( PTH1R) signals via many intracellular pathways. The purpose of this work is to investigate a G protein binding site on an intracellular domain of the PTH1R. The carboxy-terminal, cytoplasmic tail of the PTH1R fused to glutathione-S-transferase interacts with G(i/o) proteins in vitro. All three subunits of the heterotrimer interact with the receptor C-tail. Activation of the heterotrimeric complex with GTP gamma S has no effect on G beta gamma interactions, but markedly disrupts binding of the G alpha(i/o) subunits to the receptor tail, suggesting that direct G beta gamma binding indirectly links G alpha subunits to this region of the receptor. G beta gamma subunits alone bind the C-tail with an affinity that is comparable to the heterotrimeric G protein complex. G protein complexes consisting of G alpha(s)his(6)-beta(1)gamma(2) and G alpha(q)his(6)beta(1)gamma(2) also interact with the PTH1R tail in vitro. The G beta gamma interaction domain is located on the juxta-membrane region of the tail between amino acids 468 and 491. Mutations that disrupt G beta gamma interactions block PTH signaling via phospholipase C beta/ [ Ca2+](i) and MAPK and markedly reduce signaling via adenylyl cyclase/cAMP. Herein, we define a domain on the PTH1R that is capable of binding G protein heterotrimeric complexes via direct G beta gamma interactions. C1 Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA. RP Mahon, MJ (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Wellman 501,50 Blossom St, Boston, MA 02114 USA. EM mahon@helix.mgh.harvard.edu FU NHLBI NIH HHS [HLT3207949]; NIDDK NIH HHS [K01 DK59900-01]; NIGMS NIH HHS [GM60286] NR 56 TC 36 Z9 37 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD JAN PY 2006 VL 20 IS 1 BP 136 EP 146 DI 10.1210/me.2005-0169 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 997FH UT WOS:000234230000011 PM 16099817 ER PT J AU Volinic, JL Lee, JH Eto, K Kaur, V Thomas, MK AF Volinic, JL Lee, JH Eto, K Kaur, V Thomas, MK TI Overexpression of the coactivator Bridge-1 results in insulin deficiency and diabetes SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID PANCREATIC BETA-CELLS; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; PDZ DOMAINS; ENDOCRINE PANCREAS; GENOMEWIDE SEARCH; FINNISH FAMILIES; TRANSGENIC MICE; MELLITUS; PROTEIN AB Multiple forms of heritable diabetes are associated with mutations in transcription factors that regulate insulin gene transcription and the development and maintenance of pancreatic beta-cell mass. The coactivator Bridge-1 ( PSMD9) regulates the transcriptional activation of glucose-responsive enhancers in the insulin gene in a dose-dependent manner via PDZ domain-mediated interactions with E2A transcription factors. Here we report that the pancreatic overexpression of Bridge-1 in transgenic mice reduces insulin gene expression and results in insulin deficiency and severe diabetes. Dysregulation of Bridge-1 signaling increases pancreatic apoptosis with a reduction in the number of insulin-expressing pancreatic beta-cells and an expansion of the complement of glucagon-expressing pancreatic beta-cells in pancreatic islets. Increased expression of Bridge- 1 alters pancreatic islet, acinar, and ductal architecture and disrupts the boundaries between endocrine and exocrine cellular compartments in young adult but not neonatal mice, suggesting that signals transduced through this coactivator may influence postnatal pancreatic islet morphogenesis. Signals mediated through the coactivator Bridge-1 may regulate both glucose homeostasis and pancreatic beta-cell survival. We propose that coactivator dysfunction in pancreatic beta-cells can limit insulin production and contribute to the pathogenesis of diabetes. C1 Massachusetts Gen Hosp, Lab Mol Endocrinol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Thomas, MK (reprint author), Massachusetts Gen Hosp, Lab Mol Endocrinol, Thier 340,50 Blossom St, Boston, MA 02114 USA. EM mthomas1@partners.org FU NIDDK NIH HHS [DK59419, DK58783] NR 75 TC 16 Z9 16 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD JAN PY 2006 VL 20 IS 1 BP 167 EP 182 DI 10.1210/me.2005-0127 PG 16 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 997FH UT WOS:000234230000013 PM 16099819 ER PT J AU Kelly, KA Clemons, PA Yu, AM Weissleder, R AF Kelly, Kimberly A. Clemons, Paul A. Yu, Amy M. Weissleder, Ralph TI High-throughput identification of phage-derived imaging agents SO MOLECULAR IMAGING LA English DT Article DE macrophages; phage display; high throughput ID MULTIMODAL NANOPARTICLE; IRON-OXIDE; EXPRESSION; CANCER; CELLS; INFLAMMATION; MACROPHAGES; PEPTIDE AB The use of phage-displayed peptide libraries is a powerful method for selecting peptides with desired binding properties. However, the validation and prioritization of "hits" obtained from this screening approach remains challenging. Here, we describe the. development and testing of a new analysis method to identify and display hits from phage-display experiments and high-throughput enzyme-linked immunosorbent assay screens. We test the method using a phage screen against activated macrophages to develop imaging agents with higher specificity for active disease processes. The new methodology should be useful in identifying phage hits and is extendable to other library screening methods such as small-molecule and nanoparticle libraries. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA. MIT, Cambridge, MA 02139 USA. Harvard Univ, Eli & Edythe Broad Inst, Cambridge, MA 02138 USA. RP Kelly, KA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 149 13th St,Room 5420, Charlestown, MA 02129 USA. EM kkelly9@partners.org FU NCI NIH HHS [P50 CA86355] NR 21 TC 13 Z9 15 U1 0 U2 2 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1535-3508 J9 MOL IMAGING JI Mol. Imaging PD JAN-MAR PY 2006 VL 5 IS 1 BP 24 EP 30 DI 10.2310/7290.2006.00003 PG 7 WC Biochemical Research Methods; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical Imaging GA 064KB UT WOS:000239086900003 PM 16779967 ER PT J AU Runnels, JM Zamiri, P Spencer, JA Veilleux, I Wei, XB Bogdanov, A Lin, CP AF Runnels, Judith M. Zamiri, Parisa Spencer, Joel A. Veilleux, Isreal Wei, Xunbin Bogdanov, Alexei Lin, Charles P. TI Imaging molecular expression on vascular endothelial cells by in vivo immunofluorescence microscopy SO MOLECULAR IMAGING LA English DT Article DE imaging; in vivo confocal microscopy; multiphoton microscopy; adhesion molecules; selectins ID INTERCELLULAR-ADHESION MOLECULE-1; SCANNING LASER MICROSCOPY; E-SELECTIN; LEUKOCYTE TRAFFICKING; DIABETIC-RETINOPATHY; LYMPH-NODES; P-SELECTINS; HUMAN SKIN; RECRUITMENT; INFLAMMATION AB Molecular expression on the vascular endothelium is critical in regulating the interaction of circulating cells with the blood vessel wall. Leukocytes as well as circulating cancer cells gain entry into tissue by interacting with adhesion molecules on the endothelial cells (EC). Molecular targets on the EC are increasingly being explored for tissue-specific delivery of therapeutic and imaging agents. Here we use in vivo immunofluorescence microscopy to visualize the endothelial molecular expression in the vasculature of live animals. High-resolution images are obtained by optical sectioning through the intact skin using in vivo confocal and multiphoton microscopy after in situ labeling of EC surface markers with fluorescent antibodies. Other vascular beds such as the bone marrow and ocular blood vessels can be imaged with little or no tissue manipulation. Live imaging is particularly useful for following the dynamic expression of inducible molecules such as E-selectin during an inflammatory response. C1 Massachusetts Gen Hosp, Wellman Ctr Photobiol, Adv Microscopy Program, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA 02114 USA. RP Lin, CP (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BHX 630,55 Fruit St, Boston, MA 02114 USA. EM Lin@helix.mgh.harvard.edu RI Spencer, Joel/A-4590-2013 FU NEI NIH HHS [EY14106, R01 EY014106]; NIBIB NIH HHS [EB000664, R01 EB000664, R01 EB000664-01] NR 48 TC 13 Z9 14 U1 1 U2 7 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1535-3508 J9 MOL IMAGING JI Mol. Imaging PD JAN-MAR PY 2006 VL 5 IS 1 BP 31 EP 40 DI 10.2310/7290.2006.00004 PG 10 WC Biochemical Research Methods; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical Imaging GA 064KB UT WOS:000239086900004 PM 16779968 ER PT J AU Moller-Kristensen, M Shi, L Ip, E Gowdal, L Hamblin, MR Thiel, S Jensenius, JC Ezekowitz, A Takahashi, K AF Moller-Kristensen, M Shi, L Ip, E Gowdal, L Hamblin, MR Thiel, S Jensenius, JC Ezekowitz, A Takahashi, K TI MBL deficient mice have increased susceptibility to Pseudomonas aeruginosa infection after burn injury SO MOLECULAR IMMUNOLOGY LA English DT Meeting Abstract CT 10th Meeting on Complement in Human Disease CY SEP 09-13, 2005 CL Heidelberg, GERMANY C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lab Dev Immunol,Dept Pediat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Lab Photomed,Dept Dermatol, Boston, MA 02114 USA. Univ Aarhus, Dept Med Microbiol & Immunol, DK-8000 Aarhus, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD JAN PY 2006 VL 43 IS 1-2 MA 33 BP 134 EP 134 PG 1 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 966LO UT WOS:000232021600046 ER PT J AU Ruseva, M Thiel, S Takahashi, K Ezekowitz, A Jensenius, JC Gadjeva, M AF Ruseva, M Thiel, S Takahashi, K Ezekowitz, A Jensenius, JC Gadjeva, M TI Mannan-binding lectin (MBL) modulate the humoral response depending on genetic background SO MOLECULAR IMMUNOLOGY LA English DT Meeting Abstract CT 10th Meeting on Complement in Human Disease CY SEP 09-13, 2005 CL Heidelberg, GERMANY C1 Univ Aarhus, Dept Med Microbiol & Immunol, Aarhus, Denmark. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD JAN PY 2006 VL 43 IS 1-2 MA 100 BP 158 EP 158 PG 1 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 966LO UT WOS:000232021600113 ER PT J AU Nyborg, AC Herl, L Berezovska, O Thomas, AV Ladd, TB Jansen, K Hyman, BT Golde, TE AF nyborg, Andrew C. Herl, Lauren Berezovska, Oksana Thomas, Anne V. Ladd, Thomas B. Jansen, Karen Hyman, Bradley T. Golde, Todd E. TI Signal peptide peptidase (SPP) dimer formation as assessed by fluorescence lifetime imaging microscopy (FLIM) in intact cells SO MOLECULAR NEURODEGENERATION LA English DT Article AB Background: Signal peptide peptidase (SPP) is an intramembrane cleaving protease identified by its cleavage of several type II membrane signal peptides. Conservation of intramembrane active site residues demonstrates that SPP, SPP family members, and presenilins (PSs) make up a family of intramembrane cleaving proteases. Because SPP appears to function without additional protein cofactors, the study of SPP may provide structural insights into the mechanism of intramembrane proteolysis by this biomedically important family of proteins. Previous studies have shown that SPP isolated from cells appears to be a homodimer, but some evidence exists that in vitro SPP may be active as a monomer. We have conducted additional experiments to determine if SPP exists as a monomer or dimer in vivo. Results: Fluorescence lifetime imaging microscopy (FLIM) can be is used to determine intra-or intermolecular interactions by fluorescently labeling epitopes on one or two different molecules. If the donor and acceptor fluorophores are less than 10 nm apart, the donor fluorophore lifetime shortens proportionally to the distance between the fluorophores. In this study, we used two types of fluorescence energy transfer (FRET) pairs; cyan fluorescent protein (CFP) with yellow fluorescent protein (YFP) or Alexa 488 with Cy3 to differentially label the NH2- or COOH-termini of SPP molecules. A cell based SPP activity assay was used to show that all tagged SPP proteins are proteolytically active. Using FLIM we were able to show that the donor fluorophore lifetime of the CFP tagged SPP construct in living cells significantly decreases when either a NH2- or COOH-terminally YFP tagged SPP construct is co-transfected, indicating close proximity between two different SPP molecules. These data were then confirmed in cell lines stably co-expressing V5- and FLAG-tagged SPP constructs. Conclusion: Our FLIM data strongly suggest dimer formation between two separate SPP proteins. Although the tagged SPP constructs are expressed throughout the cell, SPP dimer detection by FLIM is seen predominantly at or near the plasma membrane. C1 [nyborg, Andrew C.; Ladd, Thomas B.; Jansen, Karen; Golde, Todd E.] Mayo Clin Jacksonville, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA. [Herl, Lauren; Berezovska, Oksana; Thomas, Anne V.; Hyman, Bradley T.] Massachusetts Gen Hosp, Massachusetts Inst Neurodegenerat Dis, Alzheimers Dis Res Unit, Charlestown, MA 02129 USA. RP Golde, TE (reprint author), Mayo Clin Jacksonville, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA. EM nyborg.andrew@mayo.edu; Lauren.herl@ucsf.edu; oberezovska@partners.org; Anne.Thomas@nf.mpg.de; ladd.thomas@mayo.edu; jansen.karen@mayo.edu; bhyman@partners.org; tgolde@mayo.edu FU Mayo Foundation; NIH/NINDS [NS39072]; NIH [PO1 AG15379-08]; Deutsche Forschungsgemeinschaft [TH 1129/1-1] FX We thank members of the Golde and Hyman Labs for their critical analyses and thoughtful contributions. This work was supported by the Mayo Foundation and an NIH/NINDS grant NS39072 to T. E. G. and an NIH grant PO1 AG15379-08 B. T. H. and a research fellowship from the Deutsche Forschungsgemeinschaft TH 1129/1-1 A.V.T. NR 54 TC 12 Z9 12 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1326 J9 MOL NEURODEGENER JI Mol. Neurodegener. PY 2006 VL 1 AR 16 DI 10.1186/1750-1326-1-16 PG 8 WC Neurosciences SC Neurosciences & Neurology GA V02AA UT WOS:000206894900016 PM 17105660 ER PT J AU Mylonakis, E Calderwood, SB Ausubel, FM AF Mylonakis, Eleftherios Calderwood, Stephen B. Ausubel, Frederick M. BE Heitman, J Filler, SG Edwards, JE Mitchell, AP TI Heterologous Hosts and the Evolution and Study of Fungal Pathogenesis SO MOLECULAR PRINCIPLES OF FUNGAL PATHOGENESIS LA English DT Article; Book Chapter ID GALLERIA-MELLONELLA LARVAE; CANDIDA-ALBICANS MUTANTS; INNATE IMMUNE-RESPONSE; CAENORHABDITIS-ELEGANS; CRYPTOCOCCUS-NEOFORMANS; PSEUDOMONAS-AERUGINOSA; ANOPHELES-GAMBIAE; VIRULENCE FACTORS; DROSOPHILA-MELANOGASTER; ASPERGILLUS-FUMIGATUS C1 [Mylonakis, Eleftherios; Calderwood, Stephen B.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Ausubel, Frederick M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Mylonakis, E (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,Gray 5,GRJ-504, Boston, MA 02114 USA. NR 66 TC 0 Z9 1 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-577-6 PY 2006 BP 215 EP 225 PG 11 WC Infectious Diseases; Mycology; Pathology SC Infectious Diseases; Mycology; Pathology GA BPD96 UT WOS:000278639300016 ER PT J AU Hata, K Kusumi, M Yokomine, T Li, E Sasaki, H AF Hata, K Kusumi, M Yokomine, T Li, E Sasaki, H TI Meiotic and epigenetic aberrations in Dnmt3L-deficient male germ cells SO MOLECULAR REPRODUCTION AND DEVELOPMENT LA English DT Article DE spermatogenesis; genomic imprinting; DNA methylation; IAP; azoospermia ID INTRACISTERNAL-A-PARTICLE; DNA METHYLTRANSFERASES; CYTOSINE METHYLATION; MOUSE; SPERMATOGENESIS; EXPRESSION; DNMT3L; TESTIS; INHERITANCE; IMPRINTS AB The DNA methyltransferase-like protein. Dnmt3L is necessary for the establishment of genomic imprints in oogenesis and for normal spermatogenesis (Bourc'his et al., 2001; Hata et al., 2002). Also, a paternally imprinted gene, H19, loses DNA methylation in Dnmt3L(-/-) spermatogonia (Bourc'his and Bestor, 2004; Kaneda et al., 2004). To determine the reason for the impaired spermatogenesis in the Dnmt3L(-/-) testes, we have carried out a series of histological and molecular studies. We show here that Dnrht3L(-/-) germ cells were arrested and died around the early meiotic stage. A microarray-based gene expression-profiling analysis revealed that various gonad-specific and/or sex-chromosome-linked genes were downregulated in the Dnmt3L(-/-) testes. In contrast, expression of retrovirus-like intracisternal A-particle (IAP) sequences was upregplated; consistent with this observation, a specific IAP copy showed complete loss of DNA methylation. These findings indicate that Dnmt3L regulates germ cell-specific gene expression and IAP suppression, which are critical for. male germ cell proliferation and meiosis. C1 ROIS, Natl Inst Genet, Div Human Genet, Dept Integrated Genet, Mishima, Shizuoka 4118540, Japan. Grad Univ Adv Studies SOKENDAI, Sch Life Sci, Dept Genet, Mishima, Shizuoka, Japan. Univ Tokyo, Fac Med, Dept Obstet & Gynecol, Tokyo, Japan. Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Cardiovasc Res Ctr, Charlestown, MA USA. RP Hata, K (reprint author), ROIS, Natl Inst Genet, Div Human Genet, Dept Integrated Genet, Mishima, Shizuoka 4118540, Japan. EM khata@lab.nig.ac.jp NR 28 TC 56 Z9 58 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1040-452X J9 MOL REPROD DEV JI Mol. Reprod. Dev. PD JAN PY 2006 VL 73 IS 1 BP 116 EP 122 DI 10.1002/mrd.20387 PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology; Reproductive Biology SC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology; Reproductive Biology GA 989UZ UT WOS:000233700700013 PM 16211598 ER PT J AU Giesecke, AV Fang, R Joung, JK AF Giesecke, Astrid V. Fang, Rui Joung, J. Keith TI Synthetic protein-protein interaction domains created by shuffling Cys(2)HiS(2) zinc-fingers SO MOLECULAR SYSTEMS BIOLOGY LA English DT Article DE artificial transcription factor; Cys(2)His(2) zinc-finger; domain shuffling; protein engineering; protein-protein interactions ID GCN4 LEUCINE-ZIPPER; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; COILED-COIL; IKAROS FAMILY; CRYSTAL-STRUCTURE; RECOGNITION CODE; GENE-EXPRESSION; DRUG DISCOVERY; PHAGE DISPLAY AB Cys(2)His(2) zinc-fingers (C2H2 ZFs) mediate a wide variety of protein-DNA and protein-protein interactions. DNA-binding C2H2 ZFs can be shuffled to yield artificial proteins with different DNA-binding specificities. Here we demonstrate that shuffling of C2H2 ZFs from transcription factor dimerization zinc-finger (DZF) domains can also yield two-finger DZFs with novel protein-protein interaction specificities. We show that these synthetic protein-protein interaction domains can be used to mediate activation of a single-copy reporter gene in bacterial cells and of an endogenous gene in human cells. In addition, the synthetic two-finger domains we constructed can also be linked together to create more extended, four-finger interfaces. Our results demonstrate that shuffling of C2H2 ZFs can yield artificial protein-interaction components that should be useful for applications in synthetic biology. C1 Massachusetts Gen Hosp, Dept Pathol, Mol Pathol Unit, Charlestown, MA 02129 USA. Univ Regensburg, Inst Zool, D-8400 Regensburg, Germany. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Joung, JK (reprint author), Massachusetts Gen Hosp, Dept Pathol, Mol Pathol Unit, 149 13th St,Room 7139,7th Floor, Charlestown, MA 02129 USA. EM jjoung@partners.org NR 53 TC 5 Z9 5 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1744-4292 J9 MOL SYST BIOL JI Mol. Syst. Biol. PY 2006 VL 2 AR 2006.0011 DI 10.1038/msb4100053 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 122RX UT WOS:000243245400013 ER PT J AU Quackenbush, J AF Quackenbush, John TI Weighing our measures of gene expression SO MOLECULAR SYSTEMS BIOLOGY LA English DT Editorial Material ID SEQUENCE C1 Dana Farber Canc Inst, Boston, MA 02115 USA. RP Quackenbush, J (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 2 TC 8 Z9 8 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1744-4292 J9 MOL SYST BIOL JI Mol. Syst. Biol. PY 2006 VL 2 AR 63 DI 10.1038/msb4100096 PG 2 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 122RX UT WOS:000243245400060 PM 17102808 ER PT J AU Quackenbush, J AF Quackenbush, John TI Standardizing the standards SO MOLECULAR SYSTEMS BIOLOGY LA English DT Editorial Material ID BIOLOGY MARKUP LANGUAGE; MICROARRAY DATA; REPRESENTATION; XML C1 Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Quackenbush, J (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. NR 15 TC 14 Z9 14 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1744-4292 J9 MOL SYST BIOL JI Mol. Syst. Biol. PY 2006 VL 2 AR 2006.0010 DI 10.1038/msb4100052 PG 3 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 122RX UT WOS:000243245400010 PM 16738556 ER PT J AU Martin, FC Handforth, A AF Martin, Fredricka C. Handforth, Adrian TI Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor SO MOVEMENT DISORDERS LA English DT Article DE essential tremor; harmaline; gap junction; connexin; carbenoxolone; mefloquine ID POSITRON EMISSION TOMOGRAPHY; NEURONAL GAP-JUNCTIONS; LONG-CHAIN ALCOHOLS; INFERIOR OLIVE; PHARMACOLOGICAL-PROPERTIES; CEREBELLAR DYSFUNCTION; NERVOUS-SYSTEM; RAT-BRAIN; IN-VIVO; EXPRESSION AB Excessive olivo-cerebellar synchrony is implicated in essential tremor. Because synchrony in some networks is mediated by gap junctions, we examined whether the gap junction blockers heptanol, octanol, carbenoxolone, and mefloquine suppress tremor in the mouse harmaline model, and performed an open-treatment clinical study of mefloquine for essential tremor. Digitized motion was used to quantify tremor in mice administered harmaline, 20 mg/kg s.c. In mice the broad-spectrum gap junction blockers heptanol, octanol (350 mg/kg i.p. each), and carbenoxolone (20 mg/kg) suppressed harmaline tremor. Mefloquine (50 mg/kg), which blocks gap junctions containing connexin 36, robustly suppressed harmaline tremor. Glycyrrhizic acid (related to carbenoxolone) and chloroquine (related to mefloquine), which do not block gap junctions, failed to suppress harmaline tremor in mice. Clinically, tremor was assessed with standard rating scales, and subjects asked to take 62.5, 125, and 250 mg mefloquine weekly for 12 weeks at each dose. None of the four human subjects showed a meaningful tremor reduction with mefloquine, likely because clinical levels were below those required for efficacy. In view of recent genetic evidence, the anti-tremor mechanism of these compounds is uncertain but may represent a novel therapeutic target, possibly involving gap junctions other than those containing connexin 36. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Serv Neurol, Los Angeles, CA USA. RP Handforth, A (reprint author), 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM charles.handforth@med.va.gov NR 69 TC 29 Z9 31 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PY 2006 VL 21 IS 10 BP 1641 EP 1649 DI 10.1002/mds.20940 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 101MQ UT WOS:000241745300011 PM 16773639 ER PT S AU Fang, Q Boas, D Boverman, G Zhang, Q Kauffman, T AF Fang, Qianqian Boas, David Boverman, Greg Zhang, Quan Kauffman, Tina BE Azar, FS Metaxas, DM TI Nonlinear image reconstruction algorithm for diffuse optical tomography using iterative block solver and automatic mesh generation from tomosynthesis images - art. no. 60810O SO Multimodal Biomedical Imaging SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Multimodal Biomedical Imaging CY JAN 21, 2003-JAN 24, 2006 CL San Jose, CA SP SPIE DE breast imaging; diffuse optical tomography; mesh generation; tomosynthesis ID SYSTEMS AB In this paper, we report a nonlinear 3D image reconstruction algorithm featuring 3D finite element forward modeling with an iterative multi-right-hand-side solver and an automatic mesh generation technique for efficient geometry modeling. The forward mesh was generated based on 3D tomosynthesis images acquired simultaneously with optical measurements. An efficient iterative solver based on a QMR algorithm with the capacity of solving multi-RHS was used to enhance the computational efficiency. The mesh generation algorithm was developed based on a moving mesh process and is able to generate high-quality mesh with low computational complexity. In addition, an approximated adjoint method was used to form the Jacobian matrix for the inverse problem. The performance of the was satisfactory performances in numerical simulations. For a typical reconstruction, the run-time was under 5 minutes on a Pentium-based PC. It is worth mentioning that the mesh generation module not only works for binary 2D or 3D image stacks, but also for any other binary description of the object, which makes it generalizable to many other potential applications. C1 Massachusetts Gen Hosp, Charlestown, MA 02148 USA. RP Fang, Q (reprint author), Massachusetts Gen Hosp, Charlestown, MA 02148 USA. NR 15 TC 1 Z9 1 U1 0 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-6123-7 J9 P SOC PHOTO-OPT INS PY 2006 VL 6081 BP O810 EP O810 AR 60810O DI 10.1117/12.662689 PG 10 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA BEF86 UT WOS:000237152400017 ER PT S AU Tegos, GP AF Tegos, George P. BE Rai, M Carpinella, MC TI Natural substrates and inhibitors of multidrug resistant pumps (MDRs) redefine the plant antimicrobials SO NATURALLY OCCURRING BIOACTIVE COMPOUNDS SE Advances in Phytomedicine LA English DT Article; Book Chapter ID P-GLYCOPROTEIN INHIBITORS; LARGE PERIPLASMIC LOOPS; STAPHYLOCOCCUS-AUREUS; EFFLUX PUMPS; PSEUDOMONAS-AERUGINOSA; DRUG-RESISTANCE; ESCHERICHIA-COLI; ABC-TRANSPORTERS; SACCHAROMYCES-CEREVISIAE; ACTIVE-TRANSPORT C1 [Tegos, George P.] Massachusettes Gen Hosp, Wellman Labs Photomed, Boston, MA 02114 USA. [Tegos, George P.] Harvard Sch, Dept Dermatol, Boston, MA 02114 USA. RP Tegos, GP (reprint author), Massachusettes Gen Hosp, Wellman Labs Photomed, 50 Blossom St, Boston, MA 02114 USA. NR 76 TC 10 Z9 10 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1572-557X BN 978-0-08-046492-3 J9 ADV PHYTOMED PY 2006 VL 3 BP 45 EP 59 PG 15 WC Biotechnology & Applied Microbiology; Plant Sciences; Chemistry, Medicinal SC Biotechnology & Applied Microbiology; Plant Sciences; Pharmacology & Pharmacy GA BCN99 UT WOS:000310808300005 ER PT J AU Grabher, C Look, AT AF Grabher, C Look, AT TI Fishing for cancer models SO NATURE BIOTECHNOLOGY LA English DT Editorial Material ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ZEBRAFISH; DISCOVERY C1 Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Grabher, C (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA. EM clemens_grabher@dfci.harvard.edu; thomas_look@dfci.harvard.edu RI Grabher, Clemens/H-2064-2013 NR 11 TC 17 Z9 20 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1087-0156 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD JAN PY 2006 VL 24 IS 1 BP 45 EP 46 DI 10.1038/nbt0106-45 PG 2 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA 001SE UT WOS:000234555800020 PM 16404393 ER PT J AU Henry, EP Peterson, JR Salvarezza, SB Rodriguez-Boulan, E Chen, JL Stamnes, M Macia, E Feng, Y Shair, MD Kirchhausen, T AF Henry, EP Peterson, JR Salvarezza, SB Rodriguez-Boulan, E Chen, JL Stamnes, M Macia, E Feng, Y Shair, MD Kirchhausen, T TI Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro SO NATURE CHEMICAL BIOLOGY LA English DT Article ID GUANINE-NUCLEOTIDE EXCHANGE; BINDING PROTEIN CDC42; TRANS-GOLGI NETWORK; N-WASP; BREFELDIN-A; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; ACTIN CYTOSKELETON; CHEMICAL INHIBITOR; LIVING CELLS AB Inspired by the usefulness of small molecules to study membrane traffic, we used high-throughput synthesis and phenotypic screening to discover secramine, a molecule that inhibits membrane traffic out of the Golgi apparatus by an unknown mechanism. We report here that secramine inhibits activation of the Rho GTPase Cdc42, a protein involved in membrane traffic, by a mechanism dependent upon the guanine dissociation inhibitor RhoGDI. RhoGDI binds Cdc42 and antagonizes its membrane association, nucleotide exchange and effector binding. In vitro, secramine inhibits Cdc42 binding to membranes, GTP and effectors in a RhoGDI-dependent manner. In cells, secramine mimics the effects of dominant-negative Cdc42 expression on protein export from the Golgi and on Golgi polarization in migrating cells. RhoGDI-dependent Cdc42 inhibition by secramine illustrates a new way to inhibit Rho GTPases with small molecules and provides a new means to study Cdc42, RhoGDI and the cellular processes they mediate. C1 Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA. Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. Harvard Univ, Sch Med, Harvard Inst Chem & Cell Biol, Boston, MA 02115 USA. Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA. Cornell Univ, Weill Med Coll, Dyson Vis Res Inst, New York, NY 10021 USA. Univ Iowa, Coll Med, Iowa City, IA 52242 USA. RP Shair, MD (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, 200 Longwood Ave, Boston, MA 02115 USA. EM shair@chemistry.harvard.edu; kirchhausen@crystal.harvard.edu NR 42 TC 2 Z9 2 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1552-4450 EI 1552-4469 J9 NAT CHEM BIOL JI Nat. Chem. Biol. PD JAN PY 2006 VL 2 IS 1 BP 39 EP 46 DI 10.1038/nchembio751 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 993RC UT WOS:000233971600013 ER PT J AU Jaff, MR AF Jaff, MR TI Does balloon angioplasty improve quality of life in patients with hypertension and renal artery stenosis? SO NATURE CLINICAL PRACTICE NEPHROLOGY LA English DT Editorial Material DE balloon angioplasty; hypertension; renal artery stenosis C1 Massachusetts Gen Hosp, Boston, MA USA. RP Jaff, MR (reprint author), Massachusetts Gen Hosp, 32 Fruit St,Yawkey 5938, Boston, MA USA. EM mjaff@partners.org NR 4 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1745-8323 J9 NAT CLIN PRACT NEPHR JI Nat. Clin. Pract. Nephrol. PD JAN PY 2006 VL 2 IS 1 BP 18 EP 19 DI 10.1038/ncpneph0072 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 014YA UT WOS:000235515500007 PM 16932383 ER PT J AU Jain, RK Duda, DG Clark, JW Loeffler, JS AF Jain, RK Duda, DG Clark, JW Loeffler, JS TI Lessons from phase III clinical trials on anti-VEGF therapy for cancer SO NATURE CLINICAL PRACTICE ONCOLOGY LA English DT Review DE antiangiogenic; bevacizumab; multitargeted; normalization; anti-vascular endothelial growth factor (anti-VEGF) ID ENDOTHELIAL GROWTH-FACTOR; INTERSTITIAL FLUID PRESSURE; METASTATIC COLORECTAL-CANCER; HER2-POSITIVE BREAST-CANCER; RECEPTOR TYROSINE KINASES; REFRACTORY SOLID TUMORS; RENAL-CELL CARCINOMA; ANTIANGIOGENIC THERAPY; SURROGATE MARKER; DRUG DEVELOPMENT AB In randomized phase III trials two anti-vascular endothelial growth factor (VEGF) approaches have yielded survival benefit in patients with metastatic cancer. In one approach, the addition of bevacizumab, a VEGF-specific antibody, to standard chemotherapy improved overall survival in colorectal and lung cancer patients and progression-free survival in breast cancer patients. In the second approach, multitargeted tyrosine kinase inhibitors that block VEGF receptor and other kinases in both endothelial and cancer cells, demonstrated survival benefit in gastrointestinal stromal tumor and renal-cell-carcinoma patients. By contrast, adding bevacizumab to chemotherapy failed to increase survival in patients with previously treated and refractory metastatic breast cancer. Furthermore, addition of vatalanib, a kinase inhibitor developed as a VEGF receptor-selective agent, to chemotherapy did not show a similar benefit in metastatic colorectal cancer patients. These contrasting responses raise critical questions about how these agents work and how to combine them optimally. We summarize three of the many potential mechanisms of action of anti-VEGF agents, and also discuss progress relating to the identification of potential biomarkers for anti-VEGF-agent efficacy in humans. C1 Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA. MGH, Ctr Canc, Clin Programs, Boston, MA USA. Dana Farber Partners Canc Care, Boston, MA USA. RP Jain, RK (reprint author), Harvard Univ, Sch Med, Dept Radiat Oncol, 100 Blossom St,Cox 7, Boston, MA 02114 USA. EM jain@steele.mgh.harvard.edu NR 94 TC 666 Z9 700 U1 7 U2 60 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1743-4254 J9 NAT CLIN PRACT ONCOL JI Nat. Clin. Pract. Oncol. PD JAN PY 2006 VL 3 IS 1 BP 24 EP 40 DI 10.1038/ncponc0403 PG 17 WC Oncology SC Oncology GA 998OE UT WOS:000234327600010 PM 16407877 ER PT J AU Rosenbauer, F Owens, BM Yu, L Tumang, JR Steidl, U Kutok, JL Clayton, LK Wagner, K Scheller, M Iwasaki, H Liu, CH Hackanson, B Akashi, K Leutz, A Rothstein, TL Plass, C Tenen, DG AF Rosenbauer, F Owens, BM Yu, L Tumang, JR Steidl, U Kutok, JL Clayton, LK Wagner, K Scheller, M Iwasaki, H Liu, CH Hackanson, B Akashi, K Leutz, A Rothstein, TL Plass, C Tenen, DG TI Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1 SO NATURE GENETICS LA English DT Article ID HEMATOPOIETIC STEM-CELLS; TRANSCRIPTION FACTOR PU.1; B-1 CELLS; B-LYMPHOCYTE; MICE; LEUKEMIA; METHYLATION; EXPRESSION; PROGENITORS; MACROPHAGE AB Tight regulation of transcription factors, such as PU.1, is crucial for generation of all hematopoietic lineages. We previously reported that mice with a deletion of an upstream regulatory element (URE) of the gene encoding PU.1 (Sfpi1) developed acute myeloid leukemia. Here we show that the URE has an essential role in orchestrating the dynamic PU.1 expression pattern required for lymphoid development and tumor suppression. URE deletion ablated B2 cells but stimulated growth of B1 cells in mice. The URE was a PU.1 enhancer in B cells but a repressor in T cell precursors. TCF transcription factors coordinated this repressor function and linked PU.1 to Wnt signaling. Failure of appropriate PU.1 repression in T cell progenitors with URE deletion disrupted differentiation and induced thymic transformation. Genome-wide DNA methylation assessment showed that epigenetic silencing of selective tumor suppressor genes completed PU.1-initiated transformation of lymphoid progenitors with URE deletion. These results elucidate how a single transcription factor, PU.1, through the cell context - specific activity of a key cis-regulatory element, affects the development of multiple cell lineages and can induce cancer. C1 Harvard Inst Med, Boston, MA 02115 USA. Harvard Stem Cell Inst, Boston, MA 02115 USA. Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany. Ohio State Univ, Div Hematol Oncol, Columbus, OH 43210 USA. Boston Univ, Med Ctr, Evans Mem Dept Clin Res, Dept Med, Boston, MA USA. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RP Rosenbauer, F (reprint author), Harvard Inst Med, Room 954,77 Ave Louis Pasteur, Boston, MA 02115 USA. EM f.rosenbauer@mdc-berlin.de; dtenen@bidmc.harvard.edu RI Plass, Christoph/H-7192-2014; Leutz, Achim/K-9643-2013; OI Leutz, Achim/0000-0001-8259-927X; Rosenbauer, Frank/0000-0001-7977-9421; Tenen, Daniel/0000-0002-6423-3888 NR 50 TC 124 Z9 125 U1 3 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD JAN PY 2006 VL 38 IS 1 BP 27 EP 37 DI 10.1038/ng1679 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 997EG UT WOS:000234227200014 PM 16311598 ER PT J AU McCarroll, SA Hadnott, TN Perry, GH Sabeti, PC Zody, MC Barrett, JC Dallaire, S Gabriel, SB Lee, C Daly, MJ Altshuler, DM AF McCarroll, SA Hadnott, TN Perry, GH Sabeti, PC Zody, MC Barrett, JC Dallaire, S Gabriel, SB Lee, C Daly, MJ Altshuler, DM CA Int HapMap Consortium TI Common deletion polymorphisms in the human genome SO NATURE GENETICS LA English DT Article ID SEGMENTAL DUPLICATIONS; GENE-EXPRESSION AB The locations and properties of common deletion variants in the human genome are largely unknown. We describe a systematic method for using dense SNP genotype data to discover deletions and its application to data from the International HapMap Consortium to characterize and catalogue segregating deletion variants across the human genome. We identified 541 deletion variants (94% novel) ranging from 1 kb to 745 kb in size; 278 of these variants were observed in multiple, unrelated individuals, 120 in the homozygous state. The coding exons of ten expressed genes were found to be commonly deleted, including multiple genes with roles in sex steroid metabolism, olfaction and drug response. These common deletion polymorphisms typically represent ancestral mutations that are in linkage disequilibrium with nearby SNPs, meaning that their association to disease can often be evaluated in the course of SNP-based whole-genome association studies. C1 Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02141 USA. MIT, Cambridge, MA 02141 USA. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Med, Simches Res Ctr, Boston, MA 02114 USA. RP Altshuler, DM (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, 55 Fruit St, Boston, MA 02114 USA. EM altshuler@molbio.mgh.harvard.edu RI McCarroll, Steven/A-8433-2009; Altshuler, David/A-4476-2009; OI Altshuler, David/0000-0002-7250-4107; McCarroll, Steven/0000-0002-6954-8184 NR 19 TC 485 Z9 507 U1 5 U2 46 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD JAN PY 2006 VL 38 IS 1 BP 86 EP 92 DI 10.1038/ng1696 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 997EG UT WOS:000234227200022 PM 16468122 ER PT J AU Takahashi, C Contreras, B Iwanaga, T Takegami, Y Bakker, A Bronson, RT Noda, M Loda, M Hunt, JL Ewen, ME AF Takahashi, C Contreras, B Iwanaga, T Takegami, Y Bakker, A Bronson, RT Noda, M Loda, M Hunt, JL Ewen, ME TI Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor SO NATURE GENETICS LA English DT Article ID CELL LUNG-CANCER; N-RAS; K-RAS; DIFFERENTIATION; RB; MOUSE; PROTEIN; GENE; ACTIVATION; MUTATIONS AB Mutations in the gene encoding the retinoblastoma tumor suppressor predispose humans and mice to tumor development(1,2). Here we have assessed the effect of Nras loss on tumor development in Rb1 heterozygous mice. Loss of one or two Nras alleles is shown to significantly reduce the severity of pituitary tumors arising in Rb1(+/-) animals by enhancing their differentiation. By contrast, C-cell thyroid adenomas occurring in Rb1(+/-) mice progress to metastatic medullary carcinomas after loss of Nras. In Rb1(+/-) Nras(+/-) animals, distant medullary thyroid carcinoma metastases are associated with loss of the remaining wild-type Nras allele. Loss of Nras in Rb1-deficient C cells results in elevated Ras homolog family A ( RhoA) activity, and this is causally linked to the invasiveness and metastatic behavior of these cells. These findings suggest that the loss of the proto-oncogene Nras in certain cellular contexts can promote malignant tumor progression. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Rodent Histopathol Core, Boston, MA 02115 USA. Kyoto Univ, Grad Sch Med, 21st Century Ctr Excellence Program, Kyoto 6068501, Japan. Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 6068501, Japan. Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA. Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA. RP Ewen, ME (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM chtakaha@virus.kyoto-u.ac.jp; mark_ewen@dfci.harvard.edu FU NCI NIH HHS [R01 CA065842-11A1, R01 CA065842] NR 28 TC 27 Z9 29 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD JAN PY 2006 VL 38 IS 1 BP 118 EP 123 DI 10.1038/ng1703 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 997EG UT WOS:000234227200027 PM 16369533 ER PT J AU Robicsek, A Strahilevitz, J Jacoby, GA Macielag, M Abbanat, D Park, CH Bush, K Hooper, DC AF Robicsek, A Strahilevitz, J Jacoby, GA Macielag, M Abbanat, D Park, CH Bush, K Hooper, DC TI Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase SO NATURE MEDICINE LA English DT Article ID MEDIATED QUINOLONE RESISTANCE; CHLORAMPHENICOL ACETYLTRANSFERASE; UNITED-STATES; FUSIDIC ACID; PLASMID; BINDING AB Antimicrobial-modifying resistance enzymes have traditionally been class specific, having coevolved with the antibiotics they inactivate. Fluoroquinolones, antimicrobial agents used extensively in medicine and agriculture, are synthetic and have been considered safe from naturally occurring antimicrobial-modifying enzymes. We describe reduced susceptibility to ciprofloxacin in clinical bacterial isolates conferred by a variant of the gene encoding aminoglycoside acetyltransferase AAC(6')-lb. This enzyme reduces the activity of ciprofloxacin by N-acetylation at the amino nitrogen on its piperazinyl substituent. Although approximately 30 variants of this gene have been reported since 1986, the two base-pair changes responsible for the ciprofloxacin modification phenotype are unique to this variant, first reported in 2003 and now widely disseminated. An intense increase in the medical use of ciprofloxacin seems to have been accompanied by a notable development: a single-function resistance enzyme has crossed class boundaries, and is now capable of enzymatically undermining two unrelated antimicrobial agents, one of them fully synthetic. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. Lahey Clin Fdn, Burlington, MA 01805 USA. Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ 08869 USA. RP Hooper, DC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,GRJ 512, Boston, MA 02114 USA. EM dhooper@partners.org FU NIAID NIH HHS [AI43312, AI57576, R01 AI057576] NR 17 TC 455 Z9 557 U1 9 U2 34 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2006 VL 12 IS 1 BP 83 EP 88 DI 10.1038/nm1347 PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 999VO UT WOS:000234419000056 PM 16369542 ER PT J AU Bentires-Alj, M Gil, SG Chan, R Wang, ZGC Wang, YP Imanaka, N Harris, LN Richardson, A Neel, BG Gu, HH AF Bentires-Alj, M Gil, SG Chan, R Wang, ZGC Wang, YP Imanaka, N Harris, LN Richardson, A Neel, BG Gu, HH TI A role for the scaffolding adapter GAB2 in breast cancer SO NATURE MEDICINE LA English DT Article ID DOCKING PROTEIN GAB2; TYROSINE PHOSPHATASE; PTPN11 MUTATIONS; NEU ONCOGENE; GENE; CELL; TUMORS; TRANSFORMATION; EXPRESSION; LEUKEMIA AB The scaffolding adapter GAB2 maps to a region (11q13-14) commonly amplified in human breast cancer, and is overexpressed in breast cancer cell lines and primary tumors, but its functional role in mammary carcinogenesis has remained unexplored. We found that overexpression of GAB2 (Grb2-associated binding protein 2) increases proliferation of MCF10A mammary cells in three-dimensional culture. Coexpression of GAB2 with antiapoptotic oncogenes causes lumenal filling, whereas coexpression with Neu (also known as ErbB2 and HER2) results in an invasive phenotype. These effects of GAB2 are mediated by hyperactivation of the Shp2-Erk pathway. Furthermore, overexpression of Gab2 potentiates, whereas deficiency of Gab2 ameliorates, Neu-evoked breast carcinogenesis in mice. Finally, GAB2 is amplified in some GAB2-overexpressing human breast tumors. Our data suggest that GAB2 may be a key gene within an 11q13 amplicon in human breast cancer and propose a role for overexpression of GAB2 in mammary carcinogenesis. Agents that target GAB2 or GAB2-dependent pathways may be useful for treating breast tumors that overexpress GAB2 or HER2 or both. C1 Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ Liege, Lab Med Chem & Human Genet, Ctr Biomed Integrat Genoproteom, B-4000 Liege, Belgium. Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Bentires-Alj, M (reprint author), Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, NRB 1030,77 Ave Louis Pasteur, Boston, MA 02115 USA. EM mbentire@bidmc.harvard.edu RI Mohamed, Bentires-Alj/F-4484-2015 OI Mohamed, Bentires-Alj/0000-0001-6344-1127 FU NIAID NIH HHS [AI 51612]; NIDDK NIH HHS [DK50693] NR 47 TC 115 Z9 121 U1 2 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2006 VL 12 IS 1 BP 114 EP 121 DI 10.1038/nm1341 PG 8 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 999VO UT WOS:000234419000060 PM 16369543 ER PT J AU Evgenov, NV Medarova, Z Dai, GP Bonner-Weir, S Moore, A AF Evgenov, NV Medarova, Z Dai, GP Bonner-Weir, S Moore, A TI In vivo imaging of islet transplantation SO NATURE MEDICINE LA English DT Article ID MAGNETIC-RESONANCE TRACKING; BETA-CELL MASS; T-CELLS; MRI; NANOPARTICLES; MACROPHAGES AB Type 1 diabetes mellitus is characterized by the selective destruction of insulin-producing beta cells, which leads to a deficiency in insulin secretion and, as a result, to hyperglycemia. At present, transplantation of pancreatic islets is an emerging and promising clinical modality, which can render individuals with type 1 diabetes insulin independent without increasing the incidence of hypoglycemic events. To monitor transplantation efficiency and graft survival, reliable noninvasive imaging methods are needed. If such methods were introduced into the clinic, essential information could be obtained repeatedly and noninvasively. Here we report on the in vivo detection of transplanted human pancreatic islets using magnetic resonance imaging (MRI) that allowed noninvasive monitoring of islet grafts in diabetic mice in real time. We anticipate that the information obtained in this study would ultimately result in the ability to detect and monitor islet engraftment in humans, which would greatly aid the clinical management of this disease. C1 Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Massachusetts Gen Hosp,Mol Imaging Lab,MGH,MIT,HM, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. RP Moore, A (reprint author), Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Massachusetts Gen Hosp,Mol Imaging Lab,MGH,MIT,HM, Room 2301,Bldg 149,13th St, Charlestown, MA 02129 USA. EM amoore@helix.mgh.harvard.edu OI Bonner-Weir, Susan/0000-0003-4682-0656 FU NIDDK NIH HHS [DK071225] NR 23 TC 177 Z9 185 U1 0 U2 13 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2006 VL 12 IS 1 BP 144 EP 148 DI 10.1038/nm1316 PG 5 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 999VO UT WOS:000234419000065 PM 16380717 ER PT J AU Pittet, MJ Swirski, FK Reynolds, F Josephson, L Weissleder, R AF Pittet, Mikael J. Swirski, Filip K. Reynolds, Frederick Josephson, Lee Weissleder, Ralph TI Labeling of immune cells for in vivo imaging using magnetofluorescent nanoparticles SO NATURE PROTOCOLS LA English DT Article ID T-CELLS; DENDRITIC CELLS; TRACKING; CANCER; LYMPHOCYTES; PEPTIDE; TRANSDUCTION; PROTAMINE; MIGRATION; PROTEINS AB Observation of immune and stem cells in their native microenvironments requires the development of imaging agents to allow their in vivo tracking. We describe here the synthesis of magnetofluorescent nanoparticles for cell labeling in vitro and for multimodality imaging of administered cells in vivo. MION-47, a prototype monocrystalline iron oxide nanoparticle, was first converted to an intermediate bearing a fluorochrome and amine groups, then reacted with either HIV-Tat peptide or protamine to yield a nanoparticle with membrane-translocating properties. We describe how to assess optimal cell labeling with tests of cell phenotype and function. Synthesis of magnetofluorescent nanoparticles and cell-labeling optimization can be realized in 48 h, whereas nanoparticle uptakes and retention studies may generally take up to 120 h. Labeled cells can be detected by magnetic resonance imaging, fluorescence reflectance imaging, fluorescence-mediated tomography, confocal microscopy and flow cytometry, and can be purified based on their fluorescent or magnetic properties. The present protocol focuses on T-cell labeling but can be used for labeling a variety of circulating cells. C1 Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. RP Pittet, MJ (reprint author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. EM mpittet@hms.harvard.edu NR 28 TC 108 Z9 109 U1 0 U2 35 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 1 BP 73 EP 79 DI 10.1038/nprot.2006.11 PG 7 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 232EX UT WOS:000251002200011 PM 17406214 ER PT J AU Bush, G Whalen, PJ Shin, LM Rauch, SL AF Bush, George Whalen, Paul J. Shin, Lisa M. Rauch, Scott L. TI The counting Stroop: a cognitive interference task SO NATURE PROTOCOLS LA English DT Article ID ANTERIOR CINGULATE CORTEX; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; FUNCTIONAL MRI; SELECTIVE ATTENTION; FMRI; CONFLICT; ACTIVATION; PARADIGM AB The counting Stroop is a validated Stroop task variant. Initially designed as a functional magnetic resonance imaging ( fMRI) task for identifying brain regions subserving cognition and attention ( dorsal anterior midcingulate cortex ( daMCC) and dorsolateral prefrontal cortex ( DLPFC)), it has been used to study cognition in healthy volunteers and to identify functional brain abnormalities in neuropsychiatric disorders, such as attention deficit hyperactivity disorder ( ADHD). During the counting Stroop, subjects report by button- press the number of words ( one to four) appearing on the screen, regardless of word meaning. Neutral- word control trials contain single semantic category common animals ( e. g., 'dog' written three times), while interference trials contain number words that are incongruent with the correct response ( e. g., 'two' written four times). The counting Stroop can be completed in approximately 20 min per subject and can be used offline ( behavioral performance) or with fMRI, positron emission tomography, event- related potentials, magnetoencephalography or intracranial recordings. C1 Massachusetts Gen Hosp, Dept Psychiat, Psychiatr Neurosci Div, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, MIT, HMS, Athinoula A Martinos Ctr Funct & Struct Biomed I, Boston, MA 02114 USA. Dartmouth Coll, Dept Psychol, Hanover, NH 03755 USA. Tufts Univ, Dept Psychol, Medford, MA 02155 USA. RP Bush, G (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Psychiatr Neurosci Div, Boston, MA 02114 USA. EM geo@nmr.mgh.harvard.edu FU NIMH NIH HHS [MH-01215] NR 31 TC 22 Z9 23 U1 3 U2 12 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 EI 1750-2799 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 1 BP 230 EP 233 DI 10.1038/nprot.2006.35 PG 4 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 232EX UT WOS:000251002200034 PM 17406237 ER PT J AU Whalen, PJ Bush, G Shin, LM Rauch, SL AF Whalen, Paul J. Bush, George Shin, Lisa M. Rauch, Scott L. TI The emotional counting Stroop: a task for assessing emotional interference during brain imaging SO NATURE PROTOCOLS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; ANTERIOR CINGULATE CORTEX; FUNCTIONAL MRI; TRIAL; FMRI AB The emotional counting Stroop ( ecStroop) is an emotional variant of the counting Stroop. Both of these tasks require a motor response instead of a spoken response for the purpose of minimizing head movement during functional MRI ( fMRI). During this task, subjects report, by button press, the number of words ( 1 - 4) that appear on a screen, regardless of word meaning. Neutral word- control trials contain common words ( e. g., 'cabinet' written three times), while interference trials contain emotional words ( e. g., 'murder' written three times). The degree to which this task represents a true 'Stroop' interference task, in the sense that emotional words will increase motor- response times compared with neutral words, depends upon the subjects of the study and the words that are presented. Much research on the emotional Stroop task demonstrates that interference effects are observed in psychopathological groups in response to words that are specific to their disorder, and in normal subjects when the words are related to current concerns endorsed by them. The ecStroop task described here will produce reaction time- interference effects that are comparable to the traditional color- naming emotional Stroop. This protocol can be completed in similar to 20 min per subject. The protocol described here employs neutral words and emotional words that include general- negative words, as well as words specific to combat- related trauma. However, this protocol is amenable to any emotional word lists. C1 Dartmouth Coll, Dept Psychol & Brain Sci, Hanover, NH 03755 USA. Massachusetts Gen Hosp, Dept Psychiat, Psychiat Neurosci Div, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, MIT, HMS, Athinoula A Martinos Ctr Funct & Struct Biomed I, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Tufts Univ, Dept Psychol, Medford, MA 02155 USA. RP Whalen, PJ (reprint author), Dartmouth Coll, Dept Psychol & Brain Sci, 6207 Moore Hall, Hanover, NH 03755 USA. EM paul.j.whalen@dartmouth.edu FU PHS HHS [NIMH 069315, NIMH 16259, NIMH 01215] NR 17 TC 32 Z9 32 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 1 BP 293 EP 296 DI 10.1038/nprot.2006.45 PG 4 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 232EX UT WOS:000251002200044 PM 17406247 ER PT J AU Bush, G Shin, LM AF Bush, George Shin, Lisa M. TI The Multi-Source Interference Task: an fMRI task that reliably activates the cingulo-frontal-parietal cognitive/attention network SO NATURE PROTOCOLS LA English DT Article ID MEDIAL PREFRONTAL CORTEX; COUNTING STROOP; FUNCTIONAL MRI; ATTENTIONAL SELECTION; RESPONSE CONFLICT; HUMAN BRAIN; ANTERIOR; SYSTEMS; ORGANIZATION; PERFORMANCE AB In this protocol we describe how to perform the Multi- Source Interference Task ( MSIT), a validated functional magnetic resonance imaging ( fMRI) task that reliably and robustly activates the cingulo- frontal- parietal cognitive/ attention network ( CFP network) within individual subjects. The MSIT can be used to ( i) identify the cognitive/ attention network in normal volunteers and ( ii) test its integrity in people with neuropsychiatric disorders. It is simple to perform, can be completed in less than 15 min and is not language specific, making it appropriate for children, adults and the elderly. Since its validation, over 100 adults have performed the task. The MSIT produces a robust and temporally stable reaction time interference effect ( range 200 - 350 ms), and single runs of the MSIT have produced CFP network activation in approximately 95% of tested subjects. The robust, reliable and temporally stable neuroimaging and performance data make the MSIT a useful task with which to study normal human cognition and psychiatric pathophysiology. C1 Massachusetts Gen Hosp, Div Neurosci, Psychiatr Neurosci Div, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, MIT, HMS, Athinoula A Martinos Ctr Funct & Struct Biomed I, Charlestown, MA 02129 USA. Harvard Med Sch Boston & Cambridge, Charlestown, MA 02129 USA. Tufts Univ, Dept Psychol, Medford, MA 02155 USA. RP Bush, G (reprint author), Massachusetts Gen Hosp, Div Neurosci, Psychiatr Neurosci Div, Bldg 149,Thirteenth St, Charlestown, MA 02129 USA. EM geo@nmr.mgh.harvard.edu FU PHS HHS [NIMH 01611] NR 47 TC 96 Z9 98 U1 1 U2 24 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 1 BP 308 EP 313 DI 10.1038/nprot.2006.48 PG 6 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 232EX UT WOS:000251002200047 PM 17406250 ER PT J AU Medarova, Z Evgenov, NV Dai, G Bonner-Weir, S Moore, A AF Medarova, Zdravka Evgenov, Natalia V. Dai, Guangping Bonner-Weir, Susan Moore, Anna TI In vivo multimodal imaging of transplanted pancreatic islets SO NATURE PROTOCOLS LA English DT Article ID DISEASE; MASS; MICE; MRI AB Interest is increasing in the transplantation of pancreatic islets as a means to achieve insulin independence in individuals with type I diabetes. The success of this approach is hampered by the absence of methods to follow the fate of transplanted islets non-invasively. In vivo imaging seems to be the most appropriate technique to achieve this goal in small animals and eventually in humans. Here we describe a protocol for labeling and subsequent imaging of transplanted islets in vivo using magnetic resonance imaging (MRI) and optical imaging. The whole series of experiments can be carried out in roughly 48 h. We believe that our approach can significantly advance the current ability to determine islet distribution, and possibly survival, after transplantation. This information would be essential not only for the long-term monitoring of graft function but also for the design of improved transplantation and immunomodulatory methods. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging Dept R, Boston, MA 02129 USA. Harvard Univ, Sch Med, Joslin Diabets Ctr, Boston, MA 02215 USA. RP Moore, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging Dept R, Boston, MA 02129 USA. EM amoore@helix.mgh.harvard.edu OI Bonner-Weir, Susan/0000-0003-4682-0656 FU NIDDK NIH HHS [DK072137, DK071225] NR 19 TC 34 Z9 35 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 1 BP 429 EP 435 DI 10.1038/nprot.2006.63 PG 7 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 232EX UT WOS:000251002200062 PM 17406265 ER PT J AU Kretschmer, K Heng, TSP von Boehmer, H AF Kretschmer, Karsten Heng, Tracy S. P. von Boehmer, Harald TI De novo production of antigen-specific suppressor cells in vivo SO NATURE PROTOCOLS LA English DT Article ID REGULATORY T-CELLS; DENDRITIC CELLS; STEADY-STATE; VITRO; UNRESPONSIVENESS; RECEPTORS; INDUCTION; PEPTIDE; SELF AB Foxp3-expressing regulatory T cells (T(reg)) play an essential role in maintaining tolerance to self antigens and are generated under physiological conditions when developing T cells encounter antigens expressed by thymic epithelial cells. We have addressed the possibility that T(reg) can be exploited to prevent or even suppress ongoing immune responses to foreign antigens. To this end, one must develop methods that permit the de novo generation of T(reg) specific for foreign antigens in peripheral lymphoid tissue. This report describes the methodology of generating T(reg) by delivering minute doses of peptide contained in fusion Abs directed against the DEC-205 endocytic receptor on steady-state dendritic cells. The process, from cloning and production of fusion Abs to antigen-specific T(reg) induction in vivo, takes similar to 2 months. The results show that delivery of T-cell receptor agonist ligands under subimmunogenic conditions represents a suitable approach for converting naive T cells into T(reg). C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA. RP von Boehmer, H (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA. EM harald_von_boehmer@dfci.harvard.edu RI Kretschmer, Karsten/E-8174-2010 NR 23 TC 29 Z9 29 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 2 BP 653 EP 661 DI 10.1038/nprot.2006.105 PG 9 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 232FA UT WOS:000251002500021 PM 17802642 ER PT J AU Grieger, JC Choi, VW Samulski, RJ AF Grieger, Joshua C. Choi, Vivian W. Samulski, R. Jude TI Production and characterization of adeno-associated viral vectors SO NATURE PROTOCOLS LA English DT Article ID TRANSDUCTION IN-VIVO; RATE-LIMITING STEP; VIRUS TYPE-4 AAV4; EFFICIENT TRANSDUCTION; GENE-TRANSFER; HELPER VIRUS; INSECT CELLS; TITER; SEROTYPES; ADENOVIRUS AB The adeno-associated virus (AAV) is one of the most promising viral vectors for human gene therapy. As with any potential therapeutic system, a thorough understanding of it at the in vitro and in vivo levels is required. Over the years, numerous methods have been developed to better characterize AAV vectors. These methods have paved the way to a better understanding of the vector and, ultimately, its use in clinical applications. This review provides an up-to-date, detailed description of essential methods such as production, purification and titering and their application to characterize current AAV vectors for preclinical and clinical use. C1 Univ N Carolina, Gene Therapy Ctr, Curriculum Genet & Mol Biol, Dept Pharmacol, Chapel Hill, NC 27599 USA. Alpha Vax Inc, Res Triangle Pk, NC 27709 USA. Harvard Med Sch, Childrens Hosp, CBR Inst Biomed Res, Dept Genet, Boston, MA 02115 USA. RP Samulski, RJ (reprint author), Univ N Carolina, Gene Therapy Ctr, Curriculum Genet & Mol Biol, Dept Pharmacol, Chapel Hill, NC 27599 USA. EM rjs@med.unc.edu FU NHLBI NIH HHS [HL051818, HL066973]; NIGMS NIH HHS [GM059299] NR 59 TC 211 Z9 223 U1 1 U2 23 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 3 BP 1412 EP 1428 DI 10.1038/nprot.2006.207 PG 17 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 234IT UT WOS:000251155400043 PM 17406430 ER PT J AU Hu, M Yao, J Polyak, K AF Hu, Min Yao, Jun Polyak, Kornelia TI Methylation-specific digital karyotyping SO NATURE PROTOCOLS LA English DT Article ID DNA METHYLATION; CANCER-CELLS; CPG-ISLANDS; GENE-EXPRESSION; GENOMIC DNA; IDENTIFICATION; MICROARRAY; EPIGENOME; PATTERNS; PROMOTER AB Epigenetic alterations, including DNA methylation and histone modifications, are known to regulate various physiological and pathological processes. In mammalian cells, DNA methylation occurs at cytosines of CpG dinucleotides. Several methods have been developed for the genome-wide analysis of methylation patterns. However, none of these are quantitative or sequence-based, and the identification of the exact location of the methylated CpG is difficult. In this protocol, we describe a recently developed method - methylation-specific digital karyotyping (MSDK) - that enables comprehensive and unbiased genome-wide DNA methylation analysis. Using a combination of a methylation-sensitive mapping enzyme (for example, AscI) and a fragmenting enzyme (for example, NlaIII), short sequence tags can be obtained and uniquely mapped to genome location. The number of tags in an MSDK library reflects the methylation status of the mapping enzyme sites. Generation of MSDK libraries can be completed in 7-10 days, whereas sequencing and data analysis requires an additional 3-4 weeks. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Polyak, K (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM Kornelia_Polyak@dfci.harvard.edu FU NCI NIH HHS [CA89393, CA94074, CA116235] NR 30 TC 21 Z9 25 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 3 BP 1621 EP 1636 DI 10.1038/nprot.2006.278 PG 16 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 234IT UT WOS:000251155400068 PM 17406428 ER PT J AU Wright, DA Thibodeau-Beganny, S Sander, JD Winfrey, RJ Hirsh, AS Eichtinger, M Fu, F Porteus, MH Dobbs, D Voytas, DF Joung, JK AF Wright, David A. Thibodeau-Beganny, Stacey Sander, Jeffry D. Winfrey, Ronnie J. Hirsh, Andrew S. Eichtinger, Magdalena Fu, Fengli Porteus, Matthew H. Dobbs, Drena Voytas, Daniel F. Joung, J. Keith TI Standardized reagents and protocols for engineering zinc finger nucleases by modular assembly SO NATURE PROTOCOLS LA English DT Article ID ARTIFICIAL TRANSCRIPTION FACTORS; DNA-BINDING PROTEINS; CONTROLLING GENE-EXPRESSION; GROWTH-FACTOR-A; HOMOLOGOUS RECOMBINATION; PHENOTYPIC ALTERATION; RESTRICTION ENZYMES; INCREASE PRODUCTION; CHIMERIC NUCLEASES; BUILDING-BLOCKS AB Engineered zinc finger nucleases can stimulate gene targeting at specific genomic loci in insect, plant and human cells. Although several platforms for constructing artificial zinc finger arrays using "modular assembly" have been described, standardized reagents and protocols that permit rapid, cross-platform "mixing-and-matching" of the various zinc finger modules are not available. Here we describe a comprehensive, publicly available archive of plasmids encoding more than 140 well-characterized zinc finger modules together with complementary web-based software (termed ZiFiT) for identifying potential zinc finger target sites in a gene of interest. Our reagents have been standardized on a single platform, enabling facile mixing-and-matching of modules and transfer of assembled arrays to expression vectors without the need for specialized knowledge of zinc finger sequences or complicated oligonucleotide design. We also describe a bacterial cell-based reporter assay for rapidly screening the DNA-binding activities of assembled multi-finger arrays. This protocol can be completed in approximately 24-26 d. C1 Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA. Iowa State Univ, Interdepartmental Grad Program Bioinformat & Comp, Ames, IA 50011 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA. Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA. Iowa State Univ, Dept Genet Dev & Cell Biol, Ames, IA 50011 USA. Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA. RP Joung, JK (reprint author), Massachusetts Gen Hosp, Mol Pathol Unit, 149 13th St, Charlestown, MA 02129 USA. EM jjoung@partners.org FU NCI NIH HHS [R21 CA120681, T32 CA09216]; NHLBI NIH HHS [R01 HL0792595]; NIGMS NIH HHS [R01 GM069906, R01 GM072621]; NIH HHS [DP1 OD006862] NR 60 TC 108 Z9 125 U1 5 U2 27 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 3 BP 1637 EP 1652 DI 10.1038/nprot.2006.259 PG 16 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 234IT UT WOS:000251155400069 PM 17406455 ER PT J AU Hu, M Polyak, K AF Hu, Min Polyak, Kornelia TI Serial analysis of gene expression SO NATURE PROTOCOLS LA English DT Article ID BREAST-TUMOR PROGRESSION; LONGER CDNA FRAGMENTS; GENOME ANNOTATION; TRANSCRIPTOME CHARACTERIZATION; SAGE ANALYSIS; CELL-LINES; PLASMODIUM-FALCIPARUM; B-CELLS; IDENTIFICATION; CANCER AB Serial analysis of gene expression ( SAGE) is a method used to obtain comprehensive, unbiased and quantitative gene-expression profiles. Its major advantage over arrays is that it does not require a priori knowledge of the genes to be analyzed and reflects absolute mRNA levels. Since the original SAGE protocol was developed in a short-tag (10-bp) format, several modifications have been made to produce longer SAGE tags for more precise gene identification and to decrease the amount of starting material necessary. Several SAGE-like methods have also been developed for the genome-wide analysis of DNA copy-number changes and methylation patterns, chromatin structure and transcription factor targets. In this protocol, we describe the 17-bp longSAGE method for transcriptome profiling optimized for a small amount of starting material. The generation of such libraries can be completed in 7-10d, whereas sequencing and data analysis require an additional 2-3 wk. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Polyak, K (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,D740C, Boston, MA 02115 USA. EM kornelia_polyak@dfci.harvard.edu NR 80 TC 15 Z9 17 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 4 BP 1743 EP 1760 DI 10.1038/nprot.2006.269 PG 18 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 234IU UT WOS:000251155500010 PM 17487157 ER PT J AU West, JA Park, IH Daley, GQ Geijsen, N AF West, Jason A. Park, In-Hyun Daley, George Q. Geijsen, Niels TI In vitro generation of germ cells from murine embryonic stem cells SO NATURE PROTOCOLS LA English DT Article ID TRANSITION NUCLEAR PROTEINS; MOUSE EMBRYOGENESIS; RETINOIC ACID; EXPRESSION; MICE; GENE; SPERMATOGENESIS; DIFFERENTIATION; ACROSOME; LINEAGE AB The demonstration of germ cell and haploid gamete development from embryonic stem cells (ESCs) in vitro has engendered a unique set of possibilities for the study of germ cell development and the associated epigenetic phenomenon. The process of embryoid body (EB) differentiation, like teratoma formation, signifies a spontaneous differentiation of ESCs into cells of all three germ layers, and it is from these differentiating aggregates of cells that putative primordial germ cells (PGCs) and more mature gametes can be identified and isolated. The differentiation system presented here requires the differentiation of murine ESCs into EBs and the subsequent isolation of PGCs as well as haploid male gametes from EBs at various stages of differentiation. It serves as a platform for studying the poorly understood process of germ cell allocation, imprint erasure and gamete formation, with 4-6 weeks being required to isolate PGCs as well as haploid cells. C1 Childrens Hosp Boston, Div Pediat Hematol Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Grad Program Biol & Biomed Sci, Boston, MA 02115 USA. Harvard Univ, Stem Cell Inst, Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02115 USA. RP Daley, GQ (reprint author), Childrens Hosp Boston, Div Pediat Hematol Oncol, Boston, MA 02115 USA. EM george.daley@childrens.harvard.edu; ngeijsen@partners.org RI West, Jason/I-4445-2014 OI West, Jason/0000-0002-7252-8651 NR 55 TC 54 Z9 58 U1 3 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 4 BP 2026 EP 2036 DI 10.1038/nprot.2006.303 PG 11 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 234IU UT WOS:000251155500045 PM 17487192 ER PT J AU Nahmias, Y Odde, DJ AF Nahmias, Yaakov Odde, David J. TI Micropatterning of living cells by laser-guided direct writing: application to fabrication of hepatic endothelial sinusoid-like structures SO NATURE PROTOCOLS LA English DT Article ID LIVER-REGENERATION; BASEMENT-MEMBRANE; OPTICAL TRAPS; IN-VITRO; HEPATOCYTES; DIFFERENTIATION; REORGANIZATION; GUIDANCE; INVITRO; DESIGN AB Here, we describe a simple protocol for the design and construction of a laser-guided direct writing (LGDW) system able to micropattern the self-assembly of liver sinusoid-like structures with micrometer resolution in vitro. To the best of our knowledge, LGDW is the only technique able to pattern cells '' on the fly '' with micrometer precision on arbitrary matrices, including soft gels such as Matrigel. By micropatterning endothelial cells on Matrigel, one can control the self-assembly of vascular structures and associated liver tissue. LGDW is therefore uniquely suited for studying the role of tissue architecture and mechanical properties at the single-cell resolution, and for studying the effects of heterotypic cell - cell interactions underlying processes such as liver morphogenesis, differentiation and angiogenesis. The total time required to carry out this protocol is typically 7 h. C1 Massachusetts Gen Hosp, Harvard Med Sch, Ctr Engn Med, Boston, MA 02114 USA. Univ Minnesota, Dept Biomed Engn, Minneapolis, MN 55455 USA. RP Odde, DJ (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Ctr Engn Med, 51 Blossom St, Boston, MA 02114 USA. EM oddex002@umn.edu RI Odde, David/H-4925-2011; Nahmias, Yaakov/H-4725-2013; OI Odde, David/0000-0001-7731-2799; Nahmias, Yaakov/0000-0002-6051-616X NR 47 TC 56 Z9 59 U1 4 U2 21 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 5 BP 2288 EP 2296 DI 10.1038/nprot.2006.386 PG 9 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 234IV UT WOS:000251155600015 PM 17406470 ER PT J AU Bradner, JE McPherson, OM Koehler, AN AF Bradner, James E. McPherson, Olivia M. Koehler, Angela N. TI A method for the covalent capture and screening of diverse small molecules in a microarray format SO NATURE PROTOCOLS LA English DT Article ID GLASS SLIDES; IMMOBILIZATION; DISCOVERY; LIGANDS; LIBRARIES; BINDING; ARRAYS AB This protocol describes a robust method for the covalent capture of small molecules with diverse reactive functional groups in microarray format, and outlines a procedure for probing small-molecule microarrays (SMMs) with proteins of interest. A vaporcatalyzed, isocyanate-mediated surface immobilization scheme is used to attach bioactive small molecules, natural products and small molecules derived from diversity-oriented synthesis pathways. Additionally, an optimized methodology for screening SMMs with purified proteins and cellular lysates is described. Finally, a suggested model for data analysis that is compatible with commercially available software is provided. These procedures enable a platform capability for discovering novel interactions with potential applications to immunoglobulin profiling, comparative analysis of cellular states and ligand discovery. With the appropriate materials and experimental setup, the printing of SMMs can be completed in 14 hours over 3 days. Screening and data analysis requires 2 days. A detailed timeline is provided. C1 Broad Inst Harvard, MIT, Cambridge, MA 02142 USA. Harvard Med Sch, Dana Farber Canc Inst, Div Hematol Neoplasia, Boston, MA 02115 USA. RP Koehler, AN (reprint author), Broad Inst Harvard, MIT, 7 Cambridge Ctr, Cambridge, MA 02142 USA. EM koehler@fas.harvard.edu NR 18 TC 37 Z9 39 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2006 VL 1 IS 5 BP 2344 EP 2352 DI 10.1038/nprot.2006.282 PG 9 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 234IV UT WOS:000251155600023 PM 17406478 ER PT J AU Bismar, TA Demichelis, F Riva, A Kim, R Varambally, S He, L Kutok, J Aster, JC Tang, J Kuefer, R Hofer, MD Febbo, PG Chinnaiyan, AM Rubin, MA AF Bismar, Tarek A. Demichelis, Francesca Riva, Alberto Kim, Robert Varambally, Sooryanarayana He, Le Kutok, Jeff Aster, Jonathan C. Tang, Jeffery Kuefer, Rainer Hofer, Matthias D. Febbo, Phillip G. Chinnaiyan, Arul M. Rubin, Mark A. TI Defining aggressive prostate cancer using a 12-gene model SO NEOPLASIA LA English DT Review DE metastasis; cancer; proteomics; prostate cancer; bioinformatics ID FATTY-ACID SYNTHASE; E-CADHERIN EXPRESSION; KINASE INHIBITOR P27(KIP1); METHYLACYL-COA RACEMASE; IN-SITU HYBRIDIZATION; KI67 LABELING INDEX; X-LINKED INHIBITOR; GENE-EXPRESSION; IMMUNOHISTOCHEMICAL DETECTION; NEOPLASTIC TRANSFORMATION AB The critical clinical question in prostate cancer research is: How do we develop means of distinguishing aggressive disease from indolent disease? Using a combination of proteomic and expression array data, we identified a set of 36 genes with concordant dysregulation of protein products that could be evaluated in situ by quantitative immunohistochemistry. Another five prostate cancer biomarkers were included using linear discriminant analysis, we determined that the optimal model used to predict prostate cancer progression consisted of 12 proteins. Using a separate patient population, transcriptional levels of the 12 genes encoding for these proteins predicted prostate-specific antigen failure in 79 men following surgery for clinically localized prostate cancer (P=.0015). This study demonstrates that cross-platform models can lead to predictive models with the possible advantage of being more robust through this selection process. C1 Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. ITC Irst, SRA Div, Trento, Italy. Univ Trent, Dept Informat & Commun Technol, Trento, Italy. Childrens Hosp, Informat Program, Boston, MA 02115 USA. Univ Michigan, Dept Pathol & Urol, Ann Arbor, MI 48109 USA. Univ Hosp, Ulm, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. RP Rubin, MA (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. EM marubin@partners.org OI Riva, Alberto/0000-0001-9150-8333; Rubin, Mark/0000-0002-8321-9950; Demichelis, Francesca/0000-0002-8266-8631 FU NCI NIH HHS [P50CA69568, P30 CA046592, P50 CA090381, CA97063, U01 CA111275-01, U01 CA111275, R01 CA097063, P50 CA069568, P50CA90381, 5P30 CA46592]; NIA NIH HHS [R01 AG021404, R01AG21404] NR 80 TC 67 Z9 73 U1 1 U2 3 PU NEOPLASIA PRESS PI ANN ARBOR PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648 USA SN 1522-8002 J9 NEOPLASIA JI Neoplasia PD JAN PY 2006 VL 8 IS 1 BP 59 EP 68 DI 10.1593/neo.05664 PG 10 WC Oncology SC Oncology GA 067AD UT WOS:000239271400008 PM 16533427 ER PT J AU Yishak, AA Costacou, T Virella, G Zgibor, J Fried, L Walsh, M Evans, RW Lopes-Virella, M Kagan, VE Otvos, J Orchard, TJ AF Yishak, AA Costacou, T Virella, G Zgibor, J Fried, L Walsh, M Evans, RW Lopes-Virella, M Kagan, VE Otvos, J Orchard, TJ TI Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE adhesion molecules; antioxidants; diabetic nephropathy; immune complexes; lipids ID CORONARY-ARTERY-DISEASE; OXIDIZED LDL; ANTIOXIDANTS; PROGRESSION AB Background. Predictors of diabetic nephropathy are only partly known and traditional risk factors do not adequately explain disease risk. We thus examined novel risk factors for overt nephropathy (ON) in type 1 diabetes. Methods. The EDC is a prospective study of childhood-onset type 1 diabetes. When first seen (1986-1988), mean age was 28 and diabetes duration 19 years. In the subsequent 10 years, 56 of 485 subjects without ON in 1986-88 developed ON. An age, duration (+/- 3 years), and sex-matched control was identified for 47 cases. Forty-two matched pairs had available stored plasma samples obtained prior to ON onset in cases, and complete standard risk factor data. Results. Cases had a higher baseline albumin excretion rate (AER), HbA(1), pulse rate, non-HDL cholesterol, fibrinogen, small LDL and lower eGDR and LDL particle size compared to controls (all P values < 0.05). Multiple measures of immune complexes were increased in cases (P < 0.05), whereas borderline elevations were seen for total antioxidant reserve (P = 0.06) and retinol (P = 0.08). Multivariably, other than AER, LDL particle size and IgG-IC were predictive beyond the standard predictors. Conclusion. Besides AER, the immunecomplexes and lipoprotein subclasses may provide additional information in the assessment of ON risk in type 1 diabetes. C1 Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. Vet Pittsburgh Hlth Care Syst Pittsburgh, Pittsburgh, PA USA. Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Dept Med, Charleston, SC USA. LipoSci Inc, Raleigh, NC USA. RP Orchard, TJ (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Diabet & Lipid Res Bldg,3512 5th Ave, Pittsburgh, PA 15213 USA. EM tjo@pitt.edu OI orchard, trevor/0000-0001-9552-3215 FU NIDDK NIH HHS [DK34818] NR 19 TC 19 Z9 19 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD JAN PY 2006 VL 21 IS 1 BP 93 EP 100 DI 10.1093/ndt/gfi103 PG 8 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 000BO UT WOS:000234436100021 PM 16144851 ER PT J AU Odden, MC Whooley, MA Shlipak, MG AF Odden, Michelle C. Whooley, Mary A. Shlipak, Michael G. TI Depression, stress, and quality of life in persons with chronic kidney disease: The Heart and Soul Study SO NEPHRON CLINICAL PRACTICE LA English DT Article DE chronic kidney disease; kidney disease, depression; kidney disease, stress; kidney disease, quality of life ID STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; SINGLE-ITEM; HEALTH; INSUFFICIENCY; SYMPTOMS; ASSOCIATION; MORTALITY; ISCHEMIA AB Background: The effect of mild chronic kidney disease (CKD) on depression, stress, quality of life (QOL), and health status is not well understood. We compared these outcomes in subjects with and without CKD. Methods: We performed a cross- sectional study of 967 outpatients enrolled in the Heart and Soul Study. CKD was defi ned as a measured creatinine clearance <60 ml/min. Outcome measures included depressive symptoms measured using the Patient Health Questionnaire (PHQ), stress measured using the Perceived Stress Scale (PSS), and QOL and overall health rated as excellent, very good, good, fair, or poor. Results: The prevalence of depressive symptoms (17 vs. 19%, p = 0.4) or perceived stress (11 vs. 16%, p = 0.09) did not vary signifi cantly by CKD. The prevalence of fair or poor QOL was not signifi cantly different in subjects with CKD, compared with those without CKD (24 vs. 23%, p = 0.65). Age-adjusted analyses revealed a signifi cant association of CKD with QOL (p = 0.003), however, this association no longer reached statistical significance after adjustment for confounders (p = 0.06). Subjects with CKD were more likely to report poor or fair overall health than subjects without CKD (42 vs. 34%, p = 0.03). After multivariate adjustment, CKD remained signifi cantly associated with worse overall health (OR = 1.65, 95% Cl 1.21 - 2.24, p = 0.001), and modestly associated with QOL ( OR = 1.31, 95% Cl 0.99-1.75, p = 0.06), but had no association with depression (p = 0.48) or stress (p = 0.24). Conclusion: In this study of persons with coronary artery disease, subjects with CKD had reduced overall health and modestly reduced QOL; however, mental health was similar in those with and without CKD. These fi ndings suggest that self-assessed overall health may decline at earlier stages of renal dysfunction than mental health outcomes or QOL. C1 San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 4150 Clement St,111A-1, San Francisco, CA 94121 USA. EM shlip@itsa.ucsf.edu FU NHLBI NIH HHS [R01 HL079235, R01 HL079235-01A1] NR 34 TC 28 Z9 30 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2110 J9 NEPHRON CLIN PRACT JI Nephron. Clin. Pract. PY 2006 VL 103 IS 1 BP C1 EP C7 DI 10.1159/000090112 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 163PS UT WOS:000246174100001 PM 16340237 ER EF